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ABSTRACT 
Palmitoylation is a reversible post-translational modification of proteins which involves the 
addition of the C16 saturated fatty acid palmitic acid to sulfhydryl groups on cysteine 
residues, forming a thioester linkage.  The addition of palmitate allows proteins to associate 
with different cellular membranes and membrane subdomains.  Palmitoylation is catalysed 
by the DHHC family of palmitoyl-acyl transferases (PATs), named for their characteristic 
DHHC motif in a cysteine-rich domain (CRD).  Reversibility is conferred by palmitoyl-protein 
thioesterases (PPTs), which cleave the thioester linkage.  The study of palmitoylation has 
recently gathered pace with the development of methods which allow proteome-scale 
identification of candidate palmitoyl-proteins. 
Despite the importance of model organisms in several key studies in the field, 
palmitoylation has barely been studied in the simple eukaryote Caenorhabditis elegans, the 
nematode worm.  This study commenced with the use of the C. elegans genome data to 
identify its PATs and PPTs, using the DHHC-CRD and homology respectively.  The 15 DHHC 
PATs were officially named using a dhhc-x system and the two previously known PPTs were 
confirmed as the only ones with homology to other known PPTs.  The current knowledge on 
palmitoylation enzymes and substrates was collated and analysed to predict possible 
phenotypes resulting from mutation or knockdown of the enzymes and potential 
substrates. 
All available C. elegans strains containing a mutation in an individual PAT or PPT were 
obtained, covering about half of the PATs and both PPTs, and assayed for various gross 
phenotypes.  In addition a complete library of bacteria able to express double-stranded 
RNA against PAT or PPT genes was sourced and used to perform similar assays using 
feeding RNA interference (RNAi).  A number of small but significant differences were seen 
both with mutant and RNAi-treated strains, especially in lifespan assays.  To test for 
possible redundancy and compensation amongst the enzymes, double RNAi was performed 
against selected closely related PATs and both PPTs.  This resulted in the largest phenotype 
seen: a reduction in lifespan after simultaneous knockdown of both ppt-1 and ath-1. 
As there are no known palmitoyl-proteins in C. elegans, the proteomic approaches  
acyl-biotin exchange (ABE) and acyl-resin-assisted capture (acyl-RAC) were employed to 
provide a list of candidates.  These were first optimised using rat brain material and the 
results compared with previous proteomic studies to find that two-thirds of the hits had 
been previously found.  With this validation, both methods were applied to wild-type  
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C. elegans lysates to give 91 hits as putative palmitoyl-proteins.  Mutants for the PPT ath-1 
were also profiled by ABE, showing 33 hits which were not present in the wild-type profile.  
These are potential ATH-1 substrates whose lack of depalmitoylation in the mutant leads to 
their enrichment relative to wild-type.  However, further repeats of these analyses are 
required for rigorous statistical testing. 
Taken together, this study shows the first characterisation of palmitoylation in C. elegans, 
encompassing all of the DHHC PAT and PPT enzymes, putative palmitoyl-proteins and 
potential substrates of the PPT enzyme ATH-1.  
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1.1 POST-TRANSLATIONAL LIPID MODIFICATIONS 
Proteins are the workhorses of life at the subcellular level.  They show an astonishing 
variety of forms and functions dictated by the physical and chemical properties of their 
primary amino acid sequence.  These properties allow the formation of catalytic sites, 
channel pores, binding sites and structural units to name but a few.  On top of this diverse 
functionality lies another layer of complexity afforded by post-translational modifications.  
The addition of chemical adducts to specific parts of proteins allows their function to be 
regulated with respect to changes in the environment or temporal effects.  
Phosphorylation, arguably the most studied, involves the addition and removal of 
phosphate groups and often serves to modulate enzymatic activity.  There is, however, a 
panoply of larger accessory chemical groups which serve as post-translational 
modifications.  These may be based on sugars, as in glycosylation; peptides, as in 
ubiquitination; and lipids. 
The discovery that proteins could have a lipid moiety was made in 1951 with the 
observation that some protein material could be purified from brain tissue which was 
insoluble in aqueous solvents but soluble in mixtures of chloroform and methanol (Folch 
and Lees, 1951).  No proteins had previously been observed to be soluble in these mixtures 
and various protocols for extracting them from tissues were developed (Folch-Pi and 
Stoffyn, 1972).  The main types of protein lipidation which occur in eukaryotes are 
prenylation, myristoylation and palmitoylation, the subject of this thesis.  The first 
identification of a protein modified with palmitic acid was a vesicular stomatitis virus 
glycoprotein (Schmidt and Schlesinger, 1979) and the first palmitoylated eukaryotic protein 
discovered was the transferrin receptor, whose modification was shown to be sensitive to 
treatment with hydroxylamine (HA) (Omary and Trowbridge, 1981).  This chapter will give 
an introduction to lipid modifications of proteins in general, followed by a discussion of the 
enzymes required for addition and removal of palmitate and progress in the field to date. 
1.1.1 PRENYLATION AND MYRISTOYLATION 
Prenylation occurs post-translationally at a C-terminal CaaX motif (where “a” is an aliphatic 
residue, i.e. one lacking an aromatic ring).  An irreversible thioether link is formed between 
the cysteine residue and a 15-carbon farnesyl or a 20-carbon geranylgeranyl group by 
farnesyltransferase or geranylgeranyltransferase I respectively before cleavage of the  
C-terminal aaX (Resh, 2006).  The identity of the amino acid at residue X determines 
whether the protein will be farnesylated or geranylgeranylated: an alanine, cysteine, 
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glutamine, methionine or serine residue results in farnesylation, whereas a leucine or 
phenylalanine residue results in geranylgeranylation (Maurer-Stroh and Eisenhaber, 2005).  
Finally the prenylated cysteine residue is carboxymethylated in the endoplasmic reticulum 
(ER).  Proteins which are commonly prenylated include many signalling proteins, such as 
Ras proteins (Braun and Fenaux, 2008; Resh, 2006), which may have implications in cancer. 
Myristoylation is an irreversible fatty acylation which occurs on approximately 0.5% of 
proteins (Maurer-Stroh et al., 2002).  It is the addition of a 14-carbon saturated or 
unsaturated fatty acid to glycine residues.  The fatty acid used is usually myristate, which 
was originally discovered as a group blocking Edman degradation of the N-terminus of cyclic 
adenosine monophosphate (cAMP)-dependent protein kinase (Carr et al., 1982).  Its  
co-translational addition to the N-terminal sequence MGXXX(S/C/T) through an amide bond 
after removal of the initial methionine by methionine aminopeptidase is catalysed by 
myristoyl-coenzyme A (CoA):protein N-myristoyltransferase (NMT) (Martin et al., 2011), 
leaving an amide link to the glycine residue.  Myristoylation is presumably a fundamentally 
important modification of some proteins, as fungi require it for viability and one of the 
vertebrate enzymes, NMT-1, is required for early development and cell division (Resh, 
2006; Yang et al., 2005).  Myristoylation can also occur post-translationally to internal 
glycines in the consensus sequence DEVDGXXX(S/C/T) when it is exposed by cysteinyl-
aspartyl proteases (caspases) in apoptotic cells, for example on the apoptotic protein Bid 
(Zha et al., 2000).  Although normally occurring on glycine residues, myristoylation has been 
observed on lysine residues by an amide linkage in the insulin receptor (Hedo et al., 1987) 
and interleukin 1 subunits (Bursten et al., 1988). 
Most lipid modifications serve to attach soluble proteins to cellular membranes.  A single 
farnesyl group on a protein will not lead to a membrane association of more than 1-2 
minutes (Peitzsch and McLaughlin, 1993) and the binding energy of a myristoylated peptide 
to the lipid bilayer is too low for stable association (Peitzsch and McLaughlin, 1993).  
Additional hydrophobicity is required for a more stable interaction.  The two-signal 
hypothesis argues that a second membrane attachment signal is required for stable 
membrane attachment.  This can be a polybasic domain, such as in the myristoylated 
tyrosine kinase Src (Murray et al., 1998), or by palmitoylation, for example in myristoylated 
Gα subunits (Manahan et al., 2000).  In the case of Ras, a farnesylated protein, this occurs 
in the hypervariable region by palmitoylation, either singly as in N-Ras or doubly as in H-Ras 
(Hancock et al., 1989), or by a polybasic region in K(B)-Ras (Hancock et al., 1990).  A subset 
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of palmitoylated proteins are already irreversibly lipidated in this way and so are called 
dually lipidated proteins. 
Although prenylation and myristoylation are irreversible events there is still scope for 
regulation of membrane attachment.  The myristoyl moiety can undergo conformational 
changes which allow it either to be available for membrane attachment or hidden within a 
pocket, a so-called myristoyl switch.  The myristoyl switch may often be regulated by 
binding of a ligand.  Examples of proteins whose membrane attachment is regulated in this 
way include recoverin, a calcium-binding retinal protein (Ames et al., 1996) and c-Abl, a 
tyrosine kinase which is regulated by phosphotyrosine-containing ligands (Hantschel et al., 
2003).  An analogous mechanism involving binding of other proteins can also regulate 
attachment of prenylated proteins to membranes.  The guanosine triphosphatase (GTPase) 
Rho, for example, is geranylgeranylated and is removed from the plasma membrane (PM) 
by binding to Rho guanine nucleotide dissociation inhibitor (RhoGDI) and maintained in an 
inactive form in this complex in the cytosol (Hoffman et al., 2000).  Despite these switch 
mechanisms, prenylated and myristoylated proteins retain their lipid moieties indefinitely.  
Only palmitoylation allows for regulation through addition and removal of the lipid group. 
1.1.2 PALMITOYLATION 
Palmitoylation of proteins was originally described as a fatty acid which binds to vesicular 
stomatitis virus glycoprotein (Schmidt and Schlesinger, 1979) and was later found to be a 
post-translational modification in eukaryotic cells (Omary and Trowbridge, 1981).  It has not 
been demonstrated in bacteria.  There are now three forms of palmitoylation which are 
recognised.  S-palmitoylation is the addition of the 16-carbon saturated fatty acid palmitic 
acid to cysteine residues by a thioester bond.  It is the major subgroup of the process called 
S-acylation, which includes fatty acids with different lengths of hydrocarbon chain and 
numbers of unsaturated bonds.  This is a reversible process, with S-palmitoylation catalysed 
by the DHHC family of palmitoyl acyl-tranferases (PATs) and depalmitoylation catalysed by 
palmitoyl-protein thioesterases (PPTs). 
A small group of proteins are subject to irreversible N-palmitoylation, in which palmitic acid 
is added to cysteine residues by an amide bond.  The protein whose N-palmitoylation has 
been most extensively studied is the mammalian Sonic hedgehog (Shh) protein.  Shh is 
unusual in that it requires dual N-palmitoylation and cholesteroylation, a rare C-terminal 
modification, for its functionality (Ingham, 2001).  N-palmitoylation is catalysed by the 
membrane-bound O-acyltransferase (MBOAT) family of enzymes, and the MBOAT for 
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Hedgehog proteins is Hedgehog acyltransferase (Hhat) (Chamoun et al., 2001).  The residue 
which is palmitoylated is a conserved cysteine in the sequence CGPGP, which is revealed by 
removal of a signal peptide.  As it appears that the amino group cannot be directly 
palmitoylated but a sulfhydryl group is required, the mechanism is thought to consist of an 
initial thioester bond between the palmitate and cysteine sulfhydryl followed by 
translocation of the palmitate group to an amide link (Pepinsky et al., 1998).  The dual 
lipidation of Hedgehog proteins has been shown to be required for their function as 
secreted morphogens, specifically for interactions with heparan sulphate proteoglycans 
(HSPGs) and the receptor Patched (Callejo et al., 2006).  This may prevent it from simply 
diffusing away.  Another protein known to be N-palmitoylated is Drosophila melanogaster 
Wingless, a member of the Wnt family of proteins and also secreted, by the MBOAT 
Porcupine (Franch-Marro et al., 2008). 
The first instance of modification of a protein by O-palmitoylation was recently identified 
(Zou et al., 2011).  Contrary to the introduction to their paper, O-palmitoylation has not 
strictly been previously demonstrated, as the studies they cite actually relate to O-acylation 
of ghrelin with octanoic acid (Yang et al., 2008) and Wnt proteins by palmitoleic acid 
(Franch-Marro et al., 2008).  The study does find O-palmitoylation related to the enzyme 
acyl-CoA:lysophosphatidylcholine acyltransferase 1 (Lpcat1), which is required for synthesis 
of pulmonary surfactant in lung epithelia (Zou et al., 2011).  Upon a Ca2+ stimulus, Lpcat1 
translocated to the nucleus where it palmitoylated histone H4.  The palmitate group was 
shown to be insensitive to reduction, and so could not be S-palmitoylation.  The 
palmitoylated residue was determined as serine-47 in histone H4.  Palmitoylation was much 
reduced when Lpcat1 histidine-135 was mutated to alanine, suggesting this residue is 
essential for catalysis.  Histone H4 O-palmitoylation is thought to be a mechanism 
regulating RNA synthesis in lung epithelial cells, and there is potential cross-regulation as 
histone H4 serine residues are also known to be phosphorylated (Zou et al., 2011).  There is 
already an example of phosphorylation of residue close to a palmitoylatable cysteine 
preventing the S-palmitoylation of phosphodiesterase 10A (PDE10A) and thus altering its 
subcellular localisation (Charych et al., 2010). 
S-palmitoylation is the process investigated in this thesis.  Unless otherwise stated, the 
term ‘palmitoylation’ will henceforward refer to S-palmitoylation.  
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1.1.3 PALMITATE SYNTHESIS 
Palmitate synthesis in mammals is carried out in the cytosol by fatty acid synthase (Stryer, 
1995).  The source materials are acetyl-CoA, derived from citrate by adenosine 
triphosphate (ATP)-citrate lyase, reduced nicotinamide adenine dinucleotide phosphate 
(NADPH), derived from the pentose phosphate pathway and metabolism of oxaloacetate, 
and malonyl-CoA, derived from acetyl-CoA by acetyl-CoA decarboxylase.  Each monomer of 
the fatty acid synthase comprises three domains linked by flexible joiners, and the 
functional enzyme is a dimer of two identical monomers.  The first domain of each 
monomer contains an acetyl transferase, a malonyl transferase and a β-ketoacyl synthase 
(also called condensing enzyme) region.  This first domain of each monomer is physically 
located opposite the second and third domains of the other monomer (Figure 1.1A).  The 
second domain contains the acyl carrier protein, β-ketoacyl reductase, dehydratase and 
enoyl reductase; the third domain is a thioesterase.  The first step of palmitate synthesis is 
O-linkage of the acetyl of acetyl-CoA and the malonyl of malonyl-CoA to a serine in the 
active site of the acetyl transferase and malonyl transferase respectively.  The acetyl group 
moves to the β-ketoacyl synthase/condensing enzyme in a cysteine S-linkage whilst the 
malonyl group is transferred to an S-linkage on a phosphopantetheinyl group on the acyl 
carrier protein in the second domain of the other monomer (Figure 1.1B). 
Once these initial steps have been performed, elongation of the hydrocarbon chain takes 
place.  A condensation reaction transfers the acetyl group onto two of the three malonyl 
group carbons to form an acetoacetyl-S-phosphopantetheinyl group with the third malonyl 
carbon released in carbon dioxide.  This intermediate is reduced to a butyryl group by the 
β-ketoacyl reductase, dehydratase and enoyl reductase portions of the second domain.  
The butyryl group is transferred back to the cysteine residue in the β-ketoacyl 
synthase/condensing enzyme in the first domain.  Another malonyl group is added to the 
acyl carrier protein and is used to provide a further two-carbon section for a condensation 
reaction (Figure 1.1C).  The cycle continues until the C16 palmitate is produced.  The 
thioesterase moiety in the third domain cleaves this from the β-ketoacyl 
synthase/condensing enzyme in the first domain (Stryer, 1995).  Palmitoyl-CoA, which is the 
substrate for palmitoylation, is produced by palmitoyl-CoA synthetase from palmitate, ATP 
and unacylated CoA (CoASH) (Brandes et al., 1973). 
The process of palmitate synthesis is similar in Saccharomyces cerevisiae.  The fatty acid 
synthase complex has a molecular weight of 2400 kDa and is composed of two different 
subunits in the arrangement α6β6.  In this context, the α subunit contains the acyl carrier 
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FIGURE 1.1: Schematic of palmitate synthesis 
(A) Schematic showing the arrangement of two fatty acid synthase monomers into a functional 
dimer.  Each monomer is situated so domain 1 is adjacent to domains 2 and 3 of the other monomer.  
(B) The initial steps of synthesis.  An acetyl group is O-linked to the acetyl transferase and a malonyl 
group to malonyl transferase on domain 1 of one monomer.  The acetyl group is transferred to an  
S-linkage to the β-ketoacyl synthase while the malonyl group becomes S-linked to the acyl carrier 
protein on domain 2 of the opposing monomer.  (C) The elongation cycle.  A condensation reaction 
between the C2 malonyl group and the existing chain (C2 acetyl initially) gives an intermediate which 
is then reduced to give a saturated hydrocarbon chain extended by two carbons.  The elongation 
cycle continues until C16 palmitate is produced.  It is cleaved from the enzyme by the thioesterase 
domain.  ACP, acyl carrier protein; AT, acetyl transferase; D, dehydratase; ER, enoyl reductase; KR,  
β-ketoacyl reductase; KS, β-ketoacyl synthase; MT, malonyl transferase; T, thioesterase.  
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protein, condensing enzyme and β-ketoacyl reductase; the β subunit contains the acetyl 
transacylase, malonyl transacylase, β-hydroxyacyl dehydratase and enoyl reductase 
moieties (Stryer, 1995). 
1.2 DHHC PALMITOYL ACYL-TRANSFERASES 
1.2.1 DISCOVERY OF DHHCS 
It took a long time for the enzymes responsible for in vivo palmitoylation to be identified.  
In vitro palmitoylation assays assessing palmitoyl-CoA incorporation into known palmitoyl-
proteins were clouded by nonenzymatic palmitoylation.  Spontaneous palmitoylation was 
observed on Gαi1, Gαo and Gαz and, at a slower rate, Gαs and Gαq (Duncan and Gilman, 
1996) and in synaptosomal-associated protein of 25 kDa (SNAP-25) when it was bound to 
syntaxin-1 (Veit, 2000).  This also raised the question as to whether enzymes were required 
at all for protein palmitoylation.  Indeed, there is evidence that palmitoylation of the  
S. cerevisiae protein blocked early in transport 3 (Bet3) occurs autocatalytically in vivo.  
Bet3 is palmitoylated nonenzymatically in vitro (Kummel et al., 2010) and structural studies 
performed using Bet3 purified from S. cerevisiae (Turnbull et al., 2005) and overexpressed 
in Escherichia coli (Kim et al., 2005) found it to be palmitoylated at cysteine-68 but that the 
palmitate moiety was submerged in a hydrophobic pocket, orientated inwards.  The finding 
in E. coli is particularly surprising as there is no evidence of bacteria being able to acylate 
proteins and they lack the necessary enzymes.  In addition Bet3 palmitoylation was not 
found to be diminished in any mutant S. cerevisiae strains deficient for PATs (Roth et al., 
2006).  Even after the DHHC group of enzymes was identified as PATs, in vitro 
palmitoylation assays tended to fail due to the poor activity of these transmembrane 
proteins in vitro. 
The first identifications of palmitoylating enzymes were made using similar methods in  
S. cerevisiae and were published more-or-less concurrently.  Palmitoylation of Ras2 had 
been observed to be deficient in strains carrying mutations in the effect on Ras function 2 
(ERF2) (Bartels et al., 1999) and ERF4/suppressor of hyperactive Ras 5 (SHR5) (Jung et al., 
1995) genes.  This was studied further to determine their roles in Ras palmitoylation (Lobo 
et al., 2002).  A strain carrying a mutant form of Ras2 with a polybasic domain instead of a 
farnesylated CaaX motif, which therefore required its palmitoylation for viability, showed 
that both Erf2 and Erf4 were needed for palmitoylation of Ras2.  Palmitoylation of yeast 
casein kinase 2 (Yck2) was investigated in relation to the protein ankyrin repeat-containing 
protein 1 (Akr1) based on the observation that localisation of Yck2 is altered in an akr1Δ 
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strain from the plasma membrane to the cytoplasm (Roth et al., 2002).  Yck2 incorporated 
[3H]-palmitate in wild-type cells but not in akr1Δ cells, and [3H]-palmitate was also 
incorporated into Ras2 providing Erf2 and Erf4 were present.  Mutation of two C-terminal 
cysteine residues of Yck2 to serine abolished this labelling and replicated the mislocalisation 
in wild-type cells.  The only sequence homology shared by Akr1 and Erf2 was in a domain 
containing a motif first described as a potential zinc finger through computational analysis 
of the S. cerevisiae genome (Bohm et al., 1997).  This domain, originally called a NEW1 
domain, contains several conserved cysteine residues and an aspartic acid-histidine-
histidine-cysteine (DHHC) motif.  Both studies tested the importance of this motif.  Mutants 
of the first histidine residue (to alanine) and the conserved cysteine residue (to serine) of 
the DHHC motif of Erf2 were tested (Lobo et al., 2002).  Two similar mutant forms of Akr1 
were also engineered: one with the aspartic acid and first histidine residues mutated to 
alanine and the other with the cysteine residue mutated to alanine (Roth et al., 2002).  
None of these mutants was able to palmitoylate its substrate, and so the DHHC cysteine-
rich domain (DHHC-CRD) was shown to be a defining feature of PATs responsible for  
S-palmitoylation.  This family of PATs is often referred to as the DHHCs. 
The identification of the DHHC-CRD as the unifying motif of the PAT enzymes responsible 
for S-palmitoylation allowed rapid identification of the complete family in some organisms, 
comprising eight putative members in S. cerevisiae (Mitchell et al., 2006) and 23 in Homo 
sapiens (Korycka et al., 2012) and Mus musculus (Fukata and Fukata, 2010).  In addition 
there are certain structural similarities which are found in the DHHCs, such as the presence 
of at least four transmembrane domains (TMDs) with the DHHC-CRD positioned on the 
cytoplasmic face of the membrane, usually between TMD2 and -3 (Fukata and Fukata, 
2010; Kihara et al., 2005; Korycka et al., 2012; Mitchell et al., 2006).  Most of the DHHCs 
appear to be ER- or Golgi-localised (Ohno et al., 2006).  Interestingly the mammalian 
orthologue of Erf2, DHHC9, also requires the orthologue of Erf4/Shr5, Golgi complex-
associated protein of 16 kDa (GCP16), for its palmitoyltransferase activity towards H- and  
N-Ras (Swarthout et al., 2005).  None of the other DHHCs have yet been shown to need an 
accessory protein for function like this, suggesting Erf4/Shr5 and GCP16 are needed more 
for substrate specificity than catalysis.  Whilst the partner protein is required for activity, it 
is Erf2 and DHHC9 which have been shown to be responsible for the palmitate transfer 
(Lobo et al., 2002; Swarthout et al., 2005).  Conversely the mammalian PAT for R-Ras, 
DHHC19, does not have a binding partner for function and is itself prenylated at its CaaX 
motif (Baumgart et al., 2010).  This is an example of how the DHHC enzymes can be 
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particularly specific in some cases, with different Ras family members being palmitoylated 
by different enzymes.  Although individual tissues display individual profiles of DHHC 
expression, many may be present at once.  The messenger RNA (mRNA) of 19 and 18 
DHHCs was detected in human testis and liver respectively (Ohno et al., 2006), and the 
cervical cancer HeLa cell line expresses 20 DHHCs (Lakkaraju et al., 2012).  Similarities and 
differences between DHHCs are discussed further in Chapter 3. 
1.2.2 REACTION MECHANISM 
The studies which identified Erf2/Erf4 and Akr1 as DHHCs using [3H]-palmitate labelling of 
Ras2 and Yck2 respectively also observed labelling of Erf2 and Akr1 themselves (Lobo et al., 
2002; Roth et al., 2002).  Several other DHHCs were also observed to incorporate palmitate, 
including H. sapiens DHHC9 (Swarthout et al., 2005) and DHHC15 (Fukata et al., 2004).  
Initial proteomic scale studies in S. cerevisiae also identified Akr1 as a palmitoyl-protein 
(Roth et al., 2006) and the first mammalian proteomic study found DHHC17/huntingtin-
interacting protein 14 (HIP14) to be palmitoylated (Kang et al., 2008).  These observations 
led to the hypothesis that palmitoylation of substrates proceeded by formation of a 
palmitoyl-enzyme intermediate followed by transfer of palmitate to the substrate.  A 
reaction mechanism of palmitoylation by Erf2 was recently elucidated (Mitchell et al., 
2010).  Generation of deletion mutants showed that only the DHHC-CRD of Erf2 was 
required for autopalmitoylation and palmitoylation of Ras2.  Mutation of any of the 
cysteine residues and some of the histidine residues in the DHHC-CRD were shown to give 
loss-of-function in Erf2 through a complementation assay.  This would account for the high 
conservation of these residues in the DHHC enzymes (see Chapter 3).  Study of the reaction 
kinetics found that palmitoyl-Erf2 is formed within five seconds in burst kinetics consistent 
with one active site per Erf2/Erf4 complex.  In the absence of the substrate, there was 
found to be gradual hydrolysis resulting in release of the palmitate group.  However if Ras2 
was present then its association with the Erf2/Erf4 complex resulted in palmitate transfer 
to the substrate.  The presence of Ras2 also appeared to stimulate Erf2/Erf4 activity.  
Palmitoylation of Ras2 did not occur when the first histidine or the cysteine residue of the 
DHHC motif was mutated, consistent with earlier reports (Lobo et al., 2002; Roth et al., 
2002). 
Thus, the following reaction mechanism is currently proposed (Mitchell et al., 2010).  The 
enzyme undergoes autopalmitoylation with burst kinetics by formation of a thioester to the 
cysteine residue in the DHHC motif, the single catalytic site.  Palmitoyl-CoA undergoes 
nucleophilic attack by the cysteine residue, which is first deprotonated.  This is regulated by 
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one ionisable group with a pKa of 7.2, thought to be the first histidine in the DHHC motif, or 
there may be enough of a change in pH of the microenvironment of the residue to promote 
it directly.  The palmitoyl-enzyme intermediate then either transfers the palmitoyl moiety 
to the substrate or releases it through a reaction with water.  The kinetics of the 
autopalmitoylation step presumably means that the palmitoyl-enzyme is regenerated 
quickly. 
1.3 PALMITOYL-PROTEIN THIOESTERASES 
Palmitoylation is a reversible modification, with depalmitoylation mediated by the PPTs.  
These are understudied compared with the DHHCs and palmitoylated proteins themselves.  
This is partly due to the difficulty in identifying the physiological PPTs for specific proteins 
and the lack of any unifying sequence which can be used to search genomic data for new 
candidates.  The known PPTs were purified based on assays to remove [3H]-palmitate from 
well-known palmitoyl-proteins.  Unlike the integral membrane DHHC proteins, the PPTs are 
soluble.  PPT1 was identified through its ability to depalmitoylate H-Ras, Gαo, Gαi and Gαs in 
vitro (Camp and Hofmann, 1993), although it is localised within lysosomes and, in neurons, 
synaptic vesicles so its physiological substrates are more likely to be secreted or outward-
facing proteins (Camp et al., 1994; Hellsten et al., 1996; Lehtovirta et al., 2001; Verkruyse 
and Hofmann, 1996).  The lysosomal localisation may be important in the role of PPT1 in 
lysosomal storage disorders (Hellsten et al., 1996; Verkruyse and Hofmann, 1996).  
Mutations in PPT1 have been shown to cause the neurodegenerative disease infantile 
neuronal ceroid lipofuscinosis (INCL) (Vesa et al., 1995), which is discussed below.  There is 
evidence that PPT1 contributes to the catabolism of acylated proteins in the lysosome and 
that dysfunction of this pathway is responsible for the build up of lipids inside lysosomes 
found in INCL (Lu et al., 1996).  An analysis of rat tissue expression showed PPT1 is highly 
expressed in the spleen, brain and testes but not in pancreas, lung, muscle tissues, liver or 
kidney (Camp and Hofmann, 1993). 
When PPT1 was originally identified, a sensitivity to diethylpyrocarbonate (DEPC) was 
noted, which is consistent with a catalytic histidine residue (Camp and Hofmann, 1993).  
The catalytic triad of a serine, an aspartate and a histidine residue was later confirmed in a 
crystal structure (Bellizzi et al., 2000) and is common to other members of the PPT enzyme 
family and indeed to thioesterases in general (Calero et al., 2003; Devedjiev et al., 2000).  
PPT1 was shown to be specific to thioesters, being unable to depalmitoylate many 
oxyester-linked substrates, and even to specific thioesters, as it could depalmitoylate 
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palmitoyl-CoA but not palmitoyl-carnitine (Camp and Hofmann, 1993).  An enzyme with 
homology to PPT1 has been named PPT2, although it only appears to be able to remove 
palmitate from palmitoyl-CoA and not palmitoyl-proteins (Calero et al., 2003; Soyombo and 
Hofmann, 1997). 
A separate branch of the PPT family is the acyl-protein thioesterases (APTs).  Interestingly  
S. cerevisiae only has one known PPT enzyme, which is APT1 (Duncan and Gilman, 2002), 
although another yeast, Schizosaccharomyces pombe, does have a PPT1 orthologue (Cho 
and Hofmann, 2004).  APT1 is a cytosolic enzyme which was purified by its depalmitoylation 
of Gαi1 (Duncan and Gilman, 1998).  The enzyme was shown to be specific for 
depalmitoylation as [3H]-myristate was not removed.  APT1 also has lysophospholipase 
activity but was shown to have a strong preference for deacylating proteins.  Other 
substrates demonstrated in this study were Ras and Gαs.  This enzyme is more likely than 
PPT1 to be the main physiological PPT as its cytosolic localisation would give it access to 
more palmitoyl-proteins (Duncan and Gilman, 1998).  Indeed, a study was published soon 
afterwards identifying APT1 as the PPT for endothelial nitric oxide synthase (eNOS) (Yeh et 
al., 1999).  Interestingly, a recent palmitoyl-proteomics study pulled out APT1 as one of its 
hits and its palmitoylation was verified by Western blot and studies using 2-bromopalmitate 
(2-BP), which inhibits palmitoylation by preventing palmitate synthesis (Yang et al., 2010).  
This has potential importance in giving APT1 access to many palmitoylated proteins which 
will be membrane-associated and also gives scope for direct regulation of depalmitoylating 
activity by the palmitoylation machinery.  The other family member, APT2, has been 
identified by homology to APT1.  APT1, but not APT2, has recently been shown to regulate 
the depalmitoylation of large conductance Ca2+-activated K+ (BK) channels, which are 
palmitoylated on their intracellular S0-S1 loop (Tian et al., 2012).  The identification of 
further PPTs and substrates for specific enzymes is an area of the field requiring 
considerable research.  As with phosphatases in phosphorylation and deubiquitinases in 
ubiquitination, knowledge of their workings will provide a much more complete picture of 
palmitoylation. 
1.4 INVESTIGATING PALMITOYLATION 
1.4.1 CLASSICAL STUDIES 
Initial characterisations of palmitoylation usually involved labelling of proteins with  
[3H]-palmitate.  Indeed, the first report of a palmitoylated protein from a virus used this 
method (Schmidt and Schlesinger, 1979), as did the first characterisation of a eukaryotic 
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palmitoyl-protein, the transferrin receptor (Omary and Trowbridge, 1981).  A study 
observing for the first time palmitoylation of the β2 adrenergic receptor using  
[3H]-palmitate showed that mutation of cysteine-341 to glycine abolished palmitoylation 
and had functional consequences, including uncoupling of the receptor from Gs (O'Dowd et 
al., 1989).  An important study examining postsynaptic density protein of 95 kDa (PSD-95) 
found its hydrophobic partitioning in rat brain and CV-1 origin, simian vacuolating virus 40 
transformed (COS) cell membranes was due to its palmitoylation (Topinka and Bredt, 1998).  
The intensity of PSD-95 labelling with [3H]-palmitate was very high, indicating it is a major 
palmitoyl-protein in rat brain.  PSD-95 palmitoylation was also shown to be important for 
its interaction with the K+ channel Kv1.4, uncovering a major functional role for 
palmitoylation at the synapse. 
After the identification of Erf2 and Akr1 as PATs, the main focus of research was to confirm 
the PAT activity of the other DHHC-CRD-containing proteins in S. cerevisiae.  The next DHHC 
to be confirmed was spore wall formation 1 (Swf1) which was shown to palmitoylate 
several soluble N-ethylmaleimide (NEM)-sensitive fusion protein (NSF) attachment protein 
(SNAP) receptor (SNARE) proteins (Valdez-Taubas and Pelham, 2005).  Palmitoylation of the 
synaptobrevin homologue suppressor of the null allele of cyclase-associated protein 1 
(Snc1) was examined using the shift in its mobility on a polyacrylamide gel when palmitate 
is removed using HA.  Snc1 migrated at the unpalmitoylated molecular weight in a swf1Δ 
strain and when its juxtamembrane (and only) cysteine residue was mutated to alanine.  
The syntaxin 8 homologue Syn8 was also shown to be palmitoylated by Swf1 in this way.  A 
different approach was taken for target SNARE (t-SNARE) affecting a late Golgi 
compartment 1 (Tlg1) as the mobility shift was small and labelling with [3H]-palmitate was 
unsuccessful.  Instead, the cell lysate was treated with a biotin construct which selectively 
labels thioreactive groups on unpalmitoylated cysteine residues.  Unpalmitoylated Tlg1 was 
detected in swf1Δ cells but not in wild-type cells.  A complementary experiment detecting 
palmitoylated proteins by blocking free thiols with NEM, treating with HA and labelling the 
revealed thiols, similar to the acyl-biotin exchange (ABE) assay discussed below, detected 
Tlg1 only in the wild-type cells. 
The first demonstration of palmitoyltransferase activity from the S. cerevisiae enzyme 
protein fatty acyltransferase 3 (Pfa3) arose from the observation that stressed pfa3Δ cells 
give a fragmented vacuolar morphology similar to cells lacking vacuole protein 8 (Vac8) 
(Smotrys et al., 2005).  Pfa3 was found to be localised to the vacuolar membrane and 
vacuolar fusion depended upon its catalytic cysteine residue.  Pfa3 could incorporate  
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[3H]-palmitate into Vac8 in vitro and levels of [3H]-palmitoylated Vac8 were reduced by 80% 
in pfa3Δ cells compared with wild-type levels.  A similar screen for phenotypes similar to a 
strain lacking chitin synthase-related 3 (Chs3) found Pfa4 to be responsible for its 
palmitoylation (Lam et al., 2006).  This regulated Chs3 exit from the ER and subsequent 
chitin synthesis. 
As discussed above, the identification of Erf2/Erf4 and Akr1 as PATs in S. cerevisiae was 
conducted by examining incorporation of [3H]-palmitate into Ras2 and Yck2 respectively 
under different conditions (Lobo et al., 2002; Roth et al., 2002), and allowed this 
methodology to be used to investigate broader relationships in palmitoylation.  Shortly 
after the identification of the first DHHCs in S. cerevisiae came studies which examined 
them in a mammalian context.  A total of 23 proteins containing the DHHC-CRD were found 
in the M. musculus genome and were co-expressed in COS-7 cells with the known 
palmitoyl-protein PSD-95 to see which enzymes would promote its palmitoylation (Fukata 
et al., 2004).  They found that DHHC2/reduced expression in metastasis (REAM),  
DHHC3/Golgi-associated DHHC zinc finger-containing protein (GODZ), DHHC7/Sertoli cell 
gene with a zinc finger domain (SERZ), and DHHC15 were responsible for palmitoylating 
PSD-95 and this was blocked in a dose-dependent manner by 2-BP, an inhibitor of palmitate 
synthesis.  The palmitate modification was sensitive to both dithiothreitol (DTT) and HA 
treatment.  An examination of the specificities of the DHHCs responsible for palmitoylating 
PSD-95 using the known palmitoyl-proteins growth associated protein of 43 kDa 
(GAP43/neuromodulin), Lck, SNAP-25b and H-Ras showed distinct but overlapping 
specificities within the mammalian enzymes.  A similar screen in S. cerevisiae using 
overexpression of DHHCs and biotin labelling as in ABE below found several known 
substrates are palmitoylated by many DHHCs.  For example, Vac8 was palmitoylated by 
Akr1, Erf2, Pfa3, Pfa4 and Pfa5 (Hou et al., 2009). 
The effects of palmitoylation on dynamics of association with membranes can be assessed 
using live cell imaging techniques.  A screen of the mammalian DHHC enzymes in HeLa cells 
found that DHHC3/GODZ and DHHC7/SERZ were responsible for palmitoylation of Gα 
subunits in the Golgi (Tsutsumi et al., 2009).  Total internal reflection fluorescence 
microscopy (TIRFM) was used to examine the localisation of Gα subunits to the PM.  As a 
proof-of-principle, inhibition of overall palmitoylation with 2-BP and mutation of the 
palmitoylated cysteine residues to serine abolished membrane localisation of green 
fluorescent protein (GFP)-tagged Gαq whereas Gαq artificially targeted to the PM with a 
polybasic domain was unaffected.  Small inhibiting RNA (siRNA) knockdown of DHHC3 or -7 
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reduced the intensity of GFP fluorescence at the PM indicating reduced Gαq localisation 
there.  A fluorescence recovery after photobleaching (FRAP) approach was also taken.  
Recovery of fluorescence at the Golgi was shown to be dependent on palmitoylation of Gαq 
by use of 2-BP and cycloheximide.  siRNA-mediated knockdown of DHHC3 or -7 resulted in a 
diffuse cytoplasmic localisation of Gαq, showing these enzymes are required for trapping of 
Gαq at the Golgi membrane from which it is trafficked to the PM.  Palmitoylation of Gα 
subunits was also shown to be required for coupling of G-protein coupled receptors to 
downstream effects (Tsutsumi et al., 2009).  This study shows how live cell imaging has the 
potential to elucidate the function of palmitoylation of specific proteins in detail. 
The study of proteins which may undergo rapid palmitate turnover can be facilitated by the 
use of PPT inhibitors to prevent depalmitoylation.  These can provide a complementary 
perturbation to the use of 2-BP, which inhibits palmitate synthesis and therefore the rate of 
palmitoylation.  An example of the use of PPT inhibitors is in the study of H- and N-Ras.  
These normally undergo a cycle of different membrane localisations based on their 
palmitoylation status.  Unpalmitoylated (but always farnesylated) Ras is distributed 
between the cytosol and endomembranes.  Palmitoylation at the Golgi traps Ras there, 
committing it to the bulk-flow exocytotic pathway which traffics it to the PM.  Ras can then 
be removed from the PM by depalmitoylation (Rocks et al., 2005).  A protein structure 
similarity clustering strategy, which compares the tertiary structures of similar proteins, 
was used to design potential selective inhibitors of APT1, resulting in the chemical 
palmostatin B which covalently modifies the active site of both APT1 and -2 (Dekker et al., 
2010; Rusch et al., 2011).  This inhibited depalmitoylation of H- and N-Ras, altering their 
Golgi and PM distribution to endomembranes in general.  This effect was replicated by 
siRNA-mediated knockdown of APT1.  In this way, inhibitors were used to confirm the 
model above.  PPT inhibitors can also be used to study the dynamics of palmitoylation.  A 
recent proteomic study using click chemistry (discussed below) in T cells found the PPT1 
inhibitor hexadecylfluorophosphonate (HDFP) (Martin et al., 2012).  A pulse-chase 
experiment showed proteins with rapid palmitate turnover.  Treatment with HDFP gave a 
time-dependent enhancement of palmitoylation of proteins and, using HDFP as the chase in 
pulse-chase experiments, uncovered a subset of these proteins which were stabilised by 
HDFP but depalmitoylated in control cells.  Among proteins identified as having PPT1-
regulated rapid palmitate turnover were H- and N-Ras and Gαs (Martin et al., 2012). 
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1.4.2 PALMITOYL-PROTEOMICS 
The limitations of classical methods of examining palmitoylation, such as 
immunoprecipitation of the protein in question, and therefore prior knowledge of its likely 
palmitoylation, and the autoradiograph exposure times of weeks to months (Drisdel and 
Green, 2004) led to the development of techniques which could be used on a larger scale 
and with extracts from tissues.  These methods rely on the cleavage of the relatively labile 
thioester bond between cysteine residues and palmitate molecules by neutral HA.  In ABE 
the revealed sulfhydryl groups are labelled with a thioreactive biotin construct followed by 
pulldown on streptavidin- or neutravidin-conjugated beads (Drisdel and Green, 2004; Kang 
et al., 2008; Roth et al., 2006), whereas in acyl-resin-assisted capture (acyl-RAC) they are 
bound directly to thioreactive sepharose (Forrester et al., 2011).  An alternative to these 
cysteine-centric approaches is a palmitate-centric approach relying on metabolic labelling.  
Instead of [3H]-palmitate, the palmitate analogues 17-octadecynoic acid (17-ODYA) (Martin 
and Cravatt, 2009; Martin et al., 2012) or alk-16 (Yount et al., 2010) can be used.  The 
proteins labelled with these reagents are reacted with azide reporters using so-called click 
chemistry (Speers and Cravatt, 2004) allowing overall visualisation by fluorescence in 
polyacrylamide gels and purification for mass spectrometric analysis.  However, this 
method is perhaps best used in cell culture whereas ABE and acyl-RAC enable purification 
of palmitoyl-proteins from any protein mixture, which can be derived from animal tissues.  
The dynamics of palmitoylation are more easily studied by click chemistry methods, for 
example in pulse-chase experiments. 
The power of this proteomic approach was demonstrated in the first two studies to use it.  
An analysis of S. cerevisiae using ABE found 47 palmitoyl-proteins, including 12 of the 15 
known at the time (Table 1.1) (Roth et al., 2006).  This unbiased approach could therefore 
rapidly identify many more palmitoyl-proteins than classical methods.  An analysis of rat 
embryonic neurons soon afterwards found 50 known palmitoyl-proteins and 113 novel 
candidates (Kang et al., 2008).  21 of these candidates were confirmed by [3H]-palmitate 
labelling, which remains the gold standard for verifying new palmitoyl-proteins from such 
studies.  The number of organisms, tissues and cell lines which have been subjected to 
proteomic analysis is rising as the field gains momentum (Table 1.1).  Part of the value of 
this approach is that it may prompt researchers to consider the effects of palmitoylation on 
their protein of interest. 
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Study Method Source material No. hits Notes 
(Roth et al., 2006) ABE Saccharomyces 
cerevisiae 
47  
(Kang et al., 2008) ABE rat cultured 
embryonic neurons 
and synaptosomes 
163  
(Zhang et al., 2008) PICA HeLa cells 50 probed DHHC2 substrates 
(Martin and Cravatt, 2009) click chemistry: 
17-ODYA 
Jurkat T cells 125  
(Yang et al., 2010) ABE, PalmPISC DU145 human 
prostate cancer cells 
169 408 total hits from lipid rafts; 
112 from rest of membrane; 
273 in common 
(Yount et al., 2010) click chemistry: 
alk-16 
mouse D2.4 
dendritic cells 
60  
(Dowal et al., 2011) ABE, PalmPISC human platelets 215  
(Merrick et al., 2011) ABE RAW 264.7 
macrophages 
80  
(Forrester et al., 2011) acyl-RAC bovine brain 
membranes and 
HEK293 cells 
88 site-specific analysis 
(Martin et al., 2012) click chemistry: 
17-ODYA 
mouse T cell 
hybridomas 
415 coupled to SILAC; PPT inhibitors 
used to study dynamics 
(Ivaldi et al., 2012) ABE human B 
lymphocytes 
95  
(Marin et al., 2012) ABE human EA.hy 926 
endothelial cells 
184  
(Hemsley et al., 2012) ABE Arabidopsis thaliana 581  
TABLE 1.1: Findings from published palmitoyl-proteomic analyses 
All published palmitoyl-proteomic studies to date are listed along with the method used, source 
material and number of high confidence palmitoyl-proteins identified.  17-ODYA, 17-octadecynoic 
acid; ABE, acyl-biotin exchange; acyl-RAC, acyl-resin-assisted capture; PalmPISC, palmitoyl protein 
identification and site characterisation; PICA, palmitoyl-cysteine isolation capture and analysis; PPT, 
palmitoyl-protein thioesterase; SILAC, stable isotope labelling of amino acids in cell culture.
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1.4.3 PALMITOYLATION SITES 
Palmitoylation of eukaryotic proteins has been known for nearly 30 years (Magee and 
Courtneidge, 1985) but there remains a lack of a consensus motif for determining which 
cysteine residues will be palmitoylated and which will not.  This is in contrast to the specific 
consensus for myristoylation of MGXXX(S/C/T) and which is mediated by only two 
vertebrate myristoyltransferases, and the CaaX motif for prenylation by farnesyltransferase 
or geranylgeranyltransferase.  It has been hypothesised that this very lack of a consensus 
for palmitoylation may be the reason for having such a relatively large number of PATs 
(Greaves et al., 2009).  Nonetheless there are some programs which use previously 
gathered information on palmitoylation sites to try to predict potential palmitoylation sites 
from a primary amino acid sequence.  One such program is clustering and scoring strategy 
(CSS)-palm (http://csspalm.biocuckoo.org/) (Ren et al., 2008), which has recently been 
updated to version 3.0.  This uses a manually curated set of 439 palmitoylation sites on 194 
proteins as its source.  Another program called composition of k-spaced amino acid pairs 
(CKSAAP)-palm uses a different algorithm which appears to detect some types of palmitoyl-
protein which CSS-palm does not (http://doc.aporc.org/wiki/CKSAAP-Palm) (Wang et al., 
2009).  Whilst these pieces of software may be useful for finding potential palmitoylation 
sites in proteins, they are no substitute for finding or confirming the relevant sites 
experimentally. 
The most common way to identify the palmitoylated cysteine residues in a protein is a 
protein-centric approach.  Usually palmitoylation of a protein has been confirmed by  
[3H]-palmitate incorporation.  The use of truncations can be used to refine which region 
contains the palmitoylated residue(s) and abolition of [3H]-palmitate labelling after 
mutation of the candidate cysteine(s) to alanine or serine, which cannot be palmitoylated, 
confirms the site.  This method has been used to identify palmitoylated residues on many 
proteins.  Examples of this approach include the discovery of palmitoylation of cysteine-181 
and -184 in H-Ras and cysteine-181 in N-Ras (Hancock et al., 1989), PSD-95 on cysteine-3 
and -5 (Topinka and Bredt, 1998), and cysteine-3 in Gαo (Parenti et al., 1993). 
With the advent of proteomic techniques for assessing protein palmitoylation, some groups 
have modified these methods to try to identify not only the proteins but also their 
palmitoylation sites at the same time.  The first to adopt this kind of approach was a 
technique dubbed palmitoyl-cysteine isolation capture and analysis (PICA) (Zhang et al., 
2008).  The principle of this assay is labelling of formerly palmitoylated sites with heavy or 
light isotope coded affinity tag (ICAT) reagents, digestion with trypsin and mass 
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spectrometric analysis.  The differences in mass allowed identification of cytoskeleton-
associated protein 4 (CKAP4/p63) as a substrate for DHHC2, which palmitoylates it on 
cysteine-100.  A technique called palmitoyl protein identification and site characterisation 
(PalmPISC) used a similar principle by treating two samples to label both chemically on 
palmitoylation sites.  The chemical was eluted in one sample and the mass shift used to 
identify the palmitoylation site in a mass spectrometric analysis.  PalmPISC was used to 
detect 143 putative palmitoylation sites in samples from lipid raft and non-raft membrane 
subdomains (Yang et al., 2010) and 103 putative palmitoyl-proteins in platelets (Dowal et 
al., 2011).  The most recently published method, acyl-RAC, also assessed palmitoylation 
sites by omitting the elution step and digesting the proteins on the resin.  Comparison of 
the heavy-labelled experimental sample with the light-labelled control allowed 
identification of palmitoylated cysteine residues on 84 peptides from HEK293 cells 
(Forrester et al., 2011).  Novel palmitoylation sites on ribosomal protein S11 (Rps11), the 
secretory pathway protein Sec61b and microsomal glutathione S-transferase 3 (MGST3) 
were validated by comparison of wild-type and cysteine-to-serine mutations.  Proteomic 
scale techniques such as these offer a promising way to generate new leads in discovery of 
palmitoylation sites. 
In an attempt to classify DHHCs based on their preferences for certain types of substrate, 
an assay system was developed by expressing the H. sapiens DHHCs in S. cerevisiae (Ohno 
et al., 2012).  The types of proteins which are palmitoylated can be roughly grouped into 
categories based on their properties or the location of the palmitoylated cysteine residue(s) 
(Table 1.2) (Ohno et al., 2012; Resh, 1999; Roth et al., 2006).  Model substrates 
representing each of these groups were Myc-tagged and co-expressed with FLAG-tagged  
S. cerevisiae or H. sapiens DHHC proteins in S. cerevisiae strains optimised so each substrate 
underwent no background palmitoylation.  The enzymes which palmitoylated each model 
substrate are shown in Table 1.2.  There were some DHHCs which were not observed to 
palmitoylate any of the model substrates or sometimes even to form palmitoyl-enzyme 
intermediates.  The authors attributed this to the possible specificity of these enzymes to 
substrates not used in this system – for example DHHC6 has been previously shown to 
palmitoylate calnexin on two cysteine residues adjacent to its single transmembrane 
domain (TMD) (Lakkaraju et al., 2012) but did not palmitoylate the model substrate of this 
category, S. cerevisiae suppressor of Sec one (Sso1).  This system has promise as a way of 
assessing the broad specificities of the DHHC families of other organisms and may be 
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Region Example substrate 
Example DHHCs (Ohno et al., 2012) 
S. cerevisiae H. sapiens 
N-terminal region of 
soluble proteins 
PSD-95: Cys-3 and Cys-5 
(Topinka and Bredt, 1998) 
Akr1, Pfa4, 
Pfa5 
DHHC2, 3, 7, 8, 15, 17 
C-terminal region of 
soluble proteins 
Yck1: two Cys residues at the extreme 
C-terminus (Roth et al., 2002) 
Akr1, Pfa3, 
Pfa4, Pfa5 
DHHC2, 3, 5, 6, 7, 8, 9, 11, 
14, 15, 17, 18, 20, 21 
internal regions of 
soluble proteins 
SNAP-25b: Cys-85, Cys-88, Cys-90, 
Cys-92 (Lane and Liu, 1997) 
 DHHC3, 7, 17 
dually lipidated proteins: 
near N-myristoylation or 
C-terminal prenylation 
Gpa2: N-terminally myristoylated 
(Harashima and Heitman, 2005) 
Akr1, Erf2, 
Pfa3, Pfa5 
DHHC1, 2, 3, 5, 6, 7, 8, 9, 11, 
12, 14, 15, 17, 18, 20, 21 
cytosolic region adjacent to the 
TMD of singly membrane-
spanning proteins 
Sso1 (Roth et al., 2006) Pfa3, Swf1 DHHC2, 20 
cytosolic regions adjacent to a 
TMD in multiply membrane-
spanning proteins 
Agp1 (Roth et al., 2006) Pfa4 DHHC2, 3, 7, 11, 15, 20, 21 
TABLE 1.2: Grouping of palmitoylated proteins by site of palmitoylation 
Palmitoylated proteins can be grouped based on commonalities in the location of the palmitoylated 
residue(s).  The example substrates and enzymes able to palmitoylate them are shown (Ohno et al., 
2012).  N.B. The gene-based nomenclature for the H. sapiens DHHCs is used here for consistency 
with the rest of the thesis.  An alternative protein nomenclature is used in (Ohno et al., 2012).  Agp, 
high affinity glutamine permease; Akr, ankyrin repeat-containing; Erf, effect on Ras function; Gpa,  
G protein α subunit; Pfa, protein fatty acyltransferase; PSD, postsynaptic density; SNAP-25, 
synaptosomal protein of 25 kDa; Sso, suppressor of Sec one; Swf, spore wall formation; TMD, 
transmembrane domain; Yck, yeast casein kinase.  
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improved by including another model substrate in each group to try to eliminate false 
negatives. 
1.5 FUNCTIONS OF PALMITOYLATION 
1.5.1 MEMBRANE TARGETING 
The classical function of lipid modifications of proteins is to mediate attachment of soluble 
proteins to cellular membranes.  This is also the case for palmitoylation, which can also 
occur on TMD-containing proteins and may regulate their association with different 
subcellular membranes.  Data on many of the palmitoyl-proteins from S. cerevisiae would 
support the role of palmitoylation in membrane targeting.  Erf2 with Erf4/Shr5 was 
responsible for proper membrane attachment and function of Ras2 (Lobo et al., 2002).  
Mislocalisation of Yck2 is seen in akr1Δ mutants (Roth et al., 2002).  Swf1 was observed to 
prevent ubiquitination and subsequent degradation of Tlg1 by transmembrane ubiquitin 
ligase 1 (Tul1), maintaining its proper localisation to the trans-Golgi network and ER 
(Valdez-Taubas and Pelham, 2005).  Pfa3 is responsible for palmitoylation of the vacuole 
protein Vac8, and disruption of this event leads to a vacuole fractionation phenotype 
(Smotrys et al., 2005).  Palmitoylation by Pfa4 is necessary for the exit of Chs3 from the ER 
and therefore its correct trafficking (Lam et al., 2006).  Well-studied examples in mammals 
are the palmitoylation-dependent localisation of Ras, discussed above (Rocks et al., 2005), 
and of PSD-95 and its regulation of cell surface levels of α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) receptors (El-Husseini Ael et al., 2002; Fukata et al., 2004; 
Topinka and Bredt, 1998).  In some cases, expression of DHHCs on specific endomembranes 
may serve to tether proteins there, as may happen with Pfa3 and Vac8 at the vacuole.  
Some of the Golgi-based DHHCs have a much broader substrate specificity, such as 
DHHC2/REAM, -3/GODZ and -17/HIP14 (Ohno et al., 2006), and may serve to palmitoylate 
proteins more generally in trafficking pathways. 
One of the interesting questions in palmitoylation research is why TMD-containing proteins 
would be palmitoylated.  One of the possibilities which has been proposed is the resolution 
of hydrophobic mismatching (Charollais and Van Der Goot, 2009; Greaves et al., 2009).  
Membrane systems within the cell differ in their thickness due to their particular 
composition of protein and lipid components.  For example, a study in rat polarised 
hepatocytes reported membrane thicknesses of 42.5 Å and 35.6 Å for the apical and 
basolateral PM respectively, 39.5 Å for the Golgi and 37.5 Å for the ER (Mitra et al., 2004).  
This means that a TMD which is the right length for the thickness of one membrane system 
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may not be for another.  If the TMD is too short, there is a negative mismatch; if it is too 
long there is a positive mismatch (Figure 1.2).  An example of a protein affected by this is 
lipoprotein receptor-related protein 6 (LRP6), which traffics from the ER to the PM and 
whose palmitoylation on a juxtamembrane cysteine residue is required for exit from the ER 
(Abrami et al., 2008).  Shortening of the 23 residue TMD by two amino acids allowed an 
unpalmitoylatable LRP6 mutant to traffic to the PM.  Given this corresponds to a reduction 
in TMD length by roughly the same proportion as the difference between the apical PM and 
ER membrane thicknesses, this suggests that palmitoylation allows resolution of what 
would otherwise be a positive hydrophobic mismatch at the ER membrane.  A study in 
model membranes suggested that palmitoylation could accommodate a positive mismatch 
by allowing the TMD to tilt in the membrane (Figure 1.2B) (Abrami et al., 2008; Joseph and 
Nagaraj, 1995).  This may then induce a negative hydrophobic mismatch for LRP6 once it 
has reached the PM.  This new mismatch could be resolved by depalmitoylation by a PPT 
enzyme, or possibly by some physical alternatives to accommodate the palmitate group 
which have been suggested (Greaves et al., 2009): palmitoylated LRP6 may segregate into a 
relatively disordered membrane subdomain; it may be associated with another protein 
which stabilises its membrane configuration; a relatively ordered membrane subdomain 
may prevent TMD tilting; or hydrophobic forces within the membrane may dominate and 
palmitoylation only contributes when there is a mismatch and subsequent TMD 
destabilisation. 
Negative hydrophobic mismatches could be resolved by palmitoylating a juxtamembrane 
cysteine residue to increase the effective TMD length (Figure 1.2A).  Palmitoylation may 
also allow transmembrane proteins to associate with more ordered lipid microdomains 
(Figure 1.2C) (Uittenbogaard and Smart, 2000).  This can result from TMDs containing 
residues with a large number of bulky side groups, such as aromatic rings, which tend to 
associate preferentially with disordered membrane subdomains.  Palmitoylation of a 
juxtamembrane cysteine in these circumstances allow the TMD to localise in more ordered 
subdomains.  A proteome scale study which examined palmitoyl-protein abundance in lipid 
rafts in human prostate cancer cells found a subset localised to lipid raft fractions, although 
more were found in non-raft fractions (Yang et al., 2010). 
1.5.2 PALMITATE TURNOVER 
Palmitoylation has the distinguishing feature of being a reversible process, unique among 
the lipid modifications of proteins.  As such, some studies have looked at the implications of 
palmitoylation and depalmitoylation cycles beyond simple targeting to different 
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FIGURE 1.2: Resolution of hydrophobic mismatching by palmitoylation 
Hydrophobic mismatching occurs when the length of a TMD is different from the thickness of the 
membrane in which it resides.  This can be resolved by palmitoylation (red line) of a juxtamembrane 
cysteine residue on the cytosolic side of the membrane.  (A) A negative hydrophobic mismatch 
occurs when the TMD is too short.  Palmitoylation increases the effective hydrophobic length of the 
TMD.  (B) A positive hydrophobic mismatch occurs when the TMD is too long.  Palmitoylation 
induces a tilt in the TMD to accommodate it in the membrane.  (C) TMDs with many bulky side 
groups preferentially associate with more disordered regions of the membrane.  Palmitoylation can 
alter this preference and allow association with more ordered subdomains.  C, cysteine residue; 
TMD, transmembrane domain.  
A
C
negative mismatch increased
hydrophobic length
B
positive mismatch TMD tilting
ordered subdomain
C
disordered subdomain
C
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membranes.  One of the classic examples is palmitate turnover on the important signalling 
molecule Gαs.  [3H]-palmitate labelling showed that palmitoylated Gαs is present solely in 
the particulate (i.e. membrane-bound) fraction of S49 cyc- mouse lymphoma cells 
expressing haemagglutinin (HA)-tagged Gαs (Wedegaertner and Bourne, 1994).  In contrast, 
Gαs carrying the activating mutation R201C exhibited considerably less palmitoylation and 
was almost entirely present in the soluble fraction.  Pulse-chase experiments showed  
[3H]-palmitate on activated Gαs had a half-life of about two minutes, compared with 90 
minutes in the wild-type protein.  This was consistent with results from an experiment 
using isoproterenol, a β-adrenoreceptor agonist, which showed near-maximal palmitate 
incorporation within five minutes of treatment and a half-life of about two minutes.  This 
was a result of receptor activation rather than a downstream effect, as the stimulation of 
cAMP production by forskolin had no effect on palmitate turnover.  In addition, another Gαs 
mutant G226A, which cannot dissociate from the βγ subunit, abolished the effect of 
isoproterenol on palmitate turnover.  This study was intriguing because it gave a possible 
mechanism of desensitisation of this signaling pathway mediated by the G protein itself 
rather than the receptor.  As receptors are activated by agonists, the α subunit dissociates 
from the βγ subunit which allows it to be depalmitoylated, presumably by APT1 (Duncan 
and Gilman, 1998).  Receptor activation also stimulates palmitoylation of Gαs, which would 
make it available to receptors, and this step is potentially open to regulation from other 
signals which may affect the activity of PATs. 
Another key study on the importance of dynamic palmitoylation examined its role on  
PSD-95 (El-Husseini Ael et al., 2002).  Treatment of cultured DIV 14 hippocampal neurons 
with the palmitate synthesis inhibitor 2-BP reduced PSD-95 palmitoylation and shifted a 
proportion of it into the soluble fraction.  In addition, synaptic clusters of both PSD-95 and 
the related protein PSD-93 were dispersed with 2-BP treatment.  Pharmacological blockade 
of glutamate receptors with kynurenic acid (targeting ionotropic receptors), 6-cyano-7-
nitroquinoxaline-2,3-dione (CNQX) (AMPA receptors) or 2-amino-5-phosphonovalerate 
(APV) (N-methyl-D-aspartate (NMDA) receptors) prevented this effect.  Removal of 
extracellular Ca2+ also reversed 2-BP-induced declustering, suggesting Ca2+ entry may be 
involved.  The normal half-life of palmitate on PSD-95 was found to be approximately two 
hours, which increased to four hours upon treatment with kynurenic acid.  This regulation 
of PSD-95 was shown to have an effect on synaptic responsivity, as AMPA receptor GluR1 
subunit clustering was also reduced by 2-BP treatment, with a concurrent reduction in both 
amplitude and frequency of miniature excitatory postsynaptic currents (mEPSCs).  Thus 
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palmitoylation can have an effect on synaptic strength through regulation of clustering of 
postsynaptic receptor subunits.  Interestingly, a recent study shows that the palmitoylated 
cysteine residues in PSD-95, Cys-3 and -5, are also sites of S-nitrosylation.  2-BP treatment 
was shown to increase nitrosylation of these residues, raising the possibility of competing 
modifications providing a fine-tuning mechanism on PSD-95 function (Ho et al., 2011). 
Different palmitoyl-proteins undergo different dynamics of depalmitoylation.  To 
investigate this, cultured neurons were treated with 2-BP for five hours and a proteomic 
analysis was performed (Kang et al., 2008).  If there is rapid turnover of palmitate on a 
protein, it will be depalmitoylated but then cannot be repalmitoylated, so should disappear 
from the list of palmitoyl-proteins when compared with untreated neurons.  On the other 
hand, proteins undergoing little or no palmitate turnover will remain palmitoylated and 
therefore still be detected.  This analysis showed that PSD-95, Ras isoforms, RhoA and -B, 
cell division cycle 42 (Cdc42) and syntaxin 1b are subject to rapid palmitate turnover; 
SNAP25, syntaptotagmin 1, secretory carrier membrane protein 1 (Scamp1), glucose 
transporter type 1 (GluT-1) and calnexin were stably palmitoylated (Kang et al., 2008).  To 
investigate whether palmitoylation dynamics could play a part in physiological and 
pathophysiological situations, the same analysis was performed after treating the neurons 
with glutamate, an excitatory neurotransmitter, and kainate, which promotes seizure-like 
activity.  The general trend in these situations was in opposite directions.  For example, 
glutamate decreased levels of palmitate on PSD-95, Ras and Cdc42, whereas kainate 
increased palmitoylation of these proteins (Kang et al., 2008). 
1.5.3 DISEASE ASSOCIATIONS 
A number of links have been demonstrated between palmitoylation and various disease 
states.  Some of the DHHC enzymes have been directly implicated in disease association 
studies.  The region containing the ZDHHC2/REAM gene contains potential tumour 
suppressor genes (Qin, 2002) and mutations in it are linked with different cancers (Oyama 
et al., 2000).  ZDHHC9 is upregulated in colon cancer (Mansilla et al., 2007) and ZDHHC20 is 
overexpressed in many types of cancer (Draper and Smith, 2010).  In addition ZDHHC14 has 
been identified as a possible oncogene in diffuse B cell lymphomas and post-transplant 
lymphoproliferative disorders (Rinaldi et al., 2006) and gain of function of ZDHHC11 is 
associated with bladder cancer (Yamamoto et al., 2007).  Knockdown of DHHC8 by siRNA in 
a mouse mesothelioma model has recently been shown to enhance sensitivity to X-rays to 
suppress proliferation (Sudo et al., 2012).  Overexpression of ZDHHC20 has also been 
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shown to enhance cellular transformation, a hallmark of tumour formation (Draper and 
Smith, 2010). 
Associations have been found between X-linked mental retardation (XLMR) and both the 
ZDHHC9 (Raymond et al., 2007) and ZDHHC15 genes (Mansouri et al., 2005).  There is also a 
tentative link between the ZDHHC8 gene and schizophrenia.  This is controversial, having 
been found in some studies (Chen et al., 2004; Mukai et al., 2004; Shin et al., 2010) but not 
others (Faul et al., 2005; Glaser et al., 2005; Otani et al., 2005; Xu et al., 2010) and remains 
to be resolved. 
There are implications of a strong role of aberrant palmitoylation in neurodegenerative 
diseases.  Many proteins known to be involved in such conditions are substrates of DHHC 
enzymes.  AMPA receptor subunits, palmitoylated by DHHC3/GODZ and DHHC17/HIP14 and 
NMDA receptor subunits, palmitoylated by DHHC3/GODZ (Hayashi et al., 2009; Huang et 
al., 2009), are both involved in glutamate-induced excitotoxicity.  The enzyme β-site 
amyloid precursor protein-cleaving enzyme 1 (BACE1), which is associated with Alzheimer’s 
disease (AD) is palmitoylated by DHHC3/GODZ, -4, -7/SERZ, and -15 (Vetrivel et al., 2009).  
Huntingtin (Htt), the protein involved in Huntington’s disease (HD), is palmitoylated by 
DHHC13/HIP14-like (HIP14L) and DHHC17/HIP14 (Huang et al., 2009).  The strength of the 
interaction between DHHC17/HIP14 and Htt is inversely correlated with the length of the 
polyglutamine repeat region (Singaraja et al., 2002) and knockout mice for both 
DHHC17/HIP14 (Singaraja et al., 2011) and DHHC13/HIP14L (Sutton et al., 2012) display 
symptoms similar to a mouse model of HD, suggesting a prominent role of palmitoylation in 
its pathogenesis. 
A group of neurodegenerative disorders in which palmitoylation appears to play a 
particularly prominent role is the neuronal ceroid lipofuscinoses, or Batten disease.  This is 
a group of lysosomal storage disorders related to different genes which is characterised by 
an autofluorescent storage material which gradually accumulates over time (Cooper, 2010).  
The gene associated with the earliest-onset form, INCL, is PPT1 (Vesa et al., 1995).  This is a 
lysosomal enzyme, which fits in with the broad grouping of lysosomal storage disorders.  
There are a number of different mutations which can result in lack of mRNA expression, a 
distorted palmitate binding pocket or lack of enzymatic activity (Das et al., 2001).  
Dysfunctional PPT1 may contribute to the lysosomal pathology of INCL by allowing build-up 
of lipids in lysosomes (Lu et al., 1996).  Disruption of either PPT1 or PPT2 in mice causes 
neuronal ceroid lipofuscinosis-like symptoms (Gupta et al., 2001).  A knockout mouse for 
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Ppt1 has been made and showed a progressive synaptic pathology with loss of SNAP25 
immunoreactivity correlating with neuron loss in some brain regions and globular 
synaptobrevin aggregates around surviving neurons (Bible et al., 2004; Kielar et al., 2009).  
There was also very high expression of the inflammatory protein C-C motif chemokine 3 
(Ccl3)/macrophage inflammatory protein 1α (MIP-1α) in the thalamus suggesting an 
increased inflammatory response which may cause or be a response to the neuronal loss 
(Kielar et al., 2009).  S. cerevisiae does not have a homologue of PPT1, but the yeast  
S. pombe requires its PPT1 homologue for viability and the knockout can be rescued with 
human PPT1 (Cho and Hofmann, 2004).  Rescue of the lethal phenotype with mutant PPT1 
constructs gave phenotypes similar to lysosomal storage disorders, such as sensitivity to 
high extracellular pH (Cho and Hofmann, 2004).  D. melanogaster Ppt1 is also required for 
development and mutants show similar pathologies to INCL, including accumulation of an 
abnormal storage material and reduced lifespan (Buff et al., 2007; Chu-LaGraff et al., 2010; 
Hickey et al., 2006; Korey and MacDonald, 2003; Saja et al., 2010).  Caenorhabditis elegans 
ppt-1 mutants, however, show only a mild mitochondrial defect, suggesting other 
important contributing factors to INCL pathology may not be present in this model 
organism (Porter et al., 2005). 
Another neuronal ceroid lipofuscinosis, an adult-onset variant (ANCL) has recently been 
linked to mutations in the gene encoding cysteine string protein (CSP) (Benitez et al., 2011; 
Noskova et al., 2011; Velinov et al., 2012), a protein which has the most known 
palmitoylated cysteine residues (Gundersen et al., 1994).  Mutants of CSP show a 
neurodegenerative phenotype both in mice (Fernandez-Chacon et al., 2004) and in  
D. melanogaster (Zinsmaier et al., 1994).  In addition, palmitoylation of D. melanogaster 
CSP by its palmitoyltransferase Hip14 was shown to target it to synaptic vesicles and was 
required for synaptic functionality (Ohyama et al., 2007).  In H. sapiens, CSP is also 
palmitoylated by DHHC17/HIP14 among other DHHCs (Greaves et al., 2008), giving a 
possible role for its palmitoylation in ANCL. 
1.6 MODEL ORGANISMS 
The use of model organisms has been instrumental in the study of palmitoylation.  The 
relatively simple organism S. cerevisiae was used to identify the first confirmed PATs and 
through their common DHHC-CRD opened the study of similar enzymes in other organisms 
(Lobo et al., 2002; Roth et al., 2002).  There have been relatively few studies in  
D. melanogaster (Bannan et al., 2008), but the importance of CSP and SNAP-25 
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palmitoylation by Hip14 in synaptic transmission has been elucidated (Ohyama et al., 2007; 
Stowers and Isacoff, 2007).  CSP had previously been shown to be an important protein as 
its mutation induced paralysis and shortened survival times (Zinsmaier et al., 1994).  Hip14 
was also shown to be important for the correct membrane localisation and secretion of 
short gastrulation (Sog) (Kang and Bier, 2010).  A D. melanogaster model of INCL has also 
been made by mutating the Ppt1 gene and reproduces the progressive neurodegeneration 
of the disease (Buff et al., 2007; Chu-LaGraff et al., 2010; Glaser et al., 2003; Hickey et al., 
2006; Korey and MacDonald, 2003).  Studies in knockout mice have also informed about the 
physiological roles of some of the enzymes involved in palmitoylation.  The knockouts of 
the DHHCs HIP14 and HIP14L show pathological features similar to a mouse model of HD, 
for example (Singaraja et al., 2011; Sutton et al., 2012; Young et al., 2012).  The mouse 
knockouts of PPT1 (Bible et al., 2004; Gupta et al., 2001; Kielar et al., 2009) and PPT2 
(Gupta et al., 2001; Gupta et al., 2003) have replicated the phenotype of INCL and given 
clues as to the potential mechanisms of neurodegeneration in this disorder. 
1.6.1 C. ELEGANS 
A useful model organism whose use has been neglected so far in palmitoylation research is 
the nematode worm, Caenorhabditis elegans.  C. elegans is a simple eukaryotic organism 
whose ease of genetic manipulation makes it ideal for screening mutations of genes with 
linked function (Brenner, 1974).  Originally this was phenotype driven, performed by 
looking for common phenotypes in animals exposed to a mutagen.  The publication of the 
C. elegans genome, the first of a multicellular animal (C. elegans Sequencing Consortium, 
1998), allowed such screens to be performed based on genes belonging to the same 
biochemical families as well. 
C. elegans was first isolated as a free-living organism in soil which feeds on bacteria and can 
be cheaply and conveniently cultured in the laboratory (Brenner, 1974).  They are mostly 
hermaphrodites which self-fertilise and give rise to genetically identical progeny, making 
maintenance of strains containing mutant alleles particularly easy.  Males do occur 
spontaneously at a proportion of roughly one male per 5000 hermaphrodites and offer a 
way to introduce new alleles by crossing (Fay).  Both the hermaphrodite and male cell 
lineages have been precisely mapped, with hermaphrodites having 810 somatic cells and 
males 970 (Sulston and Horvitz, 1977).  Mutants can often result in behavioural phenotypes 
which can be readily scored against wild-type behaviour, such as unco-ordinated 
locomotion (Unc) or mechanosensation defective (Mec).  Rescue or modulation of these 
phenotypes with other mutants can give insights into the function of the proteins involved.  
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Similarly, related or highly similar phenotypes can give evidence for proteins which are 
involved in the same pathway or cellular process. 
Studies using mutant animals can be complemented by using RNA interference (RNAi), 
which was originally developed in C. elegans.  Some genes are required for viability so RNAi 
can also be used to probe the function of these genes, as surviving animals by definition 
have high enough expression for viability but not necessarily for normal function.  The RNAi 
concept originated from the observation of reduced expression of a herpes simplex virus 
gene in a mouse cell line when complementary antisense transcripts were injected (Izant 
and Weintraub, 1984).  This was further developed in C. elegans with the design of 
antisense RNAs against the unc-22 and unc-54 genes.  Injection of these constructs into the 
gonads of adult wild-type hermaphrodites induced a phenotype similar to the mutants of 
those genes in their progeny (Fire et al., 1991).  Its utility as a tool for quickly reducing gene 
expression in vivo was enhanced by the discovery that use of double-stranded RNA (dsRNA) 
increases efficacy by an order of magnitude (Fire et al., 1998).  RNAi in C. elegans has 
become particularly easy to perform with the development of protocols which enable 
feeding of bacteria expressing dsRNAs to the animals rather than having to inject them with 
the constructs (Timmons et al., 2001).  This is made possible by the ability of the gut to 
absorb the dsRNAs which are then distributed to most other tissues (Fischer, 2010) 
although some tissues, such as most neurons, are refractory to RNAi (Asikainen et al., 
2005).  Libraries of bacteria carrying vectors expressing dsRNA directed against the majority 
of the predicted and confirmed genes in C. elegans have been constructed (Kamath et al., 
2001).  The use of RNAi gives a relatively easy method of disrupting gene function without 
having to produce and validate mutant strains.  Results obtained through RNAi can also 
complement those from mutant strains, giving higher confidence that the phenotypes 
observed are not due to secondary mutations arising from the mutagenesis procedure. 
Studies on palmitoylation in C. elegans have been rare.  An attempt to create a model of 
INCL by characterising ppt-1 mutants had mixed success.  At a cellular level only a mild 
mitochondrial defect was observed, not as severe as INCL models in other organisms.  The 
ability of the group to perform many behavioural and phenotypic analyses on the animals is 
an example of how mutant strains can be quickly characterised.  Some mild phenotypes 
were found, including a delay in the moult from the final larval stage to adult animals and in 
onset of egg-laying behaviour, but not in brood size or lifespan (Porter et al., 2005).  Only 
one of the DHHC enzymes in C. elegans, spermatogenesis deficient 10 (SPE-10), has been 
studied.  However these studies mainly occurred before the identification of its DHHC-CRD 
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and focused on a defect in fusion of an organelle with the PM which affected 
spermatogenesis (Gleason et al., 2006; Shakes and Ward, 1989).  This strain also showed 
increased stress resistance and an increase in maximum lifespan (Cypser and Johnson, 
1999). 
The lack of other studies investigating palmitoylation in this important and useful model 
organism is surely unjustified.  C. elegans has the advantage of being a simple multicellular 
organism in which many fundamental processes are conserved with higher mammals, such 
as neurotransmission.  This means it combines many of the advantages of unicellular 
organisms and higher organisms.  The relatively easy genetics allows screens of mutations 
in whole gene families to be performed easily when compared with the expense and time 
involved in creating rodent knockouts and models, whilst still maintaining relevance to 
similar pathways in higher organisms.  The application of RNAi in this organism, both 
against individual genes and combinations also allows rapid screening of many genes which 
may only be possible in a similar way in mammals by use of cell lines.  Data obtained from 
experiments using C. elegans will complement those already obtained in S. cerevisiae and 
D. melanogaster and help inform further studies in the mammalian context. 
1.7 AIMS AND OBJECTIVES 
Since the discovery a decade ago of the first enzymes responsible for palmitoylating 
proteins, the field of palmitoylation has gradually gained pace, helped by the identification 
of the DHHC-CRD as their characteristic feature.  The study of specific enzyme-substrate 
interactions was mainly restricted to S. cerevisiae and mammalian cell lines.  The 
development of proteomic scale technology has allowed candidate palmitoyl-proteins to be 
found in an ever-increasing number of different cell lines, tissues and organisms.  However, 
the model organism C. elegans has yet to have any such analyses performed on it.  This 
thesis aims to address this gap in palmitoylation research with the following objectives: 
1. To determine the enzymes involved in palmitoylation in C. elegans and their 
phylogenetic relationships through in silico resources and predict potential 
interactions and phenotypes using data from other organisms. 
2. To use mutants and RNAi to disrupt each C. elegans enzyme in order to uncover 
resulting phenotypes. 
3. To adapt the ABE and acyl-RAC proteomic approaches for use with C. elegans and 
thereby produce the first palmitoyl-proteome of a whole multicellular organism. 
  
 
Chapter 2: 
MATERIALS AND METHODS
CHAPTER 2: MATERIALS AND METHODS 
32 
 
2.1 MATERIALS 
2.1.1 REAGENTS 
All chemicals and primers were obtained from Sigma (Dorset, UK) unless otherwise 
specified. 
Absolutely RNA Microprep Kit was obtained from Agilent Technologies (Stockport, UK).  
Diethyl pyrocarbonate-treated water was obtained from Ambion (Life Technologies, 
Paisley, UK).  BioScript reverse transcriptase and its buffer and isopropyl  
β-D-1-thiogalactopyranoside (IPTG) were obtained from Bioline (London, UK).  Phusion DNA 
polymerase and its buffers were obtained from Finnzymes (Vantaa, Finland; part of Thermo 
Scientific).  Antibiotics were obtained from Formedium (Hunstanton, UK).  The 30% 
ProtoGel, 4X ProtoGel resolving buffer, ammonium persulphate (APS),  
N,N,N’,N’-tetramethylethylenediamine (TEMED), ProtoGel stacking buffer, Pre-stained 
Protein Ladder and ProtoBlue Safe were obtained from Geneflow (Fradley, UK).  SYBR® Safe 
DNA Gel Stain, RNase OUT, BP clonase™ II, LR clonase™ II, T4 DNA ligase and its buffer and 
NuPAGE® 12% Bis-Tris Gels were obtained from Invitrogen (Life Technologies, Paisley, UK).  
IRBlue gel stain was obtained from Licor (Lincoln, NE, USA).  HighRanger Plus 100bp DNA 
Ladder was obtained from Norgen Biotek (Thorold, ON, Canada).  Restriction 
endonucleases and their buffers were obtained from New England Biolabs (Hitchin, UK).  
Shrimp alkaline phosphatase (SAP) was obtained from Promega (Madison, WI, USA).  
Complete Mini EDTA-free Protease Inhibitor Cocktail (PI) tablets were obtained from Roche 
(Mannheim, Germany).  Frozen rat brains were obtained from Seralab (Barnet, UK).  The 
GenElute™ Plasmid Miniprep Kit, GenElute™ Gel Extraction Kit, 425-600 μm acid-washed 
glass beads and thiopropyl Sepharose® 6B were obtained from Sigma.  The Pierce® 
Bicinchoninic Acid (BCA) Protein Assay Kit, EZ-link® biotin-HPDP and NeutrAvidin® 
UltraLink® Resin were obtained from Thermo Scientific (Rockford, IL, USA).  DH5α 
Escherichia coli cells were made in-house. 
Primary antibodies used were: mouse anti-synaptosome-associated protein of 25 kDa 
(SNAP-25) and rabbit anti-Munc18 (BD Transduction Laboratories, Ireland); mouse  
anti-syntaxin 1 (HPC1) and rabbit anti-syntaxin-3 (Synaptic Systems, Göttingen, Germany); 
rabbit anti-vesicle-associated membrane protein 2 (VAMP-2) (a gift from M. Takahashi); 
anti-cysteine string protein (CSP) raised in rabbit as previously described (Chamberlain and 
Burgoyne, 1996).  Horseradish peroxidase (HRP)-coupled secondary antibodies used were: 
anti-mouse-HRP and anti-rabbit-HRP (Sigma). 
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2.1.2 NEMATODE STRAINS AND MATERIALS 
All C. elegans strains were obtained from the Caenorhabditis Genetics Center (University of 
Minnesota, Twin Cities, MN, USA) except tm4272, which was obtained from the National 
Bioresource Project for the Experimental Animal “Nematode C. elegans” based in the lab of 
Dr Shohei Mitani (Tokyo Women’s Medical University, Tokyo, Japan). 
E. coli OP50 was obtained from the Caenorhabditis Genetics Center.  The Vidal C. elegans 
Open Reading Frame (ORF) RNAi feeding library was obtained from Source Bioscience 
(Nottingham, UK) (Rual et al., 2004).  Culture plates were obtained from Appleton Woods 
(Birmingham, UK).  2 ml round-bottom cryogenic vials used for homogenisation of worms 
were obtained from Corning (Amsterdam, the Netherlands). 
2.2 IN SILICO WORK 
2.2.1 DATABASE MINING 
Initial searches for putative worm DHHC enzymes were conducted on WormBase 
(http://www.wormbase.org/) using the Pfam tag of DHHC zinc-finger domain (PF01529).  
Palmitoyl-protein thioesterases (PPTs) were found by BLAST searching 
(http://blast.ncbi.nlm.nih.gov/) using the known human PPT sequences; no characteristic 
PPT domain has been found. 
H. sapiens, D. melanogaster and S. cerevisiae DHHCs and PPTs were found by searching the 
NCBI databases (http://www.ncbi.nlm.nih.gov/).  The numbers of enzymes found in all 
organisms were verified by reference to figures existing in the literature. 
2.2.2 SEQUENCE ANALYSIS 
Sequence alignments were performed using the Clustal Omega online program 
(http://www.ebi.ac.uk/Tools/msa/clustalo/).  Colour highlighting of salient domains was 
manually applied. 
Phylogenetic trees were generated using the Phylip v3.69 suite of programs 
(http://evolution.genetics.washington.edu/phylip/getme.html).  The output was uploaded 
to the Interactive Tree of Life server (http://itol.embl.de/index.shtml) (Letunic and Bork, 
2007) and manipulated to obtain the trees presented here. 
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2.3 NEMATODE WORK 
2.3.1 NOMENCLATURE 
The official names for all genes and proteins were used, using the source Wormbase 
(http://www.wormbase.org/).  Unnamed genes were named according to official 
conventions. 
2.3.2 CULTURE 
For normal maintenance, C. elegans were cultured in 60mm plates on nematode growth 
medium agar (NGM; 2% (w/v) agar, 0.3% (w/v) NaCl, 0.25% (w/v) peptone, 1 mM CaCl2,  
5 μg ml-1 cholesterol, 25 mM KH2PO4, 1 mM MgSO4) at 20 °C, seeded with 30 μl E. coli OP50 
culture as a food source, using standard methods (Brenner, 1974).  For proteomic studies, 
C. elegans were grown in liquid culture. 
2.3.3 FROZEN STOCKS 
C. elegans can survive freezing, which is convenient for long term storage.  The best plates 
for freezing are slightly starved and contain many L1 and L2 larvae.  The plate was washed 
off with 1.5 ml M9 buffer (5 g l-1 NaCl, 3 g l-1 KH2PO4, 6 g l-1 Na2HPO4, 1 mM MgSO4).  1.5 ml 
freezing solution (100 mM NaCl, 50 mM KH2PO4, 30% (w/v) glycerol, 5.5 mM NaOH, 3 mM 
MgSO4) was added and mixed well.  The mixture was split evenly between four cryovials, 
and put in a -80 °C freezer packed in a polystyrene box wrapped in tissue to achieve a 
slower freezing rate of approximately 1 °C per minute.  One of the aliquots was thawed the 
following day and plated to check there were surviving worms.  Working populations of 
worms were refreshed from frozen stocks periodically to combat any genetic drift from 
normal strain maintenance. 
2.3.4 FEEDING RNAI 
RNAi feeding experiments were conducted using bacteria from the Vidal C. elegans ORF 
RNAi Library (Rual et al., 2004) where available, or were cloned in-house.  All RNAi feeding 
bacteria were E. coli strain HT115 carrying the pG-L4440 vector containing the relevant 
insert. 
Plates of NGM containing 25 μg ml-1 carbenicillin and 1 mM IPTG were poured 4-7 days 
before seeding with 50 μl of the relevant bacterial strain.  RNAi plates were always kept in 
the dark, as IPTG is light sensitive.  The bacteria were allowed to induce overnight.  Ten  
L3-L4 stage worms were transferred to each plate.  Once the next generation of worms had 
reached young adult stage, three adults were moved onto individual replica plates, allowed 
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to lay eggs and removed the following day.  These progeny were used in the assays once 
they had reached adulthood. 
2.3.5 MORPHOLOGY 
Morphology of individual worms was assessed using a microscope stage controlled by 
computer through an Optiscan II box (Prior) with a video feed transmitted by a DinoEye 
Eyepiece Camera (ANMO Electronics Corporation).  WormTracker software 
(http://www.mrc-lmb.cam.ac.uk/wormtracker/; v2.0.3.1) was used to track the worms and 
collect data over a two minute period.  Data were analysed in Worm Analysis Toolbox 
software (v1.9) and Microsoft® Office Excel® 2007. 
2.3.6 LIFESPAN 
To synchronise a worm strain, a relatively full plate of gravid adults was collected and 
treated by bleaching to release eggs which were transferred to the edge of a seeded plate.  
These worms were picked onto lifespan plates once they reached adulthood, defined as  
day 0.  Plates were checked every 1-2 days to determine survival and worms were 
transferred to a fresh plate if necessary. 
2.3.7 BEHAVIOURAL ASSAYS 
Behaviour was assessed using assays testing locomotory ability in liquid and on solid media, 
locomotory ability with age in liquid and mechanosensation using standard methods 
outlined in Section 4.2.3. 
2.3.8 STATISTICAL ANALYSIS 
If two data sets were being directly compared, Student’s t-test was used.  For comparison 
of multiple data sets in one analysis, a one-way analysis of variance (ANOVA) was used.  
These tests were performed in Microsoft Office® Excel® 2007 and SigmaPlot (Systat Softare, 
Inc.; v.12.2.0.45). 
Lifespan analyses were performed using the Online Application for the Survival Analysis of 
Lifespan Assays (OASIS; http://sbi.postech.ac.kr/oasis/introduction/) (Yang et al., 2011).  
Mean lifespans were compared using the log-rank (Mantel-Cox) test, and mortality at more 
specific time points was compared using Fisher’s exact test.  Age-dependent thrashing was 
compared using one-way analysis of covariance (ANCOVA) in Microsoft Office® Excel® 2007. 
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2.4 MOLECULAR BIOLOGY 
2.4.1 DNA PURIFICATION AND VERIFICATION 
E. coli containing the relevant plasmid were cultured overnight in 5 ml LB containing a 
selection antibiotic at 37 °C, 250 rpm.  2 ml culture was pelleted in an Eppendorf tube in a 
microcentrifuge at 14000 rpm for one minute.  The supernatant was discarded and the DNA 
extracted from the bacterial pellet using a GenElute™ HP Plasmid Miniprep Kit following the 
manufacturer’s guidelines. 
The identity of purified DNA was confirmed either with digestion using restriction 
endonucleases and separation by agarose gel electrophoresis or by sequencing by DNA 
Sequencing & Services at the University of Dundee, UK. 
2.4.2 GATEWAY™ CLONING 
To form a complete library of RNAi feeding bacteria clones for the DHHCs, it was necessary 
to clone some vectors.  Complementary DNA (cDNA) was first synthesised from wild-type  
C. elegans total RNA extract.  Reverse transcriptase polymerase chain reaction (RT-PCR) was 
performed using custom-designed primers to generate an attB-flanked DNA sequence.  The 
BP reaction was performed to transfer this DNA into the attR-containing vector pDONR201.  
Successful incorporation into the vector was verified by transforming into DH5α cells, 
miniprepping and performing test digests.  This generated attL-flanked DNA sequences 
which were transferred into the attR-containing vector pG-L4440 using the LR reaction.  
Successful incorporation into the pG-L4440 vector was verified by transforming into DH5α 
cells, miniprepping and performing test digests.  The vectors were then transformed into 
HT115 cells for consistency with the Vidal RNAi library. 
2.5 PROTEIN BIOCHEMISTRY 
2.5.1 PREPARATION OF LYSATES 
2.5.1.1 RAT BRAIN 
10 ml homogenisation buffer (HB; 0.32 M sucrose, 10 mM HEPES pH 7.4) containing one 
Complete Mini EDTA-free PI tablet was made up and pre-chilled on ice.  An adult female 
Sprague Dawley rat brain, snap-frozen, was thawed on ice in about 5 ml HB.  The brain was 
cut into pieces that were as small as possible using dissection scissors on a glass plate.  The 
brain was transferred to a specialised glass tube, the remaining HB added and processed 
using an electric homogeniser (Janke & Kunkel K.G., now IKA®-Werke GmbH & Co. K.G., 
Staufen, Germany) until homogeneous.  The homogenate was spun at 3500 rcf at 4 °C for 
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five minutes to remove debris.  The supernatant was split into 1 ml aliquots in Eppendorf 
tubes and SDS added to 2% final concentration.  These were rotated for 10-20 minutes at 
room temperature and spun at 14000 rpm, 4 °C for five minutes.  The remainder of the 
supernatant was transferred to a 15 ml Falcon tube. 
2.5.1.2 NEMATODES 
Worm pellets were frozen at -80 °C and thawed on ice before use.  Up to 500 μl worms and 
an equal volume of worm homogenisation buffer (WHB: 140 mM KCl, 1 mM 
ethylenediaminetetraacetic acid (EDTA), 50 mM HEPES pH 7.4, 2% SDS) with PIs were put in 
a 2 ml round-bottom cryogenic vial.  425-600 μm acid-washed glass beads were added up 
to the meniscus using a tip box lid.  Tubes were shaken in a Mikro-Dismembrator S  
(B. Braun Biotech International, Melsungen, Germany) at 2000 rpm for two minutes.  Three 
holes were made in the base of each tube with a BD Microlance™ 3 25G (Becton Dickinson 
& Co. Ltd, Ireland).  The tube was placed in a 15ml Falcon and spun at 5000 rpm, 4 °C for 
five minutes.  The lysate was transferred to Eppendorfs and spun at 13000 rpm, 4 °C for 20 
minutes.  The supernatant was transferred to fresh tubes and used immediately. 
2.5.2 PURIFICATION OF PALMITOYL-PROTEINS 
Palmitoyl-proteins were purified from rat brain and C. elegans homogenates using two 
methods: acyl-biotin exchange (ABE) and acyl-resin-assisted capture (acyl-RAC).  These are 
summarised below, with full protocols outlined in Sections 5.2.2.4 and 5.2.2.5. 
2.5.2.1 ACYL-BIOTIN EXCHANGE 
Methyl methanethiosulphonate (MMTS) was added to 20 mM to the lysate to block free 
thiols and incubated at room temperature for two hours.  The sample was split into three 
15 ml Falcon tubes and a methanol precipitation performed as follows: 
• a three-times volume of -20 °C methanol was added and the tubes vortexed and 
spun at 3500 rcf, 4 °C for two minutes 
• the supernatant was discarded and the pellet resuspended in 1 ml solubilisation 
buffer (SB; 4% SDS, 50 mM Tris.HCl, 5 mM EDTA, pH 7.4) and incubated at 37 °C, 
220 rpm for 30 minutes 
• the solution was made up to 4 ml total volume with lysis buffer (LB; 150 mM NaCl, 
50 mM Tris.HCl, 5 mM EDTA, pH 7.4) + 0.2% Triton X-100 (LB-T) 
• the methanol precipitation was repeated three times in total 
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The combined volume was split into two 15 ml Falcons.  Hydroxylamine (HA) was added to 
1 M to the experimental tube to cleave thioester bonds between cysteine residues and 
palmitate molecules.  Tris.HCl was added to 1M to the control tube.  EZ-link®  
N-[6-(biotinamido)hexyl]-3’-(2’-pyridyldithio)propionamide (biotin-HPDP) was added to 
both tubes to 0.5 mM to label revealed thiols.  Samples were incubated at room 
temperature on a rocker overnight. 
Each sample was methoanol precipitated three times.  The final time, 250 μl SB was used 
for resuspension and was made up to 10 ml with LB-T before incubating on a rocker at 
room temperature for 30 minutes.  Meanwhile, 600 μl NeutrAvidin® UltraLink® Resin per 
tube, which binds to the biotin-HPDP-labelled protein, was washed three times in 10 ml  
LB-T and spun at 3500 rcf, 4 °C for two minutes between washes.  The samples were spun 
at 3500 rcf, 4 °C for two minutes and the supernatant was added to the washed beads and 
incubated at room temperature on a rocker for 90 minutes.  After spinning at 3500 rcf, 4 °C 
for two minutes, the pellet was washed four times with 10 ml LB-T + 0.1% SDS, spinning at 
3500 rcf, 4 °C for two minutes between washes.  Proteins were eluted in 3 ml LB-T + 1%  
β-mercaptoethanol (β-ME) by incubating at 37 °C for one hour with occasional agitation.  
The samples were spun at 3500 rcf, 4 °C for two minutes, and the supernatant split into  
0.3 ml aliquots in Eppendorfs to allow a methanol precipitation with a 10000 rpm spin at  
4 °C for five minutes.  The pellets were resuspended serially in 250μl 4X Laemmli buffer  
(8% SDS, 40% glycerol, 20% β-ME, 0.008% bromophenol blue, 0.25 M Tris.HCl, pH 6.8).  1 ml 
4X Laemmli was added to the bead pellet, which was resuspended and boiled.  The 
supernatant was taken off and stored at -20 °C (Laemmli elution). 
2.5.2.2 ACYL-RESIN-ASSISTED CAPTURE 
A bicinchoninic acid (BCA) assay was performed on all samples to determine their 
concentrations.  Each sample was diluted to 2 mg ml-1 with blocking buffer (100 mM HEPES, 
1 mM EDTA, 2.5% SDS, pH 7.4).  MMTS was added to 0.5% to block free thiols and the 
samples incubated at 40 °C for one hour with frequent vortexing.  The samples were 
methanol precipitated three times; the final time, instead of resuspending in SB, the 
samples were resuspended in 1 ml binding buffer (100 mM HEPES, 1 mM EDTA, 1% SDS,  
pH 7.4) and incubated at 37 °C, 220 rpm for 30 minutes.  Meanwhile, 0.25g thiopropyl 
Sepharose® 6B beads per sample were washed in 20 ml distilled water for 15 minutes.  
These beads bind directly to revealed thiols.  The beads were spun at 3500 rcf, 4 °C for two 
minutes, the supernatant removed and an equal volume of binding buffer added to the 
settled slurry.  Each sample was split into two and 1 ml slurry added to each.  HA was added 
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to 1 M to the experimental tube and Tris.HCl to 1 M to the control tube and a PI tablet 
added.  Samples were incubated on a rocker at room temperature overnight. 
The following day, samples were spun at 3500 rcf, 4 °C for two minutes.  The bead pellet 
was washed five times with 5 ml binding buffer, spinning at 3500 rcf, 4 °C for two minutes 
between washes.  Proteins were eluted in 3 ml LB-T + 1% β-ME by incubating at 37 °C for 
one hour with occasional agitation.  The samples were spun at 3500 rcf, 4 °C for two 
minutes, and the supernatant split into 0.3 ml aliquots in Eppendorfs to allow a methanol 
precipitation with a 10000 rpm spin at 4 °C for five minutes.  The pellets were resuspended 
serially in 250μl 4X Laemmli buffer (8% SDS, 40% glycerol, 20% β-ME, 0.008% bromophenol 
blue, 0.25 M Tris.HCl, pH 6.8).  1 ml 4X Laemmli was added to the bead pellet, which was 
resuspended and boiled.  The supernatant was taken off and stored at -20 °C (Laemmli 
elution). 
2.5.3 SDS-PAGE 
Separation of protein samples was performed using SDS-polyacrylamide gel electrophoresis 
(SDS-PAGE).  Samples were prepared by boiling in Laemmli buffer at 95 °C for five minutes.  
Gels were cast in the Mini PROTEAN 3 system (BioRad, Hemel Hempstead, UK).  Two 15% 
resolving gels were made by mixing 6.25 ml 30% ProtoGel, 3.13 ml 4X ProtoGel resolving 
buffer and 3 ml distilled H2O.  Polymerisation was initiated by adding 125 μl 10% APS and 
12.5 μl TEMED and mixing.  5 ml gel was transferred into the 1 mm space between two 
glass plates held in a casting frame.  The remaining volume was filled with distilled H2O and 
the gel allowed to set.  For the 4% stacking gel, 1.3 ml 30% ProtoGel, 2.5 ml ProtoGel 
stacking buffer and 6.1 ml distilled H2O were mixed.  Polymerisation was initiated by adding 
50 μl 10% APS and 10 μl TEMED and mixing.  The water was poured out of the casting 
apparatus and remaining drops soaked up with filter paper.  The apparatus was filled to the 
top with stacking gel and a comb inserted and the gel allowed to set.  Pre-cast NuPAGE® 
12% Bis-Tris Gels were also used. 
Gels were put into gel tanks which were filled with running buffer (0.025 M Tris, 0.192 M 
glycine, 0.1% SDS).  Combs were removed from the gels and samples were loaded alongside 
5 μl pre-stained protein ladder.  Gels were run at 180-200 V until the dye reached the 
bottom of the gel.  Gels were visualised by staining with Coomassie Blue, ProtoBlue Safe or 
IRBlue, or by silver staining.  Gels were imaged in a ChemiDoc XRS with Quantity One 
software. 
CHAPTER 2: MATERIALS AND METHODS 
40 
 
2.5.4 WESTERN BLOTTING 
Proteins were transferred to nitrocellulose submerged in transfer buffer (0.025 M Tris, 
0.192 M glycine, 20% methanol) in a BioRad Trans-blot Electrophoresis Transfer Cell, either 
at 100 V for one hour with an ice pack or 20 V overnight.  Nitrocellulose was blocked for 
one hour in Tris-buffered saline (TBS; 20 mM Tris, 140 mM NaCl, pH 7.4) with 0.1%  
Tween 20 (TBS-T) and 5% (w/v) dried skimmed milk.  The primary antibody was applied at 
an appropriate dilution in TBS-T supplemented with 5% (w/v) BSA and incubated on a 
rocker for either one hour at room temperature or at 4 °C overnight.  The nitrocellulose was 
washed three times in TBS-T for five minutes before incubation in an appropriate HRP-
conjugated secondary antibody at 1:2000 dilution for one hour on a rocker.  The 
nitrocellulose was rinsed with TBS-T and visualised using enhanced chemiluminescence 
(ECL) reagents A (2.5 mM luminol, 400 μM p-coumaric acid, 100 mM Tris.HCl pH 8.5) and B 
(0.018% H2O2, 100 mM Tris.HCl pH 8.5) mixed 1:1.  Imaging was performed in a ChemiDoc 
XRS using Quantity One software. 
2.5.5 MASS SPECTROMETRY 
The β-ME or Laemmli eluates were sent to Dr Mary Doherty (University of the Highlands 
and Islands, Inverness, UK) who kindly analysed them by liquid chromatography-tandem 
mass spectrometry (LC-MS/MS) was performed using a Thermo LTQ-Orbitrap XL LC-MSn 
mass spectrometer equipped with a nanospray source and coupled to a Waters 
nanoAcquity ultra performance liquid chromatography (UPLC) system. 
The data were subsequently analysed using Proteome Discoverer software (Thermo 
Scientific, Rockford, IL, USA) and MaxQUANT (http://maxquant.org/index.htm) and 
searched against a locally implemented MASCOT server (v2.3.01).  Results were processed 
by discarding contaminants.  The ratio of experimental:control scores was taken and any 
with a ratio of less than five were discarded (Martin and Cravatt, 2009).  A control value of 
0.2 was given to proteins present only in the experimental samples to avoid dividing by zero 
(Dowal et al., 2011; Roth et al., 2006; Yang et al., 2010).  Results were considered higher 
confidence if identified from multiple unique peptides and lower confidence if identified 
from a single unique peptide.  Unfortunately there were insufficient repeats to perform 
robust statistical analysis of the mass spectrometry output. 
  
 
Chapter 3: 
IN SILICO ANALYSIS
CHAPTER 3: IN SILICO ANALYSIS 
42 
 
3.1 INTRODUCTION 
3.1.1 INVESTIGATION OF PALMITOYL ACYL-TRANSFERASES IN DIFFERENT ORGANISMS 
3.1.1.1 IDENTIFICATION OF PALMITOYL ACYL-TRANSFERASES 
Although palmitoylation as a post-translational modification in eukaryotic cells had been 
known about for many years (Omary and Trowbridge, 1981), it was not until relatively 
recently that the enzymes involved were identified (Bohm et al., 1997; Fukata et al., 2004; 
Mitchell et al., 2006; Roth et al., 2002).  The realisation that these palmitoyl acyl-
transferases (PATs/DHHCs) shared the eponymous aspartic acid-histidine-histidine-cysteine 
(DHHC) motif in a cysteine-rich domain (CRD) allowed easy searching of whole genome data 
for putative DHHCs.  This method has allowed the prediction of 23 such genes in humans 
(Homo sapiens) and 24 in mice (Mus musculus) (Fukata et al., 2004; Fukata and Fukata, 
2010), 22 in fruit flies (Drosophila melanogaster) (Bannan et al., 2008) and eight predicted, 
of which seven are confirmed, in yeast (Saccharomyces cerevisiae) (Roth et al., 2002).  
Whilst the DHHC-CRD consensus has been refined from the initial NEW1 motif to 
Cx2Cx3(R/K)PxRx2HCx2Cx2Cx4DHHCxW(V/I)xNC(I/V)Gx2Nx3F, there is some tolerance to 
substitutions within this sequence (Mitchell et al., 2006).  The S. cerevisiae DHHCs Akr1, 
Akr2 and Pfa5 have a DHYC motif instead of DHHC, for example (Mitchell et al., 2006).  
Furthermore, the eighth S. cerevisiae DHHC, YNL155W, is more distantly related and so its 
status as a de facto palmitoyltransferase is uncertain (Mitchell et al., 2006).  The motif is 
also the active site of these enzymes (Mitchell et al., 2010) and many, though not all, of the 
predicted DHHCs have since been validated experimentally as having palmitoyltransferase 
enzymatic activity (Ohno et al., 2012), giving high confidence that genes identified using 
this consensus sequence are likely to be genuine. 
In the case of the nematode worm Caenorhabditis elegans, there has been some confusion 
in the literature, with figures of 15 (Fukata and Fukata, 2010), 16 (Mitchell et al., 2006) and 
17 (Gleason et al., 2006) DHHC genes being quoted.  However, there has been no analysis 
of these putative enzymes in terms of their palmitoylating activity.  Given the suitability of 
C. elegans as a model system for probing questions about both development and neuronal 
function (Brenner, 1974; Chalfie and Sulston, 1981), coupled with the importance of 
palmitoylation in these systems (Fukata and Fukata, 2010; Porter et al., 2005; Prescott et 
al., 2009), a more thorough analysis could open up new areas of research within the field.  
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3.1.1.2 PREDICTION OF THE PROPERTIES OF PALMITOYL ACYL-TRANSFERASES 
Numerous proteome-scale studies in recent years have enabled the identification of 
proteins which undergo palmitoylation in different cell types and organisms (Dowal et al., 
2011; Kang et al., 2008; Marin et al., 2012; Merrick et al., 2011; Roth et al., 2006; Yang et 
al., 2010).  However, there is comparatively little known about which DHHC enzyme(s) 
palmitoylate which substrate(s).  This is partly due to the workload in characterising 
individual enzymes or substrates to obtain very specific information.  A proteomic scale 
analysis gives much more information in terms of identifying many palmitoylated proteins 
but teasing out enzyme-substrate data is not so easily done.  A study investigating DHHC2 
substrates only found a handful of new candidates (Zhang et al., 2008).  However, these 
whole genome studies and some apparent general rules can give a headstart in predicting 
potential substrates for a DHHC enzyme before investigating it experimentally. 
Several attempts have been made to group the DHHC enzymes into sub-families based on 
various parameters.  A phylogenetic analysis to group enzymes based on their relatedness 
can be done to gain an initial overview of information on the DHHCs within individual 
organisms and also with a wider perspective by including families from many organisms.  A 
comparison of the S. cerevisiae DHHCs with the H. sapiens DHHCs showed several broad 
sub-families (Mitchell et al., 2006).  DHHC enzymes have a common structure of at least 
four transmembrane domains (TMDs), with the DHHC motif found in the cytoplasmic loop 
between TMD2 and TMD3 (Fukata and Fukata, 2010; Kihara et al., 2005; Korycka et al., 
2012; Mitchell et al., 2006).  Some sub-families can be explained by the presence of 
common domains that are not in the majority of the enzymes.  For example, the  
S. cerevisiae enzymes Akr1 and Akr2 cluster with the H. sapiens enzymes DHHC17 (also 
called huntingtin-interacting protein 14 (HIP14)) and DHHC13 (also called HIP14-like 
(HIP14L)).  All of these proteins have ankyrin repeat domains N-terminal of their first TMD.  
Other groups were observed to contain one S. cerevisiae DHHC and a handful of H. sapiens 
DHHCs (Mitchell et al., 2006).  A similar analysis was done including the D. melanogaster 
genes (Bannan et al., 2008).  The ankyrin repeat containing proteins in D. melanogaster 
clustered within that same group as above.  A large group of enzymes with no homology to 
S. cerevisiae or H. sapiens DHHCs was also present.  They hypothesised that this was the 
result of duplications during the evolution of different Drosophila species (Bannan et al., 
2008).  Whether these have a species-specific role would be interesting to find out.  There 
may be a high level of redundancy among this sub-group.  Whilst proteins grouped using 
phylogenetics are not necessarily direct homologues, the function, localisation and 
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substrates of the enzymes in one organism could be used as a starting point for 
investigating proteins in another.  This approach will be taken with the C. elegans family of 
enzymes. 
Some tools for large scale prediction of enzyme properties are available in S. cerevisiae.  
Whilst these are not the result of careful individual protein analysis and have the caveats 
associated with many genome-wide methods, they can be useful predictors of broad 
properties.  Among these are the green fluorescent protein (GFP) tagging project and 
various interaction studies, which are collated online via http://yeastgfp.yeastgenome.org/ 
and the Saccharomyces Genome Database (SGD).  In addition, there has been a project to 
identify interacting proteins in C. elegans through yeast two-hybrid experiments which is 
collated online at http://www.functionalnet.org/wormnet/about.html.  These resources 
may be used to give an idea of the localisation of different DHHCs and of possible classes of 
proteins which could interact with each enzyme.  These could be very broad, as in the 
classes of palmitoyltransferase substrates based on the location of the palmitoylated 
cysteine residue(s) (Ohno et al., 2012; Resh, 1999).  It may even be possible to predict 
phenotypes in knockouts of individual DHHCs from the classes of protein with which they 
interact. 
3.1.2 DISCOVERY OF PALMITOYL-PROTEIN THIOESTERASES 
The palmitoyl-protein thioesterases (PPTs) present more of a challenge to study 
systematically due to the present lack of a common identifying motif (see Section 1.3).  The 
mammalian cytosolic PPT acyl-protein thioesterase 1 (APT1) was originally discovered 
through its action in removing [3H]-palmitate from Gα subunits (Duncan and Gilman, 1998).  
Another gene, APT2, has been found by homology to APT1 but has barely been studied.  
PPT1 was also discovered through biochemical activity against palmitoylated H-Ras (Camp 
and Hofmann, 1993) and has been shown to be lysosomal rather than cytoplasmic 
(Verkruyse and Hofmann, 1996), although in neurons it is localised to synaptic vesicles and 
synaptosomes instead (Lehtovirta et al., 2001).  This is likely to limit its physiological 
substrates.  A second lysosomal enzyme, PPT2, was found through homology to PPT1 
(Soyombo and Hofmann, 1997).  It shares 26% identity with PPT1 and the ability to 
depalmitoylate palmitoyl-coenzyme A (palmitoyl-CoA), although it cannot depalmitoylate 
proteins (Calero et al., 2003; Soyombo and Hofmann, 1997).  Despite the lack of a 
consensus motif to find new PPT candidates within genomes, many of the methods 
described above can still be used to give information on localisation and possible 
substrates. 
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As DHHCs have not been studied in detail in C. elegans and the literature on its PPTs is 
limited to ppt-1, this chapter set out to perform a thorough characterisation of these 
enzyme families using various computational tools.  The members of the DHHC family will 
be confirmed through the presence of the DHHC-CRD.  Phylogenetic analyses will be 
performed on both the DHHC and PPT families to identify patterns both within the families 
and in the context of other important organisms in which they are known.  This will be 
combined with the available information in various online databases to provide predictions 
which may help with the direction and interpretation of in vivo studies. 
3.2 METHODS 
3.2.1 DATABASE MINING 
Initial searches for putative C. elegans DHHC enzymes were conducted on WormBase 
(http://www.wormbase.org/) using the Pfam tag of DHHC zinc-finger domain (PF01529).  
Palmitoyl-protein thioesterases (PPTs) were found by basic local alignment search tool 
(BLAST) searching (http://blast.ncbi.nlm.nih.gov/) using the known H. sapiens PPT 
sequences; no characteristic PPT domain has been found.   
Basic information known about the H. sapiens, D. melanogaster and S. cerevisiae DHHCs 
and PPTs were found by searching the NCBI databases (http://www.ncbi.nlm.nih.gov/).  In 
addition, the following organism-specific resources were used: Saccharomyces Genome 
Database (SGD) (http://www.yeastgenome.org/); FlyBase (http://flybase.org/); WormBase.  
Protein interaction data were obtained from SGD and from the WormNet website 
(http://www.functionalnet.org/wormnet/about.html).  The localisation data for  
S. cerevisiae proteins were obtained from the S. cerevisiae GFP tagging project 
(http://yeastgfp.yeastgenome.org/). 
3.2.2 SEQUENCE ANALYSIS 
BLAST searches to identify potential orthologues were conducted using the amino acid 
sequence of the relevant protein.  The “non-redundant protein sequences” database was 
searched with results restricted to the species of interest, depending on the analysis being 
performed. 
Sequence alignments were performed using the Clustal Omega online program 
(http://www.ebi.ac.uk/Tools/msa/clustalo/).  Colour highlighting of salient features was 
manually applied.  The colouring of the sequences in the PPT alignments was applied using 
the Clustal Omega program and are the standard property-based colours. 
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The domain structure diagram was constructed principally from information predicted by 
the InterProScan program (http://www.ebi.ac.uk/interpro/).  Where transmembrane 
domains were low confidence or ambiguous, additional evidence was sought from the 
TMpred program (http://www.ch.embnet.org/software/TMPRED_form.html).  Information 
on the palmitoyltransferase conserved C-terminus (PaCCT) was obtained from a published 
analysis (Gonzalez Montoro et al., 2009). 
3.2.3 PHYLOGENETIC ANALYSIS 
To generate phylogenetic trees, alignments were first generated using BioEdit (Isis 
Pharmaceuticals; v6.0.5) and saved in .phy format.  This was used as the “infile” for 
Seqboot, a program in the suite of programs Phylip v3.69 
(http://evolution.genetics.washington.edu/phylip/getme.html).  2000 bootstraps were 
generated and used as the “infile” for Proml, another Phylip program, using no outgroups 
and set to unrooted tree.  10 jumbles were used if computing power sufficed, otherwise 
one jumble was used.  The “outtree” output file was used as the “intree” file for the 
Consense part of the Phylip suite.  This final “outtree” file was uploaded to the Interactive 
Tree of Life server (http://itol.embl.de/index.shtml) (Letunic and Bork, 2007).  Trees were 
formatted to display as unrooted and labels and clades were coloured using the tool 
provided. 
Due to limitations in computing power, the analysis of the DHHCs containing all those from 
S. cerevisiae, D. melanogaster, C. elegans and H. sapiens was conducted using the 
conserved DHHC-CRD region only.  All other analyses could be performed with the full 
length sequences. 
3.3 RESULTS 
3.3.1 EXPLORATION OF THE DHHC ENZYME FAMILY 
3.3.1.1 IDENTIFICATION AND NAMING OF THE C. ELEGANS DHHC ENZYMES 
Before exploring palmitoylation in C. elegans, it was first necessary to confirm its DHHC 
enzymes and find what is already known about them and their counterparts in other 
organisms.  The online database WormBase (http://www.wormbase.org/) contains all the 
known genomic, transcript, protein and functional data associated with C. elegans and is 
frequently updated.  A search of WormBase (version WS207) for the Pfam tag assigned to 
the DHHC motif uncovered 15 genes.  Four of these 15 were previously named: dhhc-1, 
dhhc-2, tag-233 and spe-10.  The remainder were annotated only with their gene code.  
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These were renamed in line with official conventions using the dhhc-x nomenclature 
already started.  tag-233, a temporarily assigned gene name, was also renamed.  Where 
possible, the number assigned to the dhhc-x nomenclature was based on homology to the 
H. sapiens DHHCs.  The spe-10 name is based upon a published spermatogenesis defect 
phenotype (Cypser and Johnson, 1999; Gleason et al., 2006; Shakes and Ward, 1989) and so 
was not altered to avoid confusion within the literature.  The old and new gene names and 
their respective codes are shown in Table 3.1.  The proposal to the WormBase gene naming 
committee was accepted, and as a result the number of dhhc genes increased from two to 
14 as of release WS235 of WormBase. 
3.3.1.2 CHARACTERISTICS OF THE C. ELEGANS DHHC ENZYMES 
A sequence alignment of the primary sequence of the 15 C. elegans DHHCs was performed 
(Figure 3.1).  This confirms that all of them contain the DHHC motif required for enzymatic 
activity within a cysteine-rich region.  The positions of these cysteines relative to the DHHC 
motif are absolutely conserved and correspond to those originally observed in this domain 
(Bohm et al., 1997).  To assess whether the C. elegans DHHCs conform to the common 
structure found in this family, a domain structure diagram was constructed using domains 
predicted from the primary sequence (Figure 3.2).  In general, DHHCs have been found to 
have four TMDs, though some have more, and the DHHC-CRD is normally located in a 
cytoplasmic loop between the second and third TMDs (Fukata and Fukata, 2010; Kihara et 
al., 2005; Korycka et al., 2012; Mitchell et al., 2006).  The majority of the C. elegans DHHCs 
fit this description, although there are some exceptions.  DHHC-11 has no TMDs preceding 
the DHHC-CRD, while DHHC-13 and -14 have five and three TMDs respectively preceding 
the DHHC-CRD.  The final TMD of DHHC-9 is nearly double the length that would be 
expected at 34 residues.  Closer inspection of the sequence at this point shows a prolonged 
region containing a high proportion of hydrophobic residues.  Presumably this stretch 
contains a TMD within it, but the prediction software is unable to determine exactly where.  
DHHC-13 and -14 are the only C. elegans DHHCs which contain multiple ankyrin repeats in 
the N-terminal section of the sequence.  Three enzymes, DHHC-5 and -8 and SPE-10, also 
contain a palmitoyltransferase conserved C-terminal (PaCCT) motif.  This motif is only 
present in a subset of DHHC enzymes, but has been shown to be required for the activity of 
the S. cerevisiae DHHCs Swf1 and Pfa3 (Gonzalez Montoro et al., 2009). 
The protein sequences were next subjected to a phylogenetic analysis.  Some of the 
features of the resulting phylogenetic tree (Figure 3.3) correlate well with the domain
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Gene Previous Name/Gene Code 
dhhc-1 dhhc-1 (F09B12.2) 
dhhc-2 dhhc-2 (Y47H9C.2) 
dhhc-3 F33D11.12 
dhhc-4 ZK757.4 
dhhc-5 R13F6.5 
dhhc-6 M18.8 
dhhc-7 C17D12.1 
dhhc-8 Y39E4B.7 
dhhc-9 C43H6.7 
dhhc-10 K02G10.1 
dhhc-11 T22E7.2 
dhhc-12 F59C6.2 
dhhc-13 H32C10.3 
dhhc-14 tag-233 (D2021.2) 
spe-10 spe-10 (AC3.10) 
TABLE 3.1: DHHC genes in C. elegans 
Listed are the 15 DHHC genes found in C. elegans by searching for the conserved DHHC motif.   
dhhc-1, dhhc-2, tag-233 and spe-10 were the only ones with existing names.  The remaining genes 
were named dhhc-3 to dhhc-13 and tag-233 renamed as dhhc-14.  Where possible, homology to 
human DHHC proteins was taken into account.  spe, spermatogenesis deficient; tag, temporarily 
assigned gene name. 
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DHHC-1 VIKPGYKHCHSCHSMSPLRAHHCPVCDVCILRRDHHCSFGAVCVGHFNQRYFVAAVINLF 156 
DHHC-2 GEHVKMKYCTTCRLYRPPRCSHCAICDNCVLMFDHHCPWVGNCIGLRNYTYFYRFVFCLS 253 
DHHC-3 -GQQTIYKCQKCASIKPDRAHHCSVCERCIRRMDHHCPWVNNCVGEGNQKFFVLFTMY-- 135 
DHHC-4 GFDHGIRFCDKCCCIKPDRSHHCSMCEQCVLKFDHHCPWVNNCVNFGNYKYFILFLAYGF 185 
DHHC-5 DKEIKEDVCQLCNYRKPPRWHHCRRCNLCVHRMDHHCPILQLCIHSGNHKYFLLFLVWPL 135 
DHHC-6 ADEKKLQFCVPCNGFKVPRSHHCSKCDRCCMKMDHHCPWINNCVGHRNHQYFLRFLFFSV 159 
DHHC-7 SSATEWTMCTRCDSLRPPRAHHCRVCKRCVRKMDHHCPWVNNCVGEYNQKWFLQFIFY-- 164 
DHHC-8 GITVRMKWCVTCKFYRPPRSSHCSVCNRCIETFDHHCPWVHNCVGKRNYRYFFFFLCSLS 156 
DHHC-9 PGEEGDSFCSKCNYWKSDNAHHCSVCEKCVLGMDHHCIWINQCVGLHNHRHFFLFIANLT 161 
DHHC-10 ANESGSKFCFTCNKEAPQRSHHCPLCKMCVLRKDHHCFITGACVGLGNQRYFMVFLFWCA 184 
DHHC-11 RHVITNSFCSICEVRTYRETKHCKRCNFCIDDFDHHCVWLNNCIGGKNYRPFVVLVICVN 90 
DHHC-12 PGTPSDSFCIKCNNWKGPSTSHCKACDKCIYRMDHHCPHIGQCVGAHNQSHFFLFLFYLQ 164 
DHHC-13 EEKQIDRYCFTCWIPKTSSSHHCSQCDKCVDGFDHHCPWIHKCVYRKNLRAFVFFCLTIF 594 
DHHC-14 GIQHQQKYCFTCFIRKMDHTKHCAVCGFCVNNFDHHCPWLNSCVTRRNMREFIMFVIS-- 450 
SPE-10 DQVGRLKYCYECGHIKPDRARHCSSCGKCCIKYDHHCPWINMCVTHVNYKYFLLYIIYTS 207 
         *  *         **  *  *    ****     *:   *   *         
FIGURE 3.1: Alignment of the cysteine-rich domains of the DHHC enzymes in C. elegans 
The primary sequence of each protein is shown around the cysteine-rich domain, and the position of 
the final residue of the line shown on the right.  Absolutely conserved residues are indicated by an 
asterisk and a colon indicates residues with similar properties, in this case small hydrophobic 
residues.  The characteristic DHHC motif is highlighted in green and the nearby conserved cysteine 
residues in cyan.  
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FIGURE 3.2: Domain structure of the C. elegans DHHC enzymes 
The C. elegans DHHC enzymes are represented as diagrams to scale of the protein sequence.  The 
DHHC-CRD (green), TMDs (blue), ankyrin repeats (yellow) and PaCCT motifs (red) are shown.  The 
numbers to the right indicate the length of the sequence.  CRD, cysteine-rich domain; PaCCT, 
palmitoyltransferase conserved C-terminal; TMD, transmembrane domain.  
DHHC-1 295
DHHC-2 404
DHHC-3 260
DHHC-4 403
DHHC-5 244
DHHC-6 421
DHHC-7 302
DHHC-9 311
DHHC-10 327
DHHC-11 257
DHHC-12 310
DHHC-13 783
DHHC-14 565
DHHC-8 471
SPE-10 351
DHHC-CRD
TMD
ankyrin repeat
PaCCT
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FIGURE 3.3: Phylogenetic tree of the DHHC enzymes in C. elegans 
The 15 C. elegans DHHCs were subjected to phylogenetic analysis and the resulting tree was plotted 
using the Interactive Tree of Life (http://itol.embl.de) (Letunic and Bork, 2007).  
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structure shown in Figure 3.2.  The enzymes mostly form pairs which are closely related.  
The ankyrin repeat-containing proteins DHHC-13 and -14 are one such pair.  The exception 
is DHHC-11, which can probably be accounted for by its lack of two N-terminal TMDs 
compared with the rest of the family.  The pairs of closely related enzymes branch off from 
broader sub-families in a similar way to phylogenetic trees constructed in other species 
(Bannan et al., 2008; Fukata and Fukata, 2010; Korycka et al., 2012; Mitchell et al., 2006).  
The three PaCCT motif-containing proteins, DHHC-5 and -8 and SPE-10, appear on distant 
branches of the phylogenetic tree and so the presence of this motif would seem to have 
arisen independently in each. 
There are no published data on any of the C. elegans dhhc genes, apart from spe-10 (Cypser 
and Johnson, 1999; Gleason et al., 2006; Shakes and Ward, 1989).  There is, however, a 
small amount of information available on WormBase from large scale studies which is 
summarised in Table 3.2.  In addition the presence of a PaCCT domain as assessed by 
(Gonzalez Montoro et al., 2009) and shown in Figure 3.2 is indicated along with its precise 
position in the protein sequence.  Most of the available information is quite vague and this 
is consistent with an enzyme family whose study has been neglected so far in C. elegans. 
3.3.1.3 COMPARISON OF THE DHHC FAMILIES IN DIFFERENT ORGANISMS 
3.3.1.3.1 S. CEREVISIAE 
The single-celled organism S. cerevisiae has seven well-characterised DHHCs and one 
putative DHHC enzyme.  Table 3.3 contains a summary of the information available in SGD 
and from other sources about these enzymes.  Most of these proteins have been studied to 
some extent with the exception of YNL155W.  Four of the eight enzymes contain the PaCCT 
motif, including the two in which it was characterised, Swf1 and Pfa3.  There is a large 
amount of data available as a result of whole-genome or -proteome analyses in  
S. cerevisiae.  One of these studies involved tagging every S. cerevisiae protein with green 
fluorescent protein (GFP) and observing its localisation (Huh et al., 2003).  Unfortunately, 
for five of these enzymes there were no or ambiguous results, but some further localisation 
analysis has been done as part of studies into substrate specificity (Hou et al., 2009; Ohno 
et al., 2006; Valdez-Taubas and Pelham, 2005).  Pfa3 showed localisation to the vacuole, 
which is consistent with its known function in vacuolar membrane fusion and its substrate 
Vac8.  Akr1 showed Golgi and early Golgi localisation.  This would be consistent with many 
H. sapiens DHHCs shown to localise to the Golgi (Table 3.5). 
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Gene Chromosome Protein ID(s) Gene Expression 
PaCCT 
motif Phenotypes 
Other 
Information 
dhhc-1 X NP_510510.1     
dhhc-2 I NP_493007.2     
dhhc-3 I NP_491702.1     
dhhc-4 III a: NP_001023032.1 
b: NP_001023033.1 
c: NP_001122751.1 
d: NP_001255040.1 
e: NP_001255041.1 
f: NP_001255038.1 
g: NP_001255039.1 
ubiquitous   isoforms a-d 
have the 
DHHC motif; 
part of the  
C-terminal 
region is in all 
isoforms 
dhhc-5 III NP_498488.2 excretory cell, 
intestine 
(weak) 
a.a. 
208-223 
embryonic/post-
embryonic 
development 
variant (RNAi) 
 
dhhc-6 IV NP_502302.2 head neurons 
(larva), 
intestine 
(adult) 
 sterile, embryonic 
lethal, larval arrest, 
reduced brood size 
(RNAi) 
 
dhhc-7 I a: NP_492960.1 
b: NP_492961.1 
   isoform b has 
an N-terminal 
truncation 
before the 
DHHC region 
dhhc-8 III NP_499713.3  a.a 
234-248 
embryonic/post-
embryonic 
development 
variant (RNAi) 
predicted 
protein 
binding motif 
dhhc-9 X NP_508435.2     
dhhc-10 X NP_508805.3 ubiquitous, 
stronger in 
anterior 
pharynx 
   
dhhc-11 I NP_491675.3 spermathecal 
valve (L3/L4), 
head neurons 
   
dhhc-12 I NP_492753.2 possibly in 
two head and 
one tail 
neurons 
   
dhhc-13 IV NP_500889.1   fat content 
variant/reduced 
(RNAi) 
 
dhhc-14 X a: NP_001024514.2 
b: NP_001024515.1 
generalised, 
possibly 
neuronal 
  isoform b has 
an N-terminal 
truncation 
before the 
DHHC region 
spe-10 V NP_001021339.1  weak: 
a.a. 
287-301 
transgene induced 
cosuppression 
(RNAi); 
hermaphrodite 
sterile; unfertilised 
eggs laid; increased 
lifespan; increased 
stress resistance 
 
TABLE 3.2: Collated information on C. elegans DHHC enzymes 
Information was collected from WormBase, the National Center for Biotechnology Information 
(NCBI) website (http://www.ncbi.nlm.nih.gov) and (Gonzalez Montoro et al., 2009).  PaCCT, 
palmitoyltransferase conserved C-terminus.  
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Gene Description Protein ID PaCCT Motif Localisation Notes 
AKR1 palmitoyl transferase involved in protein 
palmitoylation; acts as a negative 
regulator of pheromone response 
pathway; required for endocytosis of 
pheromone receptors; involved in cell 
shape control; contains ankyrin repeats 
NP_010550.1  Golgi; early 
Golgi1,2 
 
AKR2 ankyrin repeat-containing protein similar 
to Akr1p; member of a family of putative 
palmitoyltransferases containing an Asp-
His-His-Cys-cysteine rich (DHHC-CRD) 
domain; possibly involved in constitutive 
endocytosis of Ste3p 
NP_014677.1  ambiguous1; 
Golgi2 
 
ERF2 subunit of a palmitoyltransferase, 
composed of Erf2p and Shr5p, that adds a 
palmitoyl lipid moiety to heterolipidated 
substrates such as Ras1p and Ras2p 
through a thioester linkage; mutants 
partially mislocalise Ras2p to the vacuole 
NP_013347.1 a.a. 
307-322 
ER2,3  
PFA3 palmitoyltransferase for Vac8p, required 
for vacuolar membrane fusion; contains 
an Asp-His-His-Cys-cysteine rich (DHHC-
CRD) domain; autoacylates; required for 
vacuolar integrity under stress conditions 
NP_014073.1 a.a. 
248-263 
vacuole1-3  
PFA4 palmitoyltransferase with autoacylation 
activity, required for palmitoylation of 
amino acid permeases containing a  
C-terminal Phe-Trp-Cys site; required for 
modification of Chs3p; member of the 
DHHC family of putative 
palmitoyltransferases 
NP_014640.1  ER2,3  
PFA5 palmitoyltransferase with autoacylation 
activity; likely functions in pathway(s) 
outside Ras; member of a family of 
putative palmitoyltransferases containing 
an Asp-His-His-Cys-cysteine rich (DHHC-
CRD) domain 
NP_010747.1 a.a. 
285-300 
PM2,3; 
vacuole-
vacuole 
junctions2 
 
SWF1 palmitoyltransferase that acts on the 
SNAREs Snc1p, Syn8p, Tlg1p and likely on 
all SNAREs; member of a family of 
putative palmitoyltransferases containing 
an Asp-His-His-Cys-cysteine rich (DHHC-
CRD) domain; may have a role in vacuole 
fusion 
NP_010411.1 a.a. 
321-336 
ER4  
YNL155W putative protein of unknown function, 
contains DHHC domain, also predicted to 
have thiol-disulfide oxidoreductase active 
site 
NP_014244.1  cytoplasm; 
nucleus1 
closest 
C. elegans 
match is AIP-1; 
closest DHHC is 
DHHC-14 
(e value 0.24) 
1http://yeastgfp.yeastgenome.org/ 
2(Ohno et al., 2006)  
3(Hou et al., 2009) 
4(Valdez-Taubas and Pelham, 2005) 
TABLE 3.3: Collated information on S. cerevisiae DHHC enzymes 
Information was collected from the Saccharomyces Genome Database (SGD; 
http://www.yeastgenome.org/), the NCBI website, (Gonzalez Montoro et al., 2009) and the yeast 
GFP fusion localization database (http://yeastgfp.yeastgenome.org/).  AIP, arsenite inducible RNA 
associated protein; AKR, ankyrin repeat-containing; Chs, chitin synthase-related; ER, endoplasmic 
reticulum; ERF, effect on Ras function; HPO, hypersensitive to pore-forming toxin; PFA, protein fatty 
acyltransferase; PM, plasma membrane; Shr, suppressor of hyperactive Ras; Snc, suppressor of the 
null allele of cyclase associated protein; Ste, sterile; SWF, spore wall formation; Syn, syntaxin; Tlg,  
t-SNARE affecting a late Golgi compartment; Vac, vacuole-related.  
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The putative DHHC, YNL155W, contains the conserved cysteine residues and the DHHC 
motif, adding to the confidence that it is a real palmitoylating enzyme.  It shows only 
distant homology to a C. elegans DHHC, DHHC-14.  However, the basis of this is a short 
stretch of sequence which includes the DHHC-CRD.  It remains to be seen whether 
YNL155W has palmitoyltransferase activity. 
3.3.1.3.2 D. MELANOGASTER 
The fruit fly D. melanogaster has 22 DHHCs, listed in Table 3.4.  Most of these have not 
been studied in detail, other than their developmental expression pattern (Bannan et al., 
2008).  The exception is huntingtin-interacting protein 14 (Hip14), which when mutated 
leads to defects in photoreceptor synaptic transmission (Ohyama et al., 2007; Stowers and 
Isacoff, 2007) and in larval neuromuscular axon guidance (Kraut et al., 2001).  This was 
found to be due to loss of proper function of two synaptic proteins which were found to be 
substrates of Hip14: cysteine string protein (CSP) and synaptosomal-associated protein of 
25 kDa (SNAP-25) (Ohyama et al., 2007; Stowers and Isacoff, 2007). 
Many of the D. melanogaster DHHCs have multiple isoforms, raising the possibility of either 
highly specific roles or a reasonable level of redundancy within the system.  It is possible 
that there are large differences in isoform expression depending on the tissue and 
developmental stage.  The analysis of developmental expression did not cover different 
isoforms of any of the DHHCs (Bannan et al., 2008).  Another feature of these DHHCs is that 
all but three of them contain a PaCCT motif.  The significance of this abundance remains to 
be seen.  It will be interesting to see whether this is a quirk of the D. melanogaster DHHCs 
or important for their function.  Potentially more interesting is whether there is any 
difference between the three which lack the PaCCT motif and the rest of the family at a 
functional level. 
3.3.1.3.3 H. SAPIENS 
Humans have 23 DHHCs encoded by the gene family named ZDHHC based on the initial 
observation of a zinc finger domain as well as the DHHC-CRD (Fukata and Fukata, 2010; 
Korycka et al., 2012).  These are numbered 1-24 as ZDHHC10 was later found to be identical 
to ZDHHC9 and was removed from this classification.  In addition there is a predicted DHHC, 
ZDHHC11B, which has high homology to ZDHHC11 but has not been officially recognised as 
yet. 
An overview of the H. sapiens DHHCs is shown in Table 3.5.  Palmitoyltransferase activity 
has been observed in all of these except DHHC1, -11, -16, and -24 (Ohno et al., 2012), and 
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Gene Protein ID(s) Isoforms/Variants PaCCT Motif Notes 
app 
(CG42318/ 
CG5620/ 
CG17144) 
H: NP_001137938.2 
I: NP_001137939.2 
J: NP_996065.2 
K: NP_648561.2 
L: NP_001137936.1 
M: NP_001137937.1 
O: NP_001246732.1 
P: NP_001246733.1 
Q: NP_001246731.1 
9 isoforms; all contain 
DHHC motif 
isoform H: a.a. 283-298 
isoform L: a.a. 283-298 
 
CG1407 A: NP_724868.2 
B: NP_610544.1 
C: NP_724869.2 
D: FBpp0303357 
4 isoforms; all contain 
DHHC motif 
isoform A: a.a. 265-279 
isoform B: a.a. 265-279 
 
CG4483 NP_648294.1  a.a. 246-260  
CG4676 NP_610853.1  a.a. 235-249  
CG4956 NP_651428.2  weak; a.a. 258-272  
CG5196 A: NP_650191.1 
B: NP_996201.1 
2 isoforms; both contain 
DHHC motif 
isoform A: a.a. 244-258 
isoform B: a.a. 212-246 
 
CG5880 NP_651539.3  a.a. 327-341  
CG8314 NP_611070.1    
CG10344 A: NP_726201.1 
B: NP_611671.1 
2 isoforms; both contain 
DHHC motif 
isoform B: a.a. 234-246  
CG13029 C: NP_648928.1 
D: FBpp0304948 
2 isoforms; only isoform 
C contains DHHC motif 
isoform C: a.a. 241-255  
CG17075 A: NP_608508.1 
B: NP_001245821.1 
2 isoforms; CDS identical   
CG17195 NP_651427.2  weak; a.a. 239-263  
CG17196 A: NP_651426.1 
B: NP_001163735.1 
2 isoforms; only isoform 
B contains DHHC motif 
isoform A: a.a. 232-246 
isoform B: a.a. 207-221 
 
CG17197 NP_651425.2  a.a. 233-247 contains DRHC 
instead of DHHC 
CG17198 NP_651424.3  weak; a.a. 255-269  
CG17287 NP_611197.1  weak; a.a. 258-272  
CG18810 NP_652670.2  weak; a.a. 243-257  
CG34449 A: NP_727339.3 
B: NP_001096921.1 
C: NP_001096922.1 
D: NP_001245592.1 
E: FBpp0303736 
5 isoforms; all contain 
DHHC motif 
isoform A: weak; a.a. 225-239 
isoform B: weak; a.a. 225-239 
isoform C: weak; a.a.225-239 
 
Dnz1 
(CG6627) 
NP_477449.1    
GABPI 
(CG17257) 
A: NP_722869.1 
B: NP_608741.1 
  contains DHHS 
instead of DHHC 
Hip14 
(CG6017) 
A: NP_648824.1 
B: FBpp0303194 
C: FBpp0305754 
3 listed isoforms; 
isoforms A and C are 
identical; all contain 
DHHC motif 
isoforms A/C: a.a. 573-587  
patsas 
(CG6618) 
NP_723724.1  a.a. 553-567  
TABLE 3.4: Collated information on D. melanogaster DHHC enzymes 
Information was collected from FlyBase (http://flybase.org/), the NCBI website and (Gonzalez 
Montoro et al., 2009).  app, approximated; Dnz1, DNZDHHC/NEW1 zinc finger protein 11; GABPI, 
β1,4-N-acetylgalactosaminyltransferase B pilot; Hip, huntingtin-interacting protein.  
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Gene Protein ID(s) Isoforms/ Variants 
PaCCT 
Motif Localisation Notes 
ZDHHC1 NP_037436.1   ER1  
ZDHHC2 NP_057437.1   ER1; Golgi1 also called REAM; deleted in 
many cancers; putative 
tumour suppressor 
ZDHHC3 1: NP_001128651.1, 
2: NP_057682.1 
2 isoforms; both 
contain DHHC 
 Golgi1 also called GODZ; mediates 
membrane Ca2+ transport3 
ZDHHC4 1: NP_001127859.1, 
2: NP_001127860.1, 
3: NP_060576.1, 
4: NP_001127861.1  
4 variants in the 
5’-UTR; protein 
sequence 
identical 
a.a. 
317-331 
Golgi1  
ZDHHC5 NP_056272.2  a.a. 
230-254 
PM1  
ZDHHC6 NP_071939.1   ER1  
ZDHHC7 1: NP_001139020.1, 
2: NP_060210.2 
2 isoforms; both 
contain DHHC 
 Golgi1 also called SERZ 
ZDHHC8 NP_037505.1  a.a. 
230-254 
Golgi1 may be associated with risk 
of schizophrenia4 
ZDHHC9 1: NP_057116.2, 
2: NP_001008223.1 
2 variants: 2 has 
alternate and 
shorter 5’-UTR 
 ER1; Golgi1 ZDHHC10 was found to be 
identical to ZDHHC9; 
upregulated in colon cancer5; 
mutated in XLMR6 
ZDHHC11 NP_079062.1   ER1 gain of function in bladder 
cancer7 
ZDHHC11B P0C7U3.1, 
XP_003403828.2, 
XP_003118580.3 
   predicted gene; similar to 
ZDHHC11 
ZDHHC12 NP_116188.2  a.a. 
229-253 
ER1; Golgi1 also called AID 
ZDHHC13 1: NP_061901.2, 
2: NP_001001483.1 
2 isoforms; both 
contain DHHC 
isoform 1: 
a.a. 
574-588 
ER1; Golgi1 also called HIP14L; chanzyme 
involved in Mg2+ transport8 
ZDHHC14 1: NP_078906.2, 
2: NP_714968.1 
2 isoforms; both 
contain DHHC 
isoform 1: 
a.a. 
299-315 
ER1 putative oncogene in 
lymphomas9 
ZDHHC15 1: NP_659406.1, 
2: NP_001139728.1, 
3: NP_001139729.1 
3 isoforms; all 
contain DHHC 
 Golgi1 loss of expression associated 
with XLMR10; isoform 3 has 
no DHHC motif 
ZDHHC16 1: NP_115703.2 
(NP_932163.1), 
2: NP_932160.1, 
3: NP_932161.1, 
4: NP_932162.1 
4 isoforms; 1 has 
two accessions; 
all contain DHHC 
 ER2 also called Aph-2 
ZDHHC17 NP_056151.2  a.a. 
584-598 
Golgi1 also called HIP14; chanzyme 
involved in Mg2+ transport8 
ZDHHC18 NP_115659.1   Golgi1  
ZDHHC19 NP_001034706.1  a.a. 
237-251 
ER1  
ZDHHC20 NP_694983.2  a.a. 
257-271 
PM1 overexpressed in many 
tumours11 
ZDHHC21 NP_848661.1   PM1; ER1  
ZDHHC22 NP_777636.2     
ZDHHC23 NP_775841.2   ER1 also called NIDD 
ZDHHC24 NP_997223.1   ER1  
1(Ohno et al., 2006) 2(Li et al., 2002) 3(Hines et al., 2010) 4(Faul et al., 2005) 
5(Mansilla et al., 2007) 6(Raymond et al., 2007) 7(Yamamoto et al., 2007) 8(Goytain et al., 2008) 
9(Rinaldi et al., 2006) 10(Mansouri et al., 2005) 11(Draper and Smith, 2010) 
TABLE 3.5: Collated information on H. sapiens DHHC enzymes 
Information was collected from the NCBI website, (Gonzalez Montoro et al., 2009) and literature 
searches.  AID, amyloid precursor protein-interacting DHHC; Aph, Abl-philin; ER, endoplasmic 
reticulum; GODZ, Golgi-associated DHHC zinc finger protein; HIP, huntingtin-interacting protein; 
HIP14L, HIP14-like; HPO, hypersensitive to pore-forming toxin; NIDD, neural nitric oxide synthase-
interacting DHHC domain-containing protein with dendritic mRNA; PM, plasma membrane; REAM, 
reduced expression associated with metastasis; SERZ, Sertoli cell gene with a zinc finger domain; 
UTR, untranslated region; XLMR, X-linked mental retardation.  
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as stated above DHHC11B is not normally viewed as a DHHC enzyme.  As with the  
S. cerevisiae DHHCs, most of the H. sapiens family show localisation to intracellular 
membranes – 11 to the Golgi, 13 to the endoplasmic reticulum (ER) – and three also show 
localisation to the plasma membrane.  Interestingly, DHHC3, -13 and -17 have been shown 
to also act in ion transport (Goytain et al., 2008; Hines et al., 2010) and all show Golgi 
localisation.  The dual properties of ion channel and enzyme qualify these proteins as 
chanzymes (Montell, 2003).  Nine H. sapiens DHHCs contain a PaCCT motif, roughly similar 
in proportion to the S. cerevisiae family.  Again, the significance of this motif has not been 
explored outside of the S. cerevisiae proteins (Gonzalez Montoro et al., 2009). 
Many of the disease associations shown in Table 3.5 are the result of genome-wide 
association studies.  However DHHC17/HIP14 was found to have an interaction with 
huntingtin (Htt) which inversely correlates with the length of the Htt expanded 
polyglutamine repeat region (Singaraja et al., 2002).  The same study found that 
DHHC17/HIP14 is expressed in a specific subset of mouse striatal neurons affected in 
Huntington’s disease (HD): those which project to the globus pallidus.  DHHC17/HIP14 has 
been found to palmitoylate Htt at cysteine-214, close to the polyglutamine tract, and this is 
also reduced with an expanded polyglutamine region (Huang et al., 2004; Yanai et al., 
2006).  It is directly involved in the pathogenesis of HD, as in mouse neurons expressing 
both wild-type and polyglutamine-expanded Htt downregulation of DHHC17/HIP14 by small 
interfering RNA (siRNA) increased formation of inclusions, whereas overexpression reduced 
inclusions (Yanai et al., 2006).  DHHC17/HIP14 is currently the only DHHC for which a 
disease association has been so thoroughly explored.  Recently the relationship of the 
similar enzyme DHHC13/HIP14-like (HIP14L) to Htt was also investigated in a knockout 
mouse (see Section 3.4.1.3) (Sutton et al., 2012). 
3.3.1.3.4 SEQUENCE ANALYSIS 
Given the lack of experimental information on the vast majority of the C. elegans DHHCs, a 
comparison with the DHHCs in the organisms named above may provide some insight.  First 
of all, it would be helpful to see how the C. elegans DHHCs fit in evolutionarily with these 
other families.  To do this, the protein sequences of DHHC enzymes from S. cerevisiae,  
D. melanogaster and H. sapiens were combined with the C. elegans sequences for a large 
scale phylogenetic analysis (Figure 3.4).  Only the conserved DHHC-CRDs were compared in 
this analysis in order to make the computation more manageable.  Comparing the locations 
of the C. elegans DHHCs on this tree with the previous one containing only the C. elegans 
family (Figure 3.3) shows that the pairs are maintained, although their precise position in 
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FIGURE 3.4: Phylogenetic tree of known and putative DHHC enzymes in evolutionarily important 
organisms 
The conserved cysteine-rich domain containing the DHHC motif in S. cerevisiae (red), C. elegans 
(blue), D. melanogaster (green) and H. sapiens (brown) were subjected to phylogenetic analysis.  The 
resulting tree was rendered and coloured using Interactive Tree of Life (Letunic and Bork, 2007).  
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relation to each other has changed in some cases.  This may reflect differing areas of 
similarity around the DHHC-CRD compared with the N- and C-termini of the full length 
sequence used for the earlier analysis.  The C. elegans DHHCs also appear mostly to be 
related, albeit distantly in some cases, to proteins in other organisms, allowing predictions 
to be made based on knowledge from other organisms.  The most distant proteins are 
DHHC-5 and the pair DHHC-13 and -14 so these may show more functional divergence from 
other organisms. 
A feature of the phylogenetic tree which stands out is the cluster of nine D. melanogaster 
DHHCs which seem to have only one close relation in H. sapiens (DHHC24) and in C. elegans 
(DHHC-10).  These genes are highly expressed in the D. melanogaster adult testes according 
to FlyAtlas (Chintapalli et al., 2007).  Of these nine, CG17195, CG17196, CG17197, CG17198 
and CG4956 are arranged concurrently in the 96F2 region of chromosome III.  They are 
believed to be the result of a gene duplication event which occurred after the split between 
the melanogaster and obscura groups in the Sophophora subgenus with CG4956 as the 
original gene as it is the only one with orthologues in all the Drosophila species (Bannan et 
al., 2008).  This accounts for their high relatedness and thus their clustering on the 
phylogenetic tree. 
Whilst the consensus sequence for DHHCs is quite precisely defined, it has been noted that 
there are variations within it which seem to be tolerated (Mitchell et al., 2006).  With this in 
mind, the enzyme sequences from the organisms of interest were aligned with the focus on 
the region containing the full consensus sequence (Figure 3.5).  There does indeed seem to 
be variation in how important individual residues in the consensus sequence are.  The only 
residues which are absolutely conserved are the aspartate of the DHHC motif and the 
asparagine which is the penultimate residue in the sequence.  Although absolutely 
conserved among the C. elegans DHHCs, many of the cysteine residues which form the CRD 
are missing from some enzymes.  The most obvious are the S. cerevisiae DHHCs Akr1 and -2 
and the H. sapiens DHHC22, which are missing five and two cysteines respectively.  Four 
other residues at the N-terminal end of the consensus are also absent from DHHC22.  These 
residues do seem to be less critical and one or more of them are also missing from the  
C. elegans DHHC-1, -6, -9 and -11 to -14.  Even the DHHC motif, required for enzymatic 
activity, is not absolutely conserved.  The S. cerevisiae DHHCs Akr1, Akr2 and Pfa5 have a 
tyrosine instead of a histidine residue in the third position, although these enzymes retain 
their palmitoyltransferase activity (Mitchell et al., 2006).  The histidine residue in the 
second position is changed to an arginine in D. melanogaster CG17197 and glutamine in 
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Akr1 KNFCIETWIRK-PLRSKFSPLNNA-----VVARFDHYCPWIFNDVGLK---------------N-HKAFIFF 
Akr2 ENFCVETLERK-PLRSKYSFFSGA-----LVARYDHYCPWIYNDVGLK---------------N-HKLFVFF 
Erf2 IKYCPSCRIWR-PPRSSHCSTCNV-----CVMVHDHHCIWVNNCIGKR---------------N-YRFFLIF 
Pfa3 FRVCQVCHVWK-PDRCHHCSSCDV-----CILKMDHHCPWFAECTGFR---------------N-QKFFIQF 
Pfa4 -NFCKKCQSYK-PERSHHCKTCNQ-----CVLMMDHHCPWTMNCVGFA---------------N-YPHFLRF 
Pfa5 PIWCSECQSLK-MERTHHSSELGH-----CIPRFDHYCMWIGTVIGRD---------------N-YRLFVQF 
Swf1 AIKCSTCRIVK-PARSKHCSICNR-----CVLVADHHCIWINNCIGKG---------------N-YLQFYLF 
YNL155W GKHCAYCRQLD--FLPFHCSFCNEDFCSNHRLKEDHHCRWLLEHEEVHKTEKSPSKSRDGSSSNDEAYFKSL 
DHHC-1 YKHCHSCHSMS-PLRAHHCPVCDV-----CILRRDHHCSFGAVCVGHF---------------N-QRYFVAA 
DHHC-2 MKYCTTCRLYR-PPRCSHCAICDN-----CVLMFDHHCPWVGNCIGLR---------------N-YTYFYRF 
DHHC-3 IYKCQKCASIK-PDRAHHCSVCER-----CIRRMDHHCPWVNNCVGEG---------------N-QKFFVLF 
DHHC-4 IRFCDKCCCIK-PDRSHHCSMCEQ-----CVLKFDHHCPWVNNCVNFG---------------N-YKYFILF 
DHHC-5 -DVCQLCNYRK-PPRWHHCRRCNL-----CVHRMDHHCPILQLCIHSG---------------N-HKYFLLF 
DHHC-6 -QFCVPCNGFK-VPRSHHCSKCDR-----CCMKMDHHCPWINNCVGHR---------------N-HQYFLRF 
DHHC-7 WTMCTRCDSLR-PPRAHHCRVCKR-----CVRKMDHHCPWVNNCVGEY---------------N-QKWFLQF 
DHHC-8 MKWCVTCKFYR-PPRSSHCSVCNR-----CIETFDHHCPWVHNCVGKR---------------N-YRYFFFF 
DHHC-9 DSFCSKCNYWK-SDNAHHCSVCEK-----CVLGMDHHCIWINQCVGLH---------------N-HRHFFLF 
DHHC-10 SKFCFTCNKEA-PQRSHHCPLCKM-----CVLRKDHHCFITGACVGLG---------------N-QRYFMVF 
DHHC-11 NSFCSICEVRT-YRETKHCKRCNF-----CIDDFDHHCVWLNNCIGGK---------------N-YRPFVVL 
DHHC-12 DSFCIKCNNWK-GPSTSHCKACDK-----CIYRMDHHCPHIGQCVGAH---------------N-QSHFFLF 
DHHC-13 DRYCFTCWIPK-TSSSHHCSQCDK-----CVDGFDHHCPWIHKCVYRK---------------N-LRAFVFF 
DHHC-14 QKYCFTCFIRK-MDHTKHCAVCGF-----CVNNFDHHCPWLNSCVTRR---------------N-MREFIMF 
SPE-10 LKYCYECGHIK-PDRARHCSSCGK-----CCIKYDHHCPWINMCVTHV---------------N-YKYFLLY 
app LKYCFTCKIFR-PPRASHCSLCDN-----CVDRFDHHCPWVGNCVGKR---------------N-YRFFYLF 
CG1407 VRFCEKCKIIK-PDRAHHCSVCSC-----CVLKMDHHCPWVNNCVNFY---------------N-YKYFVLF 
CG4483 -QFCTRCNGYK-APRSHHCRRCNR-----CVMKMDHHCPWINTCVGWS---------------N-QDSFVYF 
CG4676 WHSCQDCQTLV-PPRSWHCEVCNV-----CVLKRDHHCRFTCCCIGHH---------------N-YRYFFYY 
CG4956 WHYCSTCQKLV-PPRSWHCSLCNI-----CILKRDHHCTFFASCIGHK---------------N-QRYFLAF 
CG5196 -QYCKKCEGYK-APRSHHCRKCDR-----CVKKMDHHCPWINHCVGWA---------------N-HAYFTYF 
CG5880 VSMCGKCIAPK-PPRTHHCSICNR-----CILKMDHHCPWLNNCVGYG---------------N-HRYFFLY 
CG8314 FYKCPKCCSIK-PERAHHCSVCQR-----CIRKMDHHCPWVNNCVGEN---------------N-QKYFVLF 
CG10344 WRECGECQKLA-PPRSWHCKACKV-----CILKRDHHCIYTGCCIGLR---------------N-HRFFMGF 
CG13029 WHFCDHCQMLV-PPRSWHCKVCEC-----CILRRDHHCIFTATCVGHT---------------N-YRYFFWF 
CG17075 NGRCHLCNIRTSSNRTKHCSVCNK-----CVGKFDHHCKWLNHCIGSR---------------N-YVAFLMC 
CG17195 WHYCESCKKLR-SPRSWHCVLCNT-----CILRRDHHCIFTGTCIGHN---------------N-QRFFFWF 
CG17196 WHYCDICQKLM-PPRSWHCALCKC-----CILKRDHHCIFAATCIGHN---------------N-HRYFFWL 
CG17197 WHYCDVCEKLM-PPRSWHCILCKC-----CILKRDRHCIFTASCVGHN---------------N-QRYFFWF 
CG17198 WHFCKICQRNV-PPRSWHCNICDA-----CILKRDHHCNFVGNCVGHN---------------N-QRYFIWF 
CG17287 VRYCKTCWIIK-PDRAHHCRTCHM-----CVLKMDHHCPWIVNCVHFH---------------N-FKYFILF 
CG18810 WHECDKCGILA-PPRSRHCRKCGV-----CVLMRDHHCFFTGCCIGHE---------------N-YRYFFYF 
CG34449 MKWCVTCKFYR-PPRCSHCSVCNH-----CIETFDHHCPWVNNCIGRR---------------N-YRFFFFF 
Dnz1 WTVCTRCETYR-PPRAHHCRICKR-----CIRRMDHHCPWINNCVGER---------------N-QKYFLQF 
GABPI PNICEICRKVT-PRRAYHCPVCGT-----CVKRRDHHSYWLNCCIGER---------------N-YVWYIVG 
Hip14 ASFCSGCLVRR-PIRSKHCSVCDR-----CVARFDHHCPWVGNCIGLK---------------N-HSYFMGF 
patsas TRLCHSCRCLR-PLRAKHCRVCNR-----CVSYFDHHCPFIYNCVGLR---------------N-RMWFFLF 
DHHC1 DLHCNLCNVDV-SARSKHCSACNK-----CVCGFDHHCKWLNNCVGER---------------N-YRLFLHS 
DHHC2 IRYCDRCQLIK-PDRCHHCSVCDK-----CILKMDHHCPWVNNCVGFS---------------N-YKFFLLF 
DHHC3 VYKCPKCCSIK-PDRAHHCSVCKR-----CIRKMDHHCPWVNNCVGEN---------------N-QKYFVLF 
DHHC4 NVRCSTCDLRK-PARSKHCSVCNW-----CVHRFDHHCVWVNNCIGAW---------------N-IRYFLIY 
DHHC5 MKWCATCRFYR-PPRCSHCSVCDN-----CVEEFDHHCPWVNNCIGRR---------------N-YRYFFLF 
DHHC6 -QYCKVCQAYK-APRSHHCRKCNR-----CVMKMDHHCPWINNCCGYQ---------------N-HASFTLF 
DHHC7 IYKCPKCCCIK-PERAHHCSICKR-----CIRKMDHHCPWVNNCVGEK---------------N-QRFFVLF 
DHHC8 MKWCATCHFYR-PPRCSHCSVCDN-----CVEDFDHHCPWVNNCIGRR---------------N-YRYFFLF 
DHHC9 LKYCYTCKIFR-PPRASHCSICDN-----CVERFDHHCPWVGNCVGKR---------------N-YRYFYLF 
DHHC11 NQFCHLCKVTV-NKKTKHCISCNK-----CVSGFDHHCKWINNCVGSR---------------N-YWFFFST 
DHHC11B NQFCHLCKVTV-NKKTKHCISCNK-----CVSGFDHHCKWINNCVGSR---------------N-YWFFFST 
DHHC12 LRRCRYCLVLQ-PLRARHCRECRR-----CVRRYDHHCPWMENCVGER---------------N-HPLFVVY 
DHHC13 RTFCTSCLIRK-PLRSLHCHVCNC-----CVARYDQHCLWTGRCIGFG---------------N-HHYYIFF 
DHHC14 LKYCFTCKIFR-PPRASHCSLCDN-----CVERFDHHCPWVGNCVGKR---------------N-YRFFYMF 
DHHC15 VRFCDRCHLIK-PDRCHHCSVCAM-----CVLKMDHHCPWVNNCIGFS---------------N-YKFFLQF 
DHHC16 VSICKKCIYPK-PARTHHCSICNR-----CVLKMDHHCPWLNNCVGHY---------------N-HRYFFSF 
DHHC17 SIFCSTCLIRK-PVRSKHCGVCNR-----CIAKFDHHCPWVGNCVGAG---------------N-HRYFMGY 
DHHC18 LKYCFTCKMFR-PPRTSHCSVCDN-----CVERFDHHCPWVGNCVGRR---------------N-YRFFYAF 
DHHC19 LQWCPKCCFHR-PPRTYHCPWCNI-----CVEDFDHHCKWVNNCIGHR---------------N-FRFFMLL 
DHHC20 IRYCEKCQLIK-PDRAHHCSACDS-----CILKMDHHCPWVNNCVGFS---------------N-YKFFLLF 
DHHC21 WELCNKCNLMR-PKRSHHCSRCGH-----CVRRMDHHCPWINNCVGED---------------N-HWLFLQL 
DHHC22 KT------PCP-SPSTHFCRVCAR-----VTLRHDHHCFFTGNCIGSR---------------N-MRNFVLF 
DHHC23 EDWCAKCQLVR-PARAWHCRICGI-----CVRRMDHHCVWINSCVGES---------------N-HQAFILA 
DHHC24 WAYCYQCQSQV-PPRSGHCSACRV-----CILRRDHHCRLLGRCVGFG---------------N-YRPFLCL 
FIGURE 3.5: Alignment of the conserved region of the DHHC enzymes in organisms of interest 
An alignment highlighting the consensus Cx2Cx3(R/K)PxRx2HCx2Cx2Cx4DHHCxW(V/I)xNC(I/V)Gx2Nx3F.  
The DHHC enzymes in S. cerevisiae (red lettering), C. elegans (blue), D. melanogaster (green) and  
H. sapiens (brown) are shown.  
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H. sapiens DHHC13/HIP14L.  Again, while the former has not been studied, HIP14L is known 
to have palmitoyltransferase activity (Huang et al., 2009).  The cysteine in the DHHC motif is 
changed to a serine residue in the D. melanogaster DHHC β1,4-N-acetylgalactosaminyl-
transferase B pilot (GABPI).  Given that this cysteine residue is required to form the 
palmitoyl-enzyme intermediate (Mitchell et al., 2010) and its mutation to serine is a 
common way to inactivate DHHCs, it is likely that GABPI has no palmitoyltransferase activity 
in vivo. 
In addition to the DHHC-CRD, there are two other regions of relatively high sequence 
conservation which have been observed in DHHCs.  There is an aspartate-proline-glycine 
(DPG) motif commonly next to TMD2 and a threonine-threonine-x-glutamate (TTxE) motif 
commonly next to TMD4 (Mitchell et al., 2006).  The DPG motif can be found in C. elegans 
DHHC-2, -3, -5 and -7, and the TTxE motif in C. elegans DHHC-3, -4, -6 and -10 and SPE-10.  
The functional significance of these motifs is not yet known. 
In addition to the phylogenetic analysis and the sequence alignments, the sequences of the 
C. elegans DHHC enzymes were inputted into basic local alignment search tool (BLAST) 
searches to identify possible orthologues in the other species discussed here (Table 3.6).  
This will provide additional evidence which may add confidence to any putative 
orthologues.  As might be expected, there is some variety as to how closely related these 
proteins are to those in other species.  Generally speaking, the lowest confidence hits occur 
in the S. cerevisiae family.  This may be attributed to the small size of the family in  
S. cerevisiae and indicates that expansion of the family over evolutionary time has not been 
limited to gradual changes to existing genes.  It also agrees with the phylogenetic analysis, 
in which few of the C. elegans DHHCs are positioned particularly close to the S. cerevisiae 
DHHCs.  S. cerevisiae Pfa4 is positioned close to C. elegans DHHC-5, -9 and -12 on the 
phylogenetic tree, yet of these three only DHHC-12 shows Pfa4 as its closest match.  This 
may be because the phylogenetic tree was constructed using only the DHHC-CRD region of 
the sequences, whereas the BLAST searches were conducted with the full sequence.  A 
similar explanation accounts for the fact that DHHC-13 and -14, which have N-terminal 
ankyrin repeat regions, show Akr1 and -2 as their closest matches respectively but have a 
relatively distant position on the phylogenetic tree.  Indeed these are the highest 
confidence matches amongst the S. cerevisiae proteins.  Two isoforms of C. elegans DHHC-4 
do not match up to S. cerevisiae DHHC proteins presumably because they lack the exon 
containing the DHHC motif.  However, they do still show DHHC proteins as their closest 
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C. elegans 
DHHC 
S. cerevisiae D. melanogaster H. sapiens 
Protein E value Identity Protein E value Identity Protein E value Identity 
DHHC-1 Pfa3 8e-14 28% CG10344B 1e-24 26% DHHC24 6e-23 32% 
DHHC-2 Erf2 3e-30 31% AppH 7e-86 46% DHHC14 
isoform 2 
9e-94 42% 
DHHC-3 Pfa3 2e-22 37% CG8314 2e-86 50% DHHC3 
isoform 1 
4e-98 56% 
DHHC-4a Pfa3 2e-20 26% CG1407A 2e-78 38% DHHC2 1e-79 38% 
DHHC-4b Pfa3 1e-20 26% CG1407A 2e-78 38% DHHC2 7e-80 38% 
DHHC-4c Pfa3 6e-21 26% CG1407A 1e-75 42% DHHC2 2e-77 39% 
DHHC-4d Pfa3 2e-23 28% CG1407A 5e-81 39% DHHC2 2e-83 40% 
DHHC-4e Frk1 0.037 25% CG1407A 1e-20 36% DHHC2 5e-21 49% 
DHHC-4f Ade5,7 0.035 27% CG1407A 1e-09 30% DHHC2 4e-09 49% 
DHHC-5 Pfa3 8e-16 29% CG8314 4e-20 30% DHHC21 7e-22 30% 
DHHC-6 Pfa4 2e-19 34% CG5196A 5e-81 36% DHHC6 1e-86 35% 
DHHC-7a Pfa3 5e-17 35% Dnz1 7e-80 42% DHHC7 
isoform 2 
7e-49 34% 
DHHC-7b Pfa3 8e-18 32% Dnz1 2e-60 44% DHHC3 
isoform 1 
6e-34 35% 
DHHC-8 Erf2 4e-23 31% CG34449D 2e-76 51% DHHC8 
isoform 2 
5e-75 50% 
DHHC-9 Erf2 3e-17 26% CG5880 3e-35 29% DHHC16 
isoform 2 
1e-31 34% 
DHHC-10 Pfa4 6e-15 41% CG10344B 1e-18 44% DHHC24 3e-15 31% 
DHHC-11 Swf1 1e-15 33% CG17075A 6e-19 38% DHHC11 3e-20 28% 
DHHC-12 Pfa4 4e-16 42% CG5196B 1e-17 27% DHHC16 
isoform 2 
3e-17 29% 
DHHC-13 Akr1 2e-33 28% Hip14 3e-43 31% DHHC17 5e-42 28% 
DHHC-14a Akr2 1e-35 24% Hip14 1e-68 29% DHHC17 2e-72 30% 
DHHC-14b Swf1 1e-14 31% AppO 6e-21 27% DHHC17 6e-25 33% 
SPE-10 Pfa3 1e-17 27% CG1407B 3e-43 31% DHHC2 3e-37 31% 
TABLE 3.6: Orthologues of C. elegans DHHC enzymes in other organisms 
BLAST searches were conducted using the protein sequences of each of the C. elegans DHHC 
enzymes.  The closest matches in S. cerevisiae, D. melanogaster and H. sapiens are shown along with 
relevant parameters.  Ade, adenine-requiring; BLAST, basic local alignment search tool; Frk, fatty 
acyl-CoA synthetase and RNA processing-associated kinase.  
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matches in D. melanogaster and H. sapiens, showing DHHC-4 has relatively high homology 
to these proteins outside of the DHHC-CRD. 
The C. elegans DHHCs show somewhat higher confidence comparisons with the  
D. melanogaster family.  The highest confidence orthologues are between DHHC-2 and 
approximated (App) and between DHHC-3 and CG8314, both of which show high 
relatedness on the phylogenetic tree.  Two pairs which stand out on the phylogenetic tree, 
DHHC-7 with DNZDHHC/NEW1 zinc finger protein 11 (Dnz1) and DHHC-8 with CG34449, 
also come out as orthologues with a high degree of confidence through BLAST searching.  
The ankyrin repeat-containing proteins DHHC-13 and -14 again come closest to one of the 
D. melanogaster ankyrin repeat-containing proteins, Hip14 (the other is Patsas).  The lowest 
confidence hits come from C. elegans DHHC-10, -11 and -12.  In the case of DHHC-10 this is 
somewhat surprising given its position on the phylogenetic tree adjacent to a large 
subfamily of D. melanogaster proteins, even though the closest D. melanogaster protein is 
the same in both cases.  This suggests the DHHC-CRD is highly similar but there may be a 
large degree of divergence outside of this domain.  A similar explanation may account for 
the relatively low confidence between DHHC-11 and CG17075 despite appearing quite 
closely related on the phylogenetic tree. 
The highest overall confidence for orthologues of the C. elegans DHHCs comes from the  
H. sapiens family.  Again the highest confidence comes from the C. elegans proteins  
DHHC-2 and -3, homologous to H. sapiens DHHC14 and -3/GODZ respectively.  Another 
group has previously found DHHC-3 to be the C. elegans orthologue of DHHC3/GODZ and 
the most closely related D. melanogaster protein to be CG8314 (Uemura et al., 2002).  
Other high confidence hits include C. elegans DHHC-4 with H. sapiens DHHC2, DHHC-6 with 
DHHC6, DHHC-8 with DHHC8 and DHHC-14 with DHHC17/HIP14.  The other ankyrin repeat-
containing protein DHHC-13 is also most homologous to H. sapiens DHHC17/HIP14.  
Interestingly, when just the DHHC-CRD is analysed as in the phylogenetic tree (Figure 3.4), 
the ankyrin-repeat containing proteins from S. cerevisiae, D. melanogaster and H. sapiens 
form a subgroup even though the region is not included in the analysis.  The C. elegans 
counterparts are placed elsewhere on the tree, suggesting a degree of genetic separation 
compared with the other species.  As C. elegans are predominantly hermaphrodites and 
have genetically identical progeny, this may be a result of genetic drift from a gradual 
accumulation of mutations.  The lowest confidence comparisons between C. elegans and  
H. sapiens DHHCs again come from C. elegans DHHC-10, -11 and -12.  This suggests these 
enzymes may have arisen in C. elegans independently. 
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3.3.1.3.5 ENZYME-SUBSTRATE INTERACTIONS 
As there is no information available for substrates of the C. elegans DHHCs, some insight 
may be gained by studying the known enzyme-substrate pairs in the other organisms.  
These are listed in Table 3.7.  By far the most is known about the substrates of H. sapiens 
DHHCs.  Most of these studies have focused on finding the DHHCs responsible for 
palmitoylating a particular protein.  Some enzymes seem to have a particularly broad 
specificity and appear in many studies, for example DHHC3/GODZ, DHHC7/SERZ and 
DHHC17/HIP14.  DHHC3/GODZ and DHHC7/SERZ in particular seem to have many 
substrates in common with each other.  This may be a result of their high level of 
relatedness as seen in phylogenetic trees of just the DHHC-CRD (Figure 3.4) and the entire 
sequence (Korycka et al., 2012).  However many of the substrates of DHHC17/HIP14 do not 
seem to be shared with the similar enzyme DHHC13/HIP14L.  It is possible this is a result of 
different subcellular localisations.  DHHC17/HIP14 has been shown to be mainly localised to 
the Golgi (Huang et al., 2004; Singaraja et al., 2002).  The D. melanogaster orthologue 
Hip14 also localises to presynaptic vesicles and the plasma membrane in neurons (Ohyama 
et al., 2007; Stowers and Isacoff, 2007), although H. sapiens DHHC17/HIP14 did not 
colocalise with synaptophysin, a presynaptic marker, in rat hippocampal neurons (Huang et 
al., 2009).  DHHC13/HIP14L, in contrast, is localised to the ER.  Some proteins are 
palmitoylated by a variety of enzymes, for example SNAP-25 is palmitoylated by 
DHHC2/reduced expression associated with metastasis (REAM), DHHC3/GODZ, 
DHHC7/SERZ, DHHC8, DHHC13/HIP14L and DHHC17/HIP14.  Alternatively some enzyme-
substrate pairs seem to be highly specific, such as DHHC19 and R-Ras and DHHC17/HIP14 
and synaptotagmin-1. 
In order to try to predict possible palmitoyl-proteins in C. elegans, BLAST searches were 
conducted to find orthologues of the known palmitoyl-proteins from S. cerevisiae (Table 
3.8).  These comprised the proteins identified using a proteomic analysis (Roth et al., 2006) 
and those identified as substrates of specific DHHCs (Table 3.7).  There is a large variation in 
the confidence of these hits.  Some of the higher confidence orthologues include the casein 
kinases (Yck1-3 in S. cerevisiae; CSNK-1 in C. elegans), tubulin and G protein α subunits 
(Gpa1/2 in S. cerevisiae; GOA-1 in C. elegans).  A similar analysis was done using the 
mammalian proteins with known substrates identified in Table 3.7 (Table 3.9).  Although 
proteome scale analyses of palmitoyl-proteins exist in many mammalian tissues and cell 
types, the lists of identified proteins stretch to hundreds.  For this reason it was decided 
only to find orthologues for proteins whose DHHC partners are known.  The C. elegans 
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DHHC 
enzyme Species Substrate(s) Evidence 
Akr1 S. cerevisiae Anr2, Env7, Lcb4, Meh1, Rho3, 
Sna4, Vac8, Yck1, Yck2, Yck3, 
Ypl199c 
(Hou et al., 2009; Kihara et al., 2005; Pasula et al., 
2010; Roth et al., 2002; Roth et al., 2006; Wu and 
Brennwald, 2010) 
Erf21 S. cerevisiae Gpa2, Ras1, Ras2, Rho2, Rho3, 
Vac8, Yck3 
(Hou et al., 2009; Lobo et al., 2002; Roth et al., 2006) 
Pfa3 S. cerevisiae Vac8, Yck3 (Hou et al., 2009; Hou et al., 2005; Smotrys et al., 
2005) 
Pfa4 S. cerevisiae Agp1, Bap2, Chs3, Gap1, Gnp1, 
Hip1, Rif1, Tat1, Tat2 Vac8, 
Yck3 
(Hou et al., 2009; Lam et al., 2006; Park et al., 2011; 
Roth et al., 2006) 
Pfa5 S. cerevisiae Vac8, Yck3 (Hou et al., 2009) 
Swf1 S. cerevisiae Mnn11, Pin2, Snc1, Sso1, Sso2, 
Ste18, Syn8, Tlg1, Ypl199c 
(Roth et al., 2006; Valdez-Taubas and Pelham, 2005) 
Hip14 D. melanogaster CSP, Sog (Kang and Bier, 2010; Ohyama et al., 2007) 
DHHC2/ 
REAM 
H. sapiens ABCA1, CD9, CD151, 
CKAP4/p63, eNOS, Lck, Nde1, 
Ndel1, PI4KIIα, PSD-95, R7BP, 
SNAP-23, SNAP-25,  
stathmin 2-4 
(Fernandez-Hernando et al., 2006; Fukata et al., 
2004; Greaves et al., 2010; Jennings et al., 2009; Jia 
et al., 2011; Levy et al., 2011; Lu et al., 2012; Sharma 
et al., 2008; Shmueli et al., 2010; Singaraja et al., 
2009; Zhang et al., 2008) 
DHHC3/ 
GODZ 
H. sapiens AMPA receptor subunits 
GluR1/2, BACE1, CL3/CaMKIγ, 
CSP, DR4, eNOS, Gαi2, Gαq, Gαs, 
GABAA receptor γ2 subunit, 
GAD65, integrin α6β4, NCAM, 
Nde1, Ndel1, NR2A/B, PI4KIIα, 
PSD-95, RGS4, SNAP-23,  
SNAP-25, stathmin 2-4, STREX 
(Fernandez-Hernando et al., 2006; Fukata et al., 
2004; Greaves et al., 2010; Greaves et al., 2008; 
Hayashi et al., 2009; Huang et al., 2009; Keller et al., 
2004; Levy et al., 2011; Lu et al., 2012; Oh et al., 
2012; Ponimaskin et al., 2008; Sharma et al., 2012; 
Takemoto-Kimura et al., 2007; Tian et al., 2010; 
Tsutsumi et al., 2009; Vetrivel et al., 2009; Wang et 
al., 2010) 
DHHC4 H. sapiens BACE1 (Vetrivel et al., 2009) 
DHHC5 H. sapiens flotillin-2, GRIP1, SSTR5, 
stathmin 2, STREX 
(Kokkola et al., 2011; Levy et al., 2011; Li et al., 2012; 
Thomas et al., 2012; Tian et al., 2010) 
DHHC6 H. sapiens calnexin (Lakkaraju et al., 2012) 
DHHC7/ 
SERZ 
H. sapiens AR, BACE1, CSP, eNOS, ER, 
Gαi2, Gαq, Gαs, GABAA receptor 
γ2 subunit, GAP43, NCAM, 
Nde1, Ndel1, PDE10A2, 
PI4KIIα, PR, PSD-95, RGS4, 
SNAP-23, SNAP-25, sortilin, 
stathmin 2-4, STREX 
(Charych et al., 2010; Fang et al., 2006; Fernandez-
Hernando et al., 2006; Fukata et al., 2004; Greaves et 
al., 2010; Greaves et al., 2008; Levy et al., 2011; Lu et 
al., 2012; McCormick et al., 2008; Pedram et al., 
2012; Ponimaskin et al., 2008; Tian et al., 2010; 
Tsutsumi et al., 2009; Vetrivel et al., 2009; Wang et 
al., 2010) 
DHHC8 H. sapiens ABCA1, eNOS, GAD65, GRIP1, 
paralemmin-1, PSD-93, PSD-95, 
SNAP-25 
(Fernandez-Hernando et al., 2006; Huang et al., 
2009; Mukai et al., 2008; Singaraja et al., 2009; 
Thomas et al., 2012) 
DHHC92 H. sapiens H-Ras, N-Ras, STREX (Swarthout et al., 2005; Tian et al., 2010) 
DHHC12/
AID 
H. sapiens ABCA1 (Singaraja et al., 2009) 
DHHC13/
HIP14L 
H. sapiens GAD65, Htt (Huang et al., 2009) 
DHHC14 H. sapiens PI4KIIα (Lu et al., 2012) 
DHHC15 H. sapiens ABCA1, BACE1, CD151, CI-MPR, 
CSP, GAP43, PI4KIIα, PSD-95, 
SNAP-25, sortilin, stathmin 2-4 
(Fukata et al., 2004; Greaves et al., 2010; Greaves et 
al., 2008; Levy et al., 2011; Lu et al., 2012; 
McCormick et al., 2008; Sharma et al., 2008; 
Singaraja et al., 2009; Vetrivel et al., 2009) 
DHHC17/
HIP14 
H. sapiens AMPA receptor subunits 
GluR1/2, CSP, GAD65, H-Ras, 
Htt, Lck, N-Ras, PSD-95,  
SNAP-23, SNAP-25, stathmin 2, 
STREX, synaptotagmin-1 
(Ducker et al., 2004; Fukata et al., 2004; Greaves et 
al., 2010; Greaves et al., 2008; Huang et al., 2009; 
Huang et al., 2004; Levy et al., 2011; Tian et al., 
2010) 
DHHC18 H. sapiens Lck, H-Ras (Fukata et al., 2004) 
DHHC19 H. sapiens PDE10A2, R-Ras (Baumgart et al., 2010; Charych et al., 2010) 
DHHC20 H. sapiens ABCA1, BACE1 (Singaraja et al., 2009; Vetrivel et al., 2009) 
DHHC21 H. sapiens ABCA1, AR, eNOS, ER, Fyn, Lck, 
PI4KIIα, PR, stathmin 2-4 
(Fernandez-Hernando et al., 2006; Levy et al., 2011; 
Lu et al., 2012; Mill et al., 2009; Pedram et al., 2012; 
Singaraja et al., 2009; Tsutsumi et al., 2009) 
DHHC22 H. sapiens BK channel (Tian et al., 2012) 
DHHC23 H. sapiens BK channel (Tian et al., 2012) 
1 Requires Erf4/Shr5 for enzymatic activity (Lobo et al., 2002) 
2 Requires GCP16 for enzymatic activity (Swarthout et al., 2005)  
CHAPTER 3: IN SILICO ANALYSIS 
67 
 
orthologues of mammalian proteins generally speaking have higher confidence.  Proteins 
with close orthologues include: large conductance Ca2+-activated K+ (BK) channels  
(C. elegans SLO-1), Fyn (SRC-2), glutamine decarboxylase GAD65 (UNC-25), G protein α 
subunits (GOA-1, EGL-30, GSA-1), glutamate receptor subunits (GLR-1), phosphodiesterase 
10A2 (PDE-5), phosphatidylinositol 4-kinase IIα (ZC8.6), postsynaptic density proteins  
PSD-93 and -95 (DLG-1) and synaptotagmin-1 (SNT-1).  The two D. melanogaster proteins 
known to be palmitoylated by Hip14, CSP and Sog, correspond to DnaJ domain-containing 
protein 14 (DNJ-14, 3e-23) and cysteine-rich motor neuron protein homologue 1 (CRM-1, 
7e-11) in C. elegans. 
Many large-scale interaction studies have been performed in S. cerevisiae.  These can 
provide another level of analysis on top of the known enzyme-substrate pairs and some 
examples are shown in Table 3.10.  This resource included some, but not all, of the known 
substrates.  The soluble N-ethylmaleimide (NEM)-sensitive fusion protein (NSF)-attachment 
protein (SNAP) receptors (SNAREs) Vac8, Snc1 and Syn8 in S. cerevisiae and SNAP-23 and  
-25 in H. sapiens are known palmitoyl-proteins, suggesting the other SNARE proteins listed 
in Table 3.10 are plausible candidates as substrates.  The proteins Snc2, Sso1 and Tlg2 have 
TABLE 3.7: Known DHHC enzyme-substrate pairs 
Experimentally confirmed substrates for specific DHHC enzymes were found by literature searching.  
ABCA1, ATP-binding cassette transporter A1; Agp, high affinity glutamine permease; AMPA,  
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; Anr, Avl nine related family; AR, androgen 
receptor; BACE1, β-site amyloid precursor protein-cleaving enzyme 1; Bap, branched-chain amino 
acid permease; BK, large conductance Ca2+-activated K+ channel; CD, cluster of differentiation; Chs, 
chitin synthase-related; CI-MPR, cation-independent mannose 6-phosphate receptor; CKAP, 
cytoskeleton-associated protein; CL3/CaMKIγ, Ca2+/calmodulin-dependent protein kinase  
CLICK-III/calmodulin-dependent protein kinase 1γ; CSP, cysteine string protein; DR4, tumour necrosis 
factor-related apoptosis-inducing ligand receptor 1; eNOS, endothelial nitric oxide synthase; Env, late 
endosome and vacuole interface function; ER, oestrogen receptor; GABA, γ-amino butyric acid; GAD, 
glutamate decarboxylase; Gap, general amino acid permease; GAP43, growth-associated protein of 
43 kDa; Gnp, glutamine permease; Gpa, G protein α subunit; GRIP, glutamate receptor interacting 
protein; Lcb, long-chain base; Hip (yeast), histidine permease; Htt, Huntingtin; Lck, lymphocyte-
specific tyrosine kinase; Meh, multicopy suppressor of endoplasmic reticulum retention defective 
(Erd) suppressor 1 (Ers1) hygromycin B sensitivity; Mnn, mannosyltransferase; NCAM, neural cell 
adhesion molecule; PR, progesterone receptor; Nde1, nuclear distribution protein nudE  
homologue 1; Ndel1, nuclear distribution protein nudE-like 1; NR2A/B, N-methyl-D-aspartate 
receptor subunits 2A/2B; PDE10A2, phosphodiesterase 10A2; PI4KIIα, phosphatidylinositol 4-kinase 
type IIα; Pin, Psi+ inducibility; PSD, post-synaptic density; R7BP, regulator of G protein signalling 7 
family binding protein; REAM, reduced expression associated with metastasis; RGS, regulator of G 
protein signaling; Rho, Ras homolog; Rif, repressor activator protein 1 (Rap1)-interacting factor; Sna, 
sensitivity to Na+; SNAP, synaptosomal-associated protein of 25 kDa; Snc, suppressor of the null 
allele of cyclase associated protein; Sog, short gastrulation; Sso, suppressor of Sec one; SSTR5, 
somatostatin receptor 5; Ste, sterile; STREX, stress-regulated exon splice variant of large 
conductance Ca2+- and voltage-activated K+ channels; Swf, spore wall formation; Syn, syntaxin; Tat, 
tyrosine and tryptophan amino acid transporter; Tlg, t-SNARE affecting a late Golgi compartment; 
Vac, vacuole related; Yck, yeast casein kinase.
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Palmitoyl
protein DHHC(s) 
C. elegans 
orthologue E value  
Palmitoyl
protein DHHC(s) 
C. elegans 
orthologue E value 
Agp1 Pfa4 AAT-1 3e-08  Rho3 Akr1, Erf2 RHO-1 3e-57 
Akr1  DHHC-13 3e-29  Rif1 Pfa4 F41H10.4 7e-06 
Anr2 Akr1 T14D7.1 0.039  Sam3  AAT-1 0.006 
Bap2 Pfa4 B0454.6 6e-09  Sna4 Akr1 ALP-1 0.17 
Bet3  ZK1098.5 7e-31  Snc1 Swf1 SNB-1 3e-13 
Chs3 Pfa4 CHS-1 2e-18  Snc2  SNB-1 7e-17 
Env7 Akr1 D2045.7 5e-20  Sso1 Swf1 UNC-64 2e-26 
Gap1 Pfa4 AAT-2 3e-08  Sso2 Swf1 UNC-64 8e-28 
Gnp1 Pfa4 AAT-3 0.007  Ste18 Swf1 TBC-7 3.3 
Gpa1  GOA-1 7e-80  Syn8 Swf1 T14G8.3 0.001 
Gpa2 Erf2 GOA-1 4e-87  Tat1 Pfa4 B0454.6 3e-10 
Hem14  UNC-86 4e-04  Tat2 Pfa4 F23F1.6 3e-05 
Hip1 Pfa4 C50D2.2 3e-13  Tlg1 Swf1 SYX-6 8e-04 
Lcb4 Akr1 SPHK-1 9e-14  Tlg2  SYN-16 7e-24 
Lsb6  ZC8.6 6e-50  Tub1  TBA-2 0.0 
Meh1 Akr1 T11B7.1 0.020  Tvp18  SRU-22 0.049 
Mlf3  M02B7.5 2.1  Vac8 Akr1, Erf2, Pfa3, Pfa4, Pfa5 IMA-3 5e-10 
Mnn1  C44C10.4 0.73  Vam3  SYX-5 3e-06 
Mnn10  F28G4.3 0.069  Ybr016w  - - 
Mnn11 Swf1 Y47G6A.9 0.13  Yck1 Akr1 CSNK-1 9e-108 
Mse1  EARS-2 3e-80  Yck2 Akr1 CSNK-1 1e-109 
Nuc1  CPS-6 2e-60  Yck3  CSNK-1 9e-92 
Pin2 Swf1 ABF-5 0.011  Ycp4  Y79H2A.3 3.9 
Psr1  SCPL-1 6e-57  Ygl108c  T05E11.7 0.18 
Psr2  SCPL-1 4e-58  Ykt6  YKT-6 1e-56 
Ras1 Erf2 LET-60 7e-59  Ylr001c  C11E4.7 3.8 
Ras2 Erf2 RAP-1 9e-58  Ylr326w  F07C4.6 2.4 
Rho2 Erf2 RHO-1 2e-62  Ypl199c Akr1, Swf1 Y32B12C.1 0.001 
TABLE 3.8: Orthologues of S. cerevisiae palmitoyl-proteins in C. elegans 
BLAST searches were performed using the protein sequences above to find C. elegans orthologues.  
The S. cerevisiae proteins and the DHHC(s) responsible for their palmitoylation are from Table 3.7 
and (Roth et al., 2006).  Abbreviations are as in Table 3.7 except: AAT, amino acid transporter; ABF, 
antibacterial factor related; ALP, α-actinin-associated LIM protein (ALP)-Enigma family protein; Bet, 
blocked early in transport; CPS, cell death abnormality 3 (CED-3) protease suppressor; CSNK, casein 
kinase; EARS, glutamyl amino-acyl tRNA synthetase; GOA, G protein αo subunit; Hem, heme 
biosynthesis; IMA, importin α family; LET, lethal; Lsb, local anestheticum sensitive (Las) seventeen 
binding protein; Mlf, multicopy suppressor of leflunomide activity; Mse, mitochondrial glutamyl-
transfer-RNA synthetase; Nuc, nuclease; Psr, plasma membrane sodium response; Sam,  
S-adenosylmethionine metabolism; SCPL, small C-terminal domain phosphatase-like phosphatase; 
SNB, synaptobrevin; SPHK, sphingosine kinase; SRU, serpentine receptor class U; SYN, syntaxin; SYX, 
syntaxin; TBA, tubulin α; TBC, Tre-2/Bub2/Cdc16 domain family; Tub, tubulin; Tvp, Tlg2-vesicle 
protein; UNC, uncoordinated; Vam, vacuolar morphogenesis; YKT-6, yeast Ykt6 v-SNARE homologue.  
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Palmitoyl-protein DHHC(s) C. elegans orthologue E value 
ABCA1 DHHC2/REAM, DHHC8, DHHC12/AID, DHHC15, DHHC20, DHHC21 ABT-2 1e-114 
AR DHHC7/SERZ, DHHC21 NHR-69 7e-24 
BACE1 DHHC3/GODZ, DHHC4, DHHC7/SERZ, DHHC15, DHHC20 ASP-4 3e-24 
BK channel DHHC22, DHHC23 SLO-1 0.0 
CD9 DHHC2/REAM TSP-8 2e-21 
CD151 DHHC2/REAM, DHHC15 TSP-7 5e-21 
CI-MPR DHHC15 ZK1307.8 0.51 
CKAP4/p63 DHHC2/REAM UNC-15 2e-09 
CL3/CaMKIγ DHHC3/GODZ CMK-1 4e-134 
CSP DHHC3/GODZ, DHHC7/SERZ, DHHC15, DHHC17/HIP14 DNJ-14 7e-31 
DR4 DHHC3/GODZ F47C12.1 0.45 
eNOS DHHC2/REAM, DHHC3/GODZ, DHHC7/SERZ, DHHC8, DHHC21 EMB-8 3e-64 
ER DHHC7/SERZ, DHHC21 NHR-91 6e-31 
flotillin-2 DHHC5 STO-5 0.31 
Fyn DHHC21 SRC-2 0.0 
GABAA receptor  
γ2 subunit 
DHHC3/GODZ, DHHC7/SERZ LGC-37 5e-90 
GAD65 DHHC3/GODZ, DHHC8, DHHC13/HIP14L, DHHC17/HIP14 UNC-25 0.0 
GAP43 DHHC7/SERZ, DHHC15 UNC-73 1.5 
GluR1 DHHC3/GODZ, DHHC17/HIP14 GLR-1 1e-180 
GluR2 DHHC3/GODZ, DHHC17/HIP14 GLR-1 2e-178 
GRIP1 DHHC5, DHHC8 MAGI-1 6e-17 
Gαi2 DHHC3/GODZ, DHHC7/SERZ GOA-1 0.0 
Gαq DHHC3/GODZ, DHHC7/SERZ EGL-30 0.0 
Gαs DHHC3/GODZ, DHHC7/SERZ GSA-1 0.0 
H-Ras DHHC9, DHHC17/HIP14, DHHC18 LET-60 2e-93 
Htt DHHC13/HIP14L, DHHC17/HIP14 F21G4.6 3e-06 
integrin α6 DHHC3/GODZ INA-1 2e-78 
integrin β4 DHHC3/GODZ PAT-3 8e-135 
Lck DHHC2/REAM, DHHC17/HIP14, DHHC18, DHHC21 SRC-2 6e-157 
NCAM DHHC3/GODZ, DHHC7/SERZ HIM-4 1e-38 
Nde1 DHHC2/REAM, DHHC3/GODZ, DHHC7/SERZ NUD-2 6e-07 
Ndel1 DHHC2/REAM, DHHC3/GODZ, DHHC7/SERZ NUD-2 8e-05 
N-Ras DHHC9, DHHC17/HIP14 LET-60 1e-92 
paralemmin-1 DHHC8 Y80D3A.8 4.6 
PDE10A2 DHHC7/SERZ, DHHC19 PDE-5 6e-161 
PI4KIIα DHHC2/REAM, DHHC3/GODZ, DHHC7/SERZ, DHHC14, DHHC15, DHHC21 ZC8.6 7e-131 
PR DHHC7/SERZ, DHHC21 NHR-69 2e-25 
PSD-93 DHHC8 DLG-1 9e-135 
PSD-95 DHHC2/REAM, DHHC3/GODZ, DHHC7/SERZ, DHHC8, DHHC15, 
DHHC17/HIP14 
DLG-1 1e-155 
R7BP DHHC2/REAM Y116A8C.37 0.46 
RGS4 DHHC3/GODZ, DHHC7/SERZ RGS-2 3e-34 
R-Ras DHHC19 RAS-1 2e-71 
SNAP-23 DHHC2/REAM, DHHC3/GODZ, DHHC7/SERZ, DHHC17/HIP14 RIC-4 7e-57 
SNAP-25 DHHC2/REAM, DHHC3/GODZ, DHHC7/SERZ, DHHC8, DHHC15, 
DHHC17/HIP14 
RIC-4 4e-67 
sortilin DHHC7/SERZ, DHHC15 F45H11.5 2.5 
SSTR5 DHHC5 NPR-24 9e-42 
stathmin-2 DHHC2/REAM, DHHC3/GODZ, DHHC5, DHHC7/SERZ, DHHC15, 
DHHC17/HIP14, DHHC21 
F34D10.4 1.6 
stathmin-3 DHHC2/REAM, DHHC3/GODZ, DHHC7/SERZ, DHHC15, DHHC21 E01A2.2 0.077 
stathmin-4 DHHC2/REAM, DHHC3/GODZ, DHHC7/SERZ, DHHC15, DHHC21 DPY-6 0.21 
STREX DHHC3/GODZ, DHHC5, DHHC7/SERZ, DHHC9, DHHC17/HIP14 NHR-173 0.66 
synaptotagmin-1 DHHC17/HIP14 SNT-1 4e-143 
TABLE 3.9: Orthologues of H. sapiens palmitoyl-proteins in C. elegans 
BLAST searches using the proteins above were performed to find orthologues in C. elegans.  The  
H. sapiens proteins and the DHHC(s) responsible for their palmitoylation are from Table 3.7.  
Abbreviations are as in Table 3.7 except: ABT, ABC transporter family; ASP, aspartyl protease; CMK, 
Ca2+/calmodulin-dependent protein kinase; DLG, Drosophila discs large homologue; DNJ, DnaJ 
domain containing protein; DPY, dumpy; EGL, egg-laying defective; EMB, abnormal embryogenesis; 
GLR, glutamate receptor family (α-amino-3-hydroxy-5-methyl-4-isoxazolepentaenoic acid (AMPA)); 
GOA, G protein αo subunit; GSA, G protein αs subunit; HIM, high incidence of males; 
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high confidence of being genuine substrates.  In addition, G protein γ subunits are 
candidate substrates, as the Gγ protein Ste18 has been shown to be palmitoylated by Swf1 
(Roth et al., 2006).  There have also been some large-scale studies using C. elegans proteins 
which can be used to determine possible substrates through known interactions.  These 
interactions are collated through WormNet (http://www.functionalnet.org/wormnet/) and 
some are presented in Table 3.11.  These have been selected because they are orthologues 
of known palmitoyl-proteins in S. cerevisiae and mammals (Table 3.7).  The objective of 
Table 3.10 and Table 3.11 was to use the known data on palmitoyl-proteins and their 
cognate enzymes in other organisms to predict possible substrates and their likely enzyme 
partners in C. elegans.  Hopefully these analyses will help to direct future studies on 
palmitoyl-proteins in C. elegans and increase the confidence in hits which also appear in 
these tables. 
3.3.2 THE PALMITOYL-PROTEIN THIOESTERASE ENZYME FAMILY 
As discussed in the introduction to this chapter, there are no unifying motifs in the PPTs 
which allow easy genomic searches.  This limits the process of finding PPTs in unexplored 
genomes to searching for orthologues of known PPTs.  The two known sub-families of PPTs, 
the PPTs and the APTs, are well represented across diverse organisms, although not many 
have both types of PPT.  There is generally a reasonable degree of sequence conservation 
within orthologues of each individual protein, as can be seen in sequence alignments 
(Figure 3.6, Figure 3.7).  However, there is no one conserved region in common between 
the two sequences.  In C. elegans there are two PPTs: PPT-1 and ATH-1, which are 
orthologues of H. sapiens PPT1 and APT1 respectively. 
The complete sequences of the PPTs in S. cerevisiae, C. elegans, D. melanogaster and  
H. sapiens were subjected to phylogenetic analysis and a phylogenetic tree was constructed 
(Figure 3.8).  The tree shows a clear divide between the PPT and APT sub-families.  The APT 
sub-family seems to be derived from the S. cerevisiae thioesterase enzyme Apt1, whereas 
the PPT sub-family is only present in the more complex organisms. 
Some of the resources used for the DHHCs above can also provide some insight into the 
function of the PPTs.  The S. cerevisiae PPT Apt1 is shown by the GFP-tagging study 
LGC, ligand-gated ion channel; INA, integrin α; LET, lethal; MAGI, membrane associated guanylate 
kinase inverted homologue; NHR, nuclear hormone receptor; NPR, neuropeptide receptor family; 
NUD, Aspergillus nuclear division related; PAT, paralysed arrest at two-fold; PDE, phosphodiesterase; 
RIC, resistance to inhibitors of cholinesterase; RGS, regulator of G protein signaling; SLO, slowpoke K+ 
channel family; SNT, synaptotagmin; SRC, SRC oncogene related; STO, stomatin; TSP, tetraspanin.  
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DHHC 
enzyme 
No. of 
interactors 
Selected interactors 
Gene Type Experiment 
Akr1 145 
AKR1 physical PCA 
ENV9 genetic negative genetic 
GNP1 genetic negative genetic 
GPA1 genetic synthetic lethality 
LCB4 physical biochemical activity 
MEH1 physical biochemical activity 
PEP12 genetic negative genetic 
PEP12 physical affinity capture-MS 
PIN2 physical PCA 
RAS1 physical two-hybrid 
STE4 genetic dosage rescue 
STE4 physical two-hybrid (2), affinity capture-MS (3) 
STE18 physical two-hybrid (2) 
TLG2 physical co-purification 
YCK1 physical PCA, two-hybrid 
YCK2 genetic negative genetic 
YCK2 physical biochemical activity, co-localisation, two-hybrid 
YKT6 physical affinity capture-MS 
Akr2 21 
LCB4 physical affinity capture-Western, two-hybrid 
TAT2 genetic negative genetic 
VAM7 physical two-hybrid 
Erf2 60 
AGP1 genetic negative genetic 
RAS2 genetic synthetic lethality, 
synthetic rescue 
RAS2 physical biochemical activity, co-localisation 
VAC8 physical biochemical activity 
VAM7 genetic negative genetic (2) 
Pfa3 11 
MEH1 physical biochemical activity 
VAC8 physical affinity capture-Western, biochemical activity (2), 
co-fractionation, co-localisation 
Pfa4 64 
BOS1 genetic negative genetic 
CHS3 physical affinity capture-Western 
RIF2 genetic phenotypic enhancement 
Pfa5 15 YGL108C physical biochemical activity 
Swf1 237 
ASC1 genetic negative genetic 
SEC9 genetic negative genetic 
SEC22 genetic negative genetic 
SNC1 genetic negative genetic (2) 
SNC2 genetic synthetic lethality 
SNC2 genetic synthetic lethality 
SSO1 genetic synthetic lethality 
TLG2 genetic negative genetic (2), synthetic growth defect 
YNL155W 29 YCK2 physical biochemical activity 
TABLE 3.10: Interaction data for the S. cerevisiae DHHC enzymes 
Data from genome- and proteome-scale protein interaction studies in S. cerevisiae are collated on 
the SGD website.  Shown is the total number of interactors for each DHHC enzyme, along with a 
selection of those which may be of interest to this study.  Numbers in parentheses in the Experiment 
column indicate how many different experiments give evidence for the interaction.  Known 
palmitoyl-proteins are shown in bold.  AGP, high affinity glutamine permease; ASC, absence of 
growth suppressor of Cyp1; BOS, bet one suppressor; CHS, chitin synthase; ENV, late endosome and 
vacuole interface function; GNP, glutamine permease; GPA, G protein α subunit; LCB, long-chain 
base; MEH, multicopy suppressor of endoplasmic reticulum retention defective (Erd) suppressor 1 
(Ers1) hygromycin B sensitivity; MS, mass spectrometry; PCA, protein-fragment complementation 
assay; PEP, carboxypeptidase Y-deficient; PIN, Psi+ inducibility; RIF, repressor activator protein 1 
(Rap1)-interacting factor; SEC, secretory; SNC, suppressor of the null allele of cyclase associated 
protein; SSO, suppressor of Sec one; STE, sterile; TAT, tyrosine and tryptophan amino acid 
transporter; TLG, t-SNARE affecting a late Golgi compartment; VAC, vacuole-related; VAM, vacuolar 
morphogenesis; YCK, yeast casein kinase.  
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Gene 
No. of 
interactors 
Selected interactors 
Gene Name Description Evidence 
dhhc-1 81     
dhhc-2 109 let-60 lethal Ras family small GTPase SC-GT 
ras-1 R-Ras related small GTPase SC-GT 
dhhc-3 6     
dhhc-4 70     
dhhc-6 354     
dhhc-8 10     
dhhc-9 18     
dhhc-11 5     
dhhc-12 230     
dhhc-13 74 goa-1, gpa-3, -4, -7, -16,  
odr-3 
G-protein α subunits signal transduction SC-GT 
dhhc-14 28 unc-64 syntaxin-1 exocytosis SC-GT 
TABLE 3.11: Interaction data for the C. elegans DHHC enzymes 
The online database WormNet (http://www.functionalnet.org/wormnet/) was searched for 
interactors with the C. elegans DHHC enzymes.  The total number of interactors found and some 
interactors of potential interest are presented here.  dhhc-13 was found to interact with three other 
DHHC enzymes: dhhc-2, dhhc-4 and dhhc-14.  The genes dhhc-5, dhhc-7, dhhc-10 and spe-10 were 
not present in WormNet.  odr, chemotaxis-defective; SG-GT, yeast genetic interaction; unc, 
uncoordinated.  
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HS-PPT1  MASPGCLWLLAVALLPWTCASR--------ALQHLDPPAPLPLVIWHGMGDSCCNPLSMG 52 
MM-PPT1  MASSCSRRLLAAALLPWCCAAW--------ALGHLDPPSPPPLVIWHGMGDSCCNPMSMG 52 
XT-PPT-1  --MAACRALTLTALLLTLCNG-------------KTEADPVPLVIWHGMGDSCCNPFSMG 45 
AF-PPT1  ---------MTAALLCFLLAGPVLL--VAGSPVYKSNNDTVPLVLWHGMGDSCCNPLSMG 49 
DM-Ppt1  MISICCSRFSCILFLLFLIFSLVLSYIWWSPTKGGTNPEVLPVVLWHGMGDTCCVPFSLG 60 
CE-PPT-1  ------MR-----Y-----FPLLLCLLAITTAEFRNATKQVPVVMWHGMGDCCCNPLSMG 44 
DD-PPT1  ------------MKILFFIILIINCYL----IQNSNSENIRPVVLWHGLGDSGLDPLTMG 44 
                                           *:*:***:**    *:::* 
 
HS-PPT1  AIKKMVEKKIPGIYVLSLEIGKTLMEDVENSFFLNVNSQVTTVCQALAKDPKLQQGYNAM 112 
MM-PPT1  VIKKMVEKEIPGIYVLSLEIGKNMMEDVENSFFLNVNVQVNMVCQILEKDPKLQQGYNAI 112 
XT-PPT-1  AVKKMVEEQIPGIYVLSLEIGNSIPEDMKNSFFLNVNEQVDGVCKELAQNPNLKNGYNSM 105 
AF-PPT1  SIKKMIEEEVSGIYVLSLMIGKNVVQDTENGFFMDVNEQVSMVCSQLAQDPKLKGGYNAM 109 
DM-Ppt1  AIMNLIVEQTKGGYVRSLQIGGNVLIDWQSGFFIHPNEQVDYVCKQLLQDEHLAKGYHAI 120 
CE-PPT-1  SVKKLFEEQIPGVYVHSLQLGSSITKDIEHGFYANTNELVYMACIKIKNDPELKNGYNAI 104 
DD-PPT1  KLKELIENQLPGVYVKNIAIGDSIAEDSFNSFFKNVNEQLEIVCKMLKEDTNLTSGFNAV 104 
   : ::. ::  * ** .: :* .:  *   .*: . *  :  .*  : :: .*  *:.:: 
 
HS-PPT1  GFSQGGQFLRAVAQRCPSPPMINLISVGGQHQGVFGLPRCPGESSHICDFIRKTLNAGAY 172 
MM-PPT1  GFSQGGQFLRAVAQRCPTPPMMTLISVGGQHQGVFGLPRCPGESSHICDFIRKSLNAGAY 172 
XT-PPT-1  GFSQGGQFLRAVAQRCPSPPMKNLISIGGQHQGVYGFPRCPGEISHMCDLIRKLLNYGAY 165 
AF-PPT1  GFSQGGQFLRAVAQRCPSPPMKNLISIGGQHQGVYGLPRCPGESSNICDMIRKALNNGAY 169 
DM-Ppt1  GFSQGGQFLRAVAERCPNPPMRNLITLGGQHQGIFGLPMCPTLTEKPCDYITRLLDNAAY 180 
CE-PPT-1  GFSQGAQFLRAVAQRCPNPPMKNLVSVGGQHQGVFGAPYCIGDN-IMCNGVRRLIDLGAY 163 
DD-PPT1  GLSQGGQFLRGYVERCNDPPVYNLISLGGQHQGVSSLPRCTALNSTLCKIADDLVELGVY 164 
  *:***.****. .:**  **: .*:::******: . * *       *.     :: ..* 
 
HS-PPT1  SKVVQERLVQAEYWHDPIKEDVYRNHSIFLADINQERG-INESYKKNLMALKKFVMVKFL 231 
MM-PPT1  SKLVQERLVQAQYWHDPIKESVYRNYSIFLADINQERC-VNESYKKNLMALKKFVMVKFF 231 
XT-PPT-1  TREVQDYLVQAEYWHDPINEEQYRNGSIFLADINQERH-VNVSYKQNLQLLEKFVMVKFL 224 
AF-PPT1  TDLVQKHLVQAQYWHDPLNDGLYKKHSLFLADINQERA-VNETYRKNLQLLDKFVMVKFL 228 
DM-Ppt1  APEVQKALVQATYWHDPIMENKYRLGSTFLADINNELF-INKFYIENLQKLKKFVMVQFL 239 
CE-PPT-1  LPFVQKRVVQAQYWHDPNQVEEYKKRSIFLADINNENN-NNPTYKRNLLSLKNLVLVKFN 222 
DD-PPT1  EKYVQNTLVPGEYWQDPFNYDEYVEKSVFLADINNVRSEKNQTYKDNLLSVNNFILGEFL 224 
     **. :* . **:**     *   * ******:     *  *  **  :.:::: :*  
 
HS-PPT1  NDSIVDPVDSEWFGFYRSGQAKETIPLQETSLYTQDRLGLKEMDNAGQLVFLATEGDHLQ 291 
MM-PPT1  NDSIVDPVDSEWFGFYRSGQAKETIPLQESTLYTEDRLGLKKMDKAGKLVFLAKEGDHLQ 291 
XT-PPT-1  NDTMVDPPDTEWFGFYRPGQSKETITLQESNLYMEDRLGLKEMEKAGRLVFLGVEGNHLQ 284 
AF-PPT1  QDTVVDPVDTEWFGFLKTGQAKETETLQESVLYKEDRLGLAAMDKAGKLAFLASQGDHLQ 288 
DM-Ppt1  NDTIVQPKESQWFQYYTTGQNKVIQPFTESKVYQ--DLGLDKMHRQGQLVFLGVEGDHLA 297 
CE-PPT-1  QDHMVVPKDSSWFGFYKDGDIDTILPMNETDLYKEDRIGLKKLHESGRIHFMDVDGDHLQ 282 
DD-PPT1  ADTIVVPRESELFGYYQPGQDNIILPMEKTDLYIEDWIGIQQLDNEGRLIKISCPGNHLQ 284 
   * :* * ::. * :   *: .    : :: :*    :*:  :.. *::  :   *:**  
 
HS-PPT1  LSEEWFYAHIIPFLG---- 306 
MM-PPT1  ISKEWFTAHIIPFLK---- 306 
XT-PPT-1  FSKEWFNKNIIPFLH---- 299 
AF-PPT1  FTREWFHANLLPYLH---- 303 
DM-Ppt1  ISKAWFIQNIVPLLLEK-- 314 
CE-PPT-1  IPRSVLVNDIIKKYFM--- 298 
DD-PPT1  FTDQWFNQNVIPYLNNQIN 303 
 :    :  .::         
FIGURE 3.6: Alignment of homologues of PPT1 in diverse species 
This alignment shows short regions of homology between the PPT1 sequences of different species 
amongst more divergent stretches of sequence.  The catalytic triad (Bellizzi et al., 2000) is shaded in 
grey.  Absolutely conserved residues are indicated by an asterisk, a colon indicates residues with 
highly similar properties and a period indicates residues with less similar properties.  AF, 
Anoplopoma fimbria; CE, Caenorhabditis elegans; DD, Dictyostelium discoideum; DM, Drosophila 
melanogaster; HS, Homo sapiens; MM, Mus musculus; XT, Xenopus tropicalis.  
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HS-APT1 ----------------------------MCGNNMSTPLPAIVPAARKATAAVIFLHGLGD 32 
MM-APT1 ----------------------------MCGNNMSAPMPAVVPAARKATAAVIFLHGLGD 32 
SS-APT1 ----------------------------MCGNSMSVPLPAIIPAARKATAAVIFLHGLGD 32 
DM-Apt1 -----------------------------------MAAPVIVEATVKQTATLIFMHGLGD 25 
CE-ATH-1 ------------------------------MSAVSNGNPSIVSPRGEHKGTLIFLHGLGD 30 
SC-APT1 -----------------------------------MNGLRVAAKIQPARQTIIFLHGLGD 25 
ZM-APT-1 MSSLIRLLFTLAAAIGAASLLVASLRRRAPPPGLPAKLVPSSHMAGRNRSFVLWLHGLGD 60 
                                                    ::::***** 
 
HS-APT1 TGHGWAEAF------AGIRSSHIKYICPHAPVRPVTLNMNVAMPSWFDIIGLSP--DSQE 84 
MM-APT1 TGHGWAEAF------AGIKSPHIKYICPHAPVMPVTLNMNMAMPSWFDIVGLSP--DSQE 84 
SS-APT1 TGHGWAEAF------AGIRTPHVKYICPHAPIKPVTLNMGMSMPSWFDIIGLQT--DAEE 84 
DM-Apt1 TGHGWSSAL------AAIRPPFMKVICPTAPTQPVSLNAGFRMPSWFDLKTLDI--GGPE 77 
CE-ATH-1 QGHGWADAFK-----TEAKHDNIKFICPHSSERPVTLNMGMRMPAWFDLFGLDP--NAQE 83 
SC-APT1 TGSGWGFLAQYLQQRDPAAFQHTNFVFPNAPELHVTANGGALMPAWFDILEWDPS-FSKV 84 
ZM-APT-1 SGPANEPIRN---LFSAPEFRLAKWSFPSAPRAPVSCNNGFVMPSWFDIHELPMSAGSPQ 117 
  * .       :           :   * :    *: *    **:***:     .  .   
 
HS-APT1 DESGIKQAAENIKALIDQEVKNGIPSNRIILGGFSQGGALSLYTALTTQQKLAGVTALSC 144 
MM-APT1 DESGIKQAAETVKALIDQEVKNGIPSNRIILGGFSQGGALSLYTALTTQQKLAGVTALSC 144 
SS-APT1 DEAGIKQASENIKALIDQEVKNGIPSHRIVLGGFSQGGALSLYTALTTQQKLGGVVALSC 144 
DM-Apt1 DEPGIQSARDSVHGMIQKEISAGIPANRIVLGGFSQGGALALYSALTYDQPLAGVVALSC 137 
CE-ATH-1 DEQGINRATQYVHQLIDAEVAAGIPASRIAVGGFSMGGALAIYAGLTYPQKLGGIVGLSS 143 
SC-APT1 DSDGFMNSLNSIEKTVKQEIDKGIKPEQIIIGGFSQGAALALATSVTLPWKIGGIVALSG 144 
ZM-APT-1 DETGVLKAVEKVHAMIDREVADGIHPENIFVCGFSQGGALTLASVLLYPKKLGGGAVFSG 177 
 *. *.  : : :.  :. *:  **   .* : *** *.**:: : :     :.* . :* 
 
HS-APT1 WLPLRASFPQGPIGGANRDISILQCHGDCDPLVPLMFGSLTVEKLKTLVNPANVTFKTYE 204 
MM-APT1 WLPLRASFSQGPINSANRDISVLQCHGDCDPLVPLMFGSLTVERLKALINPANVTFKIYE 204 
SS-APT1 WLPLRNSFPQASRNSANNEMHVLQCHGEADPLVPVMFGCLTVEKLKTLCNPSNIIFKTYP 204 
DM-Apt1 WLPLHKQFPGAKVNSD--DVPIFQAHGDYDPVVPYKFGQLSASLLKSFMK--NVTFKTYS 193 
CE-ATH-1 FFLQRTKFPGS--FTANNATPIFLGHGTDDFLVPLQFGQMSEQYIKKFNP--KVELHTYR 199 
SC-APT1 FCSIPG-ILKQHKNGINVKTPIFHGHGDMDPVVPIGLGIKAKQFYQDSCEIQNYEFKVYK 203 
ZM-APT-1 WVPFSSSVTERISPEAN-KTPFLWSHGMADKVVLFEAGQAGPPFLQSAGV--NCEFKAYP 234 
 :      .             .:  **  * :*    *       :      :  :: * 
 
HS-APT1 GMMHSSCQQEMMDVKQFIDKLLPPID---- 230 
MM-APT1 GMMHSSCQQEMMDVKHFIDKLLPPID---- 230 
SS-APT1 RMPHSACPEEMMDIKQFIEKQLPPI----- 229 
DM-Apt1 GLSHSSSDDEMDDVKDIISKWVN------- 216 
CE-ATH-1 GMQHSSCGEEMRDVKTFLSAHIAH------ 223 
SC-APT1 GMAHSTVPDELEDLASFIKKSLSS------ 227 
ZM-APT-1 DLGHSLSQEELLYLESWIKSRLNASQEKDG 264 
 : **   :*:  :   :.  :         
FIGURE 3.7: Alignment of homologues of APT1 in diverse species 
This alignment shows relatively few regions of absolute homology.  The catalytic triad (Devedjiev et 
al., 2000) is shaded in grey.  Absolutely conserved residues are indicated by an asterisk, a colon 
indicates residues with highly similar properties and a period indicates residues with less similar 
properties.  CE, Caenorhabditis elegans; DM, Drosophila melanogaster; HS, Homo sapiens; MM, Mus 
musculus; SC, Saccharomyces cerevisiae; SS, Salmo salar; ZM, Zea mays.  
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FIGURE 3.8: Phylogenetic tree of PPT enzymes from evolutionarily important organisms 
The complete sequences of the known PPT family enzymes in S. cerevisiae (red), C. elegans (blue),  
D. melanogaster (green) and H. sapiens (brown) were subjected to phylogenetic analysis.  The 
resulting tree was rendered and coloured using Interactive Tree of Life (Letunic and Bork, 2007).  
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(Huh et al., 2003) to be localised to the cytoplasm and nucleus.  This is consistent with the 
known localisation of H. sapiens APT1 in the cytoplasm (Duncan and Gilman, 1998), 
compared with PPT1 and -2, which are lysosomal (Soyombo and Hofmann, 1997; Verkruyse 
and Hofmann, 1996). 
The S. cerevisiae and C. elegans interaction studies may also uncover potential substrates of 
the PPTs.  According to SGD, S. cerevisiae Apt1 has 23 interactors, although none of them 
are known palmitoyl-proteins (Roth et al., 2006).  A search of the WormNet resource shows 
that PPT-1 has 19 interactors and ATH-1 has 169.  A few of the ATH-1 interactors are likely 
palmitoyl-proteins, including G protein α subunits (GOA-1, GPA-3, -4, -7, -16) and regulators 
of G protein signaling (RGS-1, -2).  Known substrates of H. sapiens PPT1 include H-Ras 
(Camp and Hofmann, 1993), and H. sapiens APT1 can remove palmitate from Gαs, H- and  
N-Ras, eNOS, ghrelin and BK channels (Dekker et al., 2010; Duncan and Gilman, 1998; Satou 
et al., 2010; Tian et al., 2012; Yeh et al., 1999).  N-Ras is a substrate for both APT1 and -2 
(Rusch et al., 2011). 
A crystal structure of H. sapiens PPT1 showed it acts as a monomer with an α/β hydrolase 
fold and three catalytic residues: serine-115, aspartate-233 and histidine-289 (Bellizzi et al., 
2000).  A comparison with the crystal structure of PPT2 showed a similar structure – an α/β 
hydrolase fold and the catalytic residues serine-111, aspartate-228 and histidine-283 – 
although a much smaller lipid-binding groove in PPT2 accounts for its inability to remove 
palmitate from proteins (Calero et al., 2003).  The crystal structure of APT1 again shows an 
α/β hydrolase fold with the catalytic residues serine-114, aspartate-169 and histidine-203, 
but forms a dimer which hides the active site.  This would mean the dimer would have to 
dissociate for the enzyme to be active (Devedjiev et al., 2000).  These catalytic triads are 
absolutely conserved amongst orthologues in different species (Figure 3.6, Figure 3.7).  
Although substrates of the PPTs are not generally known, there has been a 
disproportionate amount of research conducted on the function of PPT1 since it was 
discovered to be mutated in the disease infantile neuronal ceroid lipofuscinosis (INCL) (Vesa 
et al., 1995).  PPT1 was found to be expressed developmentally in the rat brain and retina, 
correlating with the clinical manifestation of early loss of vision followed by neuronal 
deterioration in INCL (Zhang et al., 1999).  The most common mutations of PPT1 in INCL 
cause decreased enzymatic activity, different palmitate binding and reduced protein levels 
(Das et al., 2001).  PPT1 is also known to be glycosylated at asparagine-197 and  
asparagine-232 which is a requirement for its activity, transport to the lysosome and 
prevention of its lysosomal degradation (Hellsten et al., 1996; Lyly et al., 2007; Verkruyse 
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and Hofmann, 1996).  Interest in this disease has led to INCL models in diverse organisms, 
including M. musculus (Gupta et al., 2001), D. melanogaster (Glaser et al., 2003; Hickey et 
al., 2006), the yeast Schizosaccharomyces pombe (Cho and Hofmann, 2004) and C. elegans 
(Porter et al., 2005).  The C. elegans model showed the least severe phenotype – a mild 
developmental and reproductive phenotype resulting from a mitochondrial defect (Porter 
et al., 2005).  Deficiency of PPT2 has been shown to produce a lysosomal storage disorder 
with distinct effects from PPT1 in a mouse model (Gupta et al., 2003). 
D. melanogaster has also been used for research into the PPTs, especially Ppt1.  Loss-of-
function mutations in Ppt1 replicated the abnormal storage of autofluorescent material and 
reduced lifespan seen in INCL but not the neurodegeneration (Hickey et al., 2006).  
Drosophila Ppt1 has been found to be involved in various synaptic functions, and its 
overexpression in the visual system resulted in neurodegeneration (Buff et al., 2007; Chu-
LaGraff et al., 2010; Korey and MacDonald, 2003; Saja et al., 2010).  Although Ppt2 was 
seen to have a small amount of thioesterase activity, its overexpression was not able to 
rescue phenotypes seen in a Ppt1 knockout (Bannan et al., 2008).  Apt1 was found to be 
expressed at high levels throughout embryonic development, with neural enrichment in 
both the larval and adult central nervous system (CNS).  Consistent with the H. sapiens 
protein, Apt1 was cytoplasmic with a possible enrichment in an endosomal compartment 
(Bannan et al., 2008). 
3.4 DISCUSSION 
3.4.1 DHHCS 
3.4.1.1 DHHC ENZYMES 
In comparison with other organisms important to research, palmitoylation has been 
neglected as a field of study in the model organism C. elegans.  Database mining using the 
conserved DHHC-CRD clarified the confusion in the literature showing there are 15 DHHCs 
in C. elegans.  This contrasts with varying published figures of 15 (Fukata and Fukata, 2010), 
16 (Mitchell et al., 2006) and 17 (Gleason et al., 2006) DHHCs.  It may be that the source of 
confusion is the occasional duplications which can occur in genome databases and which 
are removed as they are curated.  Confusion has occurred in other organisms as well.  For 
example, 20 D. melanogaster DHHCs were quoted in one study (Ohyama et al., 2007) but 
this family has since been confirmed to comprise 22 members (Bannan et al., 2008).  A 
systematic naming procedure of dhhc-x was applied to the unnamed C. elegans genes and 
their products in this family.  An exception was made for spe-10, as this has been the 
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subject of published research and so a renaming might cause confusion (Cypser and 
Johnson, 1999; Gleason et al., 2006; Shakes and Ward, 1989).  Sequence analysis confirmed 
that all of these proteins contained the requisite DHHC-CRD which is the active site (Lobo et 
al., 2002; Mitchell et al., 2010).  Although palmitoyltransferase activity is yet to be directly 
observed with these enzymes, the overall structure as presented in Figure 3.2 is in line with 
enzymes whose activity has been confirmed and can be considered of very high confidence, 
justifying an initial characterisation of this family in C. elegans.  An obvious discrepancy 
occurs with DHHC-11, which omits the two TMDs normally found before the DHHC-CRD and 
is a little isolated on the phylogenetic tree (Figure 3.3).  It is possible that these TMDs are 
missing as a result of a mutation producing a protein truncated at the N-terminus.  
Alternatively, palmitoylation of one of the cysteine residues upstream of the first TMD 
could mediate membrane attachment of the N-terminus of the protein, compensating for 
the lack of TMDs in this region.  It is also possible that the missing TMDs are present in the 
genome on an exon which has been incorrectly annotated. 
Several similar pairs of C. elegans DHHCs emerged from a phylogenetic analysis of the 
family (Figure 3.3).  Interestingly, some of these pairs also share high homology with the 
same protein in other organisms, suggesting they may have arisen from duplications in the 
past (Table 3.6).  DHHC-1 and -10 are both on chromosome X and are closest to  
D. melanogaster CG10344 and H. sapiens DHHC24 but distinct S. cerevisiae proteins: Pfa3 
and Pfa4 respectively.  DHHC-4 and SPE-10 share homology to S. cerevisiae Pfa3,  
D. melanogaster CG1407 and H. sapiens DHHC2.  DHHC-9 and -12 are closest to H. sapiens 
DHHC16.  This similarity in these pairs suggests that they may share common substrates 
and functions within the cell. 
A large proportion of the D. melanogaster DHHCs, including Hip14, contain the PaCCT motif 
identified in the S. cerevisiae DHHCs Swf1 and Pfa3 (Gonzalez Montoro et al., 2009).  The 
PaCCT motif is also present in all the DHHCs which make up the cluster of D. melanogaster 
DHHCs seen in the phylogenetic tree (Figure 3.4), which may partially explain why the 
proportion containing the motif is particularly high compared with the other organisms 
presented.  Although this motif was shown to be critical for the function of these two  
S. cerevisiae DHHCs, the mechanism is not clear and no further research has been 
published.  For this reason it remains to be seen whether the PaCCT motif is particularly 
important to the D. melanogaster DHHCs.  The presence of the PaCCT motif in only three of 
the C. elegans DHHCs suggests it does not have widespread significance in this species. 
CHAPTER 3: IN SILICO ANALYSIS 
79 
 
3.4.1.2 PREDICTION OF SUBSTRATES 
The H. sapiens DHHCs seem to vary widely in their promiscuity, although this may partly be 
a function of which enzymes have been focused on.  DHHC3/GODZ, DHHC7/SERZ and 
DHHC17/HIP14 have the most substrates listed in Table 3.7, ranging from neurotransmitter 
receptors and ion channels to G proteins and structural molecules.  This broad specificity 
does not appear to be so much the case in S. cerevisiae, where Swf1 appears to be 
responsible for palmitoylating SNARE proteins and Pfa4 the amino acid permeases (AAPs) 
for example.  The subcellular localisation of DHHC enzymes has been studied in S. cerevisiae 
and H. sapiens (Table 3.3, Table 3.5).  They show varying locations within the cell, which 
may contribute to spatio-temporal specificity.  However DHHC3/GODZ, DHHC7/SERZ and 
DHHC17/HIP14 are all Golgi-localised, so the substrates they share may be regulated by 
distinct expression of the DHHCs in different cell types or during development.  
Alternatively, it may be a source of redundancy in the system. 
Some of the substrates may be suitable candidates for studying in more detail in a model 
system such as C. elegans.  Both DHHC3/GODZ and DHHC17/HIP14 have close orthologues 
in C. elegans – DHHC-3 and DHHC-14 respectively (Table 3.6).  Their substrates 
synaptotagmin-1 and ATP-binding cassette transporter A1 (ABCA1), for example, also have 
close orthologues in SNT-1 and ABT-2 respectively (Table 3.9).  Given the genetic tractability 
of C. elegans compared with mammalian systems, it would be a logical system in which 
these predicted enzyme-substrate pairs could be confirmed and refined down to which 
cysteine residues are palmitoylated.  The reverse process could also be put into action, 
using C. elegans to inform studies of H. sapiens DHHCs.  The C. elegans enzymes DHHC-2 
and -6 are close matches for H. sapiens DHHC14 and -6 respectively, neither of which have 
been characterised.  The closest C. elegans orthologues to known S. cerevisiae palmitoyl-
proteins were also investigated (Table 3.8).  Predictions made using this method would 
have the highest confidence where close orthologues exist, so perhaps they are better from 
the H. sapiens list as the matches are generally better both in enzymes and substrates.  Of 
course, all of the organisms investigated are representative of different types of organism, 
so these links may not be definitive.  For example, the substrates and interactors of  
S. cerevisiae Erf2 include Ras and Rho proteins.  DHHC-13 is the most closely related  
C. elegans enzyme, and it may therefore be predicted to be responsible for palmitoylation 
of C. elegans Ras and Rho proteins.  However, the main Ras orthologue in C. elegans is  
LET-60, which is most closely related to K-Ras(B).  K-Ras(B) is not palmitoylated because it 
lacks the requisite cysteine residue in the hypervariable region (Hancock et al., 1989) and 
CHAPTER 3: IN SILICO ANALYSIS 
80 
 
instead associates with membranes through its polybasic domain (Hancock et al., 1990).  
LET-60 also lacks cysteine residues in its hypervariable region and so it is unlikely that  
LET-60 would be palmitoylated.  Table 3.7 shows H. sapiens CSP is known to be 
palmitoylated by DHHC3/GODZ, DHHC7/SERZ, DHHC15 and DHHC17/HIP14, and the  
D. melanogaster version by its Hip14.  It is therefore possible that the C. elegans orthologue 
of CSP, DnaJ domain-containing protein 14 (DNJ-14), might be palmitoylated by DHHC-3, 
DHHC-7, DHHC-13 or -14, the most highly related enzymes (Table 3.6). 
S. cerevisiae was the model organism in which the first experiments to probe DHHC 
function and substrates were performed and the first proteome-scale analysis of 
palmitoylated proteins was conducted (Roth et al., 2006).  There is a wealth of information 
available from genome-wide interaction studies in S. cerevisiae, both about S. cerevisiae 
proteins and those from other species studied using systems such as yeast two-hybrid 
(Table 3.10, Table 3.11).  This information should be used with caution, as many of the 
known S. cerevisiae substrates are not found in this list.  The predictive power of a similar 
analysis of C. elegans interactions is probably quite low, as four of the 15 DHHCs are not 
represented at all, and those that are show very few proteins of the kinds shown in  
Table 3.7. 
An interaction between a DHHC and another protein does not necessarily mean that the 
protein is a substrate.  There have been reported interactions away from the DHHC-CRD 
which have been shown to modulate the function of the enzyme.  The S. cerevisiae DHHC 
Akr1 interacts with Ste4, a G protein β subunit (Table 3.10).  This has been shown to be 
dependent on the ankyrin repeat region of Akr1 and independent of the acyltransferase 
activity.  The ankyrin repeat region partially contributed to the cell morphology phenotype 
(Hemsley and Grierson, 2011).  This study also showed that in addition to 
autopalmitoylation, Akr1 can palmitoylate other Akr1 molecules in trans at sites away from 
the DHHC-CRD.  Another S. cerevisiae enzyme, Swf1, has also been found to regulate actin 
cytoskeleton organisation independently of the DHHC domain (Dighe and Kozminski, 2008).  
In human embryonic kidney (HEK293) cells, the H. sapiens enzyme DHHC17/HIP14 was 
found to interact with c-Jun N-terminal kinase isoform 3 (Jnk3) in the ankyrin repeat region, 
especially within the second repeat, with a resulting increase in phosphorylation and 
activity of Jnk3.  This was mediated by recruitment of mitogen-activated protein kinase 
kinase 7 (MKK7).  Palmitoylation of postsynaptic density protein 95 (PSD-95) by 
DHHC17/HIP14 inhibited the interaction with Jnk3, and this was reversed by sequestration 
of PSD-95 by N-methyl-D-aspartate receptors (NMDARs) induced by excitotoxicity.  The 
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particular binding motif in the second ankyrin repeat was unique to DHHC17/HIP14 (Yang 
and Cynader, 2011).  The H. sapiens enzyme DHHC23/neuronal nitric oxide synthase  
(nNOS)-interacting DHHC domain-containing protein with dendritic mRNA (NIDD) has been 
shown to interact with a PSD-95/Drosophila discs large tumour suppressor (Dlg1)/zonula 
occludens-1 protein (zo1) (PDZ) domain in nNOS through a glutamate-aspartate-isoleucine-
valine (EDIV) motif at its C-terminus.  This resulted in an increase in nitric oxide (NO) 
formation by nNOS (Saitoh et al., 2004).  Another study found that the four C-terminal 
amino acids (glutamate-isoleucine-serine-valine (EISV)) of DHHC5 mediate an interaction 
with the third PDZ domain of PSD-95 (Li et al., 2010).  In D. melanogaster, GABPI has been 
shown to interact with β1,4-N-acetylgalactosaminyltransferase B (β4GalNAcTB) and 
regulate its exit from the ER, an effect which is presumably independent of palmitoylation 
as GABPI lacks the requisite cysteine of the DHHC motif (Johswich et al., 2009).  It is 
therefore likely that some proteins identified in large-scale interaction studies are 
modulators rather than substrates. 
3.4.1.3 PREDICTION OF PHENOTYPES 
There is very little information available on the DHHCs in C. elegans, and the few 
phenotypes which are reported are mostly the results of large-scale RNA interference 
(RNAi) screens.  These are fairly vague, such as “development variant”, which offers little 
insight.  The one mutant which has been studied is that of spe-10 (Cypser and Johnson, 
1999; Gleason et al., 2006; Shakes and Ward, 1989).  However, these studies showed how it 
is involved in the process of spermatogenesis in C. elegans, and that the mutant has a 
general increase in stress resistance and lifespan.  Neither of them provided new 
information in terms of the palmitoyltransferase activity of SPE-10 or potential substrates.  
On the basis of this relative dearth of information, it was useful to investigate what is 
known about DHHC functions in other organisms. 
As S. cerevisiae has the fewest members of its DHHC family, some phenotypes relating to 
fundamental processes may be expected.  Indeed null strains for some of the DHHCs have 
been shown to have specific phenotypes.  Akr1 mutants are misshapen, show slow growth, 
do not survive at 37 °C and have defects in their pheromone response (Givan and Sprague, 
1997; Kao et al., 1996; Pryciak and Hartwell, 1996).  Swf1 mutants also show a significant 
growth phenotype (Roth et al., 2006) and are unable to grow in conditions of high salinity 
or with lactate as the sole carbon source (Gonzalez Montoro et al., 2009).  However, the 
fundamental importance of palmitoylation can be questioned given that a deletion strain of 
five of the S. cerevisiae DHHCs (akr1Δ akr2Δ pfa3Δ pfa4Δ pfa5Δ) is viable (Hou et al., 2009; 
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Roth et al., 2006).  This strain can even tolerate an additional conditional depletion of Swf1 
or Erf2, though not absolute deletions (Roth et al., 2006).  Of course, this may still be 
explained by overlapping specificities of the enzymes, which could lead to functional 
redundancy.  In the large phylogenetic tree (Figure 3.4), the S. cerevisiae DHHCs Akr1 and 
Akr2 and Swf1 and Erf2 form two sets of closely related pairs.  Given there are also several 
C. elegans DHHCs which form pairs in the phylogenetic analysis, it is possible that similar 
difficulties will appear when handling single knockouts.  However there are also several  
C. elegans DHHCs which are on their own in the phylogenetic tree, such as DHHC-2 and 
DHHC-8.  These may be more promising leads for knockout phenotypes. 
Although the DHHC enzymes of D. melanogaster have not been extensively studied, there 
have been some important insights using this model organism.  The DHHC Hip14 was 
shown to be responsible for palmitoylation and proper functionality of CSP, the most 
palmitoylated protein known (Ohyama et al., 2007).  This study showed that Hip14 is 
located both pre- and postsynaptically and is required for proper exocytosis of synaptic 
vesicles.  This was found to be a result of mislocalisation of CSP away from the synapse and 
was replicated by expression of an unpalmitoylatable version of CSP.  A chimeric version of 
CSP which is forced into synaptic vesicles rescued a Hip14 temperature-sensitive 
phenotype.  Thus palmitoylation of CSP by Hip14 targets it to synaptic vesicles where it 
promotes proper synaptic function.  Hip14 palmitoylation of SNAP-25 and its localisation 
were found to be independent of CSP, and the lack of effect of SNAP-25 mislocalisation is 
thought to be due to compensation by SNAP-24 (Vilinsky et al., 2002).  Another paper 
showed the developmentally secreted chordin homologue short gastrulation (Sog) as 
another substrate of Hip14 (Kang and Bier, 2010).  Hip14 and Sog were found to be 
localised to the Golgi in the Drosophila embryonic S2 cell line, where they interact.  
Palmitoylation of Sog on cysteine-27 and cysteine-28 by Hip14 was found to promote its 
secretion.  These studies illustrate how a single DHHC can have diverse substrates and 
functions depending on the tissues and cell types in which it is expressed. 
The relationship between H. sapiens DHHC17/HIP14 and Htt has led to interest in this 
particular enzyme in mammals and as a result a knockout mouse has been made (Singaraja 
et al., 2011).  These mice showed a neuropathology very similar to their HD mouse model 
(YAC128), including reduced brain weight, decreased striatal medium spiny neuron number 
and reduced striatal, cerebral cortex, hippocampal and white matter volume.  These 
changes were observed in Hip14-/- mice but not Hip14+/- mice, showing complete lack of 
Hip14 is necessary for these changes.  In addition, there were fewer excitatory  
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(i.e. glutamatergic) synapses per neuron.  Astrocyte and microglial numbers were 
unchanged.  The neuropathology was found not to be progressive but to result from 
increased cell death later in development, between embryonic days 14.5 and 17.5, which is 
different from YAC128 mice, which have no evidence of neuropathology until three months 
of age.  A reduction in dopamine- and cyclic adenosine monophosphate (cAMP)-regulated 
phosphoprotein of 32 kDa (DARPP32) and enkephalin, which is a hallmark of even mild HD, 
is also seen in these mice.  Behavioural measures were also disrupted as in YAC128 mice in 
motor co-ordination, dark-phase open-field and pre-pulse inhibition (PPI) tests.  There was 
no change in Htt palmitoylation between wild-type and knockout mice, and the closely 
related enzyme HIP14L appears to be responsible for this.  HIP14 showed reduced 
autopalmitoylation, suggesting mutant Htt alters its activity.  Expression of human 
DHHC17/HIP14 in these mice using a bacterial artificial chromosome (BAC) strategy rescued 
the anatomical, neurochemical and behavioural deficiencies (Young et al., 2012).  The only 
phenotype not rescued in the BAC mice was overall body weight.  This may be a result of 
the relatively low expression level (around 35% of wild-type), or an artefact of expressing 
human DHHC17/HIP14 in mice.  The same group has also produced a mouse knockout of 
Hip14l (Sutton et al., 2012).  Unlike the Hip14-/- mice, the Hip14l-/- mice showed a 
progressive reduction in brain weight and the volume of the striatum, cortex, thalamus, 
globus pallidus and corpus callosum.  The same reduction of DARPP32 and enkephalin but 
not substance P was seen as in the Hip14-/- and YAC128 mice.  There were some differences 
in the phenotypes observed in the Hip14l-/- mice compared with the Hip14-/- mice.  
Anatomically, the Hip14l-/- mice suffered mild hypotrichosis and alopecia.  Behaviourally, 
they showed hypoactivity and deficits in learning but normal motor function.  SNAP-25 
showed a 33% reduction in palmitoylation in Hip14l-/- mice, which is interestingly large 
given there are six other DHHCs which can palmitoylate it (Table 3.7).  Given Htt is a 
substrate for both DHHC17/HIP14 and DHHC13/HIP14L, and expanded Htt affects the 
activity of both enzymes, it seems likely that a reduction of function of both enzymes is 
involved in HD pathogenesis.  It will be interesting to see what further insight can be gained 
from these mouse models and whether mouse knockouts of other DHHC enzymes also 
show disease-like phenotypes. 
Palmitoylation as a post-translational modification in humans is relatively understudied and 
much of the information available on some of the less studied family members is in the 
form of associations from large-scale studies on specific diseases.  C. elegans is often used 
to study development and neuronal function, processes which are involved in the most 
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common associations – cancers and neurodegenerative diseases.  Whilst studies in  
C. elegans may not be able to shed further light on associations with some human diseases 
such as X-linked mental retardation (XLMR), it can be a useful proxy for more fundamental 
processes underlying these conditions.  Some of the H. sapiens DHHC enzymes have also 
been shown to have functions away from the DHHC-CRD active site, such as the 
involvement of DHHC3, DHHC13/HIP14L and DHHC17/HIP14 in ion transport (Goytain et al., 
2008; Hines et al., 2010).  This phenomenon has not been reported for DHHCs from other 
organisms as yet.  It would be interesting to investigate whether this function is more 
widespread and if it is independent of the palmitoyltransferase activity or whether they 
modulate each other.  C. elegans is in many ways an ideal system in which to investigate 
these aspects of the DHHC enzymes further, using these predictions as a guide to interpret 
the observations. 
3.4.2 PALMITOYL-PROTEIN THIOESTERASES 
The lack of any conserved motifs has limited the known PPTs to two sub-families: PPTs and 
APTs.  Despite this, crystal structures of H. sapiens PPT1, PPT2 and APT1 show the same 
basic structure of an α/β hydrolase fold and a catalytic triad of serine, aspartate and 
histidine residues (Bellizzi et al., 2000; Calero et al., 2003; Devedjiev et al., 2000).  It is 
surprising that some organisms only have one of these enzymes given the relative 
abundance of different DHHCs.  Analogous reversible post-translational modifications do 
not have quite this extreme a ratio of enzymes.  The human genome contains around 500 
kinases (Manning et al., 2002) compared with approximately 200 phosphatases (Sacco et 
al., 2012).  Similarly, in the ubiquitin system there are about 600 E3 ligases (Li et al., 2008) 
and nearly 90 deubiquitinases (Clague et al., 2012).  It is possible that there are other PPTs 
which are yet to be discovered, otherwise mutants lacking them would be expected to have 
more severe phenotypes than are observed.  Deletion of the only S. cerevisiae enzyme, 
Apt1, does not lead to any gross phenotype (Duncan and Gilman, 2002).  Inhibition of APT1 
by palmostatin B in Madin-Darby canine kidney epithelial (MDCK) cells prevented N-Ras 
depalmitoylation and altered its subcellular localisation from the plasma membrane and 
Golgi to all cellular membranes (Dekker et al., 2010).  Despite this mislocalisation of an 
important signaling molecule, the cells showed no obvious phenotype.  Similarly, a study 
identifying APT1 as the PPT for BK channels reported no phenotypes despite the channels 
becoming trapped in the ER (Tian et al., 2012).  If Apt1 is the only PPT in S. cerevisiae and it 
is responsible for depalmitoylation of substrates such as Gα and Ras then it seems likely 
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there is some compensatory mechanism which prevents manifestation of a severe 
phenotype, and an as-yet-undiscovered set of PPTs is a possible explanation. 
Although a cause of the disease INCL has been traced to a mutation in the human PPT1 
gene (Vesa et al., 1995), ppt-1 mutants in C. elegans show only a mild mitochondrial defect 
(Porter et al., 2005).  Perhaps more success has been seen in D. melanogaster mutants.  It 
has been shown that D. melanogaster requires Ppt1 for normal neuronal development, and 
that defects resulting from its mutation are similar to those seen in INCL (Buff et al., 2007; 
Chu-LaGraff et al., 2010; Korey and MacDonald, 2003; Saja et al., 2010).  Overexpression of 
Ppt2 in Ppt1 mutants failed to rescue the phenotypes, suggesting there are distinct 
specificities (Bannan et al., 2008).  The disruption of both PPTs in C. elegans and the 
comparison of palmitoyl-proteomes of wild-type and PPT mutants may help shed light on 
the roles the PPTs play.  This will be potentially valuable in expanding the knowledge of PPT 
substrates and help to answer the question of whether PPTs have distinct sets of substrates 
or whether there is an overlap. 
This chapter has identified the DHHC enzymes in C. elegans and set out the currently 
available information about both DHHCs and PPTs in three important organisms:  
S. cerevisiae, D. melanogaster and H. sapiens.  As palmitoylation is essentially unexplored in 
C. elegans, the information presented here should act as a platform for assessing data 
collected in this model organism.  Furthermore, these data may be used to predict possible 
outcomes from known phenotypes in C. elegans.  For example, the C. elegans orthologue of 
synaptotagmin-1, SNT-1, has a deficit in locomotion resulting from impaired synaptic 
release (Nonet et al., 1993).  The only known DHHC for synaptotagmin-1 is DHHC17/HIP14 
(Table 3.7), so mutants lacking the similar enzymes DHHC-13 or -14 may also show 
locomotion defects.  Mutants for the C. elegans orthologue of CSP, DNJ-14, show a 
reduction in lifespan and an age-dependent locomotion defect (unpublished data).  This 
phenotype may be harder to observe among DHHC mutants as many share CSP as a 
substrate in H. sapiens.  EGL-30, the orthologue of the important cell signaling molecule 
Gαq, gives phenotypes of disrupted viability, egg-laying and locomotion when deleted 
(Brundage et al., 1996).  H. sapiens Gαq is palmitoylated by DHHC3/GODZ and DHHC7/SERZ, 
so disruption of the similar C. elegans proteins DHHC-3 or DHHC-7 may recapitulate some 
of these phenotypes.  This examination of the effects of disruption of individual enzymes on 
C. elegans at both phenotypic and proteomic levels will complement the current knowledge 
and hopefully provide additional insights into the nature of palmitoylation. 
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4.1 INTRODUCTION 
4.1.1 PROBING GENE FUNCTION IN C. ELEGANS 
4.1.1.1 MUTATIONS 
The nematode worm Caenorhabditis elegans is a useful experimental tool for probing 
functions of genes in well conserved processes using simple assays.  There are a variety of 
mutagenesis methods which can be used on C. elegans, traditionally including treatment 
with chemical agents such as trimethylpsoralen (TMP) and ethyl methane sulphonate (EMS) 
(Barstead and Moerman, 2006; Gengyo-Ando and Mitani, 2000), using electromagnetic 
spectrum radiation such as ultraviolet (UV) light and X-rays (Gengyo-Ando and Mitani, 
2000; Sigurdson et al., 1984), and more recently using more precise transposon based 
approaches (Bessereau et al., 2001).  As most existing strains were made using random 
mutagenesis, there is a chance that mutations exist in genes other than the gene of interest 
which could contribute to any phenotypes observed.  This can be counteracted by 
outcrossing a mutant strain to wild-type N2 males several times, or alternatively several 
strains containing different alleles disrupting the same gene can be compared for common 
phenotypes. 
4.1.1.2 RNAI 
An alternative to creating mutant strains is to knock down expression from specific genes 
using RNA interference (RNAi).  In most C. elegans tissues, double stranded RNA (dsRNA) 
molecules are taken up into cells where they are processed into primary small interfering 
RNA (siRNA) molecules of about 22 nucleotides.  This is mediated by the RNase III enzyme 
dicer related 1 (DCR-1), which cleaves long dsRNA molecules sequentially, working along 
their length (Fischer, 2010).  The target messenger RNA (mRNA) of the siRNA fragments 
acts as a template for amplification.  This process, called transitive RNAi, is mediated by 
enhancer of abnormal germline proliferation one (EGO-1) in the germline (Smardon et al., 
2000) and by RNA-dependent RNA polymerase family 1 (RRF-1) in somatic cells (Sijen et al., 
2001).  The helicase dicer related helicase 3 (DRH-3) is required for the production of 
secondary siRNAs.  Most RNAi then occurs in the cytoplasm, where the RNA-induced 
silencing complex (RISC) mediates degradation of the target mRNA (Fischer, 2010).  There is 
also an element of nuclear RNAi in C. elegans, where degradation of pre-mRNAs is 
mediated by nuclear RNAi defective 3 (NRDE-3) (Guang et al., 2008). 
RNAi was initially performed by injecting dsRNA into the animals (Fire et al., 1998), 
although the observation of the spread of RNAi effects to most tissues led to simpler and 
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more cost-effective protocols based on soaking animals in dsRNA solutions (Tabara et al., 
1998) or feeding animals with bacteria expressing dsRNAs (Kamath et al., 2001; Timmons 
and Fire, 1998).  Despite the effectiveness of RNAi in many tissues, C. elegans neurons in 
particular are refractory to its effects (Fire et al., 1998).  The sensitivity of different types of 
neurons has been dissected, with γ-amino butyric acid (GABA)-ergic and some 
dopaminergic neurons particularly resistant and cholinergic, glutamatergic, touch sensitive 
and the remaining dopaminergic neurons less so (Asikainen et al., 2005).  These effects 
were seen with injection, soaking and feeding methods of dsRNA administration.  Several 
strains have been produced which partially overcome this to provide a degree of 
knockdown in neurons.  A strain deficient for rrf-3, which suppresses amplification of 
secondary siRNAs, shows a general increase in sensitivity to RNAi, including in neurons 
(Simmer et al., 2002).  The rrf-3 mutant strain had complete sensitivity to RNAi in all 
neuronal types except dopaminergic neurons, which still had a marked improvement in 
sensitivity (Asikainen et al., 2005).  A deficiency in the exonuclease enhanced RNAi 1 (eri-1) 
also gives an organism-wide increase in RNAi sensitivity (Kennedy et al., 2004).  The 
systemic RNAi defective 1 (SID-1) protein was found to be responsible for passive uptake of 
dsRNA molecules into cells (Winston et al., 2002).  It has recently been shown to enhance 
the effects of feeding RNAi in neurons alone by its specific expression under a pan-neuronal 
promoter (Calixto et al., 2010).  A similar strategy which involves expressing the dsRNAs 
against the gene of interest under control of a promoter specific to the cell type of interest 
has also been used, although this requires injection of the construct (Esposito et al., 2007). 
4.1.2 KNOWN PHENOTYPES 
The only member of the DHHC family of enzymes which has been studied in C. elegans is 
SPE-10.  The spe-10 gene was named after a spermatogenesis defect (Spe) which was first 
described in detail in this context before the DHHC-cysteine-rich domain (CRD) containing 
protein family was identified (Shakes and Ward, 1989).  In wild-type spermatogenesis, 
primary spermatocytes exist in a syncitium associated with a common cytoplasmic core 
called the rachis.  During spermatocyte maturation, fibrous bodies (FBs) made of major 
sperm protein (MSP) mature within membranous organelles (MOs).  Mature primary 
spermatocytes bud off and undergo two rounds of meiosis to produce four spermatids and 
a residual body.  The FBs disperse into the cytoplasm and the MOs move adjacent to the 
plasma membrane (PM).  As each spermatid differentiates into a spermatozoon, the MOs 
fuse with the PM and secrete their contents, leaving a permanent fusion pore.  In spe-10 
mutants, FB-MO complexes tend to break down before the spermatids have budded from 
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the rachis, resulting in FBs which do not disperse in the residual body and instead 
sometimes bud off as cytoplasts (Shakes and Ward, 1989).  The MOs tend to become large 
and vacuolated, which is visible under Nomarski optics as a cratered appearance in 
spermatids which budded from residual bodies containing FB defects.  These spermatids 
also have an off-centre nucleus, are smaller in size and resulting spermatozoa do not show 
the characteristic crawling motion of wild-type spermatozoa (Shakes and Ward, 1989).  A 
later study found that spe-10 is only expressed in animals undergoing spermatogenesis and 
most, but not all, SPE-10 protein immunofluorescence staining co-localises with an FB-MO 
marker (Gleason et al., 2006).  This study makes reference to another C. elegans DHHC-CRD 
containing protein, SPE-21, which also shows a spermatogenesis defect.  However, no trace 
of the spe-21 gene can be found on WormBase (http://www.wormbase.org/) or in any 
published literature, so it is unknown whether this gene corresponds to any of the  
C. elegans DHHC-CRD family members identified in Chapter 3.  The final study to examine 
spe-10 mutant strains looked at stress resistance (Cypser and Johnson, 1999).  They found 
an increase in lifespan in some, though not all, experiments and increased resistance to UV 
exposure and high temperature (35 °C) but not paraquat, a reactive oxygen species (ROS) 
generator. 
An initial characterisation of the C. elegans palmitoyl-protein thioesterase 1 (PPT-1) protein 
was performed with a view to gaining insight into the inherited disease infantile neuronal 
ceroid lipofuscinosis (INCL), also known as Haltia-Santavuori disease (Porter et al., 2005), 
which is caused by mutations in the human PPT1 gene (Vesa et al., 1995).  An adapted 
assay for human PPT1 activity showed C. elegans PPT-1 can act on the same substrate, and 
that the mutant strains MN1 and VC184 had tenfold lower activity.  A number of mild 
phenotypes were catalogued in this study.  There was a three hour delay in the 
developmental moult from the final larval stage, L4, into adults.  Onset of egg-laying was 
also delayed by four hours and continued two days after wild-type animals had stopped 
laying, although the total brood size was unchanged.  This coincided with an increased 
frequency of bagging, whereby eggs hatch inside the parent animal.  There was no 
difference in lifespan and there was a lack of accumulation of autofluorescent material 
which is seen in the human disease.  Electron microscopy (EM) showed defects in 
mitochondria in energetically active tissues, including neurons.  There were higher numbers 
of smaller mitochondria resulting in a decrease in mitochondrial area in cross-sections and 
their morphology was altered.  Instead of an inner membrane folded into cristae, the inner 
membrane formed whorls in one-day-old adults.  Fewer whorls were observed in  
CHAPTER 4: PHENOTYPIC ANALYSIS IN C. ELEGANS 
90 
 
six-day-old adults although there was evidence of autophagy and lysosomal degeneration.  
Despite these changes, these mutants were observed to have a much milder phenotype 
when compared with the severe deficits in human INCL (Porter et al., 2005). 
4.1.3 PREDICTIONS FROM IN SILICO ANALYSIS 
This chapter will give an initial phenotypic analysis of C. elegans strains in which DHHC or 
PPT family genes have either been mutated or had their expression reduced with the aim of 
characterising processes in which they may be involved.  By relating any phenotypes which 
are uncovered back to the in silico analyses in Chapter 3, it is hoped C. elegans will be 
validated as a model in which palmitoylation can be studied in more depth with relation to 
specific enzymes.  In turn the in silico analyses can also be used to provide predictions 
which can be tested using phenotypic assays.  For example the lack of fusion of MOs in  
spe-10 spermatogenesis described above (Shakes and Ward, 1989) could result from 
altered palmitoylation of proteins which are important in fusion.  The most closely related 
enzymes in other organisms are protein fatty acyltransferase 3 (Pfa3) in Saccharomyces 
cerevisiae and DHHC2/reduced expression associated with metastasis (REAM) in Homo 
sapiens (Table 3.6).  Pfa3 is one of the palmitoyl acyl-transferases (PATs) responsible for 
palmitoylating the vacuolar fusion protein Vac8 and DHHC2/REAM palmitoylates the 
membrane fusion proteins synaptosomal-associated protein of 23 kDa (SNAP-23) and 
SNAP-25 (Table 3.7).  In addition, Pfa3 resides on the vacuole (Table 3.3).  SPE-10 was 
shown to reside on MO membranes (Gleason et al., 2006), so may palmitoylate fusion 
proteins present there, leading to fusion of the MO with the PM.  The S. cerevisiae DHHC 
spore wall formation 1 (Swf1) is responsible for palmitoylating many proteins involved in 
membrane fusion.  Similarly, the mammalian DHHC17/Huntingtin-interacting protein 14 
(HIP14) palmitoylates many proteins involved in synaptic fusion and postsynaptic receptors 
which have orthologues in C. elegans (Table 3.7, Table 3.9).  Both Swf1 and DHHC17/HIP14 
are the orthologues of C. elegans DHHC-14 in their respective species, so disruption of 
dhhc-14 may give phenotypes which result from abnormal membrane fusion, such as 
uncoordinated (Unc) phenotypes or maybe phenotypes derived from malfunction of 
subsets of neurons, such as mechanosensation (Mec) phenotypes.  However, this approach 
is limited by the information available in other organisms.  For example, C. elegans DHHC-1 
is most closely related to S. cerevisiae Pfa3, whose only known substrate is Vac8, Drosophila 
melanogaster CG10344 and H. sapiens DHHC24, neither of which have any known 
substrates (Table 3.6, Table 3.7).  This chapter aims to help elucidate some of the possible 
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pathways regulated by each enzyme by performing behavioural assays and lifespan analysis 
on available mutant strains and complement these findings using an RNAi approach. 
4.2 METHODS 
4.2.1 NEMATODE HUSBANDRY 
4.2.1.1 STRAINS 
All C. elegans strains were obtained from the Caenorhabditis Genetics Center (CGC; 
University of Minnesota, Twin Cities, MN, USA) except tm4272, which was obtained from 
the National Bioresource Project for the Experimental Animal “Nematode C. elegans” based 
in the lab of Dr Shohei Mitani (Tokyo Women’s Medical University, Tokyo, Japan). 
The Vidal C. elegans Open Reading Frame (ORF) RNAi feeding library was obtained from 
Source Bioscience (Nottingham, UK) (Rual et al., 2004). 
4.2.1.2 CULTURE 
C. elegans were cultured in 60 mm plates on nematode growth medium agar (NGM; 2% 
(w/v) agar, 0.3% (w/v) NaCl, 0.25% (w/v) peptone, 1 mM CaCl2, 5 μg ml-1 cholesterol,  
25 mM KH2PO4, 1 mM MgSO4) at 20 °C, seeded with 30 μl E. coli OP50 culture (CGC) as a 
food source, using standard methods (Brenner, 1974). 
4.2.2 RNAI 
4.2.2.1 FEEDING RNAI 
The procedure for conducting feeding RNAi in C. elegans is summarised in Figure 4.1.  RNAi 
feeding experiments were conducted using bacteria from the Vidal C. elegans ORF RNAi 
Library (Rual et al., 2004) where available, or were cloned in-house.  All RNAi feeding 
bacteria were E. coli strain HT115, which lacks the dsRNA-specific RNase III but contains an 
isopropyl β-D-1-thiogalactopyranoside (IPTG)-inducible T7 RNA polymerase (Timmons et al., 
2001), carrying the pG-L4440 vector containing the relevant insert.  The negative control for 
most experiments was feeding of HT115 carrying the pG-L4440 vector without an insert 
(L4440).  hsp-1 was used as a positive control, as it gives a sterile phenotype (Simmer et al., 
2003). 
10 cm plates of Luria-Bertani (LB) agar (1% tryptone, 0.5% yeast extract, 1% NaCl, 1.5% 
agar) with 100 μg ml-1 ampicillin were poured.  Bacterial strains were streaked on separate 
plates and incubated overnight at 37 °C.  Two discrete colonies from each plate were each 
grown in 3 ml LB containing 100 μg ml-1 ampicillin overnight at 37 °C, 220 rpm.  DNA was 
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FIGURE 4.1: Schematic of feeding RNAi in C. elegans 
A flow diagram showing the procedure for the feeding RNAi screen.  GOI, gene of interest; IPTG 
isopropyl β-D-1-thiogalactopyranoside; NGM, nematode growth medium.  
pG-L4440 vector 
containing GOI 
transform into  
E. coli strain HT115 
culture bacteria and 
verify insert 
pour NGM + IPTG + 
carbenicillin plates 
leave in the dark for 
4-7 days 
seed plates and allow 
bacteria to induce 
overnight 
transfer ten L3/L4 
stage worms 
replica plate by 
moving three young 
adult progeny to 
individual plates 
remove replica 
worms after one day 
use young adult 
progeny for assays 
CHAPTER 4: PHENOTYPIC ANALYSIS IN C. ELEGANS 
93 
 
isolated using a miniprep kit and the correct insert verified by restriction endonuclease 
digest or by sequencing if necessary. 
For RNAi, plates of NGM containing 25 μg ml-1 carbenicillin and 1 mM IPTG were poured  
4-7 days before seeding with 50 μl of the relevant bacterial strain.  RNAi plates were always 
kept in the dark, as IPTG is light sensitive.  The dsRNA was induced overnight before ten  
L3-L4 stage worms were transferred to each plate.  Once the next generation of worms had 
reached young adult stage, three adults were moved onto individual replica plates, allowed 
to lay eggs and removed the following day.  These progeny were used in the assays once 
they had reached adulthood. 
4.2.2.2 CONFIRMATION OF RNAI LIBRARY STRAINS 
4.2.2.2.1 DNA PURIFICATION 
E. coli containing the relevant plasmid were streaked onto LB agar plates containing a 
selection antibiotic and cultured overnight at 37 °C.  Two discrete colonies were cultured in 
5 ml LB each containing a selection antibiotic at 37 °C, 250 rpm overnight.  2 ml of culture 
was pelleted in an Eppendorf tube in a microcentrifuge at 14000 rpm for one minute.  The 
supernatant was discarded and the DNA extracted from the bacterial pellet using a 
GenElute™ HP Plasmid Miniprep Kit following the manufacturer’s guidelines. 
4.2.2.2.2 RESTRICTION ENDONUCLEASE DIGESTION 
Restriction digests were used to confirm the identity of purified DNA.  5 μl miniprep DNA 
was added to 0.5 μl restriction enzyme and 1X reaction buffer in 20 μl total reaction 
volume.  The reaction was incubated at 37 °C for at least one hour.  The resulting fragments 
were combined with 6X DNA loading buffer (0.35% (w/v) orange G, 0.1% (w/v) 
bromophenol blue, 30% (w/v) sucrose) and separated by gel electrophoresis using a 0.8% 
(w/v) agarose gel containing SYBR® Safe DNA Gel Stain (Life Technologies).  Electrophoresis 
was carried out in Tris-acetate-EDTA buffer (40 mM Tris, 20 mM acetic acid, 1mM EDTA) at 
90 V for 45-60 minutes.  10 μl HighRanger Plus 100bp DNA ladder (Norgen Biotech) was run 
alongside the samples as a size reference.  Gels were visualised under UV light in a 
ChemiDoc XRS (BioRad, Hemel Hempstead, UK) with Quantity One software (BioRad; 
v4.6.3). 
4.2.2.2.3 DNA SEQUENCING 
If there was ambiguity in restriction digest results, purified DNA was sent for sequencing by 
DNA Sequencing & Services at the University of Dundee, UK.  Two tubes were sent 
containing 5 μl template miniprep DNA.  The first contained 0.2 μM pL4440 Seq Rev primer 
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and was made up to 32 μl total volume.  The second was made up to 30 μl for the M13 For 
primer to be added by the company.  The results were analysed using VectorNTI 
(Invitrogen; v11.0) or BioEdit software and basic local alignment search tool (BLAST) 
searches. 
4.2.2.3 GATEWAY™ CLONING 
4.2.2.3.1 POLYMERASE CHAIN REACTION 
To form a complete library of RNAi feeding bacteria clones for the DHHCs, some vectors 
needed to be cloned.  cDNA was first synthesised.  2 μg total RNA from wild-type worms 
extracted using an Absolutely RNA Microprep Kit (Agilent) was made up to 16.45 μl with 
diethylpyrocarbonate-treated (DEPC)-H2O.  0.8 μl 50 μM oligo(dT) primer was added and 
incubated at 70 °C for ten minutes, then on ice for two minutes.  5 μl Bioscript reaction 
buffer, 1.25 μl 10 mM dNTPs, 0.5 μl RNase OUT and 1 μl BioScript (Bioline) were added and 
reverse transcription performed under the following conditions: 25 °C (10 minutes), 42 °C 
(60 minutes), 90 °C (2 minutes).  75 μl DEPC-H2O was added to the products and stored at  
-20 °C. 
Reverse transcriptase PCR (RT-PCR) was performed using custom-designed primers, listed in 
Table 4.1.  5 μl cDNA, 2 μl 10 μM forward primer, 2 μl 10 μM reverse primer, 1 μl 10 mM 
dNTPs, 10 μl 5X high fidelity (HF) or GC-rich-optimised (GC) buffer and 0.5 μl Phusion DNA 
polymerase were made up to a total reaction volume of 50 μl with DEPC-H2O.  The PCR 
conditions were as follows: 98 °C (2 minutes); 30-35 cycles of 98 °C (15 s), 60 or 62 °C (30 s), 
72 °C (15-30 s); 72 °C (5 minutes); 4 °C store. 
4.2.2.3.2 BP REACTION 
This reaction was performed to transfer the required attB-flanked DNA sequence into an 
attP-containing vector.  7 μl PCR product, 1 μl pDONR201 (150 ng μl-1) and 2 μl BP  
clonase™ II were mixed and incubated at 25 °C for at least one hour.  1 μl proteinase K was 
added and incubated at 37 °C for ten minutes to digest the BP clonase enzyme.  Successful 
incorporation into the vector was verified by transforming into DH5α cells, miniprepping 
and performing test digests. 
4.2.2.3.3 LR REACTION 
This reaction was performed to transfer the required attL-flanked DNA into an attR-
containing vector, in this case pG-L4440.  3 μl entry vector miniprep, 3 μl pG-L4440 and 2 μl 
LR clonase™ II was made up to 10 μl and incubated at 25 °C overnight.  1 μl proteinase K 
was added and incubated at 37 °C for ten minutes.  Successful incorporation into the 
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Primer name Primer sequence 
dhhc-3 Fwd 5’-GGGGACAAGTTTGTACAAAAAAGCAGGCTTGGTCACTTGGTTGCTGGTATC-3’ 
dhhc-3 Rev 5’-GGGGACCACTTTGTACAAGAAAGCTGGGCAAACAGAATACTCGAAAGTTGGTCTC-3’ 
dhhc-4 Fwd 5’-GGGGACAAGTTTGTACAAAAAAGCAGGCTTGTCTTGTCGGGATTGCACAAG-3’ 
dhhc-4 Rev 5’-GGGGACCACTTTGTACAAGAAAGCTGGGTTACGCCGTCACCGAGTCATGTC-3’ 
dhhc-6 Fwd 5’-GGGGACAAGTTTGTACAAAAAAGCAGGCTGGATTGGCCTGCTCCAATTGC-3’ 
dhhc-6 Rev 5’-GGGGACCACTTTGTACAAGAAAGCTGGGTCTTCAGTAGTAGCCGTATCCTGGG-3’ 
dhhc-8 Fwd 5’-GGGGACAAGTTTGTACAAAAAAGCAGGCTGTGTAAACGGATATCAGCATTATTGCC-3’ 
dhhc-8 Rev 5’-GGGGACCACTTTGTACAAGAAAGCTGGGTGCGGAAGGTGCTGTAAGATAG-3’ 
dhhc-13 Fwd 5’-GGGGACAAGTTTGTACAAAAAAGCAGGCTGATGGCTGCTGATAAGAGTTTCGC-3’ 
dhhc-13 Rev 5’-GGGGACCACTTTGTACAAGAAAGCTGGGTATCTCGATGGTAGAGACATGACGAG-3’ 
dhhc-14 Fwd 5’-GGGGACAAGTTTGTACAAAAAAGCAGGCTAACCTTATTGGTGGCGTCTTGG-3’ 
dhhc-14 Rev 5’-GGGGACCACTTTGTACAAGAAAGCTGGGTCGCATAATGACTTGTAGCCATGCAG-3’ 
spe-10 Fwd 5’-GGGGACAAGTTTGTACAAAAAAGCAGGCTCGTTCAGTCAACAATTCAAGCAACC-3’ 
spe-10 Rev 5’-GGGGACCACTTTGTACAAGAAAGCTGGGTCGAACAGCACCTTCTAGTGAAGTG-3’ 
TABLE 4.1: Primers used to clone RNAi vectors 
The sequences of the oligonucleotides used for cloning RNAi vectors not already available are 
shown.  The attB sites are shown in bold italic and the annealing sequences in normal type.  
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pG-L4440 vector was verified by transforming into DH5α cells, miniprepping and 
performing test digests.  The vectors were then transformed into HT115 cells for 
consistency with the Vidal RNAi library. 
4.2.2.3.4 TRANSFORMATION OF CHEMICALLY COMPETENT E. COLI 
For DH5α cells, an aliquot was thawed on ice.  50 μl cells was mixed with 3 μl DNA from the 
BP or LR reaction in pre-chilled Eppendorf tubes and incubated on ice for 30 minutes, heat 
shocked at 42 °C for 45 s and put back on ice for two minutes.  450 μl super optimal broth 
with catabolite repression (SOC) was added and incubated at 37 °C, 220 rpm for one hour.  
100 μl was spread on LB agar plates containing an appropriate selection antibiotic and 
cultured overnight at 37 °C.  Discrete colonies were grown in LB with the antibiotic at 37 °C, 
250 rpm overnight. 
For HT115 strain, some colonies were added to 100 μl 100 mM CaCl2, mixed to 
homogeneity and left on ice.  5 μl DNA was added and incubated on ice for 30 minutes, 
heat shocked at 42 °C for 45 s and put back on ice for two minutes.  400 μl SOC was added 
and incubated at 37 °C, 220 rpm for one hour.  The cells were pelleted at 3000 rpm for one 
minute.  Most of the supernatant was discarded and the cells resuspended in a small 
volume before plating onto LB agar plates containing a selection antibiotic and culturing 
overnight at 37 °C.  Discrete colonies were grown in LB with the antibiotic at 37 °C, 250 rpm 
overnight. 
4.2.2.4 CLONING OF PPT-1/ATH-1 DOUBLE RNAI VECTOR 
An RNAi vector containing sequences for both ppt-1 and ath-1 was cloned.  Vectors 
containing ppt-1 and ath-1 individually were purified from overnight bacterial cultures.   
20 μl DNA was digested in a reaction volume of 25 μl.  pG-L4440-ppt-1 was linearised using 
Acc65I.  pG-L4440-ath-1 was digested with BsrGI to obtain the ath-1 sequence but retaining 
complementary 5’ overhangs to enable its ligation into the pG-L4440-ppt-1 vector.  Both 
digestions were incubated at 37 °C overnight to ensure complete digestion.  5’-phosphates 
were removed from linearised pG-L4440-ppt-1 by incubating with 2 μl SAP for 15 minutes 
at 37 °C.  The products were subjected to gel electrophoresis and the only pG-L4440-ppt-1 
band and the approximately 700 bp ath-1 band were excised and purified into 50 μl using a 
GenElute™ Gel Extraction Kit.  The following ligation reactions were set up: 1 μl, 0.5 μl or no 
pG-L4440-ppt-1 was added to 3 μl ath-1, 2 μl 5X T4 ligase buffer and 1 μl T4 DNA ligase, 
made up to 10 μl reaction volume and incubated at room temperature for one hour.  The 
CHAPTER 4: PHENOTYPIC ANALYSIS IN C. ELEGANS 
97 
 
DNA was transformed into DH5α cells and verified by test digest before transforming into 
HT115 cells. 
4.2.3 ASSAYS 
4.2.3.1 MORPHOLOGY 
Individual worms were placed on a freshly seeded plate and allowed to acclimatise for ten 
minutes.  Plates were placed on a microscope stage controlled by computer through an 
Optiscan II box (Prior) and adjusted so the worm was in the centre of the image on screen 
transmitted by a DinoEye Eyepiece Camera (ANMO Electronics Corporation).  WormTracker 
software (http://www.mrc-lmb.cam.ac.uk/wormtracker/; v2.0.3.1) was used to track the 
worms and collect data over a two minute period.  Data were analysed in Worm Analysis 
Toolbox software (v1.9) and Microsoft® Office Excel® 2007.  The morphological parameters 
are calculated for each frame of the video and any obvious outliers resulting from  
mis-assignment of the skeleton to the image were removed.  The mean values from all 
frames in the video of each worm were used. 
4.2.3.2 LIFESPAN 
To synchronise a worm strain, a relatively full plate of gravid adults was washed with 3.5 ml 
sterile H2O and collected in a 15 ml Falcon tube.  1.5 ml bleach mixture (two parts 
commercial bleach to one part 5 M NaOH) was added and the tube vortexed well every two 
minutes for a total of 10 minutes.  The tubes were centrifuged at 1500 rpm for one minute 
and the supernatant removed.  5 ml sterile H2O was added and the tubes vortexed before 
centrifuging again.  The supernatant was removed and the pellet of eggs was transferred to 
the edge of a seeded plate.  These worms were picked onto lifespan plates once they 
reached adulthood, defined as day 0. 
For lifespan analysis of mutants, strains of interest were compared with the wild-type N2 
strain.  NGM agar plates were prepared containing 50 μM fluorodeoxyuridine (FUdR) to 
prevent development of any eggs laid.  Plates were seeded with 50 μl OP50.  The number of 
live and dead worms on these plates was counted every couple of days, and plates were  
re-seeded or worms transferred to a fresh FUdR plate if necessary. 
For RNAi lifespan studies, worms were already synchronised as a result of the replica 
plating procedure.  Once they reached adulthood, these worms were transferred to 
lifespan plates seeded with RNAi bacteria but containing no FUdR.  All worms were only fed 
their relevant RNAi bacterial strain throughout the assay, and transferred to fresh plates if 
necessary.  All plates were seeded with 50 μl bacteria. 
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4.2.3.3 LOCOMOTION 
4.2.3.3.1 SOLID MEDIA 
Worms were synchronised by allowing a gravid adult to lay eggs on a plate overnight before 
its removal.  Worms were assayed once the progeny reached young adult age.  Individual 
worms were transferred to an unseeded or freshly seeded plate and allowed to acclimatise 
for five minutes.  The number of body bends (complete movement of the head from one 
side to the other and back again) was observed over a period of two minutes (Miller et al., 
1999). 
4.2.3.3.2 LIQUID MEDIA 
To assess locomotory ability in solution, young adult worms were subjected to thrashing 
assays (Johnson et al., 2009).  100 μl drops of Dent’s Ringer solution (DRS; 10 mM  
D-glucose, 10 mM HEPES, 140 mM NaCl, 6 mM KCl, 3 mM CaCl2, 1 mM MgCl2, pH 7.4) 
containing 0.1% (w/v) bovine serum albumin (BSA) were put in each well of a 96-well plate.  
One worm was picked into each well and allowed to equilibrate for at least 5 minutes.  The 
number of thrashes (complete movement of the head from one side to the other and back 
again) in one minute was recorded. 
For age-dependent locomotion, mutants were synchronised as for lifespan experiments.  At 
day 0 of adulthood, 50 worms of each strain were picked onto an FUdR plate.  Every couple 
of days, ten worms of each strain were subjected to thrashing assays in 30 μl drops of DRS 
on a dish, then returned to their plate.  This was continued until a strain had essentially no 
movement.  Plates were re-seeded and worms transferred to a fresh FUdR plate if 
necessary. 
4.2.3.4 MECHANOSENSATION 
This method is based on that in (Chalfie and Sulston, 1981). The root end of an eyebrow 
hair was glued to the end of a toothpick, leaving the tapered end free.  Before each assay, 
this was sterilised by dipping in 70% ethanol and allowed to air dry.  The worm to be 
assayed was transferred to an unseeded plate and allowed five minutes to acclimatise.  
Anterior touch response was tested by gently stroking the eyebrow hair behind the 
pharynx, and posterior touch response by stroking just forward of the anus.  A positive 
response was defined as stopping movement in the direction of the touch or reversal of 
direction of movement, or for posterior touch suddenly quicker forward movement. 
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4.2.4 STATISTICAL ANALYSIS 
All statistical analyses (with the exception of lifespan and age-dependent locomotion) and 
all graphs were produced using SigmaPlot (Systat Softare, Inc.; v.12.2.0.45).  If two data sets 
were being directly compared, Student’s t-test was used.  For comparison of multiple data 
sets in one analysis, a one-way analysis of variance (ANOVA) was used. 
Lifespan analyses were performed using the Online Application for the Survival Analysis of 
Lifespan Assays (OASIS; http://sbi.postech.ac.kr/oasis/introduction/) (Yang et al., 2011).  
Mean lifespans were compared using the log-rank (Mantel-Cox) test, and mortality at more 
specific time points was compared using Fisher’s exact test.  Age-dependent thrashing was 
compared using one-way analysis of covariance (ANCOVA) in Microsoft Office® Excel® 2007. 
4.3 RESULTS 
4.3.1 PREPARATORY WORK 
4.3.1.1 MUTANT STRAINS 
Before screens could be conducted for phenotypes associated with DHHC or PPT enzymes, 
certain preparatory work was necessary.  WormBase was used to find which genes had 
existing strains available containing a mutation only in that gene (Table 4.2).  These strains 
were obtained from the Caenorhabditis Genetics Center (CGC; 
http://www.cbs.umn.edu/cgc).  Mutant strains for the remaining genes in the family were 
requested from the C. elegans Knockout Consortium 
(http://celeganskoconsortium.omrf.org/) in October 2009 but are still pending. 
Further information on the strains used in this study can be found in Table 4.3.  The only 
available strain which was not obtained was the ppt-1 mutant VC183.  This strain carries the 
allele gk139, but has not been outcrossed.  Outcrossing is a process of mating a strain with 
wild-type animals in order to reduce any background mutations which have occurred due 
to the mutagenic approach in creating strains.  The MN1 strain was created by taking the 
VC183 strain and outcrossing it four times (Porter et al., 2005).  It is the MN1 strain which 
was the subject of published studies, where it was confirmed by Northern analysis to be a 
null allele (Porter et al., 2005).  The only other strain which has been outcrossed is the 
dhhc-12 mutant VC2244.  The vast majority of the strains are deletion mutants, some of 
which also contain insertions.  The spe-10 mutant BA744 only carries a point mutation but 
this does cause a premature stop codon well before the DHHC motif, so shouldn’t produce 
an active enzyme.  This is the strain that has been used in previous studies and has shown 
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Gene Available Mutant(s) RNAi Clone Source 
ath-1 RB1484 Vidal library 
dhhc-1 tm4272 Vidal library 
dhhc-2 RB1044 Vidal library 
dhhc-3  in-house 
dhhc-4  in-house 
dhhc-5  Vidal library 
dhhc-6  in-house 
dhhc-7  Vidal library 
dhhc-8  in-house 
dhhc-9 VC2067 Vidal library 
dhhc-10  Vidal library 
dhhc-11  none 
dhhc-12 VC2039, VC2244 Vidal library 
dhhc-13 VC108 in-house 
dhhc-14 VC771, VC918 in-house 
ppt-1 MN1, VC166, VC168, VC183, VC184 Vidal library 
spe-10 BA744 in-house 
TABLE 4.2: C. elegans strain and RNAi clone availability 
The DHHC and PPT genes in C. elegans are listed.  If a C. elegans strain containing a mutation in the 
gene-of-interest only is available, it is shown here.  More detailed information on the strains used in 
this study can be found in Table 4.3 and Appendix 1.  RNAi clones were either obtained from the 
Vidal C. elegans ORF RNAi Library (Rual et al., 2004) or made in-house.  ath, acyl-protein 
thioesterase; ppt, palmitoyl-protein thioesterase; spe, spermatogenesis-deficient.  
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Strain Gene Allele Mutation Outcrossed? Phenotypes 
BA744 spe-10 hc104 point mutation unclear defective spermatogenesis;  
stress resistance 
MN1 ppt-1 gk139 deletion x4 delay in L4/adult transition;  
abnormal mitochondrial morphology 
RB1044 dhhc-2 ok990 deletion no  
RB1484 ath-1 ok1735 insertion/deletion no  
RM2754 dnj-14 ok237 deletion no  
tm4272 dhhc-1 tm4272 deletion no  
VC108 dhhc-13 gk36 deletion no  
VC166 ppt-1 gk131 insertion/deletion no  
VC168 ppt-1 gk134 deletion no  
VC184 ppt-1 gk140 insertion/deletion no  
VC771 dhhc-14 gk330 deletion no  
VC918 dhhc-14 ok1032 insertion/deletion no  
VC2039 dhhc-12 gk1013 insertion/deletion no  
VC2067 dhhc-9 gk985 deletion no  
VC2244 dhhc-12 gk981 deletion x1  
TABLE 4.3: Information about C. elegans strains used in this study 
Strain information was collated from WormBase (http://www.wormbase.org/).  Detailed information 
on the nature of each mutation may be found in Appendix 1.  dnj, DnaJ domain-containing protein.  
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spermatogenesis and stress resistance phenotypes (Cypser and Johnson, 1999; Gleason et 
al., 2006; Shakes and Ward, 1989).  It is unclear whether the strain obtained from the CGC 
has been outcrossed; the listings on WormBase and the CGC website say “outcrossed: x” 
and the first study to use it outcrossed four times after obtaining it (Shakes and Ward, 
1989).  Another study found an increase in survival persisted over a further two outcrosses 
(Cypser and Johnson, 1999), suggesting phenotypes found with the BA744 strain are due to 
the mutation in spe-10.  The majority of the strains in Table 4.3 have no observed 
phenotypes. 
4.3.1.2 RNAI 
4.3.1.2.1 BACTERIAL CLONES 
An alternative to using mutant strains is to knock down expression of proteins through 
RNAi.  This may be achieved simply in C. elegans by culturing the animals on plates seeded 
with bacteria expressing dsRNA against the gene of interest (Fire et al., 1998; Kamath et al., 
2001; Timmons and Fire, 1998).  Our laboratory has the Vidal C. elegans ORF RNAi Library of 
bacterial RNAi feeding strains (Rual et al., 2004), which covers approximately 55% of  
C. elegans protein-coding genes.  A search of the database revealed that ten of the 15 
DHHCs and both PPTs are present.  Restriction analysis and DNA sequencing showed that 
the strain labelled for dhhc-6 contained a different gene and dhhc-14 actually contained no 
insert in the vector.  Sequencing showed some other vectors contained the correct gene 
but with truncations which accounted for fragments which were a different size from what 
was expected in restriction analysis.  dhhc-2 contained the sequence from 242 base pairs 
(b.p.) onwards with a G975A point mutation; dhhc-7 contained the sequence from  
isoform b, which is a truncated version of isoform a; dhhc-12 contained the sequence from 
215 b.p. onwards.  As C. elegans lacks the interferon response to long dsRNAs which exists 
in mammals (Fischer, 2010), the minimum sequence length consistently shown to give 
effective knockdown is around 500 b.p. (Hammell and Hannon, 2012; Kamath et al., 2001).  
These constructs include more than sufficient sequence. 
The genes not present in the Vidal library were cloned into the empty vector to give a 
complete set of RNAi clones for the DHHC and PPT families (Table 4.2).  Unfortunately, the 
clone which was thought to contain dhhc-11 was found to contain the same strain as an 
adjacent well in the Vidal library plates.  This strain contained ZK858.2 which encodes a 
protein of unknown function showing homology only with proteins from other nematode 
species.  Due to time constraints, the experiment including this clone had to be performed 
before the sequencing results were returned and so dhhc-11 is not present in this screen. 
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4.3.1.2.2 RNAI-SENSITIVE C. ELEGANS STRAINS 
Before RNAi experiments were commenced, tests were performed to find the best  
C. elegans strain to use, as some tissues are refractory to RNAi treatment, notably neurons 
(Timmons et al., 2001).  In the first test, a strain lacking eri-1 (RB2025) and a strain 
containing yellow fluorescent protein (yfp) and sid-1 genes expressed under the unc-119 
promoter, which drives expression in the nervous system and the lumbar and preanal 
ganglia (Calixto et al., 2010) were used.  eri-1 encodes an exonuclease with activity against 
the 3’ overhangs of siRNAs, and its knockout causes an organism-wide increase in sensitivity 
to RNAi (Kennedy et al., 2004).  sid-1 encodes a transmembrane protein which allows 
passive uptake of dsRNA by cells (Winston et al., 2002).  Its artificial expression in neurons 
has been shown to increase the effectiveness of RNAi in these cells (Calixto et al., 2010).  
These strains were tested by feeding RNAi against genes which should severely restrict 
movement when compromised: unc-18, the C. elegans orthologue of Munc-18, and unc-64, 
the orthologue of syntaxin.  TU3311 was additionally tested against unc-119, which causes 
an Unc phenotype including lack of movement on plates and locomotion in thrashing assays 
limited to ten thrashes per minute (Maduro and Pilgrim, 1995).  Thrashing assays were 
conducted and compared with wild-type N2 animals treated using the same procedure and 
a control against gfp (Figure 4.2A).  All animals were slower moving than expected on the 
control against gfp and none of the treatments against unc genes showed a reduction from 
the gfp rate. 
A number of sid-1-expressing strains have been created.  Given the absence of any 
discernible effect with the strains above, a further test was performed using TU3335.  This 
strain has an integrated transgene expressing sid-1 and yfp under the unc-119 promoter, 
mec-6 under its own promoter and the lin-15b allele n744, which also enhances RNAi 
sensitivity (Wang et al., 2005).  The strain was tested using RNAi against unc-14, a neuronal 
protein required for axonogenesis (McIntire et al., 1992) and which showed a severe Unc 
phenotype indistinguishable from the loss-of-function phenotype in most animals tested 
(Calixto et al., 2010).  However, when compared with an empty vector control in a 
thrashing assay there was only a mild, non-significant reduction in locomotion (Figure 4.2B).  
Given the failure of these supposedly hypersensitive strains to respond to RNAi against 
genes which should give clear phenotypes, it was decided instead to use the rrf-3 mutant 
strain (NL2099) which is hypersensitive to RNAi in all tissues (Simmer et al., 2002) and has 
been successfully used both in this laboratory and in large scale screens (Lejeune et al., 
2012; Simmer et al., 2003). 
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FIGURE 4.2: Locomotion in liquid medium of RNAi-sensitive strains 
Thrashing assays were performed on strains treated with RNAi.  (A) Strains used were the negative 
control wild-type N2 and neuronally RNAi-sensitive eri-1 and TU3311 (sid-1 overexpressing) strains.  
RNAi clones were against gfp (negative control), the neuronally-expressed gene unc-18, and unc-64 
and unc-119, both expressed neuronally and elsewhere.  unc-119 was not tested in the eri-1 strain.  
n = 10-29 over 1-3 experiments.  (B) Thrashing assays were performed using the TU3335 strain  
(lin-15b mutant overexpressing sid-1).  Animals were treated with RNAi against L4440 (control) or 
unc-14, which is required for axonogenesis.  n = 10 over one experiment.  eri, enhanced RNAi; gfp, 
green fluorescent protein; sid, systemic RNAi defective; unc, uncoordinated.  
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4.3.2 MORPHOLOGY 
All strains appeared to have normal morphology, behaviour and fertility during normal 
culture conditions.  To quantify their morphology a few strains were analysed using 
WormTracker software, which automatically locates an animal on a video feed of a plate, 
assigns a skeleton of points along the body and uses this to give precise morphological 
measurements.  This is an evolution of previously published methods (Geng et al., 2004).  
Wild-type N2 animals had an average length of about 1225 μm and width of 83 μm  
(Figure 4.3).  None of the mutant strains tested had a significant difference in length from 
N2.  Mutants for dhhc-1, -2, -12 (VC2039) and -14 (VC918) show a small but significant 
reduction in width to around 70-75 μm.  For RNAi experiments, the rrf-3 mutant strain was 
used.  When fed the negative control bacteria, which had no insert in the pG-L4440 vector 
(L4440), rrf-3 animals were on average about 1450 μm long and 86 μm wide (Figure 4.4).  
There is no reported figure for the length of rrf-3 mutants in the literature, although no 
obvious morphological differences were reported when this strain was first published 
(Simmer et al., 2002), and on the plates they appear identical to N2 animals by eye.  When 
rrf-3 animals were treated with RNAi against the same selection of genes as the mutants, 
no significant differences in length or width were observed. 
4.3.3 BEHAVIOUR 
4.3.3.1 LOCOMOTION 
Locomotion can be assessed in solution (Johnson et al., 2009) or on solid media (Miller et 
al., 1999).  All mutant strains were subjected to thrashing assays in solution along with a 
strain lacking dnj-14, the C. elegans orthologue of cysteine string protein (CSP).  CSP is the 
most heavily palmitoylated protein known (Gundersen et al., 1994) and its knockout gives a 
neurodegenerative phenotype in mice leading to death at about two months of age 
(Fernandez-Chacon et al., 2004) and a temperature-sensitive reduction in synaptic 
transmission in D. melanogaster leading to paralysis and premature death (Zinsmaier et al., 
1994).  Mutations in humans lead to the neurodegenerative diseases called neuronal ceroid 
lipofuscinoses (NCL) (Benitez et al., 2011; Velinov et al., 2012).  dnj-14 mutants have 
previously been observed in this laboratory to have a slight but significant decrease in 
thrashing and reduced lifespan (unpublished data).  If any mutants showed a similar 
phenotype to the dnj-14 strain, the enzyme involved may be responsible for DNJ-14 
palmitoylation.  In thrashing assays, the dnj-14 mutants did show a small decrease but it 
was not significantly different from wild-type N2 animals.  One of the dhhc-12 mutants 
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FIGURE 4.3: Morphology of selected mutant strains 
Length (A) and width (B) data were collected using WormTracker.  n = 4-10 animals over one 
experiment.  * p < 0.05 by one-way ANOVA.  ANOVA, analysis of variance.
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FIGURE 4.4: Morphology of rrf-3 mutant animals treated with RNAi against selected genes 
Length (A) and width (B) data were collected using WormTracker.  There were no morphological 
differences between animals treated with RNAi against the genes shown and the control treatment 
(L4440).  n = 4-8 animals over one experiment.  rrf, RNA-dependent RNA polymerase family.  
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(VC2039) shows a significant decrease in locomotion, and dhhc-14 (VC918) shows a 
significant increase (Figure 4.5A).  However, in both cases the other strain available for the 
gene shows a non-significant difference in the opposite direction.  The dhhc-12 strain 
VC2039 has a deletion downstream of the DHHC-CRD and strain VC2244 has a deletion 
including the DHHC-CRD and most of the protein (Appendix 1).  It is unknown whether both 
alleles result in no expression of the DHHC-12 protein as antibodies to use in Western 
blotting are unavailable.  Both dhhc-14 strains carry deletions which include the DHHC-CRD 
of DHHC-14, so no enzymatically active protein would be produced.  All the ppt-1 strains 
have deletions which include most of the PPT-1 protein, yet only VC166 and VC184 show a 
significant increase in thrashing compared with wild-type animals (Figure 4.5B).  In all these 
cases, the most likely explanation for these differences is the presence of secondary 
mutations as a result of the mutagenesis process; it seems unlikely that relatively small 
differences between alleles should produce such disparate effects.  Thrashing assays were 
also carried out on RNAi-treated rrf-3 mutants covering all the genes of interest except 
dhhc-11, as discussed above.  The only gene which gave a significant difference was dhhc-6, 
whose knockdown gave a reduction in thrashing rate (Figure 4.6). 
Locomotion of all the DHHC mutant strains was assessed on solid medium (Figure 4.7A).  In 
addition, the published MN1 strain lacking ppt-1 and the ath-1 mutant were tested (Figure 
4.7B).  None of the strains showed a significant difference from wild-type locomotion.  
Similar results were gained using an RNAi approach (Figure 4.8). 
It is possible that this lack of obvious locomotory phenotypes is due to a certain level of 
redundancy, that is, that other DHHCs can take over the roles of missing enzymes.  Feeding 
RNAi can be used to knockdown expression of multiple genes at the same time, albeit at a 
reduced efficiency compared with feeding RNAi against only one gene, by culturing the 
animals on a mixture of bacterial strains (Gouda et al., 2010; Kamath et al., 2001; Min et al., 
2010).  In order to test whether redundancy may play a part in these locomotion assays, 
pairs of closely related DHHCs were knocked down based on phylogenetic analysis  
(Figure 3.3).  These thrashing assays only showed a difference with knockdown of dhhc-1 
and -10, giving a small but significant increase in speed (Figure 4.9).  The rest of the 
combinations thrashed at the same rate as the negative control. 
4.3.3.2 MECHANOSENSATION 
One of the phenotypes which can occur due to dysfunction of a subset of neurons is a 
defect in mechanosensation, whereby animals fail to respond to a mechanical stimulus by 
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FIGURE 4.5: Locomotion of mutant strains in liquid medium 
Thrashing assays were conducted on wild-type N2 animals and mutants for dnj-14, DHHC  
enzymes (A) and PPT enzymes (B).  The strain designation is shown in parentheses.  Some data were 
collected by Tim Frost under my supervision.  n = 10-268 over 1-10 experiments.  * p < 0.05 by one-
way ANOVA.  ANOVA, analysis of variance; dnj, DnaJ domain-containing protein.  
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FIGURE 4.6: Locomotion of rrf-3 mutant animals treated using RNAi in liquid medium 
Thrashing assays were conducted on RNAi-sensitive rrf-3 mutant animals using feeding RNAi against 
DHHC enzymes (A) and PPT enzymes (B).  The negative control was the empty L4440 vector.  Data 
could not be collected for dhhc-11 as the construct was subsequently found to target a different 
gene.  n = 10-40 over 1-4 experiments.  * p < 0.05 by one-way ANOVA.  ANOVA, analysis of variance.
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FIGURE 4.7: Locomotion of mutant strains on solid medium 
Body bend assays were conducted on wild-type N2 animals and mutants for DHHC enzymes (A) and 
PPT enzymes (B).  The strain designation is shown in parentheses.  Some data were collected by Tim 
Frost under my supervision.  n = 4-45 over 1-2 experiments.  
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FIGURE 4.8: Locomotion of rrf-3 mutant animals treated using RNAi on solid medium 
Body bend assays were conducted on RNAi-sensitive rrf-3 mutant animals using feeding RNAi against 
DHHC and PPT enzymes.  The negative control was the empty L4440 vector.  n = 5-10 over one 
experiment.  
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FIGURE 4.9: Locomotion in liquid medium of rrf-3 animals treated with multiple RNAi clones 
against dhhc genes 
Thrashing assays were performed on rrf-3 animals subjected to feeding RNAi against L4440 (control) 
or combinations of dhhc genes.  n = 10-30 over 1-3 experiments.  * p < 0.05 by one-way ANOVA.  
ANOVA, analysis of variance.  
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increasing movement in the opposite direction (Chalfie and Sulston, 1981).  Selected 
mutant strains were tested for the presence of such a phenotype (Table 4.4).  All of the 
strains were found to have normal responses to both anterior and posterior mechanical 
stimuli. 
4.3.4 AGEING PHENOTYPES 
4.3.4.1 LIFESPAN 
The only DHHC enzyme whose loss has been studied previously is SPE-10.  One of the 
observations which has been made is a small increase in lifespan (Cypser and Johnson, 
1999).  dnj-14 mutants have been observed to have a reduced lifespan in this laboratory 
(unpublished data) and its orthologue CSP shows premature death in Drosophila and mouse 
models (Fernandez-Chacon et al., 2004; Zinsmaier et al., 1994).  It was therefore decided to 
investigate whether any of the other mutant strains obtained also had any differences in 
lifespan.  Survival plots of strains showing a significant difference from wild-type N2 animals 
are shown in Figure 4.10A, and those with no difference from N2 in Figure 4.10B.  Precise 
values for mean and median lifespan, 90% mortality and maximum lifespan are collated in 
Table 4.5.  As expected, the dnj-14 mutants showed a significantly reduced mean lifespan, 
as did mutants for dhhc-1, -9, -14 (VC771), and -14 (VC918).  Of these, dhhc-9 and -14 
(VC771) also showed a reduced median lifespan, and dnj-14, dhhc-1, -14 (VC771), and -14 
(VC918) had reduced time to 90% mortality.  The spe-10 mutant did not show an increased 
mean or median lifespan, although its maximum lifespan was extended considerably 
compared with wild-type.  Strains which did show an increase in mean lifespan were ppt-1 
(VC166) and ppt-1 (VC184); an increase in median lifespan was seen in dhhc-12 (VC2244),  
-13, ppt-1 (VC166) and ppt-1 (VC184); and an increase in time to 90% mortality was seen in 
dhhc-12 (VC2039), -13 and ppt-1 (VC166). 
Lifespan analysis was also carried out on rrf-3 mutants treated with RNAi against potential 
genes of interest identified in the lifespan analysis of mutants above.  In addition to dnj-14 
and spe-10, dhhc-1 and -14, which were generally shorter-lived, and ppt-1, which was 
longer-lived in two of the four mutant strains, were also tested (Figure 4.11, Table 4.5).  Of 
these, only dnj-14 showed a difference in mean and median lifespan, coming out much 
shorter in both measures.  dhhc-1 and -14 showed a significant decrease in time to 90% 
mortality, agreeing with analysis of their mutant strains.  Neither spe-10 nor ppt-1 showed 
any statistically significant difference in any measure of lifespan when knocked down. 
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Strain % Response to anterior touch % Response to posterior touch 
N2 97.5 97.5 
dhhc-2 (RB1044) 100 95 
dhhc-9 (VC2067) 100 100 
dhhc-12 (VC2039) 100 100 
dhhc-13 (VC108) 100 100 
dhhc-14 (VC771) 100 100 
spe-10 (BA744) 100 100 
ppt-1 (MN1) 100 95 
ath-1 (RB1484) 100 100 
TABLE 4.4: Mechanosensation of mutant strains 
Mechanosensation was assessed by passing an eyebrow hair over either the anterior or posterior of 
the animal.  A positive response to anterior touch was defined as a change of direction of movement 
of the animal from forwards to reverse.  A positive response to posterior touch was defined as a 
sudden increase in forward movement.  n = 20 per strain.  Data were collected by Tim Frost.  
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FIGURE 4.10: Survival analysis of mutant strains 
The lifespan of populations of synchronised animals was observed and compared with the wild-type 
N2 strain.  The gene affected is shown along with the strain code in parentheses.  (A) Strains showing 
a significantly different lifespan from N2.  p < 0.05 by log-rank (Mantel-Cox) test.  (B) Strains showing 
no significant difference from N2 lifespan.  Statistical analysis was performed using OASIS (Yang et 
al., 2011).  n = 43-165 animals over 1-5 experiments.  OASIS, online application for survival analysis.  
B
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Strain n Mean (days) Median (days) 90% mortality (days) Maximum (days) 
N2 165 20 19 26 28 
dnj-14 (RM2754) 50 17* 19 23† 23 
dhhc-1 (tm4272) 97 17* 18 24† 27 
dhhc-2 (RB1044) 100 20 19 26 34 
dhhc-9 (VC2067) 143 19* 19† 24 30 
dhhc-12 (VC2039) 50 19 20 26 26 
dhhc-12 (VC2244) 93 21 21† 26† 28 
dhhc-13 (VC108) 93 21 20† 26† 28 
dhhc-14 (VC771) 49 18* 18† 20† 24 
dhhc-14 (VC918) 48 18* 19 24† 24 
spe-10 (BA744) 95 21 19 29 35 
ppt-1 (MN1) 86 19 19 27 30 
ppt-1 (VC166) 88 21* 20† 28† 33 
ppt-1 (VC168) 43 19 19† 23 28 
ppt-1 (VC184) 48 23* 24† 28 31 
ath-1 (RB1484) 80 18 19 24 33 
      
RNAi strain n Mean (days) Median (days) 90% mortality (days) Maximum (days) 
L4440 164 17 17 25 31 
dnj-14 131 14* 13† 23 26 
dhhc-1 79 16 16 24† 25 
dhhc-14 99 19 19 22† 31 
spe-10 79 18 19 24 29 
ppt-1 59 15 14 25 30 
      
RNAi strain(s) n Mean (days) Median (days) 90% mortality (days) Maximum (days) 
L4440 164 17 17 25 31 
dhhc-1 + dhhc-10 50 18 18 24† 29 
dhhc-3 + dhhc-7 23 19 20 26 28 
dhhc-4 + spe-10 34 21* 21† 27 33 
dhhc-5 + dhhc-6 27 17 16 25† 26 
dhhc-9 + dhhc-12 44 18 18 24† 26 
dhhc-13 + dhhc-14 38 21 21† 24† 30 
ppt-1 + ath-1 98 14* 12† 25 30 
TABLE 4.5: Parameters measured in survival analysis 
Various measures were extracted from the lifespan experiments with mutants (top) and single 
(middle) and multiple (bottom) RNAi treatments of rrf-3 mutants.  Statistical tests were applied using 
OASIS (Yang et al., 2011).  * p < 0.05 by the log-rank (Mantel-Cox) test.  † p < 0.05 by Fisher’s exact 
test.  OASIS, online application for survival analysis.  
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FIGURE 4.11: Survival analysis of rrf-3 animals treated with RNAi against single genes 
The lifespan of populations of synchronised rrf-3 animals treated with RNAi against single genes was 
observed and compared with the control treated with the empty L4440 vector.  Statistical analysis 
was performed using OASIS (Yang et al., 2011).  * p < 0.05 by log-rank (Mantel-Cox) test.  n = 59-164 
animals over 1-4 experiments.  OASIS, online application for survival analysis.
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As with the locomotion assays above, RNAi was carried out against the same combinations 
of genes to test whether this made any difference to the lifespans observed in mutants and 
single RNAi experiments.  A combination of ppt-1 and ath-1 showed a much decreased 
mean and median lifespan, whereas concurrent knockdown of dhhc-4 and spe-10 resulted 
in an increase in mean and median lifespan (Figure 4.12, Table 4.5).  The remaining 
combinations showed no difference in mean lifespan from the negative control.  The 
combination of dhhc-13 and -14 showed an increased median lifespan.  The combinations 
of dhhc-1 and -10, dhhc-5 and -6, dhhc-9 and -12 and dhhc-13 and -14 all showed a 
significantly quicker time to 90% mortality than the negative controls. 
4.3.4.2 LOCOMOTION 
As palmitoylation is known to be involved in a number of neurodegenerative processes (Das 
et al., 2001; Rush et al., 2012; Singaraja et al., 2011; Sutton et al., 2012; Velinov et al., 2012; 
Vetrivel et al., 2009), a possible readout of this process would be a faster than normal 
decrease in locomotion rate as C. elegans ages.  Indeed, dnj-14 mutants have already 
shown such an effect (unpublished data).  All of the mutant strains except dhhc-1, which 
was not yet available at the time, were synchronised and subjected to thrashing assays as 
they aged.  The results of each of the three experiments performed are shown in Figure 
4.13.  None of the mutant strains showed a significant difference from the shape of decay 
in the wild-type N2 rate of thrashing.  Given this result and the time-consuming nature of 
these experiments, it was decided not to repeat this experiment using an RNAi approach. 
4.3.5 ALTERNATIVE APPROACH TO KNOCKDOWN OF MULTIPLE GENES USING RNAI 
As mentioned above, it has been observed that knockdown of two or more genes by mixing 
the feeding RNAi bacterial strains gives variable efficacy in an apparently gene-dependent 
manner (Gouda et al., 2010; Kamath et al., 2001; Min et al., 2010).  Recently described is an 
approach in which the sequences from two or more genes of interest are cloned into the 
same vector, giving efficient knockdown of all the genes involved (Figure 4.14A) (Gouda et 
al., 2010; Min et al., 2010).  As there are only two known PPTs in C. elegans, it is possible 
that concurrent knockdown of both would produce relatively severe effects compared with 
those already observed in this chapter.  With this in mind, it was decided to test this effect 
by comparing the thrashing rates of knockdown of ppt-1 and ath-1 either by mixing the 
separate bacterial strains or by feeding a bacterial strain expressing the conjugated 
sequences from the individual vectors.  However, no difference was seen from the negative 
control in either condition (Figure 4.14B). 
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FIGURE 4.12: Survival analysis of rrf-3 animals treated multiply with RNAi against single genes 
The lifespan of populations of synchronised rrf-3 animals treated with multiple RNAi strains against 
single genes was observed and compared with the control treated with the empty L4440 vector.   
(A) Treatments showing a significantly different lifespan from the control.  p < 0.05 by log-rank 
(Mantel-Cox) test.  (B) Treatments showing no significant difference from control lifespan.   
n = 23-164 animals over 1-4 experiments.  Statistical analysis was performed using OASIS (Yang et al., 
2011).  OASIS, online application for survival analysis.  
B
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FIGURE 4.13: Age-dependent decline in locomotion of mutant strains 
Thrashing assays were performed on synchronised animals at various ages and compared with the 
wild-type N2 strain.  Each individual experiment is shown for ease of viewing.  The gene affected is 
shown along with the strain code in parentheses.  No significant difference in decline of locomotion 
from wild-type was observed in any experiment as assessed by one-way ANCOVA.  n = 4-10 animals 
per strain per time point.  ANCOVA, analysis of covariance.  
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FIGURE 4.14: Comparison of strategies for simultaneous knockdown of two genes using RNAi 
(A) Cartoon showing two strategies for feeding RNAi for multiple genes.  The upper strategy was 
used for previous experiments.  The lower strategy is thought to increase the effective dose of siRNA 
to the organism.  (B) Locomotion of rrf-3 mutant animals was assessed after RNAi treatment with 
control L4440 or against ppt-1 and ath-1 by feeding with a mixture of bacteria expressing one or the 
other (ppt-1 + ath-1) or a single bacterial line expressing both from one plasmid (ppt-1/ath-1).   
n = 10-30 animals over 1-3 experiments.  dsRNA, double-stranded ribonucleic acid.  
L4
44
0
pp
t-1
 + 
ath
-1
pp
t-1
/at
h-
1
N
o.
 o
f t
hr
as
he
s p
er
 m
in
ut
e
0
20
40
60
80
100B
A
combination of 
bacteria transformed 
to express single genes
dsRNA
gene 1
dsRNA
gene 2
feed to worms
dsRNA
genes 1 and 2
bacteria transformed 
to express both genes
feed to worms
CHAPTER 4: PHENOTYPIC ANALYSIS IN C. ELEGANS 
123 
 
4.4 DISCUSSION 
4.4.1 OVERVIEW OF RESULTS 
In this chapter, a combination of mutant strains and feeding RNAi treatment were used to 
try to tease out phenotypes associated with loss of enzymes involved in palmitoylation, 
both individually and in combinations.  Both of these approaches have advantages and 
limitations.  Mutant strains can result in no expression of a protein at all or in expression of 
a truncated or functionally inert protein.  However, the methods which are classically used 
to produce these strains are likely to produce mutations elsewhere in the genome.  The 
outcrossing process to remove background mutations is laborious but improves confidence 
that any effects are specific to the gene of interest.  Of the strains used in this study, only 
ppt-1 (MN1) has been outcrossed extensively, dhhc-12 (VC2244) has been outcrossed once 
and spe-10 (BA744) may have been outcrossed four times (Table 4.3).  Studies using 
mutants were also hampered by not being able to investigate every gene in the DHHC 
family.  Although mutants for the remaining genes were requested from the C. elegans 
Knockout Consortium at the beginning of the project, funding issues have since severely 
limited their capabilities and unfortunately these strains have not been generated. 
The feeding RNAi method has the advantage that it is easy to perform and a screen of the 
entire family of DHHC enzymes can be achieved.  There is also scope for knockdown of 
multiple genes simultaneously, although an experiment comparing strategies with both 
PPTs shows this requires further optimisation (Figure 4.14).  There are two main caveats to 
the use of RNAi.  First is the efficiency of the knockdown.  When the feeding RNAi 
technique used here was first optimised, analysis of genes which produce embryonic 
lethality gave the expected phenotype in around 100% of embryos for most genes tested 
(Kamath et al., 2001).  When the rrf-3 hypersensitive RNAi strain was first characterised, 
phenotypes which could not be observed with RNAi in wild-type N2 animals could be seen 
in 0-82% of rrf-3 animals (Simmer et al., 2002).  Quantitative polymerase chain reaction 
(PCR) analysis of knockdown of oocyte maturation defective 1 (oma-1) and oma-2 in  
wild-type N2 animals showed a decrease in expression of 80-90% and also had a dilution to 
around 40% knockdown when two bacterial strains were mixed which did not occur when a 
single bacterial strain expressing both constructs was used (Gouda et al., 2010).  Second is 
the differing penetration of RNAi in different tissues in C. elegans.  Various strains have 
been created which give increased sensitivity to RNAi in all tissues or specific tissues.  These 
were tested using constructs which were expected to give clear phenotypes (Figure 4.2).  
However, none of the strains tested appeared to give expected phenotypes in our hands 
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and so the globally hypersensitive rrf-3 strain was chosen (Simmer et al., 2002).  This strain 
gave the expected sterile phenotype with the positive control knockdown of hsp-1 (Simmer 
et al., 2003) and the reduction in lifespan after dnj-14 knockdown (Figure 4.11, Table 4.5), 
giving confidence that feeding RNAi is indeed knocking down expression. 
To gain an overview of all the analyses performed in this chapter, a matrix was produced 
showing which genes were tested in which ways and the results (Figure 4.15).  In terms of 
morphology, a handful of mutants showed a slight reduction in width but this was not seen 
in any RNAi experiments and are difficult to explain based on current knowledge.  It is 
possible the mutant strains have a mild effect during development which results in a 
thinner body, or perhaps they contain fewer eggs.  It may be that phenotypes which are 
seen in mutants but not RNAi like this are due to the remaining low level of expression still 
being enough for the protein to perform its function. 
As many of the DHHC enzymes are closely related (Figure 3.3) there may be a 
compensatory effect which complements the small amount of expression of the protein.  In 
view of this, some combinatorial RNAi was also performed for the locomotion and lifespan 
assays.  Some strains showed no difference from controls in either locomotion or lifespan 
under any conditions tested.  dhhc-2, -3, -7, and -8 fell into this category.  dhhc-1 showed a 
reduction in lifespan in mutants and when treated with RNAi on its own and with dhhc-10, 
which did not show a difference on its own.  The combined knockdown of dhhc-1 and -10 
also gave an increase in thrashing rate.  The same was true for dhhc-5 and -6 and although 
they were not tested individually for lifespan, dhhc-6 did also show a decrease in thrashing 
rate.  dhhc-9 mutants showed a decrease in lifespan and, when knocked down in 
combination with dhhc-12, a reduction in time to 90% mortality.  This is interesting given 
that both dhhc-12 mutants showed an increase in lifespan, although VC2039 also shows a 
decrease in locomotion.  A similar effect was seen in dhhc-13 and -14.  Mutants for dhhc-13 
and -14 showed an increase and decrease in lifespan, respectively, but when knocked down 
in combination showed an increase in median lifespan with a decrease in time to 90% 
mortality.  This may indicate that dhhc-13 acts earlier in life whereas dhhc-14 acts towards 
the end of the animals’ lifespan to extend it.  spe-10 and dhhc-4 did not show phenotypes 
when altered on their own, but  knockdown in concert resulted in an increase in lifespan. 
Analysis of ppt-1 produced somewhat challenging data from which to draw conclusions.  
Two of the four mutant strains available showed an increase in thrashing rate, yet one of 
these showed an increase in lifespan and the other a decrease.  The VC184 strain also 
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FIGURE 4.15: Summary of observations in this chapter 
This matrix summarises the results presented in this chapter.  A significant increase in quantity or 
time is coloured green and a significant decrease is in red.  Grey indicates a test was not performed.  
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showed an increase in lifespan, although the MN1 strain and RNAi treatment against ppt-1 
showed no phenotypes.  When combined with ath-1, which showed no phenotypes on its 
own, there was a marked reduction in mean and median lifespan.  It would be interesting 
to investigate whether RNAi using the double ppt-1/ath-1 vector or a double mutant 
reproduce this finding. 
4.4.2 COMPARISON WITH EXISTING KNOWLEDGE AND IN SILICO PREDICTIONS 
The DHHC family member spe-10 has already been studied in relation to its 
spermatogenesis phenotype (Gleason et al., 2006; Shakes and Ward, 1989) and resistance 
to certain stresses (Cypser and Johnson, 1999).  The BA744 strain appeared normal and did 
not have any obvious reduction in fertility during normal strain maintenance at 20 °C (data 
not shown).  The moderate increase in lifespan previously reported in some experiments 
(Cypser and Johnson, 1999) was not observed here (Figure 4.10B, Figure 4.11, Table 4.5), 
although these experiments were performed at 20 °C in contrast to the published 
observations at 25.5 °C.  As spe-10 mutants also have a resistance to heat stress (Cypser 
and Johnson, 1999), it is possible this is the main factor determining lifespan at higher 
temperatures.  An increase in maximum lifespan was observed both in that study and here, 
however.  In addition, an increase in mean and median lifespan was seen when RNAi was 
performed on both spe-10 and its most closely related gene dhhc-4 simultaneously  
(Table 4.5). 
The main subject of the published analysis of ppt-1 was the MN1 strain (Porter et al., 2005).  
This included an analysis of lifespan at both 20 and 25 °C which showed no difference from 
wild-type N2 lifespan.  It is gratifying that their survival curves for N2 and MN1 show 
roughly the same shape as those presented here, with MN1 survival slightly below N2 for 
most of the time followed by a minority which have a longer maximum lifespan  
(Figure 4.10B).  Although the VC184 strain was also used in some assays (Porter et al., 
2005), it does not appear to have been tested for lifespan, so the observation of increased 
lifespan (Figure 4.10, Table 4.5) cannot be corroborated.  The observation that MN1 
animals seemed to age more quickly on the plates, becoming less motile earlier than N2 
animals (Porter et al., 2005), was not backed up by analysis of age-dependent locomotion 
(Figure 4.13), which showed no differences in any strains.  The lack of consistency in 
phenotypes shown between different alleles of ppt-1 are puzzling given that each one 
would be expected to result in lack of ppt-1 expression (Appendix 1).  Strains VC166 and 
VC168 show an increased thrashing rate; VC168 shows reduced median lifespan, MN1 
shows no difference from wild-type and VC166 and VC184 show increased mean and 
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median lifespan.  The allele in MN1 has been confirmed to be a null allele (Porter et al., 
2005).  Detection of wild-type PPT-1 protein was also attempted in that study but was 
hampered by not being able to detect PPT-1 in wild-type animals using either 
immunofluorescence or Western blotting.  The antibody used was able to detect PPT-1 
overexpressed in bacteria, suggesting wild-type PPT-1 levels are low and/or diffuse.  The 
same study suggested a possible explanation for the relatively mild phenotype of MN1 
animals could be as a result of compensation by ATH-1 (Porter et al., 2005).  The results of 
the multiple RNAi presented here suggest this may be the case, as even with the reduced 
dsRNA dosage from mixing the feeding bacterial strains (Gouda et al., 2010; Kamath et al., 
2001; Min et al., 2010) this gave the biggest effect on lifespan of any of the conditions 
tested, with a decrease in mean and median lifespan (Figure 4.12, Table 4.5).  As no 
difference was seen between the different multiple RNAi strategies in locomotion, perhaps 
lifespan would be a more suitable condition to test.  Animals treated with both dsRNAs 
expressed from the same vector appeared normal and had no locomotion defects, but a 
quantitative test of their lifespan could be predicted to show an additional reduction given 
the increased knockdown expected with this method (Gouda et al., 2010; Min et al., 2010).  
Unfortunately this could not be performed in this study due to time constraints. 
One of the predictions made using the in silico analyses from Chapter 3 was that disruption 
of dhhc-14 may lead to locomotion or lifespan phenotypes given its orthologues in  
S. cerevisiae and H. sapiens are known to palmitoylate important proteins in membrane 
fusion (Table 3.7).  Whilst neither mutant strain nor RNAi treatment against dhhc-14 gave 
locomotion phenotypes, VC771 showed reductions in all lifespan parameters tested, VC918 
showed reductions in mean lifespan and time to 90% mortality and treatment with RNAi 
both individually and in combination with dhhc-13 gave a reduction in time to 90% 
mortality (Table 4.5).  This is one of the most consistent phenotypes observed between 
several different disruptions of the same gene.  Its lack of locomotion phenotype but 
reduction in most lifespan parameters also mirrors what was seen with disruption of  
dnj-14.  The orthologues of DHHC-14 in D. melanogaster and H. sapiens, Hip14 and 
DHHC17/HIP14 respectively, have CSP as one of their substrates (Table 3.7).  In addition, 
the D. melanogaster knockouts of hip14 and csp show similar phenotypes of a temperature 
sensitive exocytotic defect (Ohyama et al., 2007; Zinsmaier et al., 1994).  These lines of 
evidence suggest DHHC-14 may be one of the enzymes responsible for palmitoylating  
DNJ-14 in C. elegans.  However, other predictions did not play out.  For example, it was 
suggested based on homology that DHHC-3 and -7 may be responsible for palmitoylating 
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egg-laying defective 30 (EGL-30), the Gαq orthologue, and therefore might offer 
phenotypes.  However, neither gave any phenotypes either individually or in combination 
(Figure 4.15).  It is probable that the predictive power of such in silico analyses will increase 
as more information is gathered on enzyme-substrate interactions in each species.  In 
addition, as more is discovered about palmitoylation in C. elegans, this may inform studies 
in other species.  For example, disruption of dhhc-1 gives a reduction in lifespan but its 
orthologue in H. sapiens, DHHC24, has yet to have any substrates assigned to it (Table 3.7). 
4.4.3 EXTENDING PHENOTYPIC ANALYSIS 
Although some C. elegans phenotypes associated with DHHC and PPT enzymes were 
uncovered in this chapter, it was by no means a complete analysis.  The lack of availability 
of mutants limited the mutant screen to seven of the DHHCs and there was not enough 
time in this project to do a complete screen of all assays with all the available strains.  There 
are now more avenues open to obtaining mutants in genes of interest.  There is a knockout 
project underway in the Mitani lab in Japan called the National Bioresource Project for the 
Experimental Animal “Nematode C. elegans” from which the dhhc-1 mutant tm4272 was 
obtained.  This is presently the only mutant strain for a member of either the DHHC or PPT 
family in this project, although more will surely come through as time goes on.  In addition 
a more focused and precise approach to generating knockouts in genes of interest is based 
on use of the Drosophila Mos1 transposon in methods such as Mos1-induced transgene-
instructed gene conversion (MosTIC) (Robert, 2012), Mos1-mediated single-copy insertion 
(MosSCI) (Frokjaer-Jensen et al., 2008) and Mos1-mediated targeted deletions (MosDEL) 
(Frokjaer-Jensen et al., 2010).  These methods avoid the problem of background mutations 
when strains are generated by random mutagenesis and might clarify conflicting results 
such as those seen with the ppt-1 mutant strains.  In order to perform these techniques,  
C. elegans strains containing Mos1 elements in the relevant positions in the genome are 
needed.  A library of such strains is in the early stages of development by the 
NemaGENETAG project (http://elegans.imbb.forth.gr/nemagenetag/) (Vallin et al., 2012).  A 
search using the MosLocator tool (http://www.ciml.univ-mrs.fr/applications/MosLocator/) 
found there are currently strains available with Mos1 alleles in dhhc-2, -6, and -11.  Mutants 
are currently not available for dhhc-6 and -11, so this is potentially a good source of 
targeted mutants in the future. 
The current strains and reagents available could be used in assays investigating more subtle 
phenotypes such as chemotaxis, egg-laying, developmental timing, pharyngeal pumping 
and thermotolerance, and neuronal function could be assayed using the 
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acetylcholinesterase inhibitor aldicarb.  The choice of assay could be better directed if GFP 
is expressed under the control of endogenous promoters of each of the genes of interest to 
see in which cell types they are expressed, although this would be expensive and time-
consuming to perform for all 15 DHHCs and both PPTs.  It would be useful to quantify the 
knockdown achieved by feeding RNAi using quantitative PCR, both of individual genes and 
of the different methods of combinatorial RNAi.  The best method for knocking down 
expression from multiple genes could then be used to extend the number of combinations 
tested in different assays.  Given the many substrates which can be palmitoylated by more 
than one palmitoyltransferase in mammals (Table 3.7) it may be that efficient knockdown 
of many DHHC enzymes simultaneously is required to uncover more severe phenotypes.  
This is supported by the relative difficulty of finding phenotypes in S. cerevisiae with 
knockdown of many DHHC family members simultaneously (Roth et al., 2006).  However, 
despite these issues of redundancy, there are still some severe phenotypes which can result 
from disruption of enzymes involved in palmitoylation.  In D. melanogaster, hip14 mutants 
show a relatively severe exocytotic phenotype (Ohyama et al., 2007).  Mouse knockouts of 
Hip14 and Hip14l show progressive neurodegeneration with features reminiscent of 
Huntington’s disease (HD) (Singaraja et al., 2011; Sutton et al., 2012).  In addition, the 
severe infantile neurodegenerative disorder INCL is caused by mutations in PPT1 in humans 
(Vesa et al., 1995).  Similar phenotypes may be discovered in the remaining mutants, by 
crossing existing mutants to obtain multiple knockout strains, or with complete knockdown 
in C. elegans. 
This chapter set out to explore the phenotypes associated with disruption of members of 
the DHHC and PPT families.  Mild phenotypes were found for a number of genes, mainly in 
the lifespan analysis.  As only spe-10 and ppt-1 had been previously characterised, this 
information is potentially valuable as a starting point for future studies into specific 
enzymes.  The confirmation of the prediction that dhhc-14 might have a deleterious 
phenotype from the information collected in Chapter 3 gives proof of principle that such 
analyses can be helpful.  Of course their usefulness will increase as more knowledge is 
uncovered.  More specific validation can be given to predictions of enzyme substrate 
interactions by characterising which proteins are palmitoylated in C. elegans.  This 
information can be combined with characterising which proteins remain palmitoylated in 
mutant strains to provide higher confidence enzyme-substrate pairs and complement these 
phenotypic data. 
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5.1 INTRODUCTION 
Two main techniques have emerged for purifying palmitoylated proteins from an extract, 
such as a cell lysate or a tissue homogenate.  Both techniques will be used in this chapter 
and their principles are shown in Figure 5.1.  One is acyl-biotin exchange (ABE), which was 
originally developed in response to the lack of sensitivity in existing methods and their 
restriction to living cells (Drisdel and Green, 2004; Roth et al., 2006).  The main technique of 
labelling with [3H]-palmitate was particularly cumbersome, with autoradiograph exposure 
times of weeks or months, purification of the individual protein of interest and often a prior 
knowledge of the palmitoylated protein required (Bizzozero, 1995).  Problems may also 
arise from metabolic conversion of radiolabelled palmitate to other types of fatty acid.  
Some proteomic techniques have addressed some of these problems by use of palmitate 
analogues such as 17-octadecynoic acid (17-ODYA) (Martin and Cravatt, 2009; Martin et al., 
2012) or alk-16 (Charron et al., 2009; Yount et al., 2010) which are not radioactive but 
instead may be purified using cycloaddition reactions, or so-called click chemistry.  
However, some of the limitations of [3H]-palmitate labelling are retained: the penetration 
of labelled palmitate into the cells, its ratio to unlabelled palmitate and the previous level 
of palmitoylation and its turnover must be taken into account.  The lack of sensitivity of  
[3H]-palmitate labelling means that proteins expressed at a low level, such as receptors or 
ion channels, and proteins with a high palmitate turnover may not be detected (Drisdel and 
Green, 2004).  Despite this, the use of radiolabelled palmitate remains the “gold standard” 
which is used to verify possibly contentious hits from proteomic scale screens. 
The principle of ABE derives from the labile nature of the thioester bond between palmitate 
and the modified cysteine residue.  This can be easily cleaved using neutral hydroxylamine 
(HA) (Omary and Trowbridge, 1981), revealing a free sulfhydryl group on the cysteine 
residue which can be labelled with a variety of constructs (Drisdel and Green, 2004).  The 
selectivity of this method for palmitoylation depends on prior blocking of any existing 
sulfhydryl groups on unmodified cysteine residues, which can be performed using the 
thioreactive compounds N-ethylmaleimide (NEM) or methyl methanethiosulphonate 
(MMTS).  The negative control is identically treated except with the use of Tris.HCl in place 
of HA.  A proof-of-principle was also performed in the study using a biotin construct to label 
revealed sulfhydryls.  In one case a streptavidin-horseradish peroxidise (HRP) overlay was 
used to identify palmitoylated chimeras of nicotinic receptor α7 subunits and serotonin  
(5-hydroxytryptamine; 5-HT) receptor 3A subunits; the other demonstrated selective 
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FIGURE 5.1: Proteomics methods used in this chapter 
The procedures for (A) acyl-biotin exchange and (B) acyl-resin-assisted capture are shown in cartoon 
form.  biotin-HPDP, N-[6-(biotinamido)hexyl]-3’-(2’-pyridyldithio)propionamide; HA, hydroxylamine; 
MMTS, methyl methanethiosulphonate; palm, palmitate.  
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pulldown of the purified palmitoyl-protein using a streptavidin agarose (Drisdel and Green, 
2004). 
The applicability of ABE to lysates to allow characterisation of in vivo palmitoylation was 
first demonstrated in Saccharomyces cerevisiae to characterise its palmitoylated membrane 
proteins (Roth et al., 2006).  This group took the ABE method developed by Drisdel and 
Green – labelling using a biotin construct and purifying all labelled proteins on streptavidin 
agarose – and extended it by using multi-dimensional protein identification technology 
(MudPIT) mass spectrometry to identify them.  The power of this method over previous 
ones was demonstrated by the identification of 12 of the 15 previously known palmitoyl-
proteins along with 35 new candidates.  Such an analysis would not have been possible 
using radiolabelling approaches.  A similar study soon followed using mammalian tissue, in 
this case rat cultured embryonic neurons and synaptosomes (Kang et al., 2008).  Again the 
value of the proteomic scale of ABE was shown by the identification of 68 known palmitoyl-
proteins along with 113 previously unknown high confidence candidates.  ABE has been 
applied to many mammalian cell types, including endothelial cells (Marin et al., 2012), 
platelets (Dowal et al., 2011), macrophages (Merrick et al., 2011), and B lymphocytes (Ivaldi 
et al., 2012).  The palmitoyl-proteins present in lipid rafts have been characterised in 
human prostate cancer cells by ABE (Yang et al., 2010), and the method has recently been 
used for the first characterisation of palmitoylation in Arabidopsis thaliana (Hemsley et al., 
2012). 
Acyl-resin-assisted capture (acyl-RAC) is a technique which has been described recently 
(Forrester et al., 2011) which was derived from a modification of the biotin switch assay 
used to study S-nitrosylation (Forrester et al., 2009).  It works in a similar way to ABE but 
shortens the protocol by pulling down the HA-treated proteins directly using a thioreactive 
sepharose (Figure 5.1).  This has the advantage of reducing the number of steps and 
reactions, which may enable palmitoyl-proteins to be more efficiently purified and 
therefore increase the sensitivity over ABE.  An initial proof-of-principle was performed 
using bovine brain membrane proteins, showing detection of the palmitoyl-proteins Gαz 
and growth-associated protein of 43 kDa (GAP43; neuromodulin) by immunoblotting but 
not synaptophysin, which is known not to be palmitoylated.  The characterisation of  
acyl-RAC was extended by examining H-Ras, which is known to be palmitoylated on 
cysteine residues 181 and 184 and farnesylated on cysteine-186 (Hancock et al., 1989), in 
human embryonic kidney 293 (HEK293) cells.  Wild-type but not unpalmitoylatable 
C181/184S mutants were detected, showing specificity of acyl-RAC for palmitoylation over 
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prenylation.  Treatment of cells expressing wild-type H-Ras with varying concentrations of 
the palmitoylation inhibitor 2-bromopalmitate (2-BP) showed the semi-quantitative nature 
of acyl-RAC, which is similar to ABE.  This study then extended acyl-RAC by labelling 
experimental and control HEK293 cells with reporter tags of different atomic masses.  By 
performing the trypsin digestion for mass spectrometry whilst the proteins were still bound 
to the resin, they were able to identify palmitoylation sites on 84 proteins.  These included 
both previously known sites and novel sites, a few of which were validated using cysteine to 
serine mutants.  This illustrates the potential of acyl-RAC not only to provide palmitoyl-
proteomes but palmitoyl site identification as well which will be valuable given the present 
lack of consensus motifs for predicting palmitoylation sites. 
None of these methods has been used with Caenorhabditis elegans.  In this chapter, ABE 
and acyl-RAC approaches will first be tested on rat brain homogenate and compared with 
published results to determine an efficient protocol.  Both methods will then be applied to 
wild-type C. elegans lysate to identify its palmitoyl-proteome.  These methods will also be 
applied to the acyl-protein thioesterase 1 (ath-1) knockout strain RB1484.  In the many 
published accounts of palmitoyl-proteomes in different species and cell types, some have 
looked at the effects of disrupting one or more palmitoyl acyl-transferase (PAT) enzymes 
but none have looked at mutation of a palmitoyl-protein thioesterase (PPT).  However, an 
analysis has been done using an inhibitor of PPTs to enrich palmitoyl-proteins undergoing 
rapid palmitate turnover in the analysis of mouse T cell hybridoma cells (Martin et al., 
2012).  Of the two PPTs in C. elegans, PPT-1 is the orthologue of a PPT localised to 
lysosomes, synaptic vesicles and synaptosomes (Lehtovirta et al., 2001; Verkruyse and 
Hofmann, 1996) whereas ATH-1 is the orthologue of a cytoplasmic PPT, acyl-protein 
thioesterase 1 (APT1), which is not restricted to certain subcellular regions (Duncan and 
Gilman, 1998).  APT1 was recently shown to be palmitoylated itself (Yang et al., 2010) 
which may provide an element of substrate specificity by regulation of its subcellular 
localisation.  The knockout of ath-1 was chosen to compare with the wild-type palmitoyl-
proteome as it was reasoned that it may be responsible for depalmitoylation of a wider 
range of substrates and so may have more of an effect.  It would be expected that 
disruption of PPT activity would result in a roadblock effect, with build-up of palmitate on 
proteins with either a high palmitate turnover or a slow rate of palmitoylation which is no 
longer counteracted.  These proteins would appear only in the ath-1 mutant palmitoyl-
proteome.  The wild-type palmitoyl-proteome will be the first achieved in C. elegans and 
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comparative analysis with the ath-1 mutant palmitoyl-proteome may provide some insights 
into important substrates of this enzyme. 
5.2 METHODS 
5.2.1 NEMATODE CULTURE 
5.2.1.1 STRAINS 
Wild-type N2 C. elegans and ath-1 knockout strain RB1484 were obtained from the 
Caenorhabditis Genetics Center (University of Minnesota, Twin Cities, MN, USA).  
Escherichia coli OP50 strain was obtained from the Caenorhabditis Genetics Center. 
5.2.1.2 PLATES 
C. elegans were cultured in 60 mm plates on nematode growth medium agar (NGM;  
2% (w/v) agar, 0.3% (w/v) NaCl, 0.25% (w/v) peptone, 1 mM CaCl2, 5 μg ml-1 cholesterol,  
25 mM KH2PO4, 1 mM MgSO4) at 20 °C, seeded with 30 μl E. coli OP50 culture as a food 
source, using standard methods (Brenner, 1974). 
5.2.1.3 LIQUID CULTURE 
S medium was first made.  1 ml 5 mg ml-1 cholesterol in ethanol was added to 1 l sterile  
S basal (5.845 g l-1 NaCl, 1 g l-1 K2HPO4, 6 g l-1 KH2PO4).  A trace metals solution  
(1.86 g l-1 disodium EDTA, 0.69 g l-1 FeSO4•7H2O, 0.2 g l-1 MnCl2•4H2O,  
0.29 g l-1 ZnSO4•7H2O, 0.025 g l-1 CuSO4•5H2O) and 1 M potassium citrate solution  
(20 g l-1 citric acid monohydrate, 293.5 g l-1 tri-potassium citrate monohydrate, pH 6.0) were 
also made and sterilised.  The trace metals solution was stored in the dark.  To make  
S medium, 10 ml 1 M potassium citrate pH 6.0, 10 ml trace metals solution, 3 ml 1 M CaCl2 
and 3 ml 1 M MgSO4 were added to 1 l S basal. 
1 l sterile Luria-Bertani broth (LB; 1% tryptone, 0.5% yeast extract, 1% NaCl) was seeded 
with 1 ml of an overnight culture of E. coli OP50 in LB and grown overnight at 37 °C,  
200 rpm.  The bacteria were harvested by centrifugation in clean bottles at 4000 rpm, 4 °C 
for 10 minutes.  The supernatant was discarded and the pellets resuspended in 25 ml sterile 
S medium.  Concentrated OP50 was stored at 4 °C. 
Four 100 mm NGM plates were seeded with 100 μl OP50 spread into a lawn.  The following 
day a chunk of a full plate of well-fed worms was put on each plate.  Once the plates were 
full but not starved, they were bleached to extract eggs as follows.  Each plate was washed 
with 3.5 ml sterile H2O and collected in a 15 ml Falcon tube.  1.5 ml bleach mixture (two 
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parts commercial bleach to one part 5 M NaOH) was added and the tube vortexed well 
every two minutes for a total of 10 minutes.  The tubes were centrifuged at 1500 rpm for 
one minute and the supernatant removed.  5 ml sterile H2O was added and the tubes 
vortexed before centrifuging again.  The supernatant was removed to leave the eggs in 
about 1 ml of H2O.  The eggs were added to 475 ml S medium and 25 ml concentrated OP50 
in a two litre flask.  The flask was incubated at 20 °C, 160 rpm over several days until the 
OP50 had been consumed as assessed by viewing a sample under a dissection microscope. 
To harvest the worms, the flask was tilted on ice for at least 60 minutes to allow the worms 
to collect at the bottom before removing most of the liquid.  The worms were moved into 
50 ml Falcon(s) and washed with 0.1 M NaCl.  The tubes were spun at 700 rpm, 4°C for  
2 minutes with little or no braking to preserve the worm pellet.  The supernatant was 
removed and the worms resuspended in 0.1 M NaCl added to 20 ml total and mixed with 
20 ml ice-cold 60% (w/v) sucrose.  The tubes were spun at 700 rpm, 4 °C for 5 minutes to 
‘float’ the worms.  The worms were transferred to another tube using a glass Pasteur 
pipette and washed twice with 0.1 M NaCl, spinning at 700 rpm, 4 °C for 2 minutes between 
washes.  The worms were transferred to pre-weighed Eppendorf tubes in 500 μl aliquots, 
weighed again to determine the yield of worms and stored at -80 °C. 
5.2.2 PROTEIN BIOCHEMISTRY 
5.2.2.1 PREPARATION OF LYSATES 
5.2.2.1.1 RAT BRAIN 
10 ml homogenisation buffer (HB; 0.32 M sucrose, 10 mM HEPES pH 7.4) containing one 
Complete Mini EDTA-free protease inhibitor (PI) tablet (Roche, Mannheim, Germany) was 
made up and pre-chilled on ice.  An adult female Sprague Dawley rat brain, snap-frozen 
(SeraLab, Barnet, UK), was thawed on ice in about 5 ml HB.  The brain was cut into pieces 
that were as small as possible using dissection scissors on a glass plate.  The brain was 
transferred to a specialised glass tube, the remaining HB added and processed using an 
electric homogeniser (Janke & Kunkel K.G., now IKA®-Werke GmbH & Co. K.G., Staufen, 
Germany) until homogenous.  The homogenate was spun at 3500 rcf at 4 °C for five 
minutes to remove debris.  The supernatant was split into 1 ml aliquots in Eppendorf tubes 
and sodium dodecyl sulphate (SDS) added to 2% final concentration.  These were rotated 
for 10-20 minutes at room temperature and spun at 14000 rpm, 4 °C for five minutes.  The 
supernatant was transferred to a 15 ml Falcon tube for use in the assays. 
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5.2.2.1.2 NEMATODES 
Worm pellets were frozen at -80 °C and thawed on ice before use.  Up to 500 μl worms and 
an equal volume of worm homogenisation buffer (WHB: 140 mM KCl, 1 mM EDTA,  
50 mM HEPES pH 7.4, 2% SDS) with PIs were put in a 2 ml round-bottom cryogenic vial 
(Corning, Amsterdam, the Netherlands).  425-600 μm acid-washed glass beads (Sigma, 
Dorset, UK) were added up to the meniscus using a tip box lid.  Tubes were shaken in a 
Mikro-Dismembrator S (B. Braun Biotech International, Melsungen, Germany) at 2000 rpm 
for two minutes.  Three holes were made in the base of each tube with a BD Microlance™ 3 
25G (Becton Dickinson & Co. Ltd, Ireland).  The tube was placed in a 15 ml Falcon and spun 
at 5000 rpm, 4 °C for five minutes.  The lysate was transferred to Eppendorfs and spun at 
13000 rpm, 4 °C for 20 minutes.  The supernatant was transferred to fresh tubes and used 
immediately. 
5.2.2.2 BICINCHONINIC ACID ASSAY 
The concentration of protein in a sample was determined by a BCA assay.  The working 
range of this assay is 0.02-2.0 mg ml-1, so in addition to the neat sample, dilutions of 1:10 
and 1:100 were also included.  A Pierce® BCA Protein Assay Kit was used in the 96-well 
plate format.  A series of standards of BSA in water ranging from 0 mg ml-1 to 2 mg ml-1 was 
prepared.  Three replicates of each sample were included.  The manufacturer’s procedure 
was followed and the plate read at 595 nm in an Emax Precision Microplate Reader 
(Molecular Devices) and data analysed using SOFTmax (Molecular Devices, v2.35) and 
Microsoft® Office Excel® 2007. 
5.2.2.3 PRELIMINARY TESTS 
To determine the best depalmitoylation agent, 100 μl 2 M methyl methanethiosulphonate 
(MMTS) in N,N-dimethylformamide (N,N-DMF) (20 mM final concentration) was added to 
rat brain homogenate and made up to 10 ml with lysis buffer (LB; 150 mM NaCl,  
50 mM Tris.HCl, 5 mM EDTA, pH 7.4) and a PI tablet was added.  The mixture was incubated 
at room temperature for two hours.  Three 500 μl samples were taken and treated with the 
following: 
• 500 μl 2 M hydroxylamine (HA) pH 7.4 overnight at room temperature 
• 500 μl 40 mM dithiothreitol (DTT) for one hour at 37 °C 
• 500 μl 200 mM Tris pH 8.9 (high pH sample) for one hour at room temperature 
Samples were subjected to Western blotting against cysteine string protein (CSP); its 
depalmitoylation is indicated by a mass shift from about 29 to 22 kDa. 
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The time required for complete depalmitoylation of samples was also assessed.  100 μl rat 
brain homogenate was incubated with an equal volume of 2 M HA pH 7.4 or 2 M Tris.HCl 
pH 7.4 for 30 minutes, one hour, two hours, four hours or overnight.  Samples were 
subjected to three methanol precipitations (see ABE protocol, Section 5.2.2.4) to remove 
HA.  Western blotting was performed against CSP to determine the extent of 
depalmitoylation by mass shift. 
5.2.2.4 ACYL-BIOTIN EXCHANGE 
The protocol presented here represents the optimised method, based on protocols 
previously published in proteomic analyses (Kang et al., 2008; Roth et al., 2006).  Variations 
used whilst optimising the protocol are highlighted in Table 5.1.  A schematic workflow of 
this method is shown in Figure 5.2. 
1. Rat brain homogenate was made up to 10 ml with LB and a PI tablet was added.  
Worm lysates were transferred to a 15 ml Falcon, 2 ml 20% SDS was added, LB 
added to 10 ml total volume and a PI tablet added.  From this point onwards all 
samples were treated the same.  500 μl was taken out, split into 100 μl aliquots and 
frozen at -80 °C to provide “input” for SDS-PAGE.  100 μl 2 M MMTS in N,N-DMF  
(20 mM final concentration) was added and the samples incubated at room 
temperature for two hours. 
2. The sample was split into three 15 ml Falcon tubes and a methanol precipitation 
performed three times as follows: 
a. a three-times volume of -20 °C methanol was added and the tubes 
vortexed and spun at 3500 rcf, 4 °C for two minutes 
b. the supernatant was discarded and the pellet resuspended in 1 ml 
solubilisation buffer (SB; 4% SDS, 50 mM Tris.HCl, 5 mM EDTA, pH 7.4) and 
incubated at 37 °C, 220 rpm for 30 minutes 
c. the solution was made up to 4 ml total volume with LB + 0.2% Triton X-100 
(LB-T) 
3. The combined volume was split into two 15 ml Falcons.  5 ml 2 M HA pH 7.4 was 
added to one tube and 5 ml 2 M Tris.HCl pH 7.4 to the other (1 M final 
concentration).  For the pH-based protocol, the experimental samples were treated 
with high pH buffer (200 mM Tris, 0.5% SDS, pH 8.9) and control samples with low 
pH buffer (200 mM Tris, 0.5% SDS, pH 6.5).  1.25 ml 4 mM EZ-link®  
N-[6-(biotinamido)hexyl]-3’-(2’-pyridyldithio)propionamide (biotin-HPDP) (Thermo 
Scientific, Rockford, IL, USA) stock was added to each tube (0.5 mM final 
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Method Source material Output Test Result Notes 
ABE 1x rat brain Western blot compared NEM 
and MMTS as 
blocking agents 
MMTS gave 
consistently 
stronger and 
tighter bands 
 
ABE 1x rat brain Western blot HA reaction 
speed 
overnight 
incubation 
required  
see Figure 5.4B 
compared 
biotin-BMCC 
and 
biotin-HPDP as 
thioreactive 
agents 
biotin-BMCC 
shows signal in 
control lanes; 
biotin-HPDP 
shows much more 
specific signal 
 
doubled 
amount of 
beads used 
improved signal in 
HA-treated 
samples 
 
ABE 2x rat brain SDS-PAGE 
stained with 
ProtoSafe Blue 
 enrichment in 
HA-treated 
sample 
 
Western blot  specific signal for 
CSP, SNAP-25, 
VAMP-2; no signal 
for syntaxin-3 
 
mass 
spectrometry 
 227 hits; many 
expected but also 
several suspected 
non-specific hits 
 
ABE 10x 100 mm plates  
N2 strain C. elegans 
SDS-PAGE 
stained with 
ProtoSafe Blue 
initial test on 
C. elegans 
material 
apparent slight 
overall 
enrichment in 
HA-treated over 
control sample 
lysis method: 
One Shot Cell 
Disrupter 
ABE 1x rat brain SDS-PAGE 
stained with 
ProtoSafe Blue; 
Western blot 
comparison of 
HA, DTT and 
high pH to 
cleave 
palmitates 
only HA gave an 
increase in 
mobility of CSP 
and SNAP-25 
see Figure 5.4A 
full ABE using 
pH method 
no signal in 
eluates – all in 
unbound fraction 
see Figure 5.5A 
trial of 1% β-ME 
elution 
moderate 
improvement in 
specificity 
 
ABE 1x rat brain SDS-PAGE 
stained with 
ProtoSafe Blue; 
Western blot 
1% β-ME 
elution with 
MeOH 
precipitation to 
concentrate 
eluate 
specific signal in 
HA-treated lane; 
considerable 
signal from CSP 
and syntaxin-1, 
but not Munc18 
see Figure 5.5B, C 
ABE 8x 100 mm plates  
N2 strain C. elegans 
SDS-PAGE 
stained with 
ProtoSafe Blue 
or silver stained; 
Western 
blotting1 
test using 
improved 
elution 
no difference 
between 
HA-treated and 
control in β-ME or 
Laemmli elutions; 
very little protein 
visible in final 
eluates 
lysis method: 
One Shot Cell 
Disrupter; 
tested other lysis 
methods after this 
experiment (see 
Section 5.3.1) 
ABE 5 ml concentrated  
N2 strain C. elegans 
from liquid culture 
(~4 ml homogenate) 
SDS-PAGE 
stained with 
ProtoSafe Blue 
or silver stained; 
Western 
blotting1 
much greater 
protein input 
(~16 mg) 
some specific 
bands in 
HA-treated 
sample but 
difficult to detect 
even with silver 
stain 
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Method Source material Output Test Result Notes 
ABE 10 ml concentrated  
N2 strain C. elegans 
from liquid culture 
(~7 ml homogenate) 
SDS-PAGE with 
silver staining 
MeOH 
precipitation of 
initial 
homogenate to 
remove 
potential 
non-protein 
contaminants 
BCA assay showed 
overall input 
reduced from 
~70 mg to~50 mg 
protein by this 
step 
 
greater protein 
input 
still only trace 
protein in final 
eluates 
 
acyl-RAC 
(NaCl 
control) 
1x rat brain SDS-PAGE 
stained with 
ProtoSafe Blue 
initial acyl-RAC 
test 
enrichment in 
HA-treated 
sample, although 
β-ME elution ran 
strangely 
 
Western 
blotting 
expected HA-
specific signal for 
CSP and SNAP-25 
 
ABE concentrated 
C. elegans from  
liquid culture: 
2 ml N2; 
3.5 ml dhhc-14 mutant; 
3 ml ath-1 mutant 
SDS-PAGE 
stained with 
ProtoSafe Blue 
 essentially no 
signal after input 
final method 
acyl-RAC 
(NaCl 
control) 
concentrated 
C. elegans from  
liquid culture: 
2 ml N2; 
2.5 ml dhhc-14 mutant; 
2.5 ml ath-1 mutant 
SDS-PAGE 
stained with 
ProtoSafe Blue 
 essentially no 
signal after input 
final method 
SDS-PAGE with 
silver staining 
 essentially no 
signal after input 
 
acyl-RAC 
(Tris.HCl 
control) 
1x rat brain SDS-PAGE 
stained with 
ProtoSafe Blue 
Tris.HCl control specific signal in 
HA-treated 
sample 
final method with 
mass spectrometry; 
rat and C. elegans 
material processed 
in parallel; 
see Figure 5.6B and 
Figure 5.7B 
concentrated 
C. elegans from  
liquid culture: 
1x 2 ml N2 
1x 4 ml N2 
1x 2.5 ml ath-1 mutant 
1x 5.5 ml ath-1 mutant 
SDS-PAGE with 
silver staining 
only 4 ml N2 
sample gave 
specific bands in 
HA-treated 
sample 
ABE 1x rat brain   specific signal in 
HA-treated 
sample 
final method with 
mass spectrometry; 
rat and C. elegans 
material processed 
in parallel; 
BCA assays on inputs 
showed final signal 
correlated with 
input concentration; 
see Figure 5.6A and 
Figure 5.7A, C 
concentrated 
C. elegans from  
liquid culture: 
1x 2.5 ml N2 
1x 4 ml N2 
1x 3 ml ath-1 mutant 
1x 5.5 ml ath-1 mutant 
SDS-PAGE with 
silver staining 
 both N2 samples 
and 5.5 ml ath-1 
sample gave 
specific bands in 
HA-treated 
sample 
1 Western blotting was attempted with anti-RIC-4 (SNAP-25 orthologue) and anti-DNJ-14 (CSP orthologues) antibodies, but no 
immunoreactivity was observed even in the input lane. 
TABLE 5.1: Optimisation of acyl-biotin exchange and acyl-resin-assisted capture 
All ABE and acyl-RAC experiments are listed in chronological order along with the specific aspect of 
the protocol being tested or altered, if any, and the outcome.  The final methods can be found in 
Sections 5.2.2.4 (ABE) and 5.2.2.5 (acyl-RAC).  β-ME, β-mercaptoethanol; ABE, acyl-biotin exchange; 
acyl-RAC, acyl-resin-assisted capture; ath, acyl-protein thioesterase; BCA, bicinchoninic acid;  
biotin-BMCC, 1-biotinamido-4-[4’-(maleimidomethyl)cyclohexanecarboxamido]butane; biotin-HPDP, 
N-[6-(biotinamido)hexyl]-3’-(2’-pyridyldithio)propionamide; CSP, cysteine string protein; DTT, 
dithiothreitol; HA, hydroxylamine; MeOH, methanol; MMTS, methane methylthiosulphonate; 
Munc18, mammalian UNC-18; NEM, N-ethylmaleimide; SDS-PAGE, sodium dodecylsulphate 
polyacrylamide gel electrophoresis; SNAP-25, synaptosomal-associated protein of 25 kDa; VAMP, 
vesicle-associated membrane protein.
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FIGURE 5.2: Flow diagram of acyl-biotin exchange methodology 
A summary of the experimental process of acyl-biotin exchange is shown, including approximate 
quantities of material (blue) and points at which samples are removed for subsequent SDS-PAGE and 
Western blotting analysis (red).  The numbers in blue circles refer to the step numbers in Section 
5.2.2.4.  β-ME, β-mercaptoethanol; biotin-HPDP, N-[6-(biotinamido)hexyl]-3’-(2’-
pyridyldithio)propionamide; CON, control sample; EXP, experimental sample; HA, hydroxylamine; LB, 
lysis buffer; LB-T, lysis buffer + 0.2% Triton X-100; MMTS, methyl methanethiosulphonate; PI, 
protease inhibitor; RT, room temperature; SB, solubilisation buffer; SDS-PAGE, sodium dodecyl 
sulphate polyacrylamide gel electrophoresis.  
homogenate:
rat brain (~40 mg in 9 ml)
C. elegans (~5-8 mg in ~4-5 ml)
• make up to 10 ml with LB
• + PIs
• + 20 mM MMTS
• RT, 2 h
input
500 μl 1
• split into three
• MeOH precipitate x3 2
• combine then split into two
• + 1 M HA to EXP
• + 1 M Tris.HCl to CON
• + 0.5 mM biotin-HPDP
• + LB to 10 ml
• + PIs
• RT, overnight on rocker
3
each tube:
~20 mg rat brain
~4-5 mg C. elegans
post-HA
500 μl
• split into three
• MeOH precipitate x3
• 1st time: resuspend in 1 ml SB, 
recombine into one
• 3rd time: resuspend in 250 μl SB
• + LB-T to 4 ml
• RT, 30 mins on rocker
4
• 2x 600 μl NeutrAvidin beads
• wash in 10 ml LB-T x3
5
• spin and add supernatant to beads
• RT, 90 mins on rocker 6
• spin and take unbound sample
• wash with 10 ml LB-T + 0.1% SDS x4
• + 3 ml LB-T + 1% β-ME to pellet
• 37 °C, 1 h, occasional agitation
• spin
unbound
500 μl
7
• + 1 ml 4X Laemmli and boil
• supernatant – Laemmli elution
PELLETSUPERNATANT
• split into 0.3 ml batches
• MeOH precipitate
• resuspend serially in 250 μl 
4X Laemmli – β-ME elution
8
9
EXP CON
x ~10
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3. [continued] concentration), both were made up to 10 ml with LB and a PI tablet was 
added.  Tubes were incubated at room temperature on a rocker overnight. 
4. The next day, 500 μl was taken aside from each tube, split into 100 μl aliquots and 
frozen at -80 °C to give “post-HA” for SDS-PAGE.  Each main sample was divided 
into three tubes and a methanol precipitation performed.  Each treatment was 
combined back into one tube and made up to 4 ml total with LB-T before methanol 
precipitating a second time.  In the third methanol precipitation, 250 μl SB was 
used for solubilisation and the solution was then made up to 10 ml with LB-T before 
incubating on a rocker at room temperature for 30 minutes. 
5. Meanwhile, 600 μl NeutrAvidin® UltraLink® Resin (Thermo Scientific, Rockford, IL, 
USA) was put in a 15 ml Falcon for each sample.  These were washed three times in 
10 ml LB-T and spun at 3500 rcf, 4 °C for two minutes between washes. 
6. The samples (from step 4) were spun at 3500 rcf, 4 °C for two minutes.  Their 
supernatant was added to the washed beads and incubated at room temperature 
on a rocker for 90 minutes. 
7. After spinning at 3500 rcf, 4 °C for two minutes, 500 μl of the supernatant was 
taken and stored at -80 °C to use as “unbound” in SDS-PAGE.  The pellet was 
washed four times with 10 ml LB-T + 0.1% SDS, spinning at 3500 rcf, 4 °C for two 
minutes between washes. 
8. Proteins were eluted in 3 ml LB-T + 1% β-mercaptoethanol (β-ME) by incubating at 
37 °C for one hour with occasional agitation.  The samples were spun at 3500 rcf,  
4 °C for two minutes.  The supernatant was removed and treated as step 9 below.  
1 ml 4X Laemmli buffer (8% SDS, 40% glycerol, 20% β-ME, 0.008% bromophenol 
blue, 0.25 M Tris.HCl, pH 6.8) was added to the bead pellet, which was resuspended 
and boiled – the supernatant of which (“Laemmli elution”) was taken off and stored 
at -20 °C. 
9. The supernatant from above was split into 0.3 ml aliquots in 1.5 ml Eppendorfs.  A 
three-times volume of -20 °C methanol was added, the tubes were vortexed and 
then spun at 10000 rpm, 4 °C for five minutes.  The supernatant was discarded 
carefully.  The pellet from the first tube was resuspended in 250μl 4X Laemmli 
buffer.  The same 250 μl was transferred to the next tube to resuspend that pellet 
and so on, giving the “β-ME elution”. 
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5.2.2.5 ACYL-RESIN-ASSISTED CAPTURE 
The protocol presented here represents the optimised method, based on a protocol 
previously published in a proteomic analysis (Forrester et al., 2011).  Variations used whilst 
optimising the protocol are highlighted in Table 5.1.  A schematic workflow of this method 
is shown in Figure 5.3. 
1. A BCA assay was performed on all homogenates to determine their concentrations.  
Each sample was diluted to 2 mg ml-1 with blocking buffer (100 mM HEPES, 1 mM 
EDTA, 2.5% SDS, pH 7.4).  An aliquot for SDS-PAGE was taken and frozen at -80 °C 
(“input”).  The volume of the aliquot depended on the total volume available. 
2. MMTS was added to 0.5% and the samples incubated at 40 °C for one hour with 
frequent vortexing. 
3. The samples were methanol precipitated three times in as few tubes as possible.  
They were recombined back into one tube after the first solubilisation.  The final 
time, the samples were resuspended in 1 ml binding buffer (100 mM HEPES,  
1 mM EDTA, 1% SDS, pH 7.4) instead of SB and incubated at 37 °C, 220 rpm for  
30 minutes. 
4. Meanwhile, 0.25 g thiopropyl Sepharose® 6B beads (Sigma, Dorset, UK) per sample 
were washed in 20 ml distilled water for 15 minutes.  1 g thiopropyl Sepharose® 6B 
will normally swell to 4-5 ml volume.  The beads were spun at 3500 rcf, 4 °C for two 
minutes, the supernatant removed and an equal volume of binding buffer added to 
the settled slurry. 
5. Each sample from step 3 was split into two tubes and 1 ml slurry added to each.  An 
equal volume of 2 M HA pH 7.4 was added to one tube, an equal volume of  
2 M Tris.HCl pH 7.4 to the other and a PI tablet added.  Samples were incubated on 
a rocker at room temperature overnight. 
6. The following day, samples were spun at 3500 rcf, 4 °C for two minutes.  1 ml was 
taken from the supernatant of each tube (“unbound”) and frozen at -80°C.  The 
remaining supernatant was discarded.  The bead pellet was washed five times with 
5 ml binding buffer, spinning at 3500 rcf, 4 °C for two minutes between washes. 
7. Proteins were eluted in 3 ml LB-T + 1% β-ME by incubating at 37 °C for one hour 
with occasional agitation.  The samples were spun at 3500 rcf, 4 °C for two minutes.  
The supernatant was removed and treated as step 8 below.  1 ml 4X Laemmli was 
added to the bead pellet, which was resuspended and boiled.  The supernatant was 
taken off and stored at -20 °C (“Laemmli elution”). 
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FIGURE 5.3: Flow diagram of acyl-resin-assisted capture methodology 
A summary of the experimental process of acyl-resin-assisted capture is shown, including 
approximate quantities of material (blue) and points at which samples are removed for subsequent 
SDS-PAGE and Western blotting analysis (red).  The numbers in blue circles refer to the step numbers 
in Section 5.2.2.5.  β-ME, β-mercaptoethanol; CON, control sample; EXP, experimental sample; HA, 
hydroxylamine; LB-T, lysis buffer + 0.2% Triton X-100; MMTS, methyl methanethiosulphonate; PI, 
protease inhibitor; RT, room temperature; SDS-PAGE, sodium dodecyl sulphate polyacrylamide gel 
electrophoresis.  
homogenate:
rat brain (~40 mg in 9 ml)
C. elegans (~5-8 mg in ~4-5 ml)
• dilute to 2 mg ml-1 with 
blocking buffer
• + MMTS to 5%
• 40 °C, 1 h, frequent vortexing
input
500 μl
1
• split into as few tubes as possible
• MeOH precipitate x3
• 1st time: recombine into 
one after resuspension
• 3rd time: resuspend in 
1 ml binding buffer
2
• split into two
• + 1 ml washed beads
• + 1 M HA to EXP
• + 1 M Tris.HCl to CON
• + PIs
• RT, overnight on rocker
3
each tube:
~20 mg rat brain
~4-5 mg C. elegans
4
• take 0.25 g thiopropyl Sepharose
beads per sample
• wash in 20 ml H2O for 15 mins
• spin, remove supernatant
5
6• spin and take unbound sample• wash with 5 ml binding buffer x5
• + 3 ml LB-T + 1% β-ME to pellet
• 37 °C, 1 h, occasional agitation
• spin
unbound
1 ml
7
• + 1 ml 4X Laemmli and boil
• supernatant –
Laemmli elution
PELLETSUPERNATANT
• split into 0.3 ml batches
• MeOH precipitate
• resuspend serially in 250 μl 
4X Laemmli – β-ME elution
8
EXP CON
x ~10
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8. The supernatant from step 7 was split into 0.3 ml aliquots in Eppendorfs.  A three-
times volume of -20 °C methanol was added, the tubes were vortexed and then 
spun at 10000 rpm, 4 °C for five minutes.  The supernatant was discarded carefully.  
The pellet from the first tube was resuspended in 250μl 4X Laemmli buffer.  The 
same 250 μl was transferred to the next tube to resuspend that pellet and so on, 
giving the “β-ME elution”. 
5.2.3 SAMPLE ANALYSIS 
5.2.3.1 SDS-PAGE 
Separation of protein samples was performed using SDS-polyacrylamide gel electrophoresis 
(SDS-PAGE).  Samples were prepared by boiling in Laemmli buffer at 95 °C for five minutes.  
15% gels were cast in the Mini PROTEAN 3 system (BioRad, Hemel Hempstead, UK) or pre-
cast NuPAGE® 12% Bis-Tris Gels were also used (Life Technologies, Paisley, UK). 
Samples were loaded alongside 5 μl pre-stained protein ladder (Geneflow, Fradley, UK).  
Gels were run at 180-200 V until the dye reached the bottom of the gel.  Gels were 
visualised by staining with Coomassie Blue, ProtoBlue Safe (Geneflow, Fradley, UK) or 
IRBlue (Licor, Lincoln, NE, USA), or by silver staining.  Gels were imaged in a ChemiDoc XRS 
with Quantity One software (Biorad). 
5.2.3.2 SILVER STAINING 
Silver staining of polyacrylamide gels is a more sensitive procedure, allowing protein bands 
at lower concentrations to be detected.  The gel is fixed in 50% methanol, 10% acetic acid 
for 30 minutes, then 5% methanol, 7% acetic acid for 30 minutes, followed by two  
15 minute washes in water.  0.2 mg ml-1 sodium thiosulphate was added for one minute, 
followed by two two minute washes in water.  100 ml 0.1% AgNO3 supplemented with 8 μl 
formaldehyde was added for 30 minutes, followed by a one minute wash in water.  The gel 
was developed in 100 ml 6% Na2CO3 supplemented with 48 μl formaldehyde.  The reaction 
was stopped by adding 10 ml 2.3 M citric acid.  Gels were imaged in a ChemiDoc XRS with 
Quantity One software.  Gels were stored in 20% ethanol at 4 °C. 
5.2.3.3 WESTERN BLOTTING 
Proteins were transferred to nitrocellulose submerged in transfer buffer (0.025 M Tris, 
0.192 M glycine, 20% methanol) in a BioRad Trans-blot Electrophoresis Transfer Cell, either 
at 100 V for one hour with an ice pack or 20 V overnight.  Nitrocellulose was blocked for 
one hour in Tris-buffered saline (TBS; 20 mM Tris, 140 mM NaCl, pH 7.4) with 0.1%  
Tween 20 (TBS-T) and 5% (w/v) dried skimmed milk.  The primary antibody was applied at 
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an appropriate dilution in TBS-T supplemented with 5% (w/v) BSA and incubated on a 
rocker for either one hour at room temperature or at 4 °C overnight.  The nitrocellulose was 
washed three times in TBS-T for five minutes before incubation in an appropriate HRP-
conjugated secondary antibody at 1:2000 dilution for one hour on a rocker.  The 
nitrocellulose was rinsed with TBS-T and visualised using enhanced chemiluminescence 
(ECL) reagents A (2.5 mM luminol, 400 μM p-coumaric acid, 100 mM Tris.HCl pH 8.5) and B 
(0.018% H2O2, 100 mM Tris.HCl pH 8.5) mixed 1:1.  Imaging was performed in a ChemiDoc 
XRS using Quantity One software. 
5.2.3.4 MASS SPECTROMETRY 
5.2.3.4.1 DATA COLLECTION 
The β-ME or Laemmli eluates were sent to Dr Mary Doherty (University of the Highlands 
and Islands, Inverness, UK) who kindly performed mass spectrometry on them.  Briefly, the 
protein extracts were separated using one dimensional SDS-PAGE.  Each gel lane was cut 
into 24 equal slices and digested with trypsin following reduction of any disulphide bonds 
with DTT and alkylation of free cysteine residues with iodoacetamide.  The samples were 
then transferred into clean sample tubes and centrifuged to remove any debris.  The 
protein digests were placed into glass vials prior to mass spectrometric analysis. 
Peptide analysis by liquid chromatography-tandem mass spectrometry (LC-MS/MS) was 
performed in positive ion mode using a Thermo LTQ-Orbitrap XL LC-MSn mass spectrometer 
equipped with a nanospray source and coupled to a Waters nanoAcquity ultra performance 
liquid chromatography (UPLC) system.  The samples were initially desalted and 
concentrated on a BEH C18 trapping column (Waters, Milford, MA, USA).  The peptides 
were then separated on a BEH C18 nanocolumn (1.7 μm, 75 μm x 250mm, Waters) at a flow 
rate of 400 nl min-1 using an acetonitrile-water gradient as follows: 
Time 
(minutes) 
Flow rate 
(μl min-1) 
% Buffer A 
(0.1% formic acid) 
% Buffer B 
(acetonitrile + 0.1% formic acid) 
0 0.4 99.0 1.0 
1 0.4 97.0 3.0 
21 0.4 37.5 62.5 
22.5 0.4 15.0 85.0 
24.5 0.4 15.0 85.0 
25.5 0.4 99.0 1.0 
5 μl samples were injected onto the trapping column and washed with the initial conditions 
at a flow rate of 15 μl min-1 for one minute before starting the gradient.  Spectra were 
collected using data-dependent acquisition in the range m/z 300-2000 following which 
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individual precursor ions were automatically fragmented using collision induced 
dissociation (CID). 
5.2.3.4.2 DATA ANALYSIS 
The data were subsequently analysed using Proteome Discoverer software (Thermo 
Scientific, Rockford, IL, USA) and MaxQUANT (http://maxquant.org/index.htm).  Data were 
searched against a locally implemented MASCOT server (v2.3.01).  The initial search 
parameters allowed for a single trypsin missed cleavage, carbamidomethyl modification of 
cysteine residues, oxidation of cysteine residues up to trioxidation, oxidation of 
methionine, N-terminal N-acetylation, a peptide mass tolerance of ± 10 ppm and a 
fragment mass tolerance of ± 0.8 Da.  Peptide charge was +1, +2, +3 and the data were 
searched against both Swissprot and UniRef, Taxonomy – Rat or C. elegans. 
After receiving these datasets from Dr Doherty, they were processed by removing trypsin, 
keratin and actin and discarding identifications which have been removed from official 
databases.  The ratio of experimental:control scores was taken and any with a ratio of less 
than five were discarded (Martin and Cravatt, 2009).  A control value of 0.2 was given to 
proteins present only in the experimental samples to avoid dividing by zero (Dowal et al., 
2011; Roth et al., 2006; Yang et al., 2010).  Results were considered higher confidence if 
identified from multiple unique peptides and lower confidence if identified from a single 
unique peptide. 
Venn diagrams were constructed using eulerAPE (University of Kent, 
http://www.eulerdiagrams.org/eulerAPE/; v2.0.3) and annotated in Microsoft® Office 
PowerPoint® 2010.  Unfortunately there were insufficient repeats to perform robust 
statistical analysis of the mass spectrometry output. 
5.3 RESULTS 
5.3.1 OPTIMISATION AND APPLICATION OF ABE AND ACYL-RAC 
Before attempting a proteomic analysis using C. elegans lysates, some initial tests were 
performed using rat brain homogenate to optimise the reactions as best as possible.  First 
of all, various methods of removing the palmitate groups from palmitoyl-proteins were 
investigated.  The classical ABE and acyl-RAC methods described above use HA to cleave the 
labile thioester bond between cysteine residues and palmitate groups.  However, there 
have also been reports of disruption of this bond using 20 mM dithiothreitol (DTT) (Levental 
et al., 2010) and high pH (J.R. Burgoyne, personal communication).  In light of this, free 
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thiols on proteins in rat brain homogenate were blocked using MMTS and then treated with 
HA, DTT or high pH (Figure 5.4A).  Samples were immunoblotted for cysteine string protein 
(CSP) because removal of all of its palmitate groups gives a detectable shift in molecular 
weight from approximately 29 kDa to 22 kDa (Gundersen et al., 1994).  This shift was only 
seen with treatment with HA (Figure 5.4A).  Next it was investigated whether an overnight 
treatment with HA was truly necessary for complete depalmitoylation of a sample.  Rat 
brain homogenate pre-treated with MMTS was incubated with HA for various lengths of 
time before removal of HA by methanol precipitation.  This was found to be necessary as 
the HA reaction continued to completion if the samples were simply boiled in Laemmli 
buffer (data not shown).  Samples were again immunoblotted for CSP, as it is the protein 
with the most known palmitoylated cysteine residues (Figure 5.4B).  A gradual downward 
shift in the molecular weight of CSP with increasing length of HA treatment was seen with 
complete depalmitoylation only occurring with an overnight incubation, showing this is 
required. 
Having established depalmitoylation conditions, a full scale ABE protocol was carried out on 
rat brain homogenate.  Samples were taken after the HA treatment, from the solution after 
incubation with NeutrAvidin-conjugated beads (UB; unbound) and after eluting from the 
beads by boiling in 4X Laemmli (L) and were all immunoblotted for CSP (Figure 5.4C).  All 
the HA-treated samples show the characteristic mass shift of depalmitoylated CSP.  If a 
protein is palmitoylated, it should be present in the final eluate from the HA-treated sample 
but not the control sample.  This is the case with CSP, which is specifically detected in the 
+HA eluate.  There is still quite a lot of CSP retained in the unbound +HA sample however, 
suggesting incomplete binding to the beads.  As a result of this, the quantity of beads used 
in the final binding was doubled for subsequent experiments.  Given the successful 
detection of CSP, the unbound and eluted samples were also probed for other proteins 
(Figure 5.4D).  Along with CSP, the known palmitoyl-proteins synaptosomal-associated 
protein of 25 kDa (SNAP-25) (Veit et al., 1996) and vesicle associated membrane protein 2 
(VAMP-2; synaptobrevin-2) (Veit et al., 2000) are specifically found in the +HA elution.  
Syntaxin-1 was found to be palmitoylated in the first proteomic scale screen of mammalian 
material using this method (Kang et al., 2008) and is also detected here.  Syntaxin-3 was 
also probed as an overall negative control, as it contains no cysteine residues and so cannot 
be palmitoylated.  Consistent with this, it is only detected in the unbound samples.  
Complexes of soluble NEM-sensitive fusion protein (NSF)-attachment protein (SNAP) 
receptor (SNARE) proteins have been shown to be resistant to denaturation by SDS even at 
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FIGURE 5.4: Initial optimisation tests 
(A) Rat brain homogenate was treated with final concentrations of either 1 M HA overnight at room 
temperature, 20 mM DTT for one hour at 37 °C or 100 mM Tris pH 8.9 for one hour at room 
temperature.  Samples were subjected to Western blotting and probed using anti-CSP.  Removal of 
all palmitates results in a mass shift from 29 to 22 kDa.  (B) Rat brain homogenate was treated with 
HA for the times shown.  Protein was recovered by three methanol precipitations before subjecting 
to Western blotting and probing with anti-CSP.  (C) Samples from an ABE experiment were subjected 
to Western blotting and probed with anti-CSP.  Post-HA was taken after the HA treatment; unbound 
was the fraction that did not bind to NeutrAvidin-coated beads; the elution of proteins from the 
beads was performed with Laemmli buffer.  (D) After ABE, unbound proteins and proteins eluted 
from the NeutrAvidin beads using Laemmli were subjected to Western blotting.  Western blots were 
probed using antibodies against the proteins shown.  ABE, acyl-biotin exchange; CSP, cysteine string 
protein; DTT, dithiothreitol; h, hours; HA, hydroxylamine; L, Laemmli buffer; m, minutes; o/n, 
overnight; SNAP-25, synaptosomal protein of 25 kDa; UB, unbound; VAMP, vesicle-associated 
membrane protein.  
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temperatures up to 80 °C (Hayashi et al., 1994).  As SDS is used in ABE, we were concerned 
that detection of syntaxin-1 might be a false positive if it was retained in SNARE complexes 
with SNAP-25.  If this was the case then syntaxin-3 would also be detected in this way and 
so it served as a control for this effect as well. 
The eluates from this initial ABE experiment were analysed using mass spectrometry, and 
after curation of the results there were many hits which seemed likely false positives, such 
as subunits of haemoglobin and actin at high abundance (data not shown).  To try to 
combat this, a gentler elution condition from the beads was used.  Instead of boiling in 4X 
Laemmli, the beads were incubated in a buffer containing 1% β-mercaptoethanol (β-ME) at 
37 °C for an hour with occasional agitation.  The beads were also boiled in 4X Laemmli after 
this elution to get a measure of how much of the genuine palmitoyl-proteins was being 
eluted with the β-ME.  An initial test of this elution was performed using ABE methods with 
HA or pH as the depalmitoylating agent.  Eluates were immunoblotted against SNAP-25 
(Figure 5.5A).  SNAP-25 was specifically detected in the HA-treated samples after the β-ME 
elution, and the relatively weak signal from the Laemmli elution suggests the majority of 
SNAP-25 has been released from the beads by β-ME.  The complete lack of signal from the 
elutions of the pH-based protocol indicates that high pH is not sufficient to disrupt the 
thioester link to palmitate and this is not just a quirk of CSP (Figure 5.5A).  To visualise the 
overall effect of using a β-ME elution over a Laemmli elution, samples from the HA-based 
ABE were subjected to sodium dodecyl sulphate polyacrylamide gel electrophoresis  
(SDS-PAGE) and the gel stained with ProtoBlue Safe (Figure 5.5B).  At the post-HA 
treatment and unbound stages, there are roughly equal amounts of protein in both the 
experimental and control samples.  The β-ME elution shows a clear enrichment of proteins 
in the HA-treated lane over the control lane.  Whilst enrichment can also be seen in the 
Laemmli elutions, it is to a much lesser degree and there are clearly many non-specific 
bands which appear strongly in both HA and control treatments.  These samples were also 
subjected to immunoblotting against various proteins (Figure 5.5C).  The known palmitoyl-
proteins CSP, SNAP-25 and syntaxin-1 show enrichment in the β-ME HA-treated sample in 
relation to both the control sample and the Laemmli HA-treated elution.  The negative 
control syntaxin-3 continues to show no signal in the final elutions.  Munc-18, the 
mammalian orthologue of C. elegans UNC-18, was also probed as it was one of the 
suspected false positive hits from the mass spectrometric analysis of the Laemmli elutions.  
Here it shows only the faintest hint of a signal after β-ME elution, and another faint signal 
after Laemmli elution.  The total of these two signals may have been enough to push it over 
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FIGURE 5.5: Comparison of different elution conditions 
ABE was performed on rat brain homogenate.  (A) The depalmitoylation step was performed using 
HA or high pH.  Elutions were performed with 1% β-ME then Laemmli.  Western blots were probed 
with anti-SNAP-25.  (B) Elutions were performed with 1% β-ME then Laemmli.  An SDS-PAGE gel 
stained using ProtoBlue Safe shows specific bands in the HA-treated samples, with less background 
using the β-ME elution.  (C) Western blots were probed using antibodies against the proteins shown.  
β-ME, β-mercaptoethanol; ABE, acyl-biotin exchange; CSP, cysteine string protein; HA, 
hydroxylamine; L, Laemmli; Munc18, mammalian orthologue of UNC-18; SDS-PAGE, sodium dodecyl 
sulphate polyacrylamide gel electrophoresis; SNAP-25, synaptosomal protein of 25 kDa; UB, 
unbound.  
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the threshold for a hit with an elution solely in Laemmli.  Such statistical flukes have been 
described previously in ABE and may result from chance underdetection in the control 
sample (Roth et al., 2006).  These data indicate that β-ME specifically elutes genuine 
palmitoyl-proteins from the beads whilst reducing contamination from non-specific 
proteins and so will be used from now on. 
At this point, the alternative method of acyl-RAC came to our attention.  Our initial attempt 
using rat brain homogenate and the control treatment of 2 M NaCl (Forrester et al., 2011) 
was unsuccessful.  However, changing the control treatment to 2 M Tris.HCl, as in ABE, 
solved this problem.  Stained gels of rat brain homogenate ABE and acyl-RAC show specific 
bands in the HA-treated β-ME elution (Figure 5.6, asterisks).  There is no post-HA sample in 
the acyl-RAC protocol because the HA treatment and binding to the resin occur in the same 
step.  The improved specificity of the β-ME elution over the Laemmli elution can again be 
seen, both through better enrichment in HA-treated samples over control samples  
(Figure 5.6, arrows) and non-specific bands which are present in Laemmli elutions but 
absent from β-ME elutions (Figure 5.6, dagger).  These β-ME elutions were also sent for 
mass spectrometric analysis as described below. 
As both ABE and acyl-RAC were successful on rat brain homogenate, the next step was to 
apply it to lysates from wild-type C. elegans.  There are several methods available to extract 
lysates from C. elegans, so these were compared to determine the most efficacious.  
Lysates from each method were subjected to a bicinchoninic acid (BCA) assay to determine 
protein concentration and compared with the rat brain homogenate, which was found to 
contain 4 mg ml-1 protein.  An existing method in our lab using a One Shot Cell Disruptor 
(Constant Systems, Daventry UK) gave a protein concentration of 0.6 mg ml-1.  Snap freezing 
in liquid nitrogen, thawing and sonication (Van Raamsdonk and Hekimi, 2012) resulted in a 
concentration of 3 mg ml-1.  Grinding using a pestle and mortar under liquid nitrogen (Eimer 
et al., 2007) gave a concentration of 1 mg ml-1.  An adaptation of a protocol for lysing  
S. cerevisiae by shaking with glass beads was found to give the highest protein 
concentration of 4 mg ml-1 and so was adopted as the lysis method (see Section 5.2.2.1.2). 
Initial attempts of these assays on C. elegans were made using several large plates of 
animals but this resulted in an inability to detect more than trace amounts of protein from 
the final elutions on SDS-PAGE gels after silver staining.  Mass spectrometric analysis of 
these samples turned up only non-specific and uncharacterised proteins and none of the 
expected putative palmitoyl-proteins discussed in Chapter 3.  The observation of a small 
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FIGURE 5.6: Selective purification of palmitoyl-proteins from rat brain homogenate 
Rat brain homogenate was subjected to ABE (A) or acyl-RAC (B).  SDS-PAGE gels were stained using 
IRBlue.  Purification of palmitoyl-proteins is seen by an enrichment in the +HA samples compared 
with the -HA samples in the β-ME elutions.  Examples are shown by symbols: an arrow shows bands 
enriched in the +HA samples with both β-ME and subsequent Laemmli elution; an asterisk shows 
bands enriched in the +HA samples only in the β-ME elution; a dagger shows non-specific bands 
which are present in the Laemmli elutions only.  β-ME, β-mercaptoethanol; ABE, acyl-biotin 
exchange; acyl-RAC, acyl-resin-assisted capture; HA, hydroxylamine; HA (gel lanes), post-HA 
treatment sample; L, Laemmli; MW, molecular weight; SDS-PAGE, sodium dodecyl sulphate 
polyacrylamide gel electrophoresis; UB, unbound.  
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protein pellet in early methanol precipitation steps which quickly diminished and 
disappeared led us to suspect that then main problem was the starting amount of protein 
available.  As large quantities of C. elegans can be grown relatively simply in liquid culture, 
this method was used to generate several millilitres of concentrated animals.  Protein 
extracts from these were used for both ABE and acyl-RAC.  SDS-PAGE gels of samples were 
silver stained (Figure 5.7A, B), as the final concentrations of protein were still small enough 
to be unclear at the level of Coomassie staining.  Although relatively faint, there is 
enrichment in the HA-treated sample β-ME elution in the ABE experiment of bands which 
also appear in the Laemmli elution (Figure 5.7, arrow), whilst non-specific bands appear in 
the Laemmli elution only (Figure 5.7, dagger).  The acyl-RAC protocol seems to result in 
much better protein recovery, presumably due to having much fewer methanol 
precipitation steps which probably each result in loss of a small amount of protein.   
Acyl-RAC also shows a specific β-ME HA-treatment signal, this time with several bands 
visible in the HA-treated β-ME elution only (Figure 5.7, asterisk).  The ABE protocol was 
simultaneously carried out on an extract from a liquid culture of ath-1 mutant animals, 
which again resulted in a specific β-ME signal after HA treatment (Figure 5.7C).  
Unfortunately, the acyl-RAC protocol was not successful on this strain and there was 
insufficient time to repeat it.  The β-ME eluates from the successful C. elegans experiments 
were also subjected to mass spectrometric analysis. 
5.3.2 MASS SPECTROMETRY 
Eluates from two ABE and acyl-RAC experiments on rat brain homogenate and one each of 
wild-type C. elegans ABE and acyl-RAC and ath-1 mutant strain RB1484 acyl-RAC were 
kindly analysed using mass spectrometry by our collaborator Dr Mary Doherty (University 
of the Highlands and Islands, Inverness, UK).  A list of identified proteins for both the 
experimental (HA-treated) and control (Tris.HCl-treated) conditions was obtained for each 
experiment.  After removing contaminants the ratio of the label-free quantification (LFQ) 
intensity for each protein was calculated; proteins which were not detected in the control 
sample were given a control value of 0.2 to avoid dividing by zero (Dowal et al., 2011; Roth 
et al., 2006; Yang et al., 2010).  Proteins which had an experimental:control ratio of less 
than 5 were also removed (Martin and Cravatt, 2009).  Hits were divided into higher 
confidence hits, which had identifications from multiple peptides, and lower confidence 
hits, which were identified from a single peptide. 
Analysis of ABE on rat brain homogenate yielded 105 higher confidence hits and 156 lower 
confidence hits (Appendix 3).  All high confidence hits from previous proteomic screens 
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FIGURE 5.7: Selective purification of palmitoyl-proteins from C. elegans homogenates 
Wild-type C. elegans homogenate was subjected to ABE (A) or acyl-RAC (B), and ath-1 mutant  
C. elegans homogenate was subjected to ABE (C).  SDS-PAGE gels were silver stained.  Purification of 
palmitoyl-proteins is seen by an enrichment in the +HA samples compared with the -HA samples in 
the β-ME elutions.  Examples are shown by symbols: an arrow shows bands enriched in the +HA 
samples with both β-ME and subsequent Laemmli elution; an asterisk shows bands enriched in the 
+HA samples only in the β-ME elution; a dagger shows non-specific bands which are present in the 
Laemmli elutions only.  β-ME, β-mercaptoethanol; ABE, acyl-biotin exchange; acyl-RAC,  
acyl-resin-assisted capture; ath, acyl-protein thioesterase; HA, hydroxylamine; HA (gel lanes),  
post-HA treatment sample; L, Laemmli; MW, molecular weight; SDS-PAGE, sodium dodecyl sulphate 
polyacrylamide gel electrophoresis; UB, unbound.  
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using mammalian material were collated (Appendix 2) and compared with the hits 
presented here.  Hits which had been previously found in proteomic studies accounted for 
44% (46 of 105) of higher confidence hits and 27% (42 of 156) of lower confidence hits.  Hits 
from rat brain homogenate using acyl-RAC totalled 63 higher confidence and 106 lower 
confidence hits (Appendix 4).  Of these, 56% (35 of 63) of higher confidence hits and 23% 
(24 of 106) of lower confidence hits were previously found using proteomic methods.  In 
addition a number of proteins which are known palmitoyl-proteins but were found as lower 
confidence hits in previous screens are present in these hits, notably GAP43/neuromodulin 
(Skene and Virag, 1989) and cell division control protein 42 (CDC42) (Kang et al., 2008).  
Among the hits were also some likely false positives which use thioester linkages, such as 
the ubiquitin-conjugating enzymes UBE2L3 and UBE2D3. 
100 proteins were found in common between the ABE and acyl-RAC analyses, which can be 
considered the highest confidence hits (Table 5.2).  This corresponds to 38% (100 of 261) of 
the ABE hits and 59% (100 of 169) of the acyl-RAC hits.  Of these common hits, 48% (48 of 
100) were previously found in other proteomic screens and 17% (17 of 100) in a previous 
study using rat neuronal material (Kang et al., 2008) (Figure 5.8).  Both methods have been 
shown in this analysis to be able to purify known palmitoyl-proteins.  The lower number of 
hits but higher proportion of known hits in the acyl-RAC experiment suggests that it is the 
better performing of the two methods in terms of selectivity.  However in terms of absolute 
numbers the ABE method found more known hits.  As both methods had merits, both were 
applied to C. elegans lysates. 
The application of ABE to wild-type C. elegans lysate found four higher confidence hits and 
33 lower confidence hits (Appendix 5).  In contrast, acyl-RAC found 38 higher confidence 
hits and 24 lower confidence hits (Appendix 6).  Any mammalian orthologues of these hits 
were found using basic local alignment search tool (BLAST) searching on WormBase 
(www.wormbase.org/) and these were compared with the list of previous hits from 
mammalian proteomic screens (Appendix 2) and the hits from rat brain homogenate in this 
study (Appendix 3, Appendix 4).  For the ABE hits, 25% (1 of 4) of higher confidence and 
22% (5 of 23) of lower confidence hits with mammalian orthologues had also been found 
elsewhere (Figure 5.9A).  For acyl-RAC, all of the hits had mammalian orthologues.  55% (21 
of 38) of higher confidence and 38% (9 of 24) of lower confidence hits had mammalian 
orthologues which had been previously found.  Eight proteins were common between the 
two analyses, accounting for 22% (8 of 37) ABE and 13% (8 of 62) acyl-RAC hits (Table 5.3).  
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Gene Protein Abbreviation 
Aco2 aconitate hydratase, mitochondrial   
Ak2 adenylate kinase 2, mitochondrial isoform 1   
Aldoa fructose-bisphosphate aldolase A   
Aldoc fructose-bisphosphonate aldolase C   
Amph amphiphysin   
Atp1a1 sodium/potassium transporting ATPase subunit α1   
Atp1a2 sodium/potassium transporting ATPase subunit α2   
Atp1a3 sodium/potassium transporting ATPase subunit α3   
Atp1b1 sodium/potassium transporting ATPase subunit β1   
Atp1b2 sodium/potassium transporting ATPase subunit β2   
Atp5a1 ATP synthase subunit α, mitochondrial   
Avp vasopressin-neurophysin 2-copeptin   
Cfl1 cofilin-1   
Ckb creatine kinase B-type   
Cltc clathrin heavy chain 1   
Cnp 2,3-cyclic-nucleotide 3-phosphodiesterase   
Crmp1 dihydropyrimidinase-related protein 1   
Dbn1 isoform A of drebrin   
Ddb2 damage specific DNA binding protein 2   
Dnajc5 DnaJ homolog subfamily C member 5; cysteine string protein CSP 
Dnm1 dynamin-1 isoform 1   
Dpysl2 dihydropyrimidinase-related protein 2   
Eno2 γ-enolase   
Fbn1 fibrillin-1   
Fxyd1 phospholemman   
Gap43 neuromodulin   
Gapdh glyceraldehyde-3-phosphate dehydrogenase   
Gdi1 Rab-GDP dissociation inhibitor α   
Glul glutamine synthetase   
Gnao1 guanine nucleotide-binding protein G(o) subunit α isoform α2   
Gpm6a glycoprotein m6a   
Gstm1 glutathione S-transferase μ1   
Hk1 hexokinase-1   
Hsp90aa1 heat shock protein HSP90α   
Hsp90ab1 heat shock protein HSP90β   
Hspa1l heat shock 70 kDa protein 1L   
Hspa8 heat shock cognate 71 kDa protein   
Kcnma1 calcium-activated potassium channel subunit α1 isoform 3   
Kcnq5l PREDICTED: potassium voltage-gated channel subfamily KQT member 5 isoform 1    
Khsrp far upstream element binding protein 2   
Kpnb1 importin subunit β1   
Ldha L-lactate dehydrogenase A chain   
Ldhb L-lactate dehydrogenase B chain   
Ldhb L-lactate dehydrogenase B chain   
LOC100361349 hypothetical protein LOC100361349   
LOC682206 PREDICTED: LOW QUALITY PROTEIN: zinc finger protein 91   
Lrrc4b leucine-rich repeat-containing protein   
Map1a microtubule-associated protein 1A   
Map1a microtubule-associated protein 1   
Map2 microtubule-associated protein 2 isoform MAP2x   
Mdh1 malate dehydrogenase, cytoplasmic   
Mdh2 malate dehydrogenase, mitochondrial   
Mt3 metallothionein 3   
Ncam1 neural cell adhesion molecule   
Ncdn neurochondrin   
Ndrg2 N-Myc downstream regulated gene 2   
Ndrg2 N-Myc downstream regulated gene 2 isoform 1   
Ndufv2 NADH dehydrogenase flavoprotein 2, mitochondrial   
Nfxl1 nuclear transcription factor, X-box binding-like 1   
Pafah1b2 platelet-activating factor acetylhydrolase IB subunit β2   
Palm paralemmin   
Palm paralemmin   
Pebp1 phosphatidylethanolamine-binding protein 1   
Pgam1 phosphoglycerate mutase 1   
Pkm2 pyruvate kinase isozymes M1/M2 isoform M1   
Plp1 myelin proteolipid protein   
Ppp2r1a protein phosphatase 2 regulatory subunit A   
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Gene Protein Abbreviation 
Prdx6 peroxiredoxin-6   
Rap1gds1 RAP1, GTP-GDP dissociation stimulator 1   
Rap2b Ras-related protein Rap-2B   
Sdhb succinate dehydrogenase iron-sulphur subunit, mitochondrial   
Sh3gl2 endophilin-A1   
Slc1a2 excitatory amino acid transporter 2 GLT1 subunit EAAT2 
Slc25a3 solute carrier family 25 (mitochondrial carrier, phosphate carrier), member 3   
Snap25 synaptosomal-associated protein of 25 kDa   
Snap91 clathrin coat assembly protein AP180 long isoform   
Stip1 stress-induced phosphoprotein 1   
Stx1a syntaxin-1A   
Syx1b syntaxin-1B   
Tomm70a mitochondrial import receptor subunit TOM70   
Tpi1 triosephosphate isomerase   
Trappc3 trafficking protein particle complex subunit 3 Bet3 
Tuba1a tubulin α1A chain   
Tuba4a tubulin α4A chain   
Tubb2a tubulin β2A chain   
Tubb2c tubulin β2C chain   
Tubb3 tubulin β3 chain   
Tubb4 tubulin β4   
Tubb5 tubulin β5 chain isoform 1   
Tubb5 tubulin β5 chain isoform 1   
Vamp2 vesicle-associated membrane protein 2; synaptobrevin 2   
Vcp transitional endoplasmic reticulum ATPase   
Wisp1 WNT1-inducible-signaling pathway protein 1   
Ywhae 14-3-3 protein ε   
Ywhag 14-3-3 protein γ   
Ywhah 14-3-3 protein ε   
Ywhaq 14-3-3 protein θ   
Ywhaz 14-3-3 protein ζ/δ   
Zfp438 zinc finger protein 438   
TABLE 5.2: Hits found in both ABE and acyl-RAC using rat brain homogenate 
Proteins identified in both ABE and acyl-RAC on rat brain homogenate are listed in alphabetical order 
of gene name.  The abbreviation of the protein name is also given where it is different from the gene 
name.  Hits also identified in previous proteomic studies are highlighted in green.  ABE, acyl-biotin 
exchange; acyl-RAC, acyl-resin-assisted capture.  
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FIGURE 5.8: Overlap of mammalian hits from this and previous studies 
Venn diagram showing the crossover of hits from the ABE and acyl-RAC experiments in this study 
and from (A) all proteomic studies on mammalian material to date or (B) Kang et al. (2008) only, 
which used rat neuronal material.  ABE, acyl-biotin exchange; acyl-RAC, acyl-resin-assisted capture.  
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FIGURE 5.9: Distribution of hits from C. elegans ABE and acyl-RAC experiments 
Venn diagrams showing the proportion of wild-type N2 (A) and ath-1 mutant (B) ABE hits which have 
mammalian orthologues, and how many of these orthologues are known palmitoyl-proteins.   
(C) Venn diagram showing the overlap in the hits obtained from the two experiments using wild-type 
N2 lysate and their relationship to the ath-1 mutant hits.  ath, acyl-protein thioesterase; ABE,  
acyl-biotin exchange; acyl-RAC, acyl-resin-assisted capture.  
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Gene Protein description 
Mammalian orthologue 
Gene Name 
alh-8 aldehyde dehydrogenase Aldh6a1 methylmalonate-semialdehyde dehydrogenase [acylating], mitochondrial precursor 
eef-1A.1 eukaryotic translation elongation factor Eef1a2 elongation factor 1α 2 
F46H5.3a.1  Ckm creatine kinase M-type 
tbb-2 tubulin β Tubb4b tubulin β-4B chain 
vit-2 vitellogenin Wdr87 WD repeat-containing protein 87 
vit-4 vitellogenin Apob apolipoprotein B-100 
vit-5 vitellogenin Cenpe centromere-associated protein E 
vit-6 vitellogenin Bmper BMP-binding endothelial regulator protein precursor 
TABLE 5.3: Hits found in both ABE and acyl-RAC using wild-type C. elegans lysate 
Proteins identified in both ABE and acyl-RAC on wild-type C. elegans lysate are listed in alphabetical 
order of gene name.  The mammalian orthologue of each protein is shown.  Hits are coloured 
according to their mammalian orthologue: those also identified in previous proteomic studies are 
highlighted in green; those identified in the proteomic analysis of rat brain homogenate in this study 
but not in previous studies are highlighted in blue.  ABE, acyl-biotin exchange; acyl-RAC,  
acyl-resin-assisted capture.  
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From these analyses it seems that acyl-RAC has worked better than ABE on wild-type 
lysates, although both methods seem to have problems detecting many proteins. 
At the same time, ath-1 mutant strain RB1484 was also subjected to ABE.  This gave 17 
higher confidence hits and 41 lower confidence hits (Appendix 7).  Palmitoylated proteins 
accounted for 59% (10 of 17) of higher confidence and 25% (8 of 32) of lower confidence 
hits with mammalian orthologues (Figure 5.9B).  27% (10 of 37) of the wild-type ABE hits 
and 35% (22 of 62) of acyl-RAC hits were also found in the ath-1 mutant, including seven of 
the eight proteins found in both wild-type analyses (Figure 5.9C).  This suggests the 
remaining hits (Table 5.4) may be substrates for the C. elegans ATH-1 enzyme. 
5.4 DISCUSSION 
After initial optimisation tests, the proteomic techniques ABE and acyl-RAC were applied 
first to rat brain homogenate and then wild-type and ath-1 mutant C. elegans to determine 
their palmitoyl-proteomes.  These methods are appropriate for gaining an appreciation of 
proteins which are robustly palmitoylated in the context of tissues or whole organisms, as 
living cells are not required for labelling.  In this case they give the first indication of which 
C. elegans proteins may be palmitoylated and potential substrates of the PPT ATH-1.  This 
should provide a valuable resource for future researchers wishing to pursue palmitoylation 
of specific proteins or by specific enzymes. 
Both ABE and acyl-RAC were optimised at the SDS-PAGE and Western blot level using rat 
brain homogenate.  The eluates were analysed using mass spectrometry and compared 
with similar previous studies.  The number of hits found with each method was similar to 
those found in previous studies (Table 1.1).  Both methods gave similar proportions of hits 
which had been previously found.  Although a higher proportion of acyl-RAC hits belonged 
to this category, they were fewer in absolute number.  Whilst these proteomic hits give a 
good guide as to potential palmitoyl-proteins, they should not be taken as proof.  Known 
palmitoyl-proteins were found here which had not been found in other screens, the stand-
out example being GAP43/neuromodulin.  Equally, Munc18 appeared as a lower confidence 
hit in the ABE experiment even though it appeared to have been eliminated as a palmitoyl-
protein by Western blot analysis (Figure 5.5C, Appendix 3.2), although it is possible this may 
be a statistical fluke as already discussed (Roth et al., 2006) as it was detected from only 
one unique peptide in one of the two ABE experiments.  Additionally, some well-known 
palmitoyl-proteins were not picked up in this study, for example SNAP-23 and H- and N-Ras.  
Despite these caveats, proteomics approaches do allow a large list of candidate palmitoyl- 
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Gene Protein description 
Mammalian orthologue 
Gene Name 
abl-1 oncogene Abl-related Abl1 c-Abl oncogene 1 
abtm-1 ABC transporter, mitochondrial Abcb7 ATP-binding cassette sub-family B member 7, mitochondrial 
alh-9 aldehyde dehydrogenase Aldh7a1 α-aminoadipic semialdehyde dehydrogenase 
ant-1.1 adenine nucleotide translocator Slc25a6 ADP/ATP translocase 3 
asp-1 aspartyl protease Pgc gastricsin 
bed-1 BED-type zinc finger putative transcription factor   
C08H9.2a.1  Hdlbp vigilin 
C09B9.1    
C33H5.8  Rpap3 RNA polymerase II-associated protein 3 
C35E7.7    
eef-2 eukaryotic translation elongation factor Eef2 elongation factor 2 
F01G4.6b.1  Slc25a3 phosphate carrier protein, mitochondrial 
F02H6.7  Bai1 brain-specific angiogenesis inhibitor 1 
F09G2.2  Cnppd1 cyclin Pas1/PHO80 domain-containing protein 1 
F46B3.15    
F46F11.11    
faah-5 fatty acid amide hydrolase homolog Faah1 fatty-acid amide hydrolase 1 
fbxa-16 F box A protein   
hel-1 helicase Ddx39a ATP-dependent RNA helicase DDX39 
lim-7 LIM homeodomain protein Isl2 insulin gene enhancer protein ISL-2 
nhr-134 nuclear hormone receptor Ppara peroxisome proliferator-activated receptor α 
nhr-268 nuclear hormone receptor Rarg retinoic acid receptor γ2 
nsf-1 N-ethylmaleimide sensitive factor homolog Nsf vesicle fusing ATPase 
ptr-3 patched-related family Npc1 Niemann-Pick C1 protein 
R12E2.8  Ush2a usherin 
rps-26 small ribosomal protein subunit S26 Rps26 40S ribosomal protein S26 
rps-4 small ribosomal protein subunit S4 Rps4x 40S ribosomal protein S4, X isoform 
rps-5 small ribosomal protein subunit S5 Rps5 40S ribosomal protein S5 
sdha-1 succinate dehydrogenase complex subunit A Shda1 
succinate dehydrogenase (ubiquinone) flavoprotein subunit, 
mitochondrial 
sphk-1 sphingosine kinase Sphk1 sphingosine kinase 1 
T04B2.7    
unc-15 paramyosin homolog Myh7 myosin-7 
W09D6.1c  Aasdh Acyl-CoA synthetase family member 4 
Y47D3A.28  Mcm10 minichromosome maintenance deficient 10 (S. cerevisiae) 
TABLE 5.4: Putative ATH-1 substrates 
Hits found using ABE on ath-1 mutant lysate but not using ABE or acyl-RAC on wild-type C. elegans 
lysate are shown along with their mammalian orthologue, where applicable.  Hits are coloured 
according to their mammalian orthologue: those also identified in previous proteomic studies are 
highlighted in green; those identified in the proteomic analysis of rat brain homogenate in this study 
but not in previous studies are highlighted in blue; those identified both in this and previous studies 
are highlighted in orange.  ABE, acyl-biotin exchange; acyl-RAC, acyl-resin-assisted capture.
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proteins to be produced which is not possible using classical methods of studying 
palmitoylation.  Indeed, nearly two-thirds of the acyl-RAC hits were also found in ABE 
experiments, giving additional confidence to the half of these hits which were not found in 
previous proteomic studies.  As there are currently no known palmitoyl-proteins in  
C. elegans, these methods were applied to uncover candidates. 
At the level of a silver stained SDS-PAGE gel, the ABE and particularly the acyl-RAC outputs 
from wild-type C. elegans lysates looked promising.  It was disappointing therefore to see 
so few hits from both methods.  ABE uncovered just 37 hits, only four of which were higher 
confidence, whilst acyl-RAC gave 62 hits, though nearly two-thirds of these were of higher 
confidence.  These numbers seem miserly compared with those from rat brain homogenate 
(261 ABE hits; 169 acyl-RAC hits), especially as the lysates are derived from brain material 
for rats but the whole organism for C. elegans, which might lead to the expectation of many 
identifications of proteins found away from the brain.  There were eight identifications 
which were found in both the ABE and acyl-RAC analyses.  However, when the mammalian 
homologues are compared with previous studies and the data above, only one had been 
previously found and a further two identified in rat brain homogenate here.  When the hits 
are compared with the predictions made using in silico data (Table 3.8, Table 3.9) only  
TBA-2, the orthologue of S. cerevisiae tubulin TUB1, is found in either experiment.  It 
therefore seems likely that rather than genuine palmitoyl-proteins, many of these eight are 
abundant proteins which have been purified as false positives.  However, it was 
encouraging that nearly half of the acyl-RAC hits with mammalian orthologues were known 
palmitoyl-proteins.  It remains to be seen whether any of these hits are genuine palmitoyl-
proteins. 
ABE had also been applied to the ath-1 mutant strain RB1484 with the objective of 
identifying possible ATH-1 substrates.  As ATH-1 is the orthologue of the only known 
cytoplasmic PPT, APT1, it was reasoned that it was likely to be the most physiologically 
relevant enzyme with the largest range of potential substrates.  Whilst ath-1 mutants have 
no gross phenotypes (Figure 4.15), its substrates would be expected to have reduced or no 
depalmitoylation which may enrich their palmitoylated form to levels detectable by ABE.  
Application of the PPT inhibitor hexadecafluorophosphonate (HDFP) to human embryonic 
kidney 293 (HEK293) cells showed a quantitative increase in palmitoylation of palmitoyl-
proteins over a 6 hour period (Martin et al., 2012), so there may be a substantial increase 
over the lifetime of ath-1 mutants.  Indeed, this was what was seen.  ABE on lysate from 
ath-1 mutants identified 58 proteins, compared with 37 for wild-type C. elegans.  The fact 
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that a quarter of the ABE hits on wild-type lysates, a third of the wild-type acyl-RAC hits and 
all but one of the identifications found in both wild-type experiments are also found in this 
analysis suggests that there are ATH-1 substrates enriched in the remaining identifications.  
Amongst the proteins found only in the ath-1 analysis are SPHK-1 and UNC-15, which were 
predicted to be palmitoylated as orthologues of S. cerevisiae long chain base 4 (LCB4) and 
mammalian cytoskeleton-associated protein 4 (CKAP4)/p63 respectively (Table 3.8,  
Table 3.9).  Whilst higher than the wild-type analysis, the overall number of identifications 
from ath-1 mutants was still relatively small.  This may be explained by evidence that the 
majority of palmitoyl-proteins are stably palmitoylated, with relatively few undergoing 
active palmitate turnover (Kang et al., 2008; Martin et al., 2012).  Alternatively, the other  
C. elegans PPT PPT-1 may be able to compensate by depalmitoylating some of the 
substrates of ATH-1 in its absence. 
Why are there so few identifications from the C. elegans experiments?  It proved difficult to 
apply ABE and acyl-RAC to C. elegans lysates and end up with protein in the final eluates.  
This was partially resolved by growing large liquid cultures to obtain significantly more 
starting material.  Unfortunately the technical difficulties meant there was insufficient time 
to perform repeat experiments, so the results presented using C. elegans lysates must be 
considered as preliminary.  Perhaps palmitoylation is not an important modification in  
C. elegans, which would account for so few apparent palmitoyl-proteins.  This seems 
unlikely given the 15 DHHC enzymes identified, although some mammalian DHHCs have 
been shown to have functions independent of their palmitoyltransferase activity, such as 
ion transport (Goytain et al., 2008; Hines et al., 2010) and mediation of c-Jun N-terminal 
kinase (JNK) activation (Yang and Cynader, 2011), so maybe similar functions are more 
important in C. elegans.  There are some caveats associated with the ABE and acyl-RAC 
methods of determining palmitoyl-proteins.  Both methods rely on thioester bond cleavage 
and labelling of cysteine thiols, which can only give a snapshot of the palmitoylated 
proteins present in the sample.  This can result in underrepresentation of proteins which 
undergo rapid palmitate turnover or which may only be palmitoylated on a subset of the 
total protein.  C. elegans could have a much higher proportion of rapid palmitate turnover 
than in mammals, leading to a low proportion of palmitoylated proteins at any one time 
and thus many genuine palmitoyl-proteins failing to reach the detection threshold. 
Some of these limitations of ABE and acyl-RAC and the fact that they cannot differentiate 
between thioester modification with palmitate and other rarer fatty acids can be overcome 
in cell culture with the use of palmitate analogues such as 17-ODYA (Martin and Cravatt, 
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2009; Martin et al., 2012) or alk-16 (Yount et al., 2010) to metabolically label proteins 
undergoing palmitoylation before purifying them using so-called click chemistry.  This has 
been extended recently by combining 17-ODYA labelling with a stable-isotope labelling with 
amino acids in cell culture (SILAC) approach to improve its sensitivity (Martin et al., 2012).  
In this approach, one set of mouse T cell hybridoma cells which had been grown in medium 
containing isotopically heavy arginine and lysine was treated with 17-ODYA and a control 
set grown in light (i.e. standard) medium was treated with palmitic acid.  A repeat 
experiment was also performed in which the light isotope labelled cells were treated with 
17-ODYA and the heavy isotope labelled cells with palmitic acid.  This approach identified 
about 400 palmitoyl-proteins.  C. elegans has the advantage of being easily manipulated 
through the bacteria fed to the animals.  As a result, a similar approach could be taken in  
C. elegans by culturing wild-type and mutant animals on a diet of bacteria carrying amino 
acids containing different isotopes of nitrogen or carbon (Fredens et al., 2011; Gouw et al., 
2011; Larance et al., 2011).  This would allow lysates from animals raised on isotopically 
heavy or light amino acids to be combined at the start of an ABE or acyl-RAC experiment, 
controlling for any variability that might occur in the treatment of the samples during the 
assay.  In addition to being a potentially rapid means of determining substrates of DHHC or 
PPT enzymes by profiling mutants, the accumulation of several sets of wild-type palmitoyl-
proteome data would increase the confidence of the list of palmitoyl-proteins in C. elegans.  
The increased sensitivity afforded by this method may also extend the list of candidate 
palmitoyl-proteins from the initial analysis presented here. 
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6.1 PALMITOYLATION IN C. ELEGANS 
The importance of palmitoylation of individual proteins has been known about since the 
first discoveries of the modification, first on viral proteins (Schmidt and Schlesinger, 1979) 
and subsequently on mammalian proteins (Omary and Trowbridge, 1981).  The number of 
proteins shown to be palmitoylated with functional consequences gradually increased, but 
the extent of palmitoylation as a post-translational modification leapt forwards with two 
major advances in the past decade.  The first was the identification of the enzyme family 
responsible for catalysing palmitoylation and its characteristic DHHC motif (Lobo et al., 
2002; Roth et al., 2002), resolving a debate as to whether the majority of in vivo 
palmitoylation was spontaneous or not.  The second was the advent of proteomic methods 
enabling purification of palmitoyl-proteins to provide large lists of candidates (Drisdel and 
Green, 2004; Kang et al., 2008; Roth et al., 2006).  These steps have enabled the field to 
move forward with gathering pace and gained palmitoylation recognition as an important 
regulating post-translational modification analogous to phosphorylation and ubiquitination. 
Model organisms have been useful throughout the study of palmitoylation.  The 
identification of the palmitoyl acyl-transferase (PAT) DHHC enzymes took place in 
Saccharomyces cerevisiae in studies which also showed the importance of subcellular 
localisation of proteins by palmitoylation to enable them to fully perform their functions 
(Lobo et al., 2002; Roth et al., 2002).  The fruit fly Drosophila melanogaster has been used 
to show the importance of palmitoylation of cysteine string protein (CSP) and 
synaptosomal-associateds protein of 25 kDa (SNAP-25) by Huntingtin-interacting protein 14 
(Hip14) in synaptic transmission (Ohyama et al., 2007; Stowers and Isacoff, 2007).  The 
palmitoyl-protein thioesterase 1 (Ppt1) gene in  D. melanogaster has also been mutated to 
create a model of infantile neuronal ceroid lipofuscinosis (INCL) and shows the progressive 
neurodegeneration of the human disease (Buff et al., 2007; Chu-LaGraff et al., 2010; Glaser 
et al., 2003; Hickey et al., 2006; Korey and MacDonald, 2003).  Several knockout mice 
lacking enzymes involved in palmitoylation have been made in recent years.  The knockouts 
of the DHHCs HIP14 and HIP14-like (HIP14L) show pathological features similar to a mouse 
model of Huntington’s disease (HD), for example (Singaraja et al., 2011; Sutton et al., 2012; 
Young et al., 2012).  The mouse knockouts of PPT1 (Bible et al., 2004; Gupta et al., 2001; 
Kielar et al., 2009) and PPT2 (Gupta et al., 2001; Gupta et al., 2003) have replicated the 
phenotype of INCL and given clues as to the potential mechanisms of neurodegeneration in 
this disorder.  However, the simple eukaryotic model organism Caenorhabditis elegans has 
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been relatively overlooked, with directed studies limited to a model of INCL (Porter et al., 
2005). 
In order to address this gap in palmitoylation research and characterise palmitoylation in  
C. elegans, the first step was to glean as much information as possible both from published 
data and in silico resources.  The DHHC-cysteine rich domain (CRD) was used to identify 15 
PAT enzymes in the C. elegans genome.  This number fits in well with an expansion in the 
number of PATs over evolutionary time, intermediate between S. cerevisiae and  
D. melanogaster.  The two C. elegans PPTs had previously been identified by homology to 
known PPTs (Porter et al., 2005).  The homology of these enzyme families to S. cerevisiae, 
D. melanogaster and Homo sapiens counterparts was used to make predictions about 
possible phenotypes to be found in C. elegans knockouts.  Known palmitoyl-proteins in 
other organisms were also used to predict possible substrates of these enzymes in  
C. elegans.  Whilst some of the enzymes showed relatively high homology to those in other 
organisms, there were several which appeared to be specific to nematodes.  Similar issues 
occurred with some known palmitoyl-proteins which did not have close orthologues in  
C. elegans.  In addition, there is scant information available on many of the PATs simply due 
to the relatively early stage at which research is in this field.  These factors limited the 
ability to make predictions using current knowledge to a few enzymes with well-studied 
counterparts. 
With the information gathered from in silico sources in mind, a screen of C. elegans PATs 
and PPTs was performed using both mutant and RNA interference (RNAi) approaches.  The 
initial intention was to be able to characterise mutants for each individual enzyme and 
complement these results with RNAi data.  However, the expected source of mutants for 
enzymes which were not yet available was unable to provide strains due to unforeseen 
circumstances, restricting the number of mutants which could be assayed.  Whilst a 
complete RNAi screen was undertaken, there is always the caveat with RNAi data that even 
a very efficient knockdown may still leave enough residual protein available for there to be 
no effect on its normal function.  The highest chance of detecting a phenotype would occur 
in mutants which lack the protein entirely.  Nonetheless, there was a reasonable degree of 
agreement between results obtained from mutants and RNAi-treated animals, where both 
were available. 
The majority of strains and RNAi-treated animals tested showed no difference from 
controls in many experimental conditions.  The assay which showed the most differences 
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from controls was lifespan.  One example is the case of dhhc-14, disruption of which was 
predicted to give a reduction in locomotion and lifespan.  Whilst there was no difference in 
locomotion, both dhhc-14 mutant strains and RNAi against dhhc-14 showed decreases in 
various parameters of lifespan.  Despite this example, few of the predictions made came to 
fruition, illustrating the limitations of computer-only approaches and the confounding 
factors introduced when applying data across different organisms.  In addition, all of the 
ppt-1 mutants showed slightly different phenotypes, suggesting these may be partly caused 
or at least influenced by background mutations as all the alleles should result in nulls.  
These strains could be outcrossed back to the wild-type N2 strain multiple times.  The same 
assays could then be repeated to determine whether any difference is made to the 
phenotypes observed and hopefully produce more unified results. 
There are a number of ways in which the analysis of these strains could be extended.  
Obtaining a complete set of mutant strains to cover every gene in the PAT family would be 
a priority.  Although the C. elegans Knockout Consortium no longer appears able to 
generate requested strains within six months, there are some other routes opening up for 
obtaining mutants.  Leading amongst these are the set of methods based on use of the 
Mos1 transposon (Frokjaer-Jensen et al., 2010; Frokjaer-Jensen et al., 2008; Robert, 2012).  
These have the advantage of being clean knockouts of the gene-of-interest without the 
potentially confounding background mutations generated by random mutagenesis 
methods. 
Unfortunately, confusion over whether requested mutant strains would be forthcoming 
delayed some assays to the extent that many could not be performed on all strains.  
Therefore, to obtain a truly complete screen the assays presented here should be extended 
to include all the available RNAi and mutant strains.  There are more subtle assays available 
to dissect phenotypes which may result from dysfunction of specific tissues or subsets of 
neurons.  These range from relatively simple tests, such as egg-laying and food race assays, 
to various thermo-, osmo- and chemosensation assays, to more complex tests which can 
assess learning and mating behaviours and circadian rhythm.  All of these have protocols 
which are collated in WormBook (Hart (ed.)).  These assays could also be applied to all the 
mutants and RNAi-treated animals to search for more robust phenotypes.  Once such 
phenotypes are found, their dependence on the enzyme in question can be confirmed by 
rescuing the phenotype back to wild-type by injecting a plasmid allowing the gene to be 
expressed in the mutant. 
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As palmitoyl-proteomics is being applied to an ever-increasing number of cell types and 
tissues from different organisms and there are no confirmed palmitoyl-proteins in  
C. elegans, it seemed a natural step to attempt to use the power of such methods to come 
up with a list of candidate palmitoyl-proteins.  Before applying the methods of acyl-biotin 
exchange (ABE) and acyl-resin-assisted capture (acyl-RAC) to C. elegans lysates, preliminary 
experiments were conducted to confirm they were working in our hands.  To this end, both 
ABE and acyl-RAC were applied to rat brain homogenate and optimised.  Nearly a thousand 
high confidence mammalian hits obtained from all the palmitoyl-proteomic studies 
performed to date were collated and compared with the hits obtained in this study.  The 
overlap of 111 hits between the ABE and acyl-RAC assays performed here and the previous 
studies along with a handful of known palmitoyl-proteins not previously detected shows 
that these methods can reliably detect known palmitoyl-proteins.  However approximately 
two thirds of the hits had not been previously found, at least at high confidence.  This 
underlines the importance of using such lists as a guide only and confirming palmitoylation 
of individual proteins on a case-by-case basis using classical methods such as [3H]-palmitate 
labelling. 
ABE and acyl-RAC were both applied to wild-type C. elegans lysates, but the results were 
disappointing.  Initial experiments showed no protein in the final pulldowns, suggesting an 
issue with protein abundance in the input.  The use of animals derived from liquid cultures, 
which yield much higher numbers of animals, appeared to resolve this issue by producing 
enrichment of protein in experimental eluates which was clearly detectable by silver 
staining of polyacrylamide gels.  However, mass spectrometric analysis of these same 
eluates produced very low levels of protein identifications.  Many of these look suspiciously 
like contaminating abundant proteins, as could be seen by the small proportion of those 
with mammalian orthologues which are known to be palmitoylated.  The time taken to 
modify the techniques to get detectable protein output unfortunately left only enough time 
for one run of each experiment.  Therefore the first thing to do when extending these 
experiments would be to repeat these experiments at least twice more, which would give 
enough runs to perform a proper statistical analysis on the mass spectrometry data.  If the 
results continue to be poor, aspects of the protocol such as the lysis conditions and input 
quantity can be looked at.  Alternative techniques to improve sensitivity such as click 
chemistry (Martin and Cravatt, 2009; Martin et al., 2012; Yount et al., 2010) and use of 
different amino acid isotopes in control and experimental samples (Fredens et al., 2011; 
Gouw et al., 2011; Larance et al., 2011) could also be explored.  Although it would be 
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extremely difficult to isolate individual C. elegans tissues in sufficient quantity to perform 
ABE or acyl-RAC on them, techniques exist to culture C. elegans embryonic cells and 
differentiate them into, for example, muscle or neuronal tissue (Christensen et al., 2002; 
Strange et al., 2007).  Culture can also be performed using cells from different larval stages 
(Zhang et al., 2011).  As palmitoyl-proteomic methods have been previously used on cell 
lines, this may be more productive in terms of reducing potential contaminating factors 
from whole animal lysates. 
6.2 THE PPT QUESTION 
A central question in the palmitoylation field at present is whether the low number of 
known PPT enzymes represents the entire family.  This is especially relevant as only one 
human PPT is both cytoplasmic and has known depalmitoylating activity: acyl-protein 
thioesterase 1 (APT1).  Although the reversible nature of palmitoylation allows scope for 
regulation, it is interesting to consider whether removal of the modification is as important 
for palmitoylation as it is for other post-translational modifications.  There are some 
proteins whose depalmitoylation is essential for their function, the most well known being 
the role of palmitoylation in the cycling of Ras between different membrane systems 
(Dekker et al., 2010; Rocks et al., 2005).  Assessment of palmitate turnover on a subset of 
proteins (Kang et al., 2008) and at a proteomic scale (Martin et al., 2012) showed that the 
majority of palmitoyl-proteins are stably palmitoylated, suggesting that under normal 
conditions depalmitoylation is not necessarily required for many proteins.  The finding that 
APT1 is itself palmitoylated (Yang et al., 2010) suggests that regulation of depalmitoylation 
may in fact be the important process.  This view is supported by the observation of changes 
in palmitoylation dynamics in response to physiological and pathophysiological stimuli 
(Kang et al., 2008). 
C. elegans has one representative from each branch of the PPT family: PPT-1 and ATH-1.  
Phenotypic analysis of mutants lacking each enzyme only showed phenotypes for ppt-1 
knockouts, which is somewhat surprising given ATH-1 is the orthologue of APT1.  RNAi 
treatment against each PPT showed no phenotypes whatsoever in the assays used.  There 
are four possible explanations for these observations: 1) there is a functional redundancy 
allowing the unaffected PPT enzyme to perform the function of the disrupted PPT; 2) there 
are other PPT enzymes which can perform the role of the disrupted PPT; 3) there is 
insufficient knockdown by RNAi to replicate mild mutant phenotypes; 4) depalmitoylation is 
a relatively unimportant process in C. elegans.  A concomitant knockdown of both PPTs by 
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RNAi gave a reduction in lifespan but the animals appeared otherwise normal.  This would 
be consistent with any of explanations 2-4, and the problems with mixing RNAi bacterial 
strains which were discussed earlier should be borne in mind.  A double mutant strain 
which lacks both ppt-1 and ath-1 would be interesting to study and would give higher 
confidence results than the RNAi studies. 
The ath-1 mutant strain was also subjected to ABE analysis to see whether any proteins 
which were not present in the wild-type study appeared as potential substrates.  Whilst the 
overall recovery of hits from the C. elegans analyses was poor, there was an increase in the 
number of hits compared with the same technique on wild-type lysates, suggesting the 
principle is sound.  If the assay can be improved upon as discussed above, analysis of ppt-1 
knockout strains would also be interesting and also a double mutant once it has been 
created.  A lack of any major changes in the double mutant hits compared with wild-type 
would strongly suggest that other PPT enzymes exist in C. elegans to compensate, and 
presumably therefore also in other organisms. 
If other PPTs do exist, how can they be found?  As there is no obvious unifying motif in the 
same way as there is for the PATs, genome data searching is not currently an option.  One 
way would be to perform depalmitoylation assays on a panel of representative palmitoyl-
proteins.  Whole cell extracts could be fractionated and tested for depalmitoylation activity.  
Through repeated fractionation, this depalmitoylation activity could be honed down to a 
fraction containing a few hundred proteins.  These could be analysed by mass spectrometry 
and any potential candidates cloned and tested individually – for example any which share 
structural homology to the published structures of the PPTs.  This type of analysis would be 
particularly effective if a cell line lacking the known PPTs could be established, thus 
eliminating them as potential hits.  The published structures could also be used to search 
for structural homologues if a method for producing predicted structures from only the 
primary sequence of proteins on a large scale can be established.  An alternative approach 
could use the fact that S. cerevisiae only has one known PPT, APT1, and the availability of 
whole genome screening techniques.  For example, a synthetic genetic array analysis could 
be performed using an APT1 knockout strain.  This enables the entire library of S. cerevisiae 
non-essential genes to be screened for synthetic sick and synthetic lethal genetic 
interactions (Boone et al., 2007).  If the lack of a severe phenotype in APT1 knockouts is due 
to compensation by other PPT(s), this type of analysis could uncover novel PPT candidates.
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6.3 FUTURE PERSPECTIVES 
The field of palmitoylation is still young, with the main surge of interest coming only in the 
past decade or so.  As such there are still many gaps in the knowledge, such as several 
enzymes with completely unknown function or substrates, as outlined in the in silico 
analysis.  Even where palmitoyl-proteins are known, the function of the palmitate moiety is 
often not clear.  That includes several proteins identified in this study, such as syntaxin 
isoforms and heat shock proteins.  In this respect, simple model organisms such as  
C. elegans can provide useful pointers, as their short lifespan and relatively easy genetic 
manipulation allow screens of whole enzyme families to be performed.  Such an analysis 
has been started through the phenotypic assays presented in this study.  However, there 
are still several avenues which could be explored.  For example, plasmids containing green 
fluorescent protein under the promoter of each PAT and PPT could be injected to allow 
examination of the tissue specificity of their expression, and potentially even the 
subcellular localisation.  This information can be used to complement expression studies 
performed in other organisms (Ohno et al., 2006).  In order to add confidence to potential 
functional orthologues in C. elegans based on sequence homology, S. cerevisiae could be 
used as an expression system to see which DHHCs palmitoylate model substrates from each 
type of palmitoyl-protein, similar to the analysis already performed with H. sapiens and  
S. cerevisiae enzymes (Ohno et al., 2012).  It would be interesting to see how this 
experiment tallies with the in silico data collected in Chapter 3. 
Whilst unexpected problems arose while conducting proteomic analyses of C. elegans 
lysates, if these can be resolved then the systematic analysis of the palmitoyl-proteome of 
mutants lacking each individual PAT becomes very achievable.  This promises to be a way of 
rapidly profiling potential substrates for each enzyme in a way which, whilst achievable 
using knockout mice, for example, would be much quicker and more cost effective in  
C. elegans.  In addition the function of palmitoylation on individual cysteine residues can be 
probed using this information along with predictions of likely palmitoylated residues.  The 
ease of genetic manipulation means that, for example, a knockout for a palmitoyl-protein 
could be rescued with a construct containing an unpalmitoylatable cysteine-to-serine 
mutation at a putative modified residue.  This would allow examination of the effects of 
disrupted palmitoylation on individual residues on the function of a protein.  The 
information gained can then be used as a resource for directing studies in the mammalian 
context.  Along with the other data which could be produced using C. elegans as a model, 
this will provide insight into the true extent of this interesting post-translational 
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modification, its importance in cell biology and its potential role in the progression of 
certain diseases. 
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APPENDIX 1: MUTATIONS IN C. ELEGANS STRAINS 
Key: 
exon 
exon of adjacent gene 
insertion 
deletion 
point mutation 
frame shift 
DHHC motif 
 
ath-1: strain RB1484, allele ok1735 
 
before exon 1 ->  
TAGAGAactgtccaccccttctcgtcaaattccacattttcttcttcaccaaaaacttttctagcttcaataatag
gttcgttgaaactattttgtgttttgtgtgtcgttgctttcttttaatgttttcatactaatcgcggacattgaca
atcagagcgctacgtttcgaaagatcctcacttctttattctttatctaaaattcatgaaaaaaaccacagaaaac
ttcagggtcatcactttcttcccgtcttctctgttcacttggtggaccgccatccgacgaagaagattcgacaaga
atgtctgcagtctccaacggaaatccttcgattgtgtcgccacgtggcgagcataaaggaacattaatcttccttc
atggactcggtgatcaagggcatggttgggcagatgctttcaagacagaagccaaacacgataatatcaagtttat
ctgtccacacaggtacttttgaatgcagaattattaattatagcagaaaagtacatttataatagaattaaacaaa
agtatcgaaaaactaagagaaaattaacaaaaaaaattttttaataaaatttcggttatatattgatgagataaaa
cataattttcttcttaaaagaggaaaaatatagaaaatttcaagctatttttcaaatcgatctttttaaatatcgg
taaaaacaaaaaatcgaaaaaccgacaccctccattatccactgaaacagattcacttttttcagctctgaacgtc
cagtaaccctcaatatgggaatgcgaatgccagcttggttcgacttatttggcctcgatccaaatgctcaggaaga
tgagcaaggaattaatcgagctacccaatatgttcatcaattgattgatgcggaagttgcagctggaattccagct
tctcgaattgctgtcggtggattttcaatgggtggagctctcgctatttacgctggtctcacatatccacagaaac
ttggaggaattgttggactcagttcattctttttgcagagaaccaaattcccaggggtgattattcaaattattta
aaaaaaaattttttttgatttttatagagcttcactgcgaacaatgctacaccaatcttcctcggacatggaacag
acgactttttggttcctcttcaattcggacaaatgtccgagcagtatattaaaaaattcaatccgaaagttgagct
tcacacctacaggggaatgcagcattcgagctgtggagaggtattttatttttaaaaaacgattttcggaacatga
gtgtcggttttccttttttaaaaatcgaaaacgatattttttttttaatataaaaaaaaggaaaaaaattgtcgac
tttagattcctcgaattctggaaaaaaaacgttttaaaataatttccagatttcgaattttcgaaaaagttataaa
aatgaaaatgccctgaaatttaaataaaaaacttttttttttcaaaaatcgagaaatctaatttttcactgttttt
taatcaaaaaatcataaattgagaaactgggaaacatgttagaaaaattgtacggaaaaaacgaggaagccattga
tttttcaaaattatgtaaaattttttgtgaaaaagaaaaatattaaaaaggattaaaacaaaaaaataaaatataa
catttcttctattcccaaaaaatctacatatttttgatatatctataaatagtttcctcgtctttttccgtatttt
tctaaaatttttccaagttttaaattttcgaattttcgacgtcctcgtttcgggtaaagaattacaaagaattaaa
caaaatgaaaacttcaaactattagatcaaactacacatcatattatgcataatcaaaattatattaatcatatta 
atgtattttcaggagatgcgtgatgtgaagaccttcttgagcgcccacattgcccactaa 
                                                   <- exon 4 
 
ATH-1 protein: 
MSAVSNGNPSIVSPRGEHKGTLIFLHGLGDQGHGWADAFKTEAKHDNIKFICPHSSERPVTLNMGMRMPAWFDLFG
LDPNAQEDEQGINRATQYVHQLIDAEVAAGIPASRIAVGGFSMGGALAIYAGLTYPQKLGGIVGLSSFFLQRTKFP
GSFTANNATPIFLGHGTDDFLVPLQFGQMSEQYIKKFNPKVELHTYRGMQHSSCGEEMRDVKTFLSAHIAH 
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dhhc-1: strain tm4272, allele tm4272 
 
exon 5 ->  
atactttgtcgccgcagtcatcaacctcttcattatgactctgccactagtctcctactcatggagccttctcaat
atcaaaatgacgaacgaaatcggcttcggaaacatttggcaagtggtcattccccatcttgcctggatcgccggat
acatctcaatctaccaattcctccacgtccttctatttgtcttcaccttcaccgtttcgctgttcactttttacct
gctgactgctcaagttttctgcatttatcagggacagacaagaatcgagtttttgatggtgagctatatgtacaat
tgaaaataatttttaaatgttttaaattattatagcagaaaataatagatcaaatggtgacgatttttgtaatact
gtttcactttatggggttattcaagtaatgtcggaaaattaaaaagtgtagaacaattacgtcacaactgtattca
agtatacaccttttaccttttttaaaaacatgtatttagatacatttgtgacgtcacaaatgtatttaaatacatt
ttgatacattacttgaataaccccattagctcgaatgtatcgaatctagattttactgcttttaatattttgctca
aacatcaaattcggccggcatctcgaatgtcgcataacatttttcttttcttccaatacaaaaattttttcgatat
ctttctgcctagaagacttccgtttggtctgtgaggaagtcaccttaactgcaacataaaatctcaaacaaatata
aatccaattttcaggacgttcacgcataccagctcggactccttgaaaacctccaccaatcgctcggctcccggtg
gccattcattgccatttcttgcttcatcccaagtcctctgccaactgatggactcggctttgtcactcgcgagatg 
ttcaatcttcataccaaagatctctaa 
                  <- exon 6 
 
DHHC-1 protein: 
MQMLYDDGENVDFNKKLQRMMPTQIQDIIATFIFLILLPCGILLHLLYVLPTWYPVMGEAWVIRATCFGVLVFNLY
SNWVYMIKTGPNGHHSALPNVIKPGYKHCHSCHSMSPLRAHHCPVCDVCILRRDHHCSFGAVCVGHFNQRYFVAAV
INLFIMTLPLVSYSWSLLNIKMTNEIGFGNIWQVVIPHLAWIAGYISIYQFLHVLLFVFTFTVSLFTFYLLTAQVF
CIYQGQTRIEFLMGRSRIPARTP-KPPPIARLPVAIHCHFLLHPKSSAN-WTRLCHSRDVQSSYQRSL 
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dhhc-2: strain RB1044, allele ok990 
 
exon 5 ->  
atgacgttgctcatttgaggcctcgttttcaagatgtcgttgtgaatggggagcatgtaaaaatgaaatattgtac
gacgtgtcggttatatcggccaccgagatgctcacattgtgcaatttgtgataattgtgttcttatgttcgatcat
cattgtaagttattttagttttaattagttagctttgacggcccatatagtaggtaatttatgagatatcaaaaaa
tgttcaaatacaaatatagagaaaaatatttatgcaatatttcgtcagtaaacagtttttgaataaaaccgaagac
aactgactagggaaccgtcagaaggtgcccatcggacttgcatatgagacctatgccattcaatagtccatgtctt
aaaatgattactcgtgaatttttagcggtaaaactccagaatcaagctcacggcgggctctcaaatatcctaaaat
atcactttaacaaagaatttaagggccaattctcctatttcactatgacagctcatatctccgcgggtaaattttt
tgcagaaaagtcgccaactaaaaagttgttggtattgctgtaaagaacaagtttgtagttgaaagttttttacaaa
aaaatttttgtttgagataaaagcgctgaagtgcggcactgctgctgttattttatgctgttattgatattctaat
gcttatatctcaaactaaattgttttggtaaaaactttcaactacaaacttgttctttacaacgatatcaacaact
ttttagttgatgacttttctgtaaaaaatttatctacggagatatgagttaccaaaatgaaattggaaaattgctt
cgttagatcgttaaattgcttccttacagtgctattttaggatatttgaaagcccgccgtgagcttggttctggag
ttttgccgctaaaaattcacgagtaaccattttaagacatgcactatcatggcataggtctcatatgcaagtccaa
tgggcaccttctgacggttccctagtgagatataagccatgaaatttcggcaagacatggtgtatcgaccaagatt
acttggtttagctttggcagcttatatcttggaggacttttctaaaaataagtttttgatgatcccctgacgttta
aaataataaattatcatttactatatataaagcgcttattctgtgtgtccatagtttgtagtctatgtagtctttg
tagtctgtgaagttttggcttctggagggatagtgacttggggttagtgtagggatatagtcggggtactgtagtg
gtacaatagtggtacggtaggaatactgtagggttacggtagttttataaaaaaattaattttcagccccagaagt
caggggccgcgccgaaggtgcggtccacggctggtccctatatattctatttcaggcccgtgggtcggcaactgta
tcggactccgaaattacacgtatttctatcgattcgtattttgtctttcaattcttgtgatctacctatttgccag
tgcagtcacacatatcagtttatgtgagttccatgtgatttttcaaatcaatttaccgtatttgctctattagtct
tgcatgcaagactaattttcaattgacctgtaggagtgcaagactaatagagaaaatacggtatattcttgtcatc
ttttaatacatagatacataaaattgggaaatttgaaaaaaaaataaaggataaaacaaaaagtttgaatgtttcc
agtagctcaagagatgccattcggagatgtcatgcgaaaaactcccgggtctgcagtcgtcattgtcatatgcttt
ttcacaacgtggttagttattataagaatttttgcgttttgaagttcaaaaagttcaaaaaaatttccaggtcaat
tattggtttggcatgcttccatacttatcttctgtgcgcggatcttacgacaaatgaagatgtaagtagattttga
aatttttattggtaaacttctacagctttaattttcaatttaaaagccaataataatgttctactatcattttaaa
agttttttttttttgaattaattctcagtttccaagctttttttatagtgtatgtttcagctaaaaggcctgtacc
gccggaagcatcgtccaacacctccatcatctacaccatcaacatctgcagctaccaattcttctgtaggacattc
gacaaaaaatccattttacgctggatgcttcaagagtttttttggaagactgttcaagtccagatttccaaggtaa
ggaactttactttttatatacaaaactataacaaaaagaaaacaaatacattgtagttagaaatttgaaaataaat
gcaaaaaaaagtgagagtaacatggtgcatcgactgaaactaccacatataactttgacagcatatatcttggttt
acagttgggatggaagaaacattcaactgaaagattatagaacaaataacgacaaatattttgccagtttatgatt
tttcgattaaacacaagacagcggagatatacgctaccgaattagtaaggagagtttatccgccatgtttctttga
cagctcatatctcggttagtagtttgattagcaaaatatgtttcactacaaaattatagaagtgtacattttaaat
attttgtcaatttacaattctaagataaaacaaaagacaacggagatataagccgtcaaagattcatggagctttt
ttggtcgatgcaccatgtttctaaactttgaaagcctatatctcggtttaaataaattgtatcaaaaatctttcaa
ctggaaatatatatttattacatgttttactataaattttctctggaaataaactgataaattcaaaatgaactga
gatataagcagcgaaagttatatggagtaatttcgatcgatgcaccatgttttcaaattttaacagctttcatctc
gcttggcttttgttttatcaaaaaactgtcaactaacaaaatattgttcaattatttcttattattttgtaattac
aattatgttaataactagaaagttaaccgatatataagcaaccgaaattatataatgcaatttcggtcgatgcccc
atgtttcaaaaatttaacagctcatttttttagatttatcaaaaagttgtcaactaacaaaatattgctcaggtgt
ttttctacaactttgcagtagaacaattattgatagctgcaaagtgaacgcccgtttaggatccgcccatttttta
cctcactccaaatttccttcgaaattttttttaaagtttgctattaaattgtctaaaaaacacaataaattaaaat
ccttgggaaagaaaaaatcaataatttaaattttccgagaggagtacaccacgaacatttatcgctagagcgcgtt
tgctctcaaaaaaaccaataatatttcagcttactcgacgcccgcggctacctggacccacatccgacaatcgaaa 
tccgagttccgaaaaaatcggaaaaatcgatcgaaaatcattaa 
                                  <- exon 10 
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DHHC-2 protein: 
MALMTQRLLDEEIAIDEETERSRDTERHETHVNQCEMSSSFSATSPSTSSAYQLEEHISAPRATPELPPSDPKRRK
WQSHPGRNRFGCGGRLVCSRSHGAFVVTVILMIATLTVYFVFDAPFLWGYSPAIPIVAAVLSLIVITNFFATSFTD
PGILPRVDNIEIIEMDRQQANGNGINDVAHLRPRFQDVVVNGEHVKMKYCTTCRLYRPPRCSHCAICDNCVLMFDH
HCPWVGNCIGLRNYTYFYRFVFCLSILVIYLFASAVTHISLLAQEMPFGDVMRKTPGSAVVIVICFFTTWSIIGLA
CFHTYLLCADLTTNEDLKGLYRRKHRPTPPSSTPSTSAATNSSVGHSTKNPFYAGCFKSFFGRLFKSRFPSYSTPA
ATWTHIRQSKSEFRKNRKNRSKII 
 
dhhc-9: strain VC2067, allele gk985 
 
exon 3 ->  
tttctggtgttcttcgtatacttcatctccacatttctagccttcacatcctttttcataatcattccatatgaac
aactgtgagtttttttgttgaaaaactattattaataaaaagtcaaacacaccacgctgtttttatgaaacttttc
ttcgattgtcaattttgtgcatatgcaattaaaaaaaaaacatatatataaactgtcccgtttagtttctggtaat
tttgagaacactgtagtaattacgaaaaagatgtacaaaccaagggtgggcgacaattgccgttcgtcgacaagtt
cggcaaatcggcagattgtcggtttgccgatttgccggatatcagttttgccaaaaatatttttagggattttttt
caaagacggtaacagttaaactgtgcctctttgtaggaacattcataggatgcgtacaatttcgcagattgaaatt
taaattctgaaatttccaaataaaaatgcaaaaacacaattcgacgtaaaattttggcaattgccgtcttaccggc
aaattcgacaaatcggcaatttgtcggcttaccaatttgctgaacattttgaaattttttactcaaccttcacact
taacagttctcgaaaaacttgtattattttagatacaaacctgcctggctactcttgctgctcggcacttgcggcc 
tgtatttcttattcaacatccaatatcattactacaaagccaggacaataccaccagttgcaaatcctgga 
                                                              <- exon 4 
 
DHHC-9 protein: 
MCHDKMNHFCDFIDRKIDDGTFIPMVKAANSSMRQIGKFLVFFVYFISTFLAFTSFFIIIPYEQLYKPAWLLLLLG
TCGLYFLFNIQYHYYKARTIPPVANPGEEGDSFCSKCNYWKSDNAHHCSVCEKCVLGMDHHCIWINQCVGLHNHRH
FFLFIANLTLAAATIIIAGYQSFSDHLFLESSQTTYCTTILEHAPLQDIICDYDGFARTSVVFCYLLSGILLVMVG
GLTSWNIYLISIGCTYIDYLKLTGSKKNTSARKRLNKGFKANWRNFLGLRRNRTFFKCVIMPTALPPVKYEDISPK
SDAYDIV 
 
dhhc-12: strain VC2039, allele gk1013 
 
exon 6 ->  
actcgtaaagaactaactgcaatcccggatgatcaatgctggcctccatattgttttaatagatattactacttga
ttacacgttctcaaggaagtatgtctgatgcatttgaacctttctaacttctcaaaGAGCACCACCTTCCGCTACT
GTAGACAACGTGTACTACTTCttccagccgaagacactatggttaaattcgcatttttccttttcgtaacacttca
ttggattatgtggggatttgttggtgtctacgtaggaatcatttcatttggattaactatggcgatgaaaatggta
atcaaattggcaacatctgaaccaattcagaatttccagtttcaaaagtcggacgctgaatctcgtaaacctttca
cttggttcacaatcaaagctcgttggagaaaatacatgaactgtcaagatgagccactttggaagatattttttat
tccgaaaacccgcaaaattgtgtcgtataacgattataaggagttaattatgtagaattattgtagaattgtctaa 
ttttctcttttttaat 
 <- after exon 8 
 
DHHC-12 protein: 
MDVCRIFNRIVYFLVEKSLGDISKFDPFDVLKLVALWGGRLCLLIFVGTLCNVTYVVIFKMIPVEWNECQNMSFFV
FRFVLLIYIYYSVVFHYYKARTLTPVVNPGTPSDSFCIKCNNWKGPSTSHCKACDKCIYRMDHHCPHIGQCVGAHN
QSHFFLFLFYLQIATGLFFLMATTFWMKWIETRKELTAIPDDQCWPPYCFNRYYYLITRSQGTEDTMVKFAFFLFV
TLHWIMWGFVGVYVGIISFGLTMAMKMFQKSDAESRKPFTWFTIKARWRKYMNCQDEPLWKIFFIPKTRKIVSYND
YKELIM 
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dhhc-12: strain VC2244, allele gk981 
 
exon 4 ->  
cgaatgccaaaatatgtcgttcttcgtgttccgttttgtgctccttatctacatttactacagtgtcgtttttcac
tactacaaggcccggactctgacacctgttgtgaatccaggggtaagcctccaaaaacaaagatatgacgtcataa
gcataaacggtcgtccgaaatcaagcatttgagacaaatactgtaatacacatttctccacgaggagtacacacaa
agaacgtaaatcgacacgttctttgttttacagtcatttctcaataagctagaaattgtagagcctttttgagatt
tttttcttaaaatttcaaatcaaacttttcagactcccagtgactcattttgtatcaaatgcaacaattggaaagg
tccatcaacatctcattgtaaagcttgtgacaaatgtatctaccgtatggatcatcattgccctcatattggacaa
tgtgttggagcacacaatcagagccacttcttcctttttcttttctatcttcaaattgcaacgggcctctttttct
tgatggctacaacgttttggatgaaatggatagaggttggtttggtgcctgccttgtgcctgcctatccttaaact
agtaaattattagtccttcagactcgtaaagaactaactgcaatcccggatgatcaatgctggcctccatattgtt 
ttaatagatattactacttgattacacgttctcaaggaa 
                              <- exon 6 
 
DHHC-12 protein 
MDVCRIFNRIVYFLVEKSLGDISKFDPFDVLKLVALWGGRLCLLIFVGTLCNVTYVVIFKMIPVEWNECQNMSFFV
FRFVLLIYIYYSVVFHYYKARTLTPVVNPGTPSDSFCIKCNNWKGPSTSHCKACDKCIYRMDHHCPHIGQCVGAHN
QSHFFLFLFYLQIATGLFFLMATTFWMKWIETRKELTAIPDDQAGLHIVLIDITT-LHVLKEPKTLWLNSHFSFS-
HFIGLCGDLLVST-ESFHLD-LWR-KCFKSRTLNLVNLSLGSQSKLVGENT-TVKMSHFGRYFLFRKPAKLCRITI
IRS-LC 
 
dhhc-13: VC108 strain, allele gk36 
 
exon 1 ->  
atggccatggaaaaaatcaaaaaatttccgattttttcagttttttttttaattgttttgatgtttttcagaaaaa
ctcgaatattgaaaaagggaaaatcgaaaagggattttcggagttttttttcgatgattcgttttgtatgtattta
tcaaaaatatgtcgatttattctcctgttattttcttttaaagatttccttagcatggcgaccactaaataaaaag
atcctacaatcttcaaagcacaagatgagtctaatctttcgccagcaaatcggaagatgtctatcgacactgaaag
atctccatgaagaagcacaagacgacattgaaaatgttgtggaaatccggaaaggaccgatcgatgctctattcgg
aacaatcttcgatattgtcgacctcgcagagagaacaatcactgaatcaaatcgcattgagcaacactcgacaaaa 
tggaaactccg 
  <- exon 2 
 
DHHC-13 protein 
MAMEKIKKFPIFSVFFLIVLMFFRKTRILKKGKSKRDFRSFFSMIRFISLAWRPLNKKILQSSKHKMSLIFRQQIG
RCLSTLKDLHEEAQDDIENVVEIRKGPIDALFGTIFDIVDLAERTITESNRIEQLDKMETPWRRNGFKNASSGTCL
PNRRNSNRSISVEWTCFG--IRSRRMWTSSLGCN---IGYYSTAAFTSR-H-FNWRKYEIDTSSLGLL-FTIWSSH
GSCQEWRRSNN-KYKRRDSSSLGCLHWKLYYNCLFARKI--YQRYER-FRSFGTYDGC--EFRTISYSYIHKS-CI
S-LH---EGEYCSSYFSCSSEFERSC-ADLFWSR-HENR-QWGFST-FDGQQIPKSS-QASDSSKYL-TGYNL-KG
YLSLVPWPIFYCNHFRLFSFLFHH-RLCNDWCSNWSIFSHKLLGGLGWTCFDSFIAFYFGTKKTNGSIWMSSSHLY
LLDGNC-ICIVNFQFKWIGSLVGSDFCLLNLGYFSIVLLDNVYNNFKN-LH-FQLDPNKSRCPSSFYNSVQRFHQR
SGRETNR-ILFYLLDSKDFILSSLLSM-QMCRWI-SSLSMDSQMCLSEESSSFRVFLSYNLHVSRVLRSIVVVHDW
CLHECIRIR-VSFRTSYCQK-RRRQVVEFG-LLSVNF-GIK-LFPTRLFFDAHFQKS-FRKPAKTNPKRPWFDGNQ
SHPRNPSCFRSRSHHLYSILTNFSSCLYHRDYSETKTPEKF--KDHNIART-SMGIQTKCED-NSKCV-SIGI-QV
WRWRRN—RTWIIFIRNIVFIFL 
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dhhc-14: strain VC771, allele gk330 
 
exon 6 -> 
ggaacttctcgaaggaaacgctaatgtgaacattcggaataaacaatcagaaacaccactggatatggctaggacg
atcaaaagtccacaaatcctaggtaacgcgctacactctaaagcgaccaaaattcaattgttcaactgcagatttg
atggaagacgctgctcgtcgccagggagtcagtcgaacaagttgtttccgacgatctttcgtgccgccaatcagca
catactttttcttcctggtcccaatgtttggatttttcatgacctatctccttttcaagtacttgccattgattat
tgccactttctccacactgatctcctgcatctttcttatggttcttattcggtttgactatcatgatcctacttac
aagctgcttccttatggagttacaattgcagaagccatcttaatggtcttatcgtggtaggtattcaagtttgaaa
atcttgccgttacactcttcacttttaatttcacttttgtcgtcaaacaaaagccaaaggataaaacggaccagat
aacgaacaggtgccgttggaaagagaaaggaagggcagattgatatctcgagtaaactagacgggtttataatgcc
atacgtatgattttatctcaatccacgtaaaaaaattattttcgaaaagtcgatcgtggggaaatagacttcaaaa
ataaaaatttaagaattttctagaacgcaaaaaagtttgctcaaattatttacaaaaatactttgaaatgactatt
tgaaattcttcaggtcagcatatgctcattggtacgtgccatggtgggctcaaatgctctttgttctttctgttct
tgctcttgcattcacattgttcaggtgagaaacagtattgtggcacttgaataacatagtgaataattttagaata
gggacactggatccgggggtcgtaagagctgccaagaactgtcatcagctatttgtgaatgaagctgaagcgggta
tccaacatcagcaaaaatactgcttcacttgcttcattcgcaaaatggatcatacaaagcactgcgccgtttgcgg 
att 
<- exon 9 
 
DHHC-14 protein: 
MNGDTEVLTHNLLKPAVVVDSFNLHAVISATQHGHVESVEAALKQGLSPNTTDDDGCSLLHWAAINNRLEVARLLI
SYNADANLIGGVLASSPIHWAARNGLVAMCAVLVKGGAVCNVRDIQGYTPIHLAIQGNHVPLVAYFLLKFEYAKDI
SDNSGMTPAMMCAKRSFTMFPLRLIVRAGADLSLKEHFSGNTALHLAAQDRNSSAVMELLEGNANVNIRNKQSETP
LDMARTIKSPQILDLMEDAARRQGVSRTSCFRRSFVPPISTYFFFLVPMFGFFMTYLLFKYLPLIIATFSTLISCI
FLMVLIRFDYHDPTYKLLPYGVTIAEAILMVLSWSAYAHWYVPWWAQMLFVLSVLALAFTLFRIGTLDPGVVRAAK
NCHQLFVNEAEAGIQHQQKYCFTCFIRKMDHTKHCAVCGFCVNNFDHHCPWLNSCVTRRNMREFIMFVISVSVSSA
IYCMATSHYALLQIEDHGLEEFLETDAFLMITIILSAMHALMLAVLFCVQMNQISQGVTTNDRIKARRAGHAHSHS
GSTDYNVIHHKPSISKRCHNLLEFFSSNGDPNW 
 
dhhc-14: strain VC918, allele ok1032 
 
exon 7 -> 
atttgatggaagacgctgctcgtcgccagggagtcagtcgaacaagttgtttccgacgatctttcgtgccgccaat
cagcacatactttttcttcctggtcccaatgtttggatttttcatgacctatctccttttcaagtacttgccattg
attattgccactttctccacactgatctcctgcatctttcttatggttcttattcggtttgactatcatgatccta
cttacaagctgcttccttatggagttacaattgcagaagccatcttaatggtcttatcgtggtaggtattcaagtt
tgaaaatcttgccgttacactcttcacttttaatttcacttttgtcgtcaaacaaaagccaaaggataaaacggac
cagataacgaacaggtgccgttggaaagagaaaggaagggcagattgatatctcgagtaaactagacgggtttata
atgccatacgtatgattttatctcaatccacgtaaaaaaattattttcgaaaagtcgatcgtggggaaatagactt
caaaaataaaaatttaagaattttctagaacgcaaaaaagtttgctcaaattatttacaaaaatactttgaaatga
ctatttgaaattcttcaggtcagcatatgctcattggtacgtgccatggtgggctcaaatgctctttgttctttct
gttcttgctcttgcattcacattgttcaggtgagaaacagtattgtggcacttgaataacatagtgaataatttta
gaatagggacactggatccgggggtcgtaagagctgccaagaactgtcatcagctatttgtgaatgaagctgaagc
gggtatccaacatcagcaaaaatactgcttcacttgcttcattcgcaaaatggatcatacaaagcactgcgccgtt
tgcggattgtaagtttttcatttctttgtatacaaaaataaactttataaatttgagttgcgtgaacaattttgat
catcattgcccatggctgaacagttgtgtgactcgccgaaacatgagggaattcatcatgtttgtcatttcggtgt
cagtgtcatcagcaatttactgcatggctacaagtcattatgcgctgctccaaattgaagatcatggtttgggtga
gtcgtttttacagtacctctaactagtaagaggttaatctgagaggttgaccactaagaggttaatcggattaaga
aaaaaaaattcaataaatgcgacttgggaaactccccaaacatgttttttatgtcatgggaaattggttgtaaaac
taaactggtaaaatgttaactgcgactaactatgcatacattccttactcaggagtttatccgaaaaatatatgaa
tatttatttttacagaagaattcctggaaactgacgcgttcttgatgatcaccatcattctctcggcgatgcaGCA 
GAAGCCATCTTAATGcgcactcatgcttgccgtgctgttctgtgttcaaatgaaccag 
                                                <- exon 11 
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DHHC-14 protein: 
MNGDTEVLTHNLLKPAVVVDSFNLHAVISATQHGHVESVEAALKQGLSPNTTDDDGCSLLHWAAINNRLEVARLLI
SYNADANLIGGVLASSPIHWAARNGLVAMCAVLVKGGAVCNVRDIQGYTPIHLAIQGNHVPLVAYFLLKFEYAKDI
SDNSGMTPAMMCAKRSFTMFPLRLIVRAGADLSLKEHFSGNTALHLAAQDRNSSAVMELLEGNANVNIRNKQSETP
LDMARTIKSPQILDLMEDAARRQGVSRTSCFRRSFVPPISTYFFFLVPMFGFFMTYLLFKYLPLIIATFSTLISCI
FLMVLIRFDYHDPTYKLLPYGVTIAEAILMVLSWSAYAHWYVPWWAQMLFVLSVLALAFTLFRIGTLDPGVVRAAK
NCHQLFVNEAEAGIQHQQKYCFTCFIRKMDHTKHCAVCGFCVNNFDHHCPWLNSCVTRRNMREFIMFVISVSVSSA
IYCMATSHYALLQIEDHGLEEFLETDAFLMITIILSAMGRSHLNNAHSCLPCCSVFK-TR-IFHESGKYFSY-YCM
QYYF--FKFSSRLPIFK-NSYCVR-RFKKSC-K-INY-RFFC-LVVRSFIIHRRQLNCK--KSLKLAFPTKLGLLE
T-TQIFVDTFKCVIDSNSHITNREHSVIQF-KLFILVTKN-IQ-LL-ISQGVTTNDRIKARRAGHAHSHSGSTDYN
VIHHKPSISKRCHNLLEFFSSNGDPNW-KYKFGFYLHRT-KTCPAPRIFQT-ESKLFYGITNLSIKNKILVNVNQK
PKFKFHPRPFPHSQSTLFHFLSVLHEILHLYNLVVKRF-MLSISLFPSFISFFVKLFVHSG-NQVLGDI-SFPSVF
LLCSSLLRISEISFSLLFS-M-INFLEIK 
 
dnj-14: RM2754 strain, allele ok237 
 
between exons 1 and 2 of glit-1 ->  
aataatcaattcagtttctttaaaataatcttacatcattattttataacattctattttctatcattttgataat
aactactagaaaagtttaaatttctaggtaaacatagtttaaaaaattcaaaatacttacttggtttactccgcca
tggggaaatggtgttgtcgttgttttaaacggatcccatagatctactggacgcgttggtggtggaacaaattgtg
aaatgaccagcggtaatgtgaataagctattgaaaattgtgccggtgaacattccatgtgacgcgatctctgaaaa
atttaattttaaaaaagaaaaataaaatatctcttcgaaaaatttcattgaaaattgaaaattgataaaagccacg
caaaaaaaagcgaaaaatttttaggcaacgagtgatcatcaggttgatgacctacggtaacacacatttcgagctg
tgtcaatatgggaaacaacgcgctgcgggaccgcatgcgaggccggcggagcgcatttacgaccctcttcctctcc
cccactatgtgtcaccactgccgtatgggaatggttgcgtctatttacactctcatttttcgccgttgtctctccc
aattttcgcgctctccgtcaaggctcataagtgttttacatattgattttgacttgtgatctgaactgttcggcga
atatttcgctaaactgtttcccctcgacactctctctagtttttttttctattggcattttaatgtgataggttta
gttttcaatttccgttgttttaaataaattcctccttgtttcctttcttttttaaatgcaaatctaatttcaggga
aatgaactcagacggattacgggaagcggaggaagggagaacaagtggaggagcatctccccgtgaagaatctcca
gccgctgatcattcgcacgatccgaaaaagggacttcatttgtacaatgttctcggcattcagaaaaatgccacag
atgacgaaatcaaaaagtgagtctttgagttgaaaatacattttctaaattcctattcttgctataaagaagtatt
gttatcagtgtaacgcagttatttttattataatcgttaaatttaatcaattgtggtttcttctgacttgaaaatt
gtacaaattgggtgtgtccattccgaacgaaatcgagtaaattttgtgaaaagtgaaaattgttggaacaatttga
cgaatgtacccaaatgaccaaatttcgtaatgtgacttctcgaaattttttaatgaggcttcaaagtttcgaaaaa
atgtttcatttttgataatttctccaatttttggtccattttccgtgttgcagcggtcaaaaattagcgtttatca
gccttctttacatattttggttgcttgtcttaccttatgtcgtcgatagaagtacatttaaagcctaggtaaccaa
ttttgatcattcatggttgactaatggcttgatttgtactttagctattaaaaaacgcgatataaactatcaaatc
acgcaaaaaatattatttaaggcattggagactggagatattggcgaaaattgagccattttttttcaagactttg
aagccccataaatgtttttgagaaattctcgtgaactgtcattacaaaattctttaatttcgccacctttattgaa
tctatactaatcttttaaaaagttcgataacttggtacgataactagatattgaaaactgacagttcagggagaga
ccaatagttttttttgaaacaattaaatttttttcagagcgtatcgcaaactagccctccgctatcatcccgacaa
aaacctagatggagatccggaaaaaacggaaatgttcaaagaaatcaactacgcaaatgcagtgctctcaaatcca
aataaacgtcgtgtctatgacgagatgggagagaccgggctgaaactgatggagcagtttggagaggatgagaaga
ttctgcagtggatgttgaagccttggttcaaatggacatttttcgcgttcggacttctcacgggtggcttcttctg
ctgctgttgtggttgtatgtgttgttgtcaatgctgttgcaatttctgttgtggaaagtacaagccgaagcacgat
gatgagtttgccgatgagacgtcggacggagatgtgattgttgatcaaccgacagcttccgagccaatgccagata 
cgaataacagacaggtgccgattgtgattgccatgcctccaccgccttctcaaaa 
                                              <- exon 2 
 
DNJ-14 protein 
MNSDGLREAEEGRTSGGASPREESPAADHSHDPKKGLHLYNVLGIQKNATDDEIKKAYRKLALRYHPDKNLDGDPE
KTEMFKEINYANAVLSNPNKRRVYDEMGETGLKLMEQFGEDEKILQWMLKPWFKWTFFAFGLLTGGFFCCCCGCMC
CCQCCCNFCCGKYKPKHDDEFADETSDGDVIVDQPTASEPMPDTNNRQVPIDCHASTAFSKRL 
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ppt-1: strain MN1, allele gk139 
 
exon 2 ->  
gtgactgttgttgcaatccgttgtctatgggatctgtgaaaaaactattcgaggagcaaattcctggagtttacgt
tcacagtcttcaattgggatctagtattacaaaagacattgagcatggattttatgcaaataccaatgaacttgtc
tatatggcatgtatcaaaattaagaacgatcctgaactaaagaatggatataatgcgatcggattctcacaaggag
cacagtttttgtaaatcgcgtttattgaatttaaattttaaaaaattttgtagaacggcaatttttcaggagagcg
gttgcccaaagatgcccaaatccaccaatgaagaatttggtgtcagtcggtggtcaacatcaaggagtttttggag
ccccgtactgcattggtgacaatattatgtgcaatggcgtgagacgtctcattgacttgggagcttatcttccatt
tgtacaaaaacggtacgagtattttttgtctttcatttcattatttttaacagttttctagagttgttcaagccca
gtactggcacgacccaaatcaagtcgaagagtataaaaaacgttctattttcttggctgatatcaataacgaaaac
gtaaggatttttaaaacatttttttgaagtattaattaataatttctgtacattttggtccttttttgttttgaaa
aaactgtttttggtgattgaaaattataactttttctgtaaaaagatgcgccgggattagtttaatgaacggtggt
gctttattttcttttctaaaaattattcctgccggttgacatttgaatttcaaaatcgttagaaaatcgtaatcat
taaaataattgaaaaaaaaagtatttttgtttcagaataacaacccgacttacaaacgcaacttattgagtctcaa 
aaacctggttctggtgaaattcaatcaagatcatatggttgtaccaaaggattcatct 
                                                 <- exon 5 
 
PPT-1 protein 
MRYFPLLLCLLAITTAEFRNATKQVPVVMWHGMGDCCCNPLSMGSVKKLFEEQIPGVYVHSLQLGSSITKDIEHGF
YANTNELVYMACIKIKNDPELKNGYNAIGFSQGAQFLRAVAQRCPNPPMKNLVSVGGQHQGVFGAPYCIGDNIMCN
GVRRLIDLGAYLPFVQKRVVQAQYWHDPNQVEEYKKRSIFLADINNENE-QPDLQTQLIESQKPGSGEIQSRSYGC
TKGFILVRVLQRR-Y-HNSPNERNRPVQRGSYWIEEAS-EWTNPFYGRGWRSLANSKKCACQRYYQKIFYVNLFDF
QKETTRIVKLVRKNEL-NYH 
 
ppt-1: strain VC166, allele gk131 
 
exon 1 ->  
atgagatattttccccttctactttgcctactggccataactacagcagaattccggaatgTTTctacaaagcagg
ttccagtggtcatgtggcatggaatgggttagttgtaacttaattactgaaaaagtgcgaacattatgatttttag
gtgactgttgttgcaatccgttgtctatgggatctgtgaaaaaactattcgaggagcaaattcctggagtttacgt
tcacagtcttcaattgggatctagtattacaaaagacattgagcatggattttatgcaaataccaatgaacttgtc
tatatggcatgtatcaaaattaagaacgatcctgaactaaagaatggatataatgcgatcggattctcacaaggag 
cacagttttt 
 <- exon 2 
 
PPT-1 protein 
MRYFPLLLCLLAITTAEFRNVATKQVPVVMWHGMGDCCCNPLSMGSVKKLFEEQIPGVYVHSLQLGSSITKDIEHG
FYANTNELVYMACIKIKNDPELKNGYNAIGFSQGAQFLRAVAQRCPNPPMKNLVSVGGQHQGVFGAPYCIGDNIMC
NGVRRLIDLGAYLPFVQKRVVQAQYWHDPNQVEEYKKRSIFLADINNENNNNPTYKRNLLSLKNLVLVKFNQDHMV
VPKDSSWFGFYKDGDIDTILPMNETDLYKEDRIGLKKLHESGRIHFMDVDGDHLQIPRSVLVNDIIKKYFM 
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ppt-1: strain VC168, allele gk134 
 
before exon 1 ->  
aactgtttttggtgattgaaaattataactttttctgtaaaaagatgcgccgggattagtttaatgaacggacccc
actctaatcatttcttcgttttcttgaagaatgagatattttccccttctactttgcctactggccataactacag
cagaattccggaatgctacaaagcaggttccagtggtcatgtggcatggaatgggttagttgtaacttaattactg
aaaaagtgcgaacattatgatttttaggtgactgttgttgcaatccgttgtctatgggatctgtgaaaaaactatt
cgaggagcaaattcctggagtttacgttcacagtcttcaattgggatctagtattacaaaagacattgagcatgga
ttttatgcaaataccaatgaacttgtctatatggcatgtatcaaaattaagaacgatcctgaactaaagaatggat
ataatgcgatcggattctcacaaggagcacagtttttgtaaatcgcgtttattgaatttaaattttaaaaaatttt
gtagaacggcaatttttcaggagagcggttgcccaaagatgcccaaatccaccaatgaagaatttggtgtcagtcg
gtggtcaacatcaaggagtttttggagccccgtactgcattggtgacaatattatgtgcaatggcgtgagacgtct
cattgacttgggagcttatcttccatttgtacaaaaacggtacgagtattttttgtctttcatttcattattttta
acagttttctagagttgttcaagcccagtactggcacgacccaaatcaagtcgaagagtataaaaaacgttctatt
ttcttggctgatatcaataacgaaaacgtaaggatttttaaaacatttttttgaagtattaattaataatttctgt
acattttggtccttttttgttttgaaaaaactgtttttggtgattgaaaattataactttttctgtaaaaagatgc
gccgggattagtttaatgaacggtggtgctttattttcttttctaaaaattattcctgccggttgacatttgaatt
tcaaaatcgttagaaaatcgtaatcattaaaataattgaaaaaaaaagtatttttgtttcagaataacaacccgac
ttacaaacgcaacttattgagtctcaaaaacctggttctggtgaaattcaatcaagatcatatggttgtaccaaag 
gattcatct 
 <-exon 5 
 
PPT-1 protein 
MRYFPLLLCLLAITTAEFRNATKQVPVVMWHGMGDCCCNPLSMGSVKKLFEEQIPGVYVHSLQLGSSITKDIEHGF
YANTNELVYMACIKIKNDPELKNGYNAIGFSQGAQFLRAVAQRCPNPPMKNLVSVGGQHQGVFGAPYCIGDNIMCN
GVRRLIDLGAYLPFVQKRVVQAQYWHDPNQVEEYKKRSIFLADINNENNNNPTYKRNLLSLKNLVLVKFNQDHMVV
PKDSSWFGFYKDGDIDTILPMNETDLYKEDRIGLKKLHESGRIHFMDVDGDHLQIPRSVLVNDIIKKYFM 
 
ppt-1: strain VC184, allele gk140 
 
exon 1 ->  
atgagatattttccccttctactttgcctactggccataactacagcagaattccggaatgctacaaagcaggttc
cagtggtcatgtggcatggaatgggttagttgtaacttaattactgaaaaagtgcgaacattatgatttttTAagg
tgactgttgttgcaatccgttgtctatgggatctgtgaaaaaactattcgaggagcaaattcctggagtttacgtt
cacagtcttcaattgggatctagtattacaaaagacattgagcatggattttatgcaaataccaatgaacttgtct
atatggcatgtatcaaaattaagaacgatcctgaactaaagaatggatataatgcgatcggattctcacaaggagc
acagtttttgtaaatcgcgtttattgaatttaaattttaaaaaattttgtagaacggcaatttttcaggagagcgg
ttgcccaaagatgcccaaatccaccaatgaagaatttggtgtcagtcggtggtcaacatcaaggagtttttggagc
cccgtactgcattggtgacaatattatgtgcaatggcgtgagacgtctcattgacttgggagcttatcttccattt
gtacaaaaacggtacgagtattttttgtctttcatttcattatttttaacagttttctagagttgttcaagcccag 
tactggcacgacccaaatcaagtcgaagagtataaaaaacgttctattttcttggctgatatcaataacgaaaac 
                                                                  <- exon 4 
 
PPT-1 protein 
MRYFPLLLCLLAITTAEFRNATKQVPVVMWHGMGDCCCNPLSMGSVKKLFEEQIPGVYVHSLQLGSSITKDIEHGF
YANTNELVYMACIKIKNDPELKNGYNAIGFSQGAQFLRAVAQRCPNPPMKNLVSVGGQHQGVFGAPYCIGDNIMCN
GVRRLIDLGAYLPFVQKMELFKPSTGTTQIKSKSIKNVLFSWLISITKTITTRLTNATY-VSKTWFW-NSIKIIWL
YQRIHLGSGSTKTVILTQFSQ-TKPTCTKRIVLD-RSFMRVDESILWTWMEITCKFQEVCLSTILSKNILC 
 
spe-10: strain BA744, allele hc104 
 
exon 3 ->  
actttatatgtacgtgacagtgacaattggttattacgttcagtcaacaattcaagcaaccatttatttgattgtt
ggatcatttctgtttgttatgtcaatgtggagtcttgcaaaaacgttgttcacgagagttggcagagttccagaaa
gatatcgacctagtaaagaacttgaagatagattgaaagcagtcacaccgatggagaaaaatTgatacgtggtaga
gaaatcgacacctgaacag 
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SPE-10 sequence 
MSWYSKIYVAVREYRAKHKITGWILTRCLNVLLFIQLILLWWSLYMYVTVTIGYYVQSTIQATIYLIVGSFLFVMS
MWSLAKTLFTRVGRVPERYRPSKELEDRLKAVTPMEKN*YVVEKSTPEQLAQQNTILEEMCTYCKVVVAECDQVGR
LKYCYECGHIKPDRARHCSSCGKCCIKYDHHCPWINMCVTHVNYKYFLLYIIYTSFLVYWYLLTSLEGAVRYFINQ
QWTDELGKFLFYLFSFIVGGVFGYYPLGELIIFHYQLISLNETTVEQTKPALLRFDNAADYNMGKYNNFQSVFGWG
LWLCPIDSSTQDGLHFDIRYVNTQQRNRFVRIEEEPSSTQSSQSSIQ  
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APPENDIX 2: HITS FROM PREVIOUS MAMMALIAN PROTEOMIC SCREENS 
High confidence hits from previous studies using palmitoyl-proteomics on mammalian 
material are shown.  The studies are numbered as follows: 
1. (Kang et al., 2008) 
2. (Zhang et al., 2008) 
3. (Martin and Cravatt, 2009) 
4. (Yang et al., 2010) 
5. (Yount et al., 2010) 
6. (Dowal et al., 2011) 
7. (Merrick et al., 2011) 
8. (Forrester et al., 2011) 
9. (Martin et al., 2012) 
10. (Ivaldi et al., 2012) 
11. (Marin et al., 2012) 
Abbr., abbreviation of protein (if different from gene name). 
Gene Protein name Abbr. 1 2 3 4 5 6 7 8 9 10 11 
0610007 
P14Rik probable ergosterol biosynthetic protein 28             
1110007 
C09Rik 
bcl10-interacting caspase-associated recruitment 
domain (CARD) protein             
1810026 
J23Rik uncharacterized protein C19orf52 homologue             
2510039 
O18Rik uncharacterized protein KIAA2013 precursor             
Abat 4-aminobutyrate aminotransferase             
Abcb6 ATP-binding cassette subfamily B member 6             
Abcc4 multidrug resistance-associated protein 4             
Abce1 ATP-binding cassette subfamily E member 1             
Acaa1b 3-ketoacyl-CoA thiolase B, peroxisomal             
Acaa2 3-ketoacyl-CoA thiolase, mitochondrial             
Acadl long-chain specific acyl-CoA dehydrogenase, mitochondrial precursor             
Acat1 acetyl-CoA acetyltransferase, mitochondrial             
Aco2 aconitate hydratase, mitochondrial             
Acsl3 acyl-CoA synthetase long-chain family member 3             
Acsl5 long-chain fatty-acid-CoA ligase 5             
Acta1 actin, α skeletal muscle             
Acta2 actin, aortic smooth muscle             
Actb actin, cytoplasmic 1             
Actbl β-actin-like protein 2             
Actc1 actin, α cardiac muscle 1             
Actg1 actin, cytoplasmic 2             
Actg2 actin, γ enteric smooth muscle             
Actn1 α-actinin 1             
Actn4 α-actinin 4             
Adam10 a disintegrin and metalloproteinase 10 precursor             
Adam17 a disintegrin and metalloproteinase 17 precursor isoform B             
Adcy6 adenylate cyclase type 6             
Adfp adipose differentiation-related protein             
Adpgk ADP-dependent glucokinase             
Afg3l2 AFG3-like protein 2             
Agpat1 lysophosphatidic acid acyltransferase α LPAATα            
Ahcy adenosylhomocysteinase             
Ahnak neuroblast differentiation-associated protein AHNAK             
AI462493 UPF0723 protein C11orf83 homologue precursor             
Ak1 adenylate kinase isoenzyme 1 isoform 2             
Akap1 A-kinase anchor protein 1, mitochondrial             
Alb serum albumin             
Aldh1b1 aldehyde dehydrogenase X,  mitochondrial precursor             
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Gene Protein name Abbr. 1 2 3 4 5 6 7 8 9 10 11 
Aldh2 aldehyde dehydrogenase, mitochondrial             
Aldh3a2 fatty aldehyde dehydrogenase             
Aldh3b1 aldehyde dehydrogenase 3B1 isoform 1             
Aldh6a1 methylmalonate-semialdehyde dehydrogenase             
Aldoa fructose bisphosphonate aldolase A isoform 1             
Alpl alkaline phosphatase 2, liver precursor             
Amy1a α-amylase 1             
Antxr1 anthrax toxin receptor 1             
Antxr2 anthrax toxin receptor 2             
Anxa2 annexin A2 isoform 1             
Anxa6 annexin A6 isoform a             
Apmap adipocyte plasma membrane associated protein             
Apoo apolipoprotein O             
Apool apolipoprotein O-like             
Arcn1 coatomer subunit δ             
Arf1 ADP-ribosylation factor 1             
Arf2 ADP-ribosylation factor 2             
Arf3 ADP-ribosylation factor 3             
Arf4 ADP-ribosylation factor 4             
Arf5 ADP-ribosylation factor 5             
Arhgdia Rho-GDP dissociation inhibitor α             
Arhgdib Rho-GDP dissociation inhibitor β             
Arl15 ADP-ribosylation factor-like protein 15             
Arl6ip1 ADP-ribosylation factor-like protein 6  interaction protein 1             
Arl6ip6 ADP-ribosylation factor-like protein 6  interaction protein 6             
Armc10 armadillo repeat-containing protein 10             
Arpc1a actin-related protein 2/3 complex subunit 1A             
Art2b T-cell ecto-ADP-ribosyltransferase 2 precursor             
Asah1 acid ceramidase             
Astn1 astroactin 1             
Atad3a 
ATPase family ATPase associated with  
diverse cellular activities (AAA) domain-containing 
protein 3A  
           
Atl1 atlastin-1             
Atp11a probable phospholipid-transporting ATPase IH             
Atp11b probable phospholipid-transporting ATPase IF             
Atp1a1 α1 subunit of sodium/potassium ATPase  isoform long             
Atp1a3 cation transporting ATPase             
Atp1b1 β1 subunit of sodium/potassium-ATPase             
Atp1b2 β2 subunit of sodium/potassium-ATPase             
Atp1b3 β3 subunit of sodium/potassium-ATPase             
Atp2a1 sarcoplasmic/endoplasmic reticulum  calcium ATPase 1             
Atp2a2 sarcoplasmic/endoplasmic reticulum  calcium ATPase 2             
Atp2a3 sarcoplasmic/endoplasmic reticulum  calcium ATPase 3             
Atp2b3 plasma membrane Ca2+ transporting ATPase 3             
Atp2c1 ATPase Ca2+-sequestering             
Atp5a1 ATP synthase subunit α, mitochondrial             
Atp5l ATP synthase subunit γ             
Atp5o ATP synthase subunit O, mitochondrial             
Atp6v0a2 V-type proton ATPase 116 kDa subunit α isoform 2             
Atp6v1b2 vacuolar ATP synthase subunit B, brain isoform             
Atp9a probable phospholipid-transporting ATPase IIa             
Atrn attractin             
AU040320 dyslexia-associated protein KIAA0319-like protein isoform 1             
Aup1 ancient ubiquitous protein 1 isoform long             
B4galt1 β-1,4-galactosyltransferase 1, long isoform             
B4galt3 β-1,4-galactosyltransferase 3             
Bak BCL2 antagonist/killer 1             
Bat5 B-associated transcript 5             
BC002199 BC002199 protein             
BC031181 UPF0729 protein C18orf32 homologue             
Bcam Lutheran blood group glycoprotein precursor             
Bckdk [3-methyl-2-oxobutanoate [lipoamide]] kinase             
Bet1 BET1 homologue             
Bet1l BET1-like protein             
Bk brain-kidney protein             
Bri3bp brain protein I3 (BRI3)-binding protein             
Bsg basigin precursor isoform 1             
Bst2 bone marrow stromal antigen 2 precursor             
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Gene Protein name Abbr. 1 2 3 4 5 6 7 8 9 10 11 
C12orf10 protein melanocyte proliferating gene 1, mitochondrial MYG1            
C14orf166 protein C14orf166             
C14orf24 protein C14orf24             
C1orf75 transmembrane protein 206             
C1orf95 protein C1orf95             
C1qbp complement component 1 Q subcomponent-binding protein, mitochondrial             
C21orf33 ES1 protein homologue, mitochondrial             
C22orf25 protein C22orf25             
C2orf18 protein C2orf18             
C2orf88 protein C2orf88             
C6orf125 uncharacterised protein C6orf125             
C8orf82 protein C8orf82             
C9orf169 protein C9orf169             
Cacfd1 calcium channel flower homologue isoform 1             
Cacng voltage-gated calcium channel γ8 subunit             
Cacybp calcyclin-binding protein             
Cad carbamoyl-phosphate synthetase 2,  aspartate transcarbamylase, and dihydroorotase             
Cadm4 cell adhesion molecule 4 SynCAM4            
Calhm2 calcium homeostasis modulator protein 2             
Calr calreticulin precursor             
Canx calnexin             
Cap1 adenylyl cyclase-associated protein 1             
Capg capping protein (actin filament), gelsolin-like             
Capn5 calpain 5             
Carns1 carnitine synthase 1             
Cars2 probable cysteinyl-tRNA synthetase             
Cask calcium/calmodulin-dependent  serine protein kinase             
Cav1 caveolin-1             
Ccdc109a coiled-coil domain-containing protein 109A             
Ccdc69 coiled-coil domain-containing protein 69             
Ccny cyclin Y             
Ccnyl1 cyclin Y-like 1             
Ccs copper chaperone for superoxide dismutase             
Cct2 T-complex protein 1 subunit β             
Cct5 T-complex protein 1 subunit ε             
Cct6a T-complex protein 1 subunit ζ             
Cct8 T-complex protein 1 subunit θ             
Cd151 CD151 antigen             
Cd1d1 antigen-presenting glycoprotein CD1d1 precursor             
Cd1d2 antigen-presenting glycoprotein CD1d2 precursor             
Cd247 CD247 antigen             
Cd28 CD28 antigen             
Cd36 platelet glycoprotein 4             
Cd37 leukocyte antigen CD37             
Cd38 ADP-ribosyl cyclase 1 isoform 1             
Cd3d T-cell surface glycoprotein CD3 δ chain precursor             
Cd44 CD44 antigen             
Cd47 leukocyte surface antigen CD47 precursor             
Cd48 CD48 antigen             
Cd5 T-cell surface glycoprotein CD5 precursor             
Cd53 leukocyte surface antigen CD53             
Cd63 CD63 antigen             
Cd69 early activation antigen CD69             
Cd70 tumour necrosis factor ligand superfamily  member 7             
Cd74 CD74 molecule, major histocompatibility complex, class II invariant chain             
Cd81 CD81 antigen             
Cd82 CD82 antigen             
Cd9 CD9 antigen             
Cd99 CD99 antigen             
Cd99l2 CD99 antigen-like protein 2             
Cdc42 cell division cycle 42             
Cdc42se1 cell division cycle 42 small effector protein 1             
Cdc42se2 cell division cycle 42 small effector protein 2             
Cdcp1 complement C1r/C1s, Uegf, Bmp1 (CUB) domain-containing protein 1 precursor             
Cdip liposaccharide induced tumour necrosis factor (TNF) factor (LITAF)-like protein             
Cdipt CDP-diacylglycerol--inositol  3-phosphatidyltransferase             
Cept choline/ethanolaminephosphotransferase 1             
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Cetp cholesteryl ester transfer protein             
Cfl1 cofilin-1             
Cfl2 cofilin-2             
Chchd3 coiled-coil-helix-coiled-coil-helix domain-containing protein 3, mitochondrial precursor             
Chd5 chromodomain helicase DNA binding protein 5             
Chdh choline dehydrogenase, mitochondrial precursor             
Chrna5 neuronal acetylcholine receptor subunit α5             
Chst11 carbohydrate sulfotransferase 11 isoform 1             
Cisd1 CDGSH iron sulphur domain 1             
Cisd2 CDGSH iron sulphur domain 2             
Ckap4 cytoskeleton-associated protein 4             
Cldn3 claudin-3             
Cldn5 claudin-5             
Cldnd1 claudin domain-containing protein 1 isoform 1             
Clec2d C-type lectin domain family 2 member D             
Clic1 chloride intracellular channel 1             
Clld6 chronic lymphocytic leukaemia deletion  region gene 6 protein             
Cln6 ceroid lipofuscinosis, neuronal 6             
Clptm1 cleft lip and palate transmembrane protein 1             
Cltc clathrin heavy chain 1 isoform 1             
Cmtm3 
chemokine-like factor (CKLF)-like myelin and 
lymphocyte (MAL) and related proteins for vesicle 
trafficking and membrane link (MARVEL) 
transmembrane domain-containing protein 3 
            
Cmtm5 
chemokine-like factor (CKLF)-like myelin and 
lymphocyte (MAL) and related proteins for vesicle 
trafficking and membrane link (MARVEL) 
transmembrane domain-containing protein 5 
            
Cmtm7 
chemokine-like factor (CKLF)-like myelin and 
lymphocyte (MAL) and related proteins for vesicle 
trafficking and membrane link (MARVEL) 
transmembrane domain-containing protein 7 
            
Cnpy2 protein canopy homologue 2 precursor             
Col4a1 collagen α-1(IV) chain             
Col4a2 collagen α-2(IV) chain             
Commd9 copper metabolism mouse u2af1-rs1 region 1 (MURR1) (COMM) domain-containing protein 9             
Comt catechol O-methyltransferase  membrane-bound isoform             
Comtd1 catechol O-methyltransferase domain-containing protein 1             
Cox16 cytochrome c oxidase assembly protein  COX16 homologue, mitochondrial             
Cox20 cytochrome c oxidase protein 20 homologue             
Cox4nb endoplasmic reticulum membrane  protein complex subunit 8             
Cox6c cytochrome c oxidase subunit VIc             
Cpd carboxypeptidase D precursor             
Csnk1g1 casein kinase I isoform γ1             
Csnk1g2 casein kinase I isoform γ2             
Csnk1g3 casein kinase I isoform γ3             
Cst4 cystatin-S             
Ctdsp1 carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 1             
Ctdspl carboxy-terminal domain phosphatase-like protein             
Ctl1 choline transporter-like protein 1             
Ctl2 choline transporter-like protein 2             
Ctnnd1 catenin δ1 isoform 1AB             
Ctnnd2 catenin δ2; neural plakophilin-related  ARM repeat protein NPRAP            
Ctse cathepsin E preproprotein             
Cxadr coxsackievirus and adenovirus receptor             
Cxcr4 chemokine (C-X-C motif) receptor 4             
Cyb5b cytochrome b5 type B             
Cyb5d2 neuferricin precursor             
Cyb5r3 NADH-dependent cytochrome c reductase             
Cyba cytochrome b-245 α polypeptide             
Cybb cytochrome b-245 β polypeptide             
Cycs cytochrome c             
Cyp51 cytochrome P450, family 51             
Daam1 dishevelled associated activator of  morphogenesis 1             
Dag1 dystroglycan             
Daglb Sn1-specific diacylglycerol lipase β             
Dbt2 dihydrolipoamide branched chain transacylase E2             
APPENDICES 
191 
 
Gene Protein name Abbr. 1 2 3 4 5 6 7 8 9 10 11 
Dcun1d3 defective in cullin neddylation 1 (DCN1) domain-containing 3             
Ddx39a nuclear RNA helicase             
Ddx39b spliceosome RNA helicase DDX39B             
Degs1 sphingolipid δ4-desaturase DES1             
Derl1 derlin-1             
Desi2/ 
Pppde1 desumoylating isopeptidase 2 DESI2            
Dhcr24 24-dehydrocholesterol reductase precursor             
Dhrs4 dehydrogenase/reductase SDR family  member 4 isoform 1             
Dhrs7b dehydrogenase/reductase SDR family  member 7B isoform 1             
Dlg2 postsynaptic density protein 93 PSD-93            
Dlg4 postsynaptic density protein 95 PSD-95            
Dlgap discs large-associated protein 4             
Dnah1 dynein heavy chain 1             
Dnajb6 DnaJ homologue subfamily B member 6             
Dnajc11 DnaJ homologue subfamily C member 11             
Dnajc5 cysteine string protein CSP            
Dolpp1 dolichyldiphosphatase 1             
Dpysl2 dihydropyrimidinase-related protein 2             
Dsg1 desmoglein-1             
Dsg2 desmoglein-2             
Dsg4 desmoglein-4             
Dsp desmoplakin             
Dync1h1 cytoplasmic dynein heavy chain             
Ebag9 estrogen receptor binding site associated  antigen 9 RCAS1            
Ece1 endothelin-converting enzyme 1             
Ecgf1 platelet-derived endothelial cell growth factor             
Eef1a1 elongation factor 1α 1             
Eef1b elongation factor 1β             
Eef1e1 eukaryotic translation elongation factor 1 ε-1             
Eef1g elongation factor 1γ             
Eef2 elongation factor 2             
Efcab14 EF-hand calcium-binding domain-containing protein 14             
Efnb3 ephrin-B3             
Efr3a S. cerevisiae EFR3 homolog A             
Efr3b S. cerevisiae EFR3 homolog B             
Eif3a eukaryotic translation initiation factor 3 subunit 10             
Eif3g eukaryotic translation initiation factor 3 subunit G             
Eif3k eukaryotic translation initiation factor 3 subunit 12             
Eif4a1 eukaryotic translation initiation factor 4A-1             
Eif5a eukaryotic translation initiation factor 5A-1             
Elovl1 elongation of very long fatty acids protein 1             
Emb embigin precursor             
Emc1 endoplasmic reticulum membrane protein complex subunit 1 isoform 2 precursor             
Eno1 α-enolase             
Eno3 β-enolase isoform 1             
Entpd1 ectonucleoside triphosphate  diphosphohydrolase 1             
Epha5 Eph receptor A5             
Ephb2 Eph receptor B2             
Eprs glutamyl-prolyl-tRNA synthetase             
Erbb2ip lamina-associated polypeptides 2 isoform 1 LAP2            
Ergic1 endoplasmic reticulum-Golgi  intermediate compartment protein 1             
Ergic2 endoplasmic reticulum-Golgi  intermediate compartment protein 2             
Ergic3 endoplasmic reticulum-Golgi  intermediate compartment protein 3             
Ero1l endoplasmic reticulum oxidoreductase 1  (ERO1)-like             
Esd S-formylglutathione hydrolase             
Esyt1 extended synaptotagmin 1             
Ethe1 ethylmalonic encephalopathy 1             
Exoc3l2 exocyst complex component 3-like protein 2             
Exoc3l4 exocyst complex component 3-like protein 4             
F3 tissue factor precursor             
Fabp4 fatty acid-binding protein, adipocyte             
Fam108a1 abhydrolase domain-containing protein FAM108A1             
Fam108b family with sequence similarity 108, member B             
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Fam108b1 family with sequence similarity 108, member B1             
Fam108c1 family with sequence similarity 108, member C1             
Fam131b family with sequence similarity 131, member B             
Fam162a family with sequence similarity 162, member A             
Fam171a2 family with sequence similarity 171, member A2             
Fam171b family with sequence similarity 171, member B             
Fam219b family with sequence similarity 219, member B             
Fam49b family with sequence similarity 49, member B             
Fam62b family with sequence similarity 62, member B             
Fam78a family with sequence similarity 78, member A             
Fas tumour necrosis factor receptor superfamily member 6             
Fasn fatty acid synthase             
Fbxl20 F-box/leucine-rich repeat (LRR)-repeat protein 20             
Fcer2 low affinity immunoglobulin ε Fc receptor             
Fgr Gardner-Rasheed feline sarcoma viral             
Fkbp8 FK506 binding protein 8 isoform a             
Flg filaggrin             
Flna filamin-A isoform 1             
Flnb filamin-B             
Flot1 flotillin 1             
Flot2 flotillin 2             
Frs2 fibroblast growth factor receptor substrate 2             
Fscn1 fascin             
Ftl ferritin light chain             
Fut7 α-1,3-fucosyltransferase isoform 1             
Fxyd5 FXYD domain-containing ion transport regulator 5             
Fxyd6 FXYD domain-containing ion transport regulator 6             
Fyn Fyn non-receptor tyrosine kinase             
Gabarapl2 γ-aminobutyric acid receptor-associated  protein-like 2             
Gabrg2 γ-amino butyric acid A receptor subunit γ2             
Galnt1 polypeptide N-acetylgalactosaminyltransferase 1             
Galnt12 polypeptide N-acetylgalactosaminyltransferase 12             
Galnt2 polypeptide N-acetylgalactosaminyltransferase 2             
Gapdh glyceraldehyde-3-phosphate dehydrogenase             
Gcs1 mannosyl-oligosaccharide glucosidase             
Gcsaml germinal centre-associated signaling and motility-like protein             
Gfpt1 glucosamine-fructose-6-phosphate aminotransferase [isomerising] 1             
Ggt7 γ-glutamyltranspeptidase             
Glg1 Golgi apparatus protein 1             
Glipr2 Golgi-associated plant pathogenesis-related protein 1             
Gls glutaminase kidney isoform             
Gm10273 predicted pseudogene 10273             
Gm10366 predicted gene 10366             
Gm10499 predicted gene 10499             
Gm614 interleukin 2 receptor γ chain             
Gna11 Gα11 G protein subunit             
Gna12 Gα12 G protein subunit             
Gna13 Gα13 G protein subunit             
Gna14 Gα14 G protein subunit             
Gna15 Gα15 G protein subunit             
Gnai1 Gαi1 G protein subunit             
Gnai2 Gαi2 G protein subunit             
Gnai3 Gαi3 G protein subunit             
Gnao Gαo G protein subunit             
Gnaq Gαq G protein subunit             
Gnas Gαs G protein subunit short             
Gnas Gαs G protein subunit XLαs isoform             
Gnaz Gαz G protein subunit             
Gnb2 guanine nucleotide-binding protein G(I)/G(S)/G(T) 
subunit β2             
Gnb2l1 guanine nucleotide-binding protein  
subunit β2-like 1             
Golga7 golgin subfamily A member 7             
Golgb1 Golgi autoantigen, golgin subfamily b,  macrogolgin 1             
Golim4 Golgi integral membrane protein 4             
Got2 aspartate aminotransferase, mitochondrial             
Gpi glucose-6-phosphate isomerase             
Gpm6a glycoprotein m6a             
Gpm6b glycoprotein m6b             
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Gpr126 developmentally regulated G protein-coupled 
receptor β1             
Gprc5a retinoic acid induced protein 3             
Gprc5c G protein-coupled receptor family 5  member C precursor             
Gprin1 G protein-regulated inducer of  neurite outgrowth 1 GRIN1            
Gpsn2 very long chain enoyl-CoA reductase             
Gria1 glutamate receptor subunit α1 GluR1            
Gria2 glutamate receptor subunit α2 GluR2            
Gria3 glutamate receptor subunit α3 GluR3            
Grid1 glutamate receptor subunit δ1 δ1-GluR            
Grk6 G protein-coupled receptor kinase 6             
Grpel1 GrpE protein homologue 1             
Gstp1 glutathione-S-transferase P             
H2-Q1 histocompatibility 2, Q region locus 1, precursor             
H2afx histone H2A             
H2afy core histone macro-H2A.1 isoform 2             
Hadha trifunctional enzyme subunit α,  mitochondrial precursor             
Hadhb trifunctional enzyme subunit β,  mitochondrial precursor             
Hccs cytochrome c-type haem lyase             
Hic2 hypermethylated in cancer 2 protein             
Hist1h2bn histone H2B type 1-N             
Hist1h4a histone H4             
Hla-a HLA class I histocompatibility antigen             
Hla-b HLA class I histocompatibility antigen             
Hla-c HLA class I histocompatibility antigen             
Hla-e major histocompatibility complex class 1, E             
Hla-g human leukocyte antigen (HLA) class I 
histocompatibility antigen, α chain G             
Hmgcs1 hydroxymethylglutaryl-CoA synthase, cytoplasmic             
Hmha1 minor histocompatibility protein HA-1             
Hmox2 haem oxygenase 2             
Hnrnpa1 heterogeneous nuclear ribonucleoprotein A1             
Hnrnpa1l2 heterogeneous nuclear ribonucleoprotein  A1-like 2             
Hnrnpa1l3 heterogeneous nuclear ribonucleoprotein  A1-like 3             
Hnrnpa2b1 heterogeneous nuclear ribonucleoproteins A2/B1             
Hnrnpa3 heterogeneous nuclear ribonucleoprotein A3             
Hnrnpk heterogeneous nuclear ribonucleoprotein K             
Hnrnpr heterogeneous nuclear ribonucleoprotein R             
Hnrnpul1 heterogeneous nuclear ribonucleoprotein  U-like protein 1             
Hp1bp3 heterochromatin protein 1-binding protein 3             
Hras H-Ras             
Hsd17b10 hydroxyacyl-CoA dehydrogenase type II isoform 1             
Hsd17b11 estradiol 17β-dehydrogenase 11 precursor             
Hsd17b12 hydroxysteroid (17-β) dehydrogenase 12             
Hsp90aa1 heat shock protein 90 α2             
Hsp90b1 endoplasmin precursor             
Hspa1a heat shock 70 kDa protein 1A             
Hspa1b heat shock 70 kDa protein 1B             
Hspa8 heat shock cognate 71 kDa protein isoform 1             
Hspa9 heat shock 70 kDa protein 9             
Hspb1 heat shock protein β1             
Hspd1 chaperonin HSP60            
Htatip2 oxidoreductase HIV-1 Tat interactive protein 2             
Hyal2 hyaluronidase 2 precursor             
Icam2 intercellular adhesion molecule 2             
Icoslg ICOS ligand             
Ifitm1 interferon-induced transmembrane protein 1             
Ifitm2 interferon-induced transmembrane protein 2             
Ifitm3 interferon-induced transmembrane protein 3             
Igf2r cation independent mannose-6-phosphate receptor precursor             
Igkc immunoglobulin κ chain C region             
Igsf8 immunoglobulin superfamily member 8             
Il27ra interleukin 27 receptor subunit α precursor             
Il2rg cytokine receptor common γ chain precursor             
Ildr2 immunoglobulin-like domain containing receptor 2             
Imp3 U3 small nucleolar ribonucleoprotein protein IMP3             
Inpp5a inositol polyphosphate-5-phosphatase 40 kDa             
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Irgm immunity-related GTPase family M protein  isoform 1             
Itga3 integrin α3             
Itga6 integrin α6             
Itgal integrin αL precursor             
Itgb1 integrin β1 precursor             
Itgb2 integrin β2 precursor             
Itgb4 integrin β4 isoform β4C precursor             
Itm2a integral membrane protein 2A             
Itm2b integral membrane protein 2B             
Itm2c integral membrane protein 2C isoform 1             
Jam3 junctional adhesion molecule C             
Jup junction plakoglobin             
Kalrn kalirin             
Khdrbs1 KH domain-containing RNA-binding signal transduction-associated protein 1             
Khsrp far upstream element-binding protein 2             
Kiaa0152 protein KIAA0152             
Kiaa2013 protein KIAA2013             
Kpnb1 importin subunit β1             
Kras KRas GTPase isoform 1 precursor             
Krt17 keratin, type I cytoskeletal 17             
L1cam neural cell adhesion molecule L1             
Lamp2 lysosome-associated membrane glycoprotein 2             
Lamtor1 late endosomal/lysosomal adaptor,  MAPK and MTOR activator 1             
Laptm4a lysosomal-associated transmembrane protein 4A             
Lars leucyl-tRNA synthetase, cytoplasmic             
Lass2 LAG1 longevity assurance homologue 2             
Lass5 LAG1 longevity assurance homologue 5             
Lat linker for activation of T cells             
Lat2 linker for activation of T cells family member 2             
Lbr lamin-B receptor             
Lck proto-oncogene tyrosine-protein kinase Lck isoform 3             
Ldha L-lactate dehydrogenase A chain isoform 1             
Ldhb L-lactate dehydrogenase B chain             
Ldlr low density lipoprotein receptor precursor             
Leprot leptin receptor gene-related protein             
Lgals1 galectin-1             
Lgals9 galectin-9 long isoform             
Lhfp lipoma high mobility group isoform I-C (HMGIC) fusion partner             
Lhfpl2 lipoma high mobility group isoform I-C (HMGIC) fusion partner-like 2             
Lman1 endoplasmic reticulum-Golgi intermediate compartment protein 53 precursor ERGIC53            
Lman2 vesicular integral membrane protein VIP36 precursor             
Lmbrd2 limb receptor 1 (LMBR) domain-containing  protein 2             
Lnp protein lunapark             
Lnpep leucyl-cysteinyl aminopeptidase isoform 1             
LOC 
665506 T-cell receptor β2 chain C region-like             
Lpcat1 lysophosphatidylcholine acyltransferase 1             
Lphn1 latrophilin 1             
Lrrc1 leucine rich repeat containing 1 isoform 1             
Lrrc32 leucine rich repeat containing 32             
Lrrc7 leucine rich repeat containing 7; densin-180             
Lrrfip1 leucine rich repeat flightless-interacting protein 1             
Lsr lipolysis-stimulated lipoprotein receptor             
Ly6a lymphocyte antigen 6A-2/6E-1 precursor             
Ly6c1 lymphocyte antigen 6 complex, locus C1             
Ly6c2 lymphocyte antigen 6 complex, locus C2             
Ly6e lymphocyte antigen 6 complex, locus E             
Ly9 lymphocyte antigen 9             
Lyn v-yes-1 Yamaguchi sarcoma viral related oncogene homologue             
M6pr cation-dependent mannose-6-phosphate receptor             
Magt magnesium transporter protein 1             
Man1b1 mannosidase α class 1B member 1             
Map1lc3b microtubule-associated proteins 1A/1B  light chain 3B             
March E3 ubiquitin-protein ligase membrane-associated ring finger (C3HC4) (MARCH)             
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Marcks myristoylated alanine rich C-kinase substrate             
Marcksl1 myristoylated alanine rich C-kinase substrate (MARCKS)-related protein             
Mbc2 extended synaptotagmin 1 isoform 1             
Mblac2 metallo-β-lactamase domain containing 2             
Mbp myelin basic protein             
Mcam melanoma cell adhesion molecule;  cell surface glycoprotein MUC18             
Mcoln1 mucolipin-1 isoform 2             
Mdga1 
meprin/A5 protein/PTPμ (MAM) domain-
containing glycophosphatidylinositol anchor 
protein 1 precursor  
           
Mdh2 malate dehydrogenase, mitochondrial             
Me1 NADP-dependent malic enzyme             
Metap2 methionine aminopeptidase 2             
Mfap3 microfibril-associated glycoprotein 3 precursor             
Mfap3l microfibril-associated glycoprotein 3-like precursor             
Mfsd6 major facilitator superfamily domain-containing protein 2             
Mgst2 microsomal glutathione S-transferase 2             
Mgst3 microsomal glutathione S-transferase 3             
Mki67 antigen KI-67             
Mlec malectin             
Mlstd2 fatty acyl-CoA reductase 1             
Mmp14 matrix metalloproteinase 14             
Mnf1 mitochondrial nucleoid factor 1             
Mobkl3 MPS one binder kinase activator-like 3             
Mobp myelin-associated oligodendrocyte basic protein             
Mpdu1 suppressor of Lec15             
Mpp1 55 kDa erythrocyte membrane protein             
Mpp2 membrane protein palmitoylated 2             
Mpp5 membrane-associated guanylate kinase (MAGUK) p55 subfamily member 5 isoform 1             
Mpp6 membrane-associated guanylate kinase (MAGUK) p55 subfamily member 6             
Mpst mercaptopyruvate sulfotransferase             
Mreg melanoregulin             
Mrpl12 39S ribosomal protein L12             
Mrps18a 28S ribosomal protein S18a, mitochondrial             
Mrps18b 28S ribosomal protein S18b, mitochondrial             
Ms4a1 B-lymphocyte antigen CD20             
Mtap6 microtubule-associated protein 6 STOP            
Mtch1 mitochondrial carrier homologue 1 isoform 1             
Mtch2 mitochondrial carrier homologue 2             
Mtdh lysine-rich Ceacam1 co-isolated Lyric            
Mthfd1l monofunctional C1-tetrahydrofolate synthase, mitochondrial             
Muc1 mucin 1, transmembrane             
Myct1 Myc target protein 1             
Myo1d unconventional myosin Id             
Myo1g myosin IG             
Myof myoferlin             
Napa α-soluble N-ethylmaleimide-sensitive fusion factor (NSF) attachment protein             
Nasp nuclear autoantigenic sperm protein             
Ncam1 neural cell adhesion molecule 1             
Ncam2 neural cell adhesion molecule 2             
Ncl nucleolin             
Ncstn nicastrin precursor             
Ndfip1 
neural precursor cell expressed developmentally 
downregulated protein 4 (NEDD4) family-
interacting protein 1  
           
Ndfip2 
neural precursor cell expressed developmentally 
downregulated protein 4 (NEDD4) family-
interacting protein 2  
           
Nfxl1 NF-X1-type zinc finger protein             
Nipsnap1 Nipsnap homolog 1             
Nme1 nucleoside diphosphate kinase A isoform a             
Nme2 nucleoside diphosphate kinase B             
Nnt NAD(P) transhydrogenase             
Nos3 nitric oxide synthase, endothelial             
Npc1 Niemann-Pick C1 protein precursor             
Nqo1 NAD(P)H dehydrogenase [quinone] 1             
Nr4a2 nuclear receptor subfamily 4 group A member 2             
Nras N-ras             
Nrm nurim             
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Nrp1 neuropilin-1 isoform 1 precursor             
Nrsn2 neurensin 2             
Nsddr neural stem cell-derived dendrite regulator             
Nucb1 nucleobindin-1 precursor             
Nup210 nuclear pore membrane glycoprotein 210 precursor             
Ociad1 ovarian carcinoma immunoreactive antigen (OCIA) domain-containing protein 1 isoform 1             
Orai1 calcium release-activated calcium channel  protein 1             
Osmr oncostatin M receptor             
Ostc oligosaccharyltransferase complex subunit OSTC             
Oxa1l inner membrane protein oxidase (cytochrome c) assembly 1-like (OXA1L), mitochondrial             
Oxsm 3-ocoacyl-[acyl carrier protein] synthase, mitochondrial             
P2rx4 purinergic receptor P2X,  ligand gated ion channel 4             
P4hb protein disulphide-isomerase PDI            
Pacsin3 protein kinase C and  casein kinase substrate in neurons 3             
Pag1 phosphoprotein associated with  glycosphingolipid-enriched microdomains 1             
Palm paralemmin-1             
Palm2 paralemmin-2             
Park7 protein DJ-1             
Parp1 poly [ADP ribose] polymerase 1             
Pcdh1 protocadherin 1             
Pcdh7 brain-heart protocadherin             
Pdaf placenta-derived apoptotic factor             
Pdcd1 programmed cell death protein 1 precursor             
Pde10a phosphodiesterase 10A             
Pdgfra α-type platelet-derived growth factor receptor             
Pdha1 pyruvate dehydrogenase E1 component subunit α, somatic form, mitochondrial             
Pdia3 protein disulphide-isomerase A3             
Pdia4 protein disulphide-isomerase A4             
Pdia6 protein disulphide-isomerase A6             
Pdro ragulator complex protein PDRO             
Pdzk1ip1 PDZ domain-containing 1 (PDZK1)-interacting protein 1             
Pecam1 platelet endothelial cell adhesion molecule             
Per1 period circadian homologue 1             
Pfdn5 prefoldin subunit 5             
Pfn1 profilin-1             
Pgam1 phosphoglycerate mutase 1             
Pgam5 phosphoglycerate mutase 5             
Pgd 6-phosphogluconate dehydrogenase, decarboxylating             
Pgrmc1 membrane-associated progesterone receptor component 1             
Pgrmc2 membrane-associated progesterone receptor component 2             
Phb prohibitin             
Phf8 plant homeo domain (PHD) finger protein 8             
Phgdh D-3-phosphoglycerate dehydrogenase             
Pi4k2a phosphatidylinositol 4-kinase type IIα             
Pi4k2b phosphatidylinositol 4-kinase type IIβ             
Pigk phosphatidylinositol glycan anchor biosynthesis, class K             
Pign glycophosphatidylinositol (GPI) ethanolamine phosphate transferase 1             
Pigt phosphatidylinositol glycan anchor biosynthesis, class T             
Pik3r1 phosphatidylinositol 3-kinase regulatory subunit α isoform 2             
Pip prolactin-inducable protein             
Pkm pyruvate kinase 3 isoform 2             
Pkm2 pyruvate kinase isozymes M1/M2             
Pknox1 homeobox protein PBX/knotted 1 homeobox 1 (PKNOX1)             
Pkp1 plakophilin 1             
Pkp4 plakophilin 4             
Plp2 proteolipid protein 2             
Plscr1 phospholipid scramblase 1             
Plscr3 phospholipid scramblase 3             
Plscr4 phospholipid scramblase 4             
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Plxnb2 plexin B2             
Pmp2 myelin P2 protein             
Podxl podocalyxin             
Pon3 serum paraoxonase/lactonase 3             
Por NADPH--cytochrome P450 reductase             
Ppia peptidylprolyl cis-trans isomerase A             
Ppib peptidylprolyl cis-trans isomerase B             
Ppif peptidylprolyl cis-trans isomerase, mitochondrial             
Ppp2r1a serine/threonine protein phosphatase 2A 65 kDa 
regulatory subunit A α isoform             
Praf2 prenylated Rab acceptor 1 family protein 2             
Prdx6 peroxiredoxin 6             
Preb prolactin regulatory element-binding protein             
Prg1 plasticity-related gene 1             
Prg2 plasticity-related gene 2             
Prkcsh glucosidase 2 subunit β precursor             
Prkdc DNA-dependent protein kinase catalytic subunit isoform 1             
Prnd prion-like protein doppel precursor             
Prnp major prion protein precursor             
Procr endothelial protein C receptor             
Psen1 presenilin-1 isoform 1             
Psip1 PC4 and splicing factor arginine/serine-rich 1 (SFRS1)-interacting protein             
Psmb8 proteasome subunit β type 8 precursor             
Psmc1 26S proteasome regulatory subunit 4             
Psmd11 26S proteasome non-ATPase regulatory subunit 11             
Ptbp1 polypyrimidine tract-binding protein 1 isoform a             
Ptgfrn prostaglandin F2 receptor negative regulator             
Ptgir prostacyclin receptor             
Ptk7 protein tyrosine kinase 7 isoform D precursor             
Ptplad1 3-hydroxyacyl-CoA dehydratase 3             
Ptprc receptor-type protein phosphatase C  isoform 2 precursor             
Ptprcap protein tyrosine phosphatase receptor type C-associated protein precursor             
Ptprf receptor-type protein tyrosine kinase F precursor             
Ptprn2 protein tyrosine phosphatase receptor type N2             
Ptrh2 peptidyl-tRNA hydrolase 2             
Pttg1ip pituitary tumour-transforming gene 1 protein-interacting protein precursor             
Pus1 tRNA pseudouridine synthase A             
Pvr poliovirus receptor             
Pycr pyrroline-5-carboxylate reductase 1             
Rab10 Ras-related GTP-binding protein 10             
Rab11a Ras-related protein Rab-11A             
Rab18 Ras-related protein Rab-18             
Rab1a Ras-related protein Rab-1A             
Rab1b Ras-related protein Rab-1B             
Rab1c Ras-related protein Rab-1C             
Rab2a Ras-related GTP-binding protein 2A             
Rab3a Ras-related GTP-binding protein 3A             
Rab4a Ras-related protein Rab-4A             
Rab5b Ras-related protein Rab-5B             
Rab5c Ras-related protein Rab-5C             
Rab7 Ras-related protein Rab-7A             
Rac1 Ras-related C3 botulinum toxin substrate 1             
Rac2 Ras-related C3 botulinum toxin substrate 2             
Rala RalA             
Ralb RalB             
Ran GTP-binding nuclear protein Ran             
Ranbp2 E3 SUMO-protein ligase RanBP2             
Rap1a Ras-related protein Rap-1a             
Rap1b Ras-related protein Rap-1b             
Rap2a Ras-related protein Rap-2a             
Rap2b Ras-related protein Rap-2b             
Rap2c Ras-related protein Rap-2c             
Rbm13 maintenance of killer 16 (MAK16)-like protein RBM13 isoform 1             
Rdh11 retinol dehydrogenase 11             
Reep5 receptor accessory protein 5;  deleted in polyposis 1             
Rell1 receptor expressed in lymphoid tissues  (RELT)-like 1             
Rer1 retention in endoplasmic reticulum 1 (RER1) homologue             
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Rfc2 replication factor C subunit 2             
Rftn1 raftilin             
Rfx1 MHC class II regulatory factor RFX1             
Rfx3 regulatory factor X3             
RGD 
1306271 similar to KIAA1549 protein             
RGD 
1563986 similar to RIKEN cDNA E330009J07 gene             
Rgs19 regulator of G protein signaling 19             
Rgs20 regulator of G protein signaling 20 isoform 6             
Rhbdd2 rhomboid domain-containing protein 2             
Rheb GTP-binding protein RheB             
Rhoa transforming protein RhoA             
Rhob Rho-related GTP-binding protein RhoB             
Rhoq Rho-related GTP-binding protein RhoQ             
Rnasek ribonuclease κ             
Rnf11 RING finger protein 11             
Rnh1 ribonuclease inhibitor             
Rnm1 ribonucleoside diphosphate reductase  large subunit             
Rp2h retinitis pigmentosa 2 homologue             
Rpl1 60S ribosomal protein L1             
Rpl10 60S ribosomal protein L10             
Rpl10a 60S ribosomal protein L10a             
Rpl11 60S ribosomal protein L11             
Rpl12 60S ribosomal protein L12             
Rpl13 60S ribosomal protein L13             
Rpl15 60S ribosomal protein L15             
Rpl17 60S ribosomal protein L17             
Rpl18a 60S ribosomal protein L18a             
Rpl19 60S ribosomal protein L19             
Rpl29 60S ribosomal protein L29             
Rpl3 60S ribosomal protein L3             
Rpl30 60S ribosomal protein L30             
Rpl3l 60S ribosomal protein L3-like             
Rpl4 60S ribosomal protein L4             
Rpl5 60S ribosomal protein L5             
Rpl6 60S ribosomal protein L6             
Rpl7 60S ribosomal protein L7             
Rpl7a 60S ribosomal protein L7a             
Rpl9 60S ribosomal protein L9             
Rplp0 ribosomal protein, large P0             
Rpn1 dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 1 precursor             
Rpn2 ribophorin II             
Rps11 40S ribosomal protein S11             
Rps15 40S ribosomal protein S15             
Rps15a 40S ribosomal protein S15a             
Rps16 40S ribosomal protein S16             
Rps17 40S ribosomal protein S17             
Rps19 40S ribosomal protein S19             
Rps2 40S ribosomal protein S2             
Rps20 40S ribosomal protein S20 isoform 2             
Rps23 40S ribosomal protein S23             
Rps27a 40S ribosomal protein S27a             
Rps2-ps6 ribosomal protein S2, pseudogene 6             
Rps3 40S ribosomal protein S3             
Rps3a 40S ribosomal protein S3a isoform 1             
Rps5 40S ribosomal protein S5             
Rps6 40S ribosomal protein S6             
Rps8 40S ribosomal protein S8             
Rras R-Ras             
Rras2 R-Ras2             
Rrs1 ribosome biogenesis regulatory protein homologue             
Rspry1 ring finger and SPIa and ryanodine receptor (SPRY) domain containing 1             
Rtn reticulon 1             
Rtn3 reticulon 3             
Rtn4 reticulon 4 isoform C             
S100a14 protain S100-A14             
S100a9 protein S100-A9             
Sacm1l phosphatidylinositide phosphatase SAC1             
Scamp1 secretory carrier membrane protein 1             
Scamp2 secretory carrier membrane protein 2             
Scamp3 secretory carrier membrane protein 3             
APPENDICES 
199 
 
Gene Protein name Abbr. 1 2 3 4 5 6 7 8 9 10 11 
Scamp4 secretory carrier membrane protein 4             
Scamp5 secretory carrier membrane protein 5             
Scarb1 scavanger receptor class B member 1             
Scarb2 
scavanger receptor class B member 2;  
CD36 antigen-like 2;  
lysosomal integral membrane protein II 
LIMP-II            
Scarf1 endothelial cells scavenger receptor             
Scn2a1 sodium channel voltage-gated type 2α1             
Scp2 nonspecific lipid transfer protein             
Scrib scribble isoform 3 LAP4            
Sdhd succinate dehydrogenase [ubiquinone] cytochrome b small subunit, mitochondrial             
Sec11a signal peptidase complex catalytic subunit SEC11A             
Sec22b vesicle trafficking protein Sec22b precursor             
Sec61b Protein transport protein Sec61 subunit β             
Selenbp1 selenium-binding protein 1             
Selplg selectin P ligand             
Sema4d semaphorin 4D             
Sep15 15 kDa selenoprotein precursor             
Sept6 septin 6             
Sept8 septin 8             
Serbp1 plasminogen activator inhibitor 1  RNA-binding protein isoform 1             
Serpinb4 serpin B4             
Sf1 splicing factor 1             
Sft2d1 vesicle transport protein SFT2-domain 1             
Sft2d3 vesicle transport protein SFT2-domain 3             
Sidt1 SID1 transmembrane family member 1             
Sidt2 SID1 transmembrane family member 2             
Sil1 endoplasmic reticulum chaperone SIL1 homologue (S. cerevisiae)             
Slc11a2 solute carrier family 11 (proton-coupled  divalent metal ion transporters), member 2             
Slc15a3 solute carrier family 15 member A3             
Slc16a3 monocarboxylate transporter 4             
Slc19a1 folate transporter 1             
Slc1a1 excitatory amino acid transporter 1 EAAC1            
Slc1a2 glutamate transporter 1;  excitatory amino acid transporter 2 
EAAC2;  
GLT1            
Slc1a3 glutamate and aspartate-sodium transporter GLAST            
Slc1a4 neutral amino acid transporter A             
Slc1a5 neutral amino acid transporter B             
Slc25a10 mitochondrial dicarboxylate carrier             
Slc25a13 solute carrier family 25 (mitochondrial carrier, adenine nucleotide translocator), member 13             
Slc25a32 solute carrier family 25 member 32             
Slc25a33 solute carrier family 25 member 33             
Slc25a36 solute carrier family 25 member 36             
Slc25a3 phosphate carrier protein,  mitochondrial precursor isoform A             
Slc25a5 ADP/ATP carrier protein;  adenine nucleotide translocator 2 ANT2            
Slc25a6 ADP/ATP translocase 3             
Slc26a2 sulphate transporter             
Slc2a1 solute carrier family 2  (facilitated glucose transporter), member 1             
Slc30a1 zinc transporter 1             
Slc32a1 vesicular inhibitory amino acid transporter             
Slc35b2 adenosine 3'-phospho 5'-phosphosulphate transporter 1             
Slc35e2 solute carrier family 35 member E2             
Slc38a2 solute carrier family 38 member A2             
Slc39a4 solute carrier family 39 (zinc transporter),  member 4             
Slc3a2 solute carrier family 3 member A2             
Slc43a3 solute carrier family 43 member A3             
Slc44a1 choline transporter-like 1 isoform 1             
Slc44a2 choline transporter-like 2             
Slc5a6 sodium-dependent multivitamin transporter             
Slc7a1 high affinity cationic amino acid transporter 1             
Slc7a5 solute carrier family 7 (cationic amino acid transporter, y+ system), member 5             
Slc8a1 sodium/calcium exchanger 1             
Slc8a2 sodium/calcium exchanger 2             
Slc9a6 sodium/hydrogen exchanger 6 isoform c             
Slc9a9 sodium/hydrogen exchanger 9             
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Smpd3 sphingomyelin phosphodiesterase 3             
Snap23 synaptosomal-associated protein of 23 kDa             
Snap25 synaptosomal-associated protein of 25 kDa             
Snd1 Staphylococcal nuclease domain-containing protein 1             
Soat1 sterol O-acyltransferase 1             
Sod1 superoxide dismutase [Cu-Zn]             
Sod2 superoxide dismutase [Mn], mitochondrial             
Sort1 sortilin 1             
Spcs2 signal peptidase complex subunit 2             
Spcs3 signal peptidase complex subunit 3             
Spint2 serine protease inhibitor, Kunitz type 2             
Spred1 sprouty protein with EVH-1 domain 1- related sequence             
Spred2 sprouty protein with EVH-1 domain 2- related sequence             
Spryd7 SPIa and ryanodine receptor (SPRY) domain-containing protein 7             
Src proto-oncogene tyrosine-protein kinase Src             
Srprb signal recognition particle receptor, B subunit             
St6gal1 β galactoside α 2,6 sialyltransferase 1             
Stard3nl metastatic lymph node protein 64 (MLN64)  N-terminal domain homologue             
Steap3 metalloreductase six-transmembrane  epithelial antigen of prostate 3             
Stip1 stress-induced phosphoprotein 1             
Stmn3 stathmin-like 3             
Stmn4 stathmin-like 4             
Stom stomatin; erythrocyte band 7  integral membrane protein             
Stt3a STT3, subunit of the oligosaccharyltransferase complex, homolog A (S. cerevisiae)             
Stt3b STT3, subunit of the oligosaccharyltransferase complex, homolog B (S. cerevisiae)             
Stx10 syntaxin 10             
Stx11 syntaxin 11             
Stx12 syntaxin 12             
Stx1a syntaxin 1a             
Stx1b2 syntaxin 1b2             
Stx2 syntaxin 2             
Stx4a syntaxin 4A (placental)             
Stx5a syntaxin 5 isoform 1             
Stx6 syntaxin 6             
Stx7 syntaxin 7             
Stx8 syntaxin 8             
Surf4 surfeit locus protein 4 isoform 1             
Susd3 sushi domain containing 3             
Svip small VCP/p97-interacting protein             
Sybl1 synaptobrevin-like protein 1 isoform 2             
Syne3 nesprin-3             
Syt1 synaptotagmin 1             
Syt11 synaptotagmin 11             
Syt13 synaptotagmin 13             
Syt2 synaptotagmin 2             
Syt3 synaptotagmin 3             
Syt5 synaptotagmin 5             
Syt7 synaptotagmin 7             
Taf15 TATA-binding protein-associated factor 2N             
Tap1 transporter 1, ATP-binding cassette, subfamily B             
Tbl2 transducin β-like protein 2             
Tbxa2r thromboxane A2 receptor             
Tc2n tandem C2 domains nuclear protein             
Tesc tescalcin             
Tfrc transferrin receptor             
Them6 UPF0670 protein thioesterase superfamily member 6 (THEM6) homolog precursor             
Thy1 Thy-1 membrane glycoprotein precursor             
Timm22 translocase of inner mitochondrial membrane 22             
Timm50 mitochondrial import inner membrane translocase subunit TIM50             
Timp1 metalloproteinase inhibitor 1             
Tlcd1 TRAM/LAG1/CLN8 (TLC) domain-containing protein 1             
Tloc1 translocation protein SEC62             
Tm2d2 two transmembrane domain (TM2) domain-containing protein 2 precursor             
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Tm4sf19 transmembrane 4 L six family member 19             
Tm9sf2 transmembrane 9 superfamily member 2             
Tmbim1 transmembrane BAX inhibitor motif-containing protein 1             
Tmco1 transmembrane and coiled-coil domains 1             
Tmed10 transmembrane emp24-like trafficking  protein 10 (yeast)             
Tmed1 transmembrane emp24 domain-containing  protein 1 precursor             
Tmem11 transmembrane protein 11             
Tmem115 transmembrane protein 115             
Tmem134 transmembrane protein 134 isoform 1             
Tmem168 transmembrane protein 168             
Tmem16f transmembrane protein 16F isoform 1             
Tmem173 transmembrane protein 173             
Tmem184c transmembrane protein 184C             
Tmem222 transmembrane protein 222             
Tmem33 transmembrane protein 33             
Tmem43 transmembrane protein 43             
Tmem50a transmembrane protein 50A             
Tmem50b transmembrane protein 50B             
Tmem55a transmembrane protein 55A             
Tmem55b transmembrane protein 55B             
Tmem59 transmembrane protein 59             
Tmem63a transmembrane protein 63A             
Tmem63b transmembrane protein 63B             
Tmem97 transmembrane protein 97             
Tmp3l tropomyosin α3 chain-like protein             
Tmppe transmembrane protein with metallophosphoesterase domain             
Tmx1 thioredoxin-related transmembrane protein 1             
Tmx3 protein disulphide-isomerase TMX3             
Tmx4 thioredoxin-related transmembrane protein 4             
Tnfaip2 tumour necrosis factor α-induced protein 2             
Tnfrsf10a tumour necrosis factor superfamily member 10A precursor             
Tnfrsf10b tumour necrosis factor superfamily member 10B long isoform precursor             
Tnfrsf8 tumour necrosis factor superfamily member 8             
Tomm40 probable mitochondrial import receptor subunit TOM40 homolog isoform 1             
Tomm70a translocase of outer mitochondrial membrane 70 homolog A (yeast)             
Tpbg trophoblast glycoprotein precursor             
Tpi1 triosephosphate isomerase             
Tpm3 tropomyosin α3 chain             
Traf3ip3 
tumour necrosis factor (TNF) receptor-associated 
factor 3 (TRAF3)-interacting Jun N-terminal kinase-
activating modulator  
           
Trap1 heat shock protein 75 kDa,  mitochondrial precursor             
Trappc3 trafficking protein particle complex 3 Bet3            
Trav4n-4 T cell receptor alpha variable 4N-4             
Tspan13 tetraspanin-13             
Tspan14 tetraspanin-14             
Tspan15 tetraspanin-15             
Tspan3 tetraspanin-3             
Tspan33 tetraspanin-33             
Tspan9 tetraspanin-9             
Ttyh1 tweety homolog 1             
Ttyh3 tweety homolog 3             
Tuba1a tubulin α-1A chain             
Tuba1b tubulin α-1B chain             
Tuba1c tubulin α-1C chain             
Tubb tubulin β             
Tubb2c tubulin β-2C chain             
Tufm elongation factor Tu, mitochondrial             
Txndc1/ 
Tmx1 thioredoxin-related transmembrane protein 1             
Txndc1 protein disulphide-isomerase thioredoxin domain-containing 1             
Txndc10 protein disulphide-isomerase thioredoxin domain-containing 10             
Txndc12 protein disulphide-isomerase thioredoxin domain-containing 12             
Txndc13 protein disulphide-isomerase thioredoxin domain-containing 13             
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Txndc14 protein disulphide-isomerase thioredoxin domain-containing 14             
Txndc4 protein disulphide-isomerase thioredoxin domain-containing 4             
Uba1 ubiquitin-like modifier-activating enzyme 1             
Uba52 ubiquitin A-52 residue ribosomal protein  fusion product 1             
Ubl3 ubiquitin-like protein 3 precursor             
Ubtd1 ubiquitin domain-containing 10             
Ubxd2 ubiquitin regulatory x (UBX) domain-containing protein 2             
Ugt1a7c UDP glucuronosyltransferase 1 family,  polypeptide A7C             
Upf1 regulator of nonsense transcripts 1 isoform 1             
Uqcrfs1 cytochrome b-c1 complex subunit Rieske             
Vamp1 vesicle-associated membrane protein 1; synaptobrevin 1             
Vamp2 vesicle-associated membrane protein 2; synaptobrevin 2             
Vamp3 vesicle-associated membrane protein 3; synaptobrevin 3             
Vamp4 vesicle-associated membrane protein 4; synaptobrevin 4             
Vamp5 vesicle-associated membrane protein 5; synaptobrevin 5             
Vamp7 vesicle-associated membrane protein 7; synaptobrevin 7             
Vangl1 vang-like protein 1 isoform 1             
Vcp transitional endoplasmic reticulum ATPase             
Vdac1 voltage-dependent anion-selective channel protein 1             
Vdac2 voltage-dependent anion-selective channel protein 2             
Vdac3 voltage-dependent anion-selective channel protein 3             
Vim vimentin             
Vsig8 V-set and immunoglobulin domain-containing protein 8             
Vsnl1 visinin-like protein 1 VILIP-1            
Vti1b vesicle transport through interaction with  t-SNAREs 1B             
Wdr46 WD repeat-containing protein 46             
Xpo1 exportin-1             
Xrcc6 X-ray repair cross-complementing protein 6             
Yes1 Yes non-receptor tyrosine kinase             
Ywhag 14-3-3 protein γ             
Ywhaq 14-3-3 protein θ             
Ywhaz 14-3-3 protein ζ/δ             
Zdhhc17 zinc finger, DHHC-type containing 17;  huntingtin-interacting protein 14 
DHHC17/ 
HIP14            
Zdhhc20 zinc finger, DHHC-type containing 20 DHHC20            
Zdhhc5 zinc finger, DHHC-type containing 5 DHHC5            
Zdhhc6 zinc finger, DHHC-type containing 6 DHHC6            
Zfyve28 zinc finger FYVE domain-containing protein 28             
Zgpat zinc finger, CCCH-type with G patch domain             
Zmpste24 CAAX prenyl protease 1 homologue             
Znf330 zinc finger protein 330             
Znf44 zinc finger protein 44 isoform 2             
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APPENDIX 3: RAT BRAIN ACYL-BIOTIN EXCHANGE (ABE) HITS 
APPENDIX 3.1 HITS WITH MULTIPLE UNIQUE PEPTIDES IN THE EXPERIMENTAL SAMPLE 
Proteins identified in previous mammalian proteomic studies are highlighted in green.  
Proteins which were not present in the control sample were given an arbitrary value of 0.2 
to avoid dividing by zero, similar to previous proteomic studies (Dowal et al., 2011; Roth et 
al., 2006; Yang et al., 2010).  Proteins with a ratio of less than 5 were discarded (Martin and 
Cravatt, 2009).  Abbr., abbreviation (if different from gene name); LFQ, label-free 
quantification. 
Gene Protein Abbr. 
Experiment 1 Experiment 2 
LFQ 
intensity 
ABE 
LFQ 
intensity 
Control 
Ratio 
LFQ ABE: 
Control 
LFQ 
intensity 
ABE 
LFQ 
intensity 
Control 
Ratio 
LFQ ABE: 
Control 
Abat 
4-aminobutyrate 
aminotransferase, 
mitochondrial  
482100 0.2 2410500 5595900 0.2 27979500 
Aco2 aconitate hydratase, mitochondrial  7894300 0.2 39471500 51073000 0.2 2.55E+08 
Adamts3 
A disintegrin and 
metalloproteinase with 
thrombospondin motifs 
3 precursor 
 725400 0.2 3627000    
Ak2 adenylate kinase 2, mitochondrial isoform 1  42217 0.2 211085    
Aldoa 
fructose-
bisphosphonate 
aldolase A  
2847400 0.2 14237000 1E+08 0.2 5.02E+08 
Aldoc 
fructose-
bisphosphonate 
aldolase C  
3773300 0.2 18866500 42040000 0.2 2.1E+08 
Arf3 ADP-ribosylation  factor 3  545520 0.2 2727600    
Atp1a1 
sodium/potassium-
transporting ATPase 
subunit α1     
9444100 0.2 47220500 
Atp1a3 
sodium/potassium-
transporting ATPase 
subunit α3  
2066500 412570 5.008847 2.17E+08 0.2 1.08E+09 
Atp5a1 ATP synthase subunit α, mitochondrial  1496700 0.2 7483500    
Atp6v1b2 V-type proton ATPase subunit B, brain isoform  322540 0.2 1612700    
Camk2a 
calcium/calmodulin-
dependent protein 
kinase type II α chain  
537040 0.2 2685200    
Camk2b 
calmodulin-dependent 
protein kinase II  
isoform βM     
7248700 0.2 36243500 
Cfl1 cofilin-1  1023800 0.2 5119000 49261000 0.2 2.46E+08 
Ckb creatine kinase B-type  22954000 0.2 1.15E+08 1.66E+08 0.2 8.28E+08 
Ckmt1 creatine kinase U-type, mitochondrial     1346400 0.2 6732000 
Cltc clathrin heavy chain 1     10668000 0.2 53340000 
Cnp 2,3-cyclic nucleotide phosphodiesterase  2106800 0.2 10534000    
Crmp1 dihydropyrimidinase-related protein 1  78921 0.2 394605    
Cs citrate synthase, mitochondrial     11948000 0.2 59740000 
Dbn1 drebrin isoform A     11220000 0.2 56100000 
Dlg4 
disks large homolog 4; 
post-synaptic density 
protein of 95 kDa 
PSD-95 493370 0.2 2466850    
Dnajc5 
DnaJ homolog subfamily 
C member 5;  
cysteine string protein 
CSP    38940000 0.2 1.95E+08 
Dnm1 dynamin-1 isoform 5  751820 0.2 3759100    
Dpysl2 dihydropyrimidinase-related protein 2  1254700 0.2 6273500 3.4E+08 0.2 1.7E+09 
Eef1a2 elongation factor 1α2  1508600 0.2 7543000    
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Gene Protein Abbr. 
Experiment 1 Experiment 2 
LFQ 
intensity 
ABE 
LFQ 
intensity 
Control 
Ratio 
LFQ ABE: 
Control 
LFQ 
intensity 
ABE 
LFQ 
intensity 
Control 
Ratio 
LFQ ABE: 
Control 
Eno2 γ-enolase  8781700 0.2 43908500 1.08E+08 0.2 5.39E+08 
Gap43 neuromodulin  7199700 0.2 35998500 59052000 0.2 2.95E+08 
Gapdh 
glyceraldehyde-3-
phosphate 
dehydrogenase     
2.99E+08 0.2 1.49E+09 
Gda guanine deaminase  4129500 0.2 20647500    
Gdi1 Rab-GDP dissociation 
inhibitor α  3899300 0.2 19496500 17001000 0.2 85005000 
Glul glutamine synthetase     35828000 0.2 1.79E+08 
Gnao1 
guanine nucleotide-
binding protein Gαo 
isoform α2  
10887000 0.2 54435000 47540000 0.2 2.38E+08 
Gnaq 
guanine nucleotide-
binding protein Gαq 
isoform α  
3197800 0.2 15989000    
Gnb1 
guanine nucleotide-
binding protein 
G(I)/G(S)/G(T) subunit 
β1 
 463150 0.2 2315750    
Got1 
aspartate 
aminotransferase, 
cytoplasmic;  
glutamate oxaloacetate 
transaminase 
 452090 0.2 2260450    
Gpm6a glycoprotein m6a  3522000 0.2 17610000 85690000 0.2 4.28E+08 
Gprin1 
G protein-regulated 
inducer of neurite 
outgrowth 1     
20692000 0.2 1.03E+08 
Gstm5 glutathione-S-
transferase μ5  145380 0.2 726900 14215000 0.2 71075000 
Hsp90aa1 heat shock protein 
HSP90α     16453000 0.2 82265000 
Kcnk12 potassium channel subfamily K member 12  39928 0.2 199640    
Khsrp far upstream element-binding protein 2     30141000 0.2 1.51E+08 
Kpnb1 importin subunit β1     1695000 0.2 8475000 
Ldha L-lactate dehydrogenase A-chain  2311700 0.2 11558500 17208000 0.2 86040000 
Ldhb L-lactate dehydrogenase B chain  10237000 0.2 51185000    
Ldhc L-lactate dehydrogenase B chain     23133000 0.2 1.16E+08 
Map1a microtubule-associated protein 1A     2.73E+08 0.2 1.36E+09 
Map2 
microtubule-associated 
protein 2 isoform 
MAP2x     
9511500 0.2 47557500 
Mdh1 malate dehydrogenase, cytoplasmic  1080800 0.2 5404000 19940000 0.2 99700000 
Mdh2 malate dehydrogenase, mitochondrial  3508000 0.2 17540000 12105000 0.2 60525000 
Mt1a metallothionein-1     584640 0.2 2923200 
Mt3 metallothionein-3     454700 0.2 2273500 
Ncdn neurochondrin  948540 0.2 4742700 17582000 0.2 87910000 
Ndrg2 N-Myc downstream regulated gene 2     12000000 0.2 60000000 
Ndufs1 
NADH-ubiquinone 
oxidoreductase 75 kDa 
subunit, mitochondrial  
1038100 0.2 5190500 4677500 0.2 23387500 
Ndufv2 
NADH dehydrogenase 
flavoprotein 2, 
mitochondrial     
7148700 0.2 35743500 
Nsf 
vesicle-fusing ATPase; 
N-ethylmaleimide-
sensitive fusion protein  
717510 0.2 3587550    
Nyw1 ischaemia related factor NYW-1  1029300 0.2 5146500    
Ola1 Obg-like ATPase 1     1901100 0.2 9505500 
Palm paralemmin isoform CRA_a     9222200 0.2 46111000 
Park7 protein DJ-1  1400300 0.2 7001500    
Pebp1 
phosphatidyl-
ethanolamine-binding 
protein 1  
5347600 0.2 26738000 23406000 0.2 1.17E+08 
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Gene Protein Abbr. 
Experiment 1 Experiment 2 
LFQ 
intensity 
ABE 
LFQ 
intensity 
Control 
Ratio 
LFQ ABE: 
Control 
LFQ 
intensity 
ABE 
LFQ 
intensity 
Control 
Ratio 
LFQ ABE: 
Control 
Pgk1 phosphoglycerate kinase 1  2498200 0.2 12491000 22283000 0.2 1.11E+08 
Pkm2 
pyruvate kinase 
isozymes M1/M2 
isoform M1  
2891100 437250 6.612007 2.75E+08 0.2 1.38E+09 
Plp1 myelin proteolipid protein  3315000 0.2 16575000 3.34E+08 0.2 1.67E+09 
Ppid peptidyl-prolyl cis-trans isomerase     9235800 0.2 46179000 
Ppp1cc 
serine/threonine 
protein phosphatase 
PP1γ catalytic subunit 
isoform γ2 
 396150 0.2 1980750    
Ppp2r1a protein phosphatase regulatory subunit 2A     7728500 0.2 38642500 
Ppp3ca 
serine/threonine 
protein phosphatase 2B 
catalytic subunit α 
isoform isoform 1 
 90627 0.2 453135    
Prdx2 peroxiredoxin-2  899260 0.2 4496300    
Prdx6 peroxiredoxin-6  154320 0.2 771600 47680000 0.2 2.38E+08 
Pygb phosphoglycerase  265320 0.2 1326600    
Rab1 Ras-related protein  Rab-1A  309210 0.2 1546050    
Rhob Rho-related GTP-binding protein RhoB     8172400 0.2 40862000 
Rtn1 reticulon-1  431750 0.2 2158750    
Scrn1 secernin-1  455160 0.2 2275800 7791400 0.2 38957000 
Sdhb 
succinate 
dehydrogenase  
iron-sulphur subunit, 
mitochondrial 
 108470 0.2 542350    
Sfrs3 splicing factor, arginine/serine-rich 3     46575000 0.2 2.33E+08 
Slc1a2 
excitatory amino acid 
transporter 2 isoform 
Glt1 
EAAT2    46687000 0.2 2.33E+08 
Slc25a4 ADP/ATP translocase 1  126470 0.2 632350    
Snap25 
synaptosomal-
associated protein of  
25 kDa  
1092200 0.2 5461000 57362000 0.2 2.87E+08 
Snap91 
clathrin coat assembly 
protein AP180  
long isoform     
4719700 0.2 23598500 
Stip1 stress-induced phosphoprotein 1     3140800 0.2 15704000 
Stx1a syntaxin-1A  1577000 0.2 7885000 23372000 0.2 1.17E+08 
Stx1b syntaxin-1B  5869800 0.2 29349000 1.33E+08 0.2 6.63E+08 
Suv39h1 
histone lysine  
N-methyltransferase 
SUV39H1  
368700 0.2 1843500    
Syt1 synaptotagmin 1  1108500 0.2 5542500 27543000 0.2 1.38E+08 
Tpi1 triosephosphate isomerase  1961300 0.2 9806500 72368000 0.2 3.62E+08 
Trappc3 
trafficking protein 
particle complex 
subunit C3 
Bet3    28084000 0.2 1.4E+08 
Ttyh1 tweety homolog 1  775360 0.2 3876800    
Tuba4a tubulin α4A chain     51013000 0.2 2.55E+08 
Tubb2a tubulin β2A chain     1.14E+09 0.2 5.7E+09 
Tubb3 tubulin β3 chain  1249300 0.2 6246500 22050000 0.2 1.1E+08 
Tubb4 tubulin β4     13458000 0.2 67290000 
Tubb5 tubulin β5 chain  isoform 1  5631900 0.2 28159500 59683000 0.2 2.98E+08 
Ubqln2 ubiquilin 2     1420100 0.2 7100500 
Uchl1 
ubiquitin  
carboxy-terminal 
hydrolase enzyme L1  
259250 0.2 1296250 47077000 0.2 2.35E+08 
Vamp2 
vesicle-associated 
membrane protein 2; 
synaptobrevin 2     
73143000 0.2 3.66E+08 
Vcp 
transitional 
endoplasmic reticulum 
ATPase  
451070 0.2 2255350 12268000 0.2 61340000 
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Gene Protein Abbr. 
Experiment 1 Experiment 2 
LFQ 
intensity 
ABE 
LFQ 
intensity 
Control 
Ratio 
LFQ ABE: 
Control 
LFQ 
intensity 
ABE 
LFQ 
intensity 
Control 
Ratio 
LFQ ABE: 
Control 
Wisp1 
WNT1-inducible 
signaling pathway 
protein 1  
34670000 0.2 1.73E+08    
Ywhae 14-3-3 protein ε  343230 0.2 1716150 2045000 0.2 10225000 
Ywhag 14-3-3 protein γ     6116700 0.2 30583500 
Ywhah 14-3-3 protein ε     18347000 0.2 91735000 
Ywhaq 14-3-3 protein θ  188190 0.2 940950 1.31E+08 0.2 6.54E+08 
Ywhaz 14-3-3 protein ζ/δ  1284800 0.2 6424000 2E+08 0.2 9.99E+08 
 
APPENDIX 3.2 HITS WITH A SINGLE UNIQUE PEPTIDE IN THE EXPERIMENTAL SAMPLE 
Proteins identified in previous mammalian proteomic studies are highlighted in green.  
Proteins which were not present in the control sample were given an arbitrary value of 0.2 
to avoid dividing by zero, similar to previous proteomic studies (Dowal et al., 2011; Roth et 
al., 2006; Yang et al., 2010).  Proteins with a ratio of less than 5 were discarded (Martin and 
Cravatt, 2009).  Abbr., abbreviation (if different from gene name); LFQ, label-free 
quantification. 
Gene Protein Abbr. 
Experiment 1 Experiment 2 
LFQ 
intensity 
ABE 
LFQ 
intensity 
Control 
Ratio 
LFQ ABE: 
Control 
LFQ 
intensity 
ABE 
LFQ 
intensity 
Control 
Ratio 
LFQ ABE: 
Control 
Actbl2 actin β-like 2     2.8E+08 0.2 1.4E+09 
Actg2 actin, α skeletal muscle  1168700 0.2 5843500    
Akt2 RACβ serine/threonine protein kinase  1248400 0.2 6242000    
Amph amphiphysin     1711500 0.2 8557500 
Ap2b1 AP-2 complex subunit 
β isoform 2  98662 0.2 493310    
Apoa5 apolipoprotein A-V     62751000 0.2 3.14E+08 
Arghdia Rho GDP-dissociation inhibitor 1  60284 0.2 301420    
Atp1a2 
sodium/potassium 
transporting ATPase 
subunit α2     
3328000 0.2 16640000 
Atp1b1 
sodium/potassium-
transporting ATPase 
subunit β1  
1003000 0.2 5015000 8045600 0.2 40228000 
Atp1b2 
sodium/potassium-
transporting ATPase 
subunit β2  
687110 0.2 3435550    
Avp 
vasopressin-
neurophysin  
2-copeptin  
313260 0.2 1566300    
B3galt2 
UDP-GlcNAc:βGal  
β-1,3,-N-acetylglucos- 
aminyl-transferase 
polypeptide 2 
    540510 0.2 2702550 
B3gnt6 
UDP-GlcNAc:βGal  
β-1,3,-N-acetylglucos- 
aminyl-transferase 6     
2226100 0.2 11130500 
Bcat1 
branched-chain-amino-
acid transferase, 
cytosolic  
228670 0.2 1143350    
Bhlhb9 basic  helix-loop-helix b9  7886700 0.2 39433500    
Bub1b 
PREDICTED:  
mitotic checkpoint 
serine/threonine-
protein kinase BUB1β 
 9368100 0.2 46840500    
Camkv 
calmodulin kinase-like 
vesicle-associated 
protein     
3359200 0.2 16796000 
Car2 carbonic anhydrase 2     942210 0.2 4711050 
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Gene Protein Abbr. 
Experiment 1 Experiment 2 
LFQ 
intensity 
ABE 
LFQ 
intensity 
Control 
Ratio 
LFQ ABE: 
Control 
LFQ 
intensity 
ABE 
LFQ 
intensity 
Control 
Ratio 
LFQ ABE: 
Control 
Cc2d2b 
PREDICTED:  
coiled-coil and C2 
domain-containing 
protein 2A-like 
 466000 0.2 2330000    
Cct2 T-complex protein 1  
subunit β  60698 0.2 303490    
Cdc42 cell division control protein 42 isoform 1     477850 0.2 2389250 
Cetn4 centrin 4  456830 0.2 2284150    
Chd2 
chromodomain 
helicase DNA-binding 
protein 2  
58531 0.2 292655    
Crmp1 dihydropyrimidinase-related protein 1     3242400 0.2 16212000 
Cs citrate synthase, mitochondrial  75932 0.2 379660    
Csrp2 cysteine- and glycine-rich protein 2  29752 0.2 148760    
Cttnbp2 cortactin-binding protein 2     3545700 0.2 17728500 
Dbn1 drebrin isoform A  41923 0.2 209615    
Ddb2 damage specific DNA binding protein 2  685390 0.2 3426950 18981000 0.2 94905000 
Defb11 β-defensin 11  4049300 0.2 20246500    
Dgkb diacylglycerol kinase β  1623600 0.2 8118000    
Dnajc5 
DnaJ homolog 
subfamily C member 5;  
cysteine string protein 
CSP 231860 0.2 1159300    
Dot1l 
histone-lysine  
N-methyltransferase,  
H3 lysine-79 specific  
458560 0.2 2292800    
Dync1h1 cytoplasmic dynein 1  heavy chain 1  348530 0.2 1742650    
Eef1a2 elongation factor 1α2     24199000 0.2 1.21E+08 
Elmo1 engulfment and  cell motility 1     999450 0.2 4997250 
Erbb4 
receptor  
tyrosine-protein kinase 
erb-B4 isoform 1  
549400 0.2 2747000    
Fabp7 fatty acid-binding protein, brain  419510 0.2 2097550    
Fam187a 
Ig-like V-type domain-
containing protein 
FAM187A precursor  
1588100 0.2 7940500    
Fam78a PREDICTED:  protein FAM78A-like  67041 0.2 335205    
Fbn1 fibrillin-1  475350 0.2 2376750 43778000 0.2 2.19E+08 
Fcgbp Fc fragment of IgG  binding protein  1636200 0.2 8181000    
Frmd6 FERM domain containing 6     567230 0.2 2836150 
Fxyd1 phospholemman     2746400 0.2 13732000 
Gdi2 Rab-GDP dissociation 
inhibitor β  348470 0.2 1742350    
Glo1 lactoylglutathione lyase  142800 0.2 714000    
Glul glutamine synthetase  516980 0.2 2584900    
Gmfb glia maturation  
factor β  37686 0.2 188430    
Got2 
aspartate 
aminotransferase, 
mitochondrial  
864330 0.2 4321650    
Gpm6b neuronal membrane glycoprotein M6-b     3147000 0.2 15735000 
Gpr135 probable G-protein coupled receptor 135  8776.8 0.2 43884    
Gstm1 glutathione  S-transferase μ1     11094000 0.2 55470000 
Henmt1 small RNA  2'-O-methyltransferase     12169000 0.2 60845000 
Hhip hedgehog-interacting protein precursor     14104000 0.2 70520000 
Hist1h1b histone cluster 1, h1b  1376200 0.2 6881000    
Hk1 hexokinase 1  132280 0.2 661400 10276000 0.2 51380000 
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Gene Protein Abbr. 
Experiment 1 Experiment 2 
LFQ 
intensity 
ABE 
LFQ 
intensity 
Control 
Ratio 
LFQ ABE: 
Control 
LFQ 
intensity 
ABE 
LFQ 
intensity 
Control 
Ratio 
LFQ ABE: 
Control 
Hsp90aa1 heat shock protein 
HSP90α  136080 0.2 680400    
Hsp90ab1 heat shock protein 
HSP90β  1072300 0.2 5361500    
Hspa1l heat shock  70 kDa protein 1L     1845500 0.2 9227500 
Hspa4 heat shock  70 kDa protein 4  69975 0.2 349875    
Hspa8 heat shock cognate  71 kDa protein  78262 0.2 391310 7078200 0.2 35391000 
Il18rap interleukin 18 receptor accessory protein  70379 0.2 351895    
Inpp1 
inositol 
polyphosphate-1-
phosphatase  
53260 0.2 266300    
Kcnh2 
potassium voltage-
gated channel 
subfamily H member 2     
1688000 0.2 8440000 
Kcnma1 
calcium-activated 
potassium channel 
subunit α1 isoform 3  
43096000 0.2 2.15E+08    
Kcnq5l 
PREDICTED: potassium 
voltage-gated channel 
subfamily KQT member 
5 isoform 1 
 40533000 0.2 2.03E+08    
Kcp 
PREDICTED: 
kielin/chordin-like 
protein-like  
44652000 0.2 2.23E+08    
Kif24 PREDICTED: kinesin family member 24  55480 0.2 277400    
Kpnb1 importin subunit β1  31994 0.2 159970    
Kras KRas isoform 2A  161670 0.2 808350    
Krit1 Krev interaction trapped protein 1  9605600 0.2 48028000 45837000 0.2 2.29E+08 
Krtap31-1 keratin associated protein 31-1  23053 0.2 115265    
Limk1 LIM domain kinase 1     374810 0.2 1874050 
LOC 
100361349 
hypothetical protein 
LOC100361349  302090 0.2 1510450    
LOC 
682206 
PREDICTED: LOW 
QUALITY PROTEIN:  
zinc finger protein 91  
2213400 0.2 11067000    
LOC 
683430 
PREDICTED: BTB/POZ 
domain-containing 
protein KCTD8-like     
3966600 0.2 19833000 
LOC 
683788 fascin     546030 0.2 2730150 
Lrit3 
PREDICTED:  
leucine-rich repeat, 
immunoglobulin-like 
domain and 
transmembrane 
domain-containing  
protein 3-like 
 478750 0.2 2393750    
Lrrc4b leucine-rich repeat-containing protein 4B  59693000 0.2 2.98E+08    
Map1a microtubule-associated protein 1A  19597 0.2 97985    
Map2 
microtubule-associated 
protein 2  
isoform MAP2x  
35219 0.2 176095    
Mog 
myelin 
oligodendrocyte 
glycoprotein  
53076 0.2 265380    
Mreg melanoregulin     347000 0.2 1735000 
Mrpl47 mitochondrial ribosomal protein L47  2238000 0.2 11190000    
Mt-co2 cytochrome c oxidase subunit 2  193660 0.2 968300    
Muc5b PREDICTED: mucin-5B  46493 0.2 232465    
Mug1 murinoglobulin-1 isoform 1  19117 0.2 95585    
Napg 
N-ethylmaleimide-
sensitive factor 
attachment protein γ     
2119600 0.2 10598000 
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Gene Protein Abbr. 
Experiment 1 Experiment 2 
LFQ 
intensity 
ABE 
LFQ 
intensity 
Control 
Ratio 
LFQ ABE: 
Control 
LFQ 
intensity 
ABE 
LFQ 
intensity 
Control 
Ratio 
LFQ ABE: 
Control 
Ncam1 neural cell adhesion molecule  8305.3 0.2 41526.5    
Ndrg2 N-Myc downstream regulated gene 2  767790 0.2 3838950    
Ndufv2 
NADH dehydrogenase 
flavoprotein 2, 
mitochondrial  
26271 0.2 131355    
Nell1 protein kinase C-binding protein NELL1  226090 0.2 1130450    
Nfxl1 
nuclear transcription 
factor, X-box  
binding-like 1  
922770 0.2 4613850    
Nrg1 neuregulin β1a  97871 0.2 489355    
Nsf 
vesicle-fusing ATPase;  
N-ethylmaleimide 
sensitive factor     
4773900 0.2 23869500 
Nup160 nucleoporin 160  64025 0.2 320125    
Pafah1b2 
platelet-activating 
factor acetylhydrolase 
IB subunit β2  
25989 0.2 129945 2223900 0.2 11119500 
Pdcd6ip programmed cell death 6-interacting protein     800850 0.2 4004250 
Pde4dip phosphodiesterase 4D interacting protein     383080 0.2 1915400 
Pdia3 protein disulphide isomerase A3     1550900 0.2 7754500 
Pdia6 protein disulphide isomerase A6     816050 0.2 4080250 
Pgam1 phosphoglycerate mutase 1     7134900 0.2 35674500 
Pgd 
6-phosphogluconate 
dehydrogenase, 
decarboxylating  
4142800 0.2 20714000    
Phgdh D-3-phosphglycerate dehydrogenase     2051200 0.2 10256000 
Pof1b premature ovarian failure 1B     170410 0.2 852050 
Ppia peptidyl-prolyl  cis-trans isomerase A  1925100 0.2 9625500    
Ppid 40 kDa peptidyl-prolyl cis-trans isomerase  312450 0.2 1562250    
Ppm1e protein phosphatase 1E  127230 0.2 636150 887270 0.2 4436350 
Prdx4 peroxiredoxin 4  126070 0.2 630350    
Prl3a1 prolactin-like protein H  66941 0.2 334705    
Pygb brain glycogen phosphorylase     866730 0.2 4333650 
Rab39 Ras oncogene family member RAB39  261740 0.2 1308700    
Rab3d GTP-binding protein Rab-3D  43974 0.2 219870    
Rac1 
ras-related C3 
botulinum toxin 
substrate 1  
118040 0.2 590200    
Rap1gds1 
RAP1 GDP-GTP 
dissociation  
stimulator 1  
23536 0.2 117680    
Rap2a RAP2A-like protein  98560 0.2 492800    
Rap2b Ras-related protein 2B  718920 0.2 3594600    
Rasgrp4 Ras guanyl-releasing  protein 4  16621 0.2 83105    
RGD 
1565117 
PREDICTED:  
40S ribosomal protein 
S26-like  
113730 0.2 568650    
Rhob Rho-related GTP-binding protein RhoB  435630 0.2 2178150    
Rps5 40S ribosomal  protein S5     2901600 0.2 14508000 
Sept10 septin-10  29590 0.2 147950    
Sept9 septin 9 isoform 1     25157000 0.2 1.26E+08 
Sh3gl2 endophilin-A1     67760000 0.2 3.39E+08 
Slc1a2 
excitatory amino acid 
transporter 2  
isoform GLT-1A 
EAAT2 959390 0.2 4796950    
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Gene Protein Abbr. 
Experiment 1 Experiment 2 
LFQ 
intensity 
ABE 
LFQ 
intensity 
Control 
Ratio 
LFQ ABE: 
Control 
LFQ 
intensity 
ABE 
LFQ 
intensity 
Control 
Ratio 
LFQ ABE: 
Control 
Slc1a3 
excitatory amino acid 
transporter 1  
isoform GLAST-1 
EAAT1 82804 0.2 414020    
Slc25a3 
phosphate carrier 
protein, mitochondrial 
isoform 2 precursor     
6941200 0.2 34706000 
Slc25a31 
PREDICTED:  
ADP/ATP translocase  
4-like     
3116600 0.2 15583000 
Slc44a4 choline transporter-like protein 4  99061 0.2 495305    
Spy synaptophysin  1050900 0.2 5254500    
Sri sorcin  30451 0.2 152255    
Srprb 
signal recognition 
particle receptor,  
B subunit  
177960 0.2 889800    
Stx12 syntaxin 12  174410 0.2 872050    
Stxbp1 
syntaxin-binding 
protein 1 isoform 2; 
Munc18  
35641 0.2 178205    
Syp synaptophysin     3448900 0.2 17244500 
Syt2 synaptotagmin-2  22717 0.2 113585    
Tecr trans-2,3,-enoyl-CoA reductase     3250400 0.2 16252000 
Tmco5b 
PREDICTED: 
transmembrane and 
coiled-coil domain-
containing protein 5B 
 116670 0.2 583350    
Tom3 tropomyosin α3 chain isoform 2  13697 0.2 68485    
Tomm70a 
mitochondrial import 
receptor subunit 
TOM70     
659410 0.2 3297050 
Tpm3 tropomyosin α3 chain isoform 1     4468000 0.2 22340000 
Tppp tubulin polymerisation promoting protein  35743 0.2 178715    
Tuba1a tubulin α1A chain     14442000 0.2 72210000 
Tubb2a tubulin β2A chain  45802000 0.2 2.29E+08    
Tubb2b tubulin β2B chain  202440 0.2 1012200 4040600 0.2 20203000 
Tubb2c tubulin β2C chain  1461700 0.2 7308500 1.52E+08 0.2 7.58E+08 
Tubb4 tubulin β4  307200 0.2 1536000    
Tubb6 tubulin β6     3071900 0.2 15359500 
Txn1 thioredoxin  886420 0.2 4432100    
Usp5 ubiquitin-specific peptidase 5  105840 0.2 529200    
Vamp1 
vesicle-associated 
membrane protein 1; 
synaptobrevin 1  
471800 0.2 2359000    
Vamp2 
vesicle-associated 
membrane protein 2; 
synaptobrevin 2  
1518900 0.2 7594500    
Ywhag 14-3-3 protein γ  59213 0.2 296065    
Zfp438 zinc finger protein 438     29177000 0.2 1.46E+08 
Zfp790 zinc finger protein 790  58494 0.2 292470    
Zmym6 zinc finger,  MYM-type 6  75237 0.2 376185    
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APPENDIX 4: RAT BRAIN ACYL-RESIN-ASSISTED CAPTURE (ACYL-RAC) HITS 
APPENDIX 4.1 HITS WITH MULTIPLE UNIQUE PEPTIDES IN THE EXPERIMENTAL SAMPLE 
Proteins identified in previous mammalian proteomic studies are highlighted in green.  
Proteins which were not present in the control sample were given an arbitrary value of 0.2 
to avoid dividing by zero, similar to previous proteomic studies (Dowal et al., 2011; Roth et 
al., 2006; Yang et al., 2010).  Proteins with a ratio of less than 5 were discarded (Martin and 
Cravatt, 2009).  Abbr., abbreviation (if different from gene name); LFQ, label-free 
quantification. 
Gene Protein Abbr. 
Experiment 1 Experiment 2 
LFQ 
intensity 
ABE 
LFQ 
intensity 
Control 
Ratio 
LFQ ABE: 
Control 
LFQ 
intensity 
ABE 
LFQ 
intensity 
Control 
Ratio 
LFQ ABE: 
Control 
Aco2 aconitate hydratase, mitochondrial     9477000 0.2 47385000 
Aldoa fructose-bisphosphate aldolase A  11648000 0.2 58240000    
Aldoc 
fructose-
bisphosphonate 
aldolase C     
9539900 0.2 47699500 
Amph amphiphysin     5547700 0.2 27738500 
Arpc3 actin related protein 2/3 complex subunit 3  228730 0.2 1143650    
Atp1a1 
sodium/potassium 
transporting ATPase  
subunit α1     
8810300 0.2 44051500 
Atp1a2 
sodium/potassium 
transporting ATPase  
subunit α2     
11684000 0.2 58420000 
Atp1a3 
sodium/potassium 
transporting ATPase  
subunit α3     
1.98E+08 0.2 9.9E+08 
Atp1b2 
sodium/potassium 
transporting ATPase  
subunit β2  
2246900 0.2 11234500    
Atp5a1 ATP synthase subunit 
α, mitochondrial     11487000 0.2 57435000 
Atp5b ATP synthase subunit 
β, mitochondrial     2137300 0.2 10686500 
Ccdc84 
PREDICTED: coiled-coil 
domain-containing 
protein 84-like     
1708700 0.2 8543500 
Cfl1 cofilin-1     60346000 0.2 3.02E+08 
Ckb creatine kinase B-type     4.59E+08 39747000 11.54251 
Cltc clathrin heavy chain 1     28208000 0.2 1.41E+08 
Dnm1 dynamin-1 isoform 1     689720 0.2 3448600 
Dpysl2 dihydropyrimidinase-related protein 2     2.03E+08 0.2 1.02E+09 
Eef1a1 elongation factor 1α 1     7635000 0.2 38175000 
Eno2 γ-enolase     3.2E+08 0.2 1.6E+09 
Gap43 neuromodulin  29902000 0.2 1.5E+08 87821000 0.2 4.39E+08 
Gapdh 
glyceraldehyde-3-
phosphate 
dehydrogenase     
2.53E+08 0.2 1.26E+09 
Gdi1 Rab-GDP dissociation 
inhibitor α     5482600 0.2 27413000 
Gnao1 
guanine nucleotide-
binding protein G(o) 
subunit α isoform α2     
27569000 0.2 1.38E+08 
Gpm6a glycoprotein m6a     69799000 0.2 3.49E+08 
Hsp90aa1 heat shock protein 
HSP90α     76342000 3223500 23.68295 
Hsp90ab1 heat shock protein 
HSP90β     13789000 0.2 68945000 
Hspa8 heat shock cognate  71 kDa protein     46962000 0.2 2.35E+08 
Khsrp far upstream element binding protein 2     23951000 0.2 1.2E+08 
Kpnb1 importin subunit β1     5954100 0.2 29770500 
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Gene Protein Abbr. 
Experiment 1 Experiment 2 
LFQ 
intensity 
ABE 
LFQ 
intensity 
Control 
Ratio 
LFQ ABE: 
Control 
LFQ 
intensity 
ABE 
LFQ 
intensity 
Control 
Ratio 
LFQ ABE: 
Control 
Ldha L-lactate dehydrogenase A chain     11049000 0.2 55245000 
Ldhb L-lactate dehydrogenase B chain     16062000 0.2 80310000 
LOC 
685110 
hypothetical protein 
LOC685110  39522 0.2 197610    
Map1a microtubule-associated protein 1A     49814000 0.2 2.49E+08 
Map2 
microtubule-associated 
protein 2 isoform 
MAP2x     
2242900 0.2 11214500 
Mbp myelin basic protein  isoform 1  6542300 0.2 32711500    
Mdh1 malate dehydrogenase, cytoplasmic     16848000 0.2 84240000 
Ncam1 neural cell adhesion molecule     9478900 0.2 47394500 
Ndrg2 N-Myc downstream regulated gene 2  4581300 0.2 22906500    
Palm paralemmin  11171000 0.2 55855000    
Pkm2 
pyruvate kinase 
isozymes M1/M2 
isoform M1     
1.2E+08 0.2 6.01E+08 
Plp1 myelin proteolipid protein     1.84E+08 0.2 9.22E+08 
Ppp2r1a protein phosphatase 2 regulatory subunit A     53305000 0.2 2.67E+08 
Prdx6 peroxiredoxin-6  5977100 0.2 29885500    
Sh3gl2 endophilin-A1     21838000 0.2 1.09E+08 
Slc1a2 
excitatory amino acid 
transporter 2  
GLT1 subunit 
EAAT2    79536000 0.2 3.98E+08 
Slc25a5 ADP/ATP translocase 2     9167600 0.2 45838000 
Slc34a2 
sodium-dependent 
phosphate transport  
protein 2B     
112260 0.2 561300 
Snap25 
synaptosomal-
associated protein of 
25 kDa     
35541000 0.2 1.78E+08 
Snap91 
clathrin coat assembly 
protein AP180  
long isoform     
1920600 0.2 9603000 
Spna2 αII spectrin     82291000 1723200 47.75476 
Stip1 stress-induced phosphoprotein 1     28265000 0.2 1.41E+08 
Stx1a syntaxin-1A     6144500 0.2 30722500 
Syx1b syntaxin-1B     82513000 0.2 4.13E+08 
Tpi1 triosephosphate isomerase     31995000 0.2 1.6E+08 
Tuba4a tubulin α4A chain     1.07E+08 0.2 5.35E+08 
Tubb2a tubulin β2A chain     6.91E+08 0.2 3.46E+09 
Tubb5 tubulin β5 chain isoform 1     1.61E+08 0.2 8.03E+08 
Uba1 ubiquitin-like modifier activating enzyme 1     1036600 0.2 5183000 
Ube2d3 ubiquitin-conjugating enzyme E2 D3  1204200 0.2 6021000    
Vamp2 
vesicle-associated 
membrane protein 2; 
synaptobrevin 2  
3591900 0.2 17959500 28661000 0.2 1.43E+08 
Ywhae 14-3-3 protein ε     23302000 0.2 1.17E+08 
Ywhah 14-3-3 protein ε     10310000 0.2 51550000 
Ywhaz 14-3-3 protein ζ/δ     1.1E+08 0.2 5.49E+08 
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APPENDIX 4.2 HITS WITH A SINGLE UNIQUE PEPTIDE IN THE EXPERIMENTAL SAMPLE 
Proteins identified in previous mammalian proteomic studies are highlighted in green.  
Proteins which were not present in the control sample were given an arbitrary value of 0.2 
to avoid dividing by zero, similar to previous proteomic studies (Dowal et al., 2011; Roth et 
al., 2006; Yang et al., 2010).  Proteins with a ratio of less than 5 were discarded (Martin and 
Cravatt, 2009).  Abbr., abbreviation (if different from gene name); LFQ, label-free 
quantification. 
Gene Protein Abbr. 
Experiment 1 Experiment 2 
LFQ 
intensity 
ABE 
LFQ 
intensity 
Control 
Ratio LFQ 
ABE: 
Control 
LFQ 
intensity 
ABE 
LFQ 
intensity 
Control 
Ratio 
LFQ ABE: 
Control 
Ak2 
adenylate kinase 2, 
mitochondrial  
isoform 1  
30414 0.2 152070    
Atp13a1 ATPase type 13A1  1876500 0.2 9382500    
Atp1b1 
sodium/potassium 
transporting ATPase 
subunit β1  
701720 0.2 3508600 14385000 0.2 71925000 
Atp6v1a 
ATPase,  
H+ transporting, 
lysosmal V1 subunit A     
485240 0.2 2426200 
Avp 
vasopressin-
neurophysin  
2-copeptin  
543660 0.2 2718300    
Basp1 brain acid  soluble protein 1     3442100 0.2 17210500 
Chchd5 
coiled-coil-helix  
coiled-coil-helix 
domain containing 5  
378840 0.2 1894200    
Cnp 2,3-cyclic-nucleotide  3-phosphodiesterase     3015600 0.2 15078000 
Crip2 cysteine-rich protein 2  298240 0.2 1491200    
Crmp1 dihydropyrimidinase-related protein 1     5177600 0.2 25888000 
Dbn1 isoform A of drebrin     387740 0.2 1938700 
Ddb2 damage specific  DNA binding protein 2  51037000 0.2 2.55E+08    
Diaph3 PREDICTED: protein diaphanous homolog 3  2184200 0.2 10921000    
Dnajc5 
DnaJ homolog 
subfamily C member 5; 
cysteine string protein 
CSP 164160 0.2 820800    
Eif2b1 translation initiation factor eIF-2B subunit α     22621000 0.2 1.13E+08 
Exoc3l exocyst complex component 3-like  923690 0.2 4618450    
Fam72a protein FAM72A  39188 0.2 195940    
Fbn1 fibrillin-1  1200800 0.2 6004000    
Fkbp1a 
peptidyl-prolyl  
cis-trans isomerase 
FKBP1A     
3521400 0.2 17607000 
Fxyd1 phospholemman  2550900 0.2 12754500    
Fxyd7 
FXYD domain-
containing ion 
transport regulator 7  
1148600 0.2 5743000    
Glul glutamine synthetase  2456300 0.2 12281500 20639000 0.2 1.03E+08 
Gnao1 
guanine nucleotide-
binding protein G(o) 
subunit α isoform α2  
846670 0.2 4233350    
Grn granulin isoform a     2966300 0.2 14831500 
Gstm1 glutathione  S-transferase μ1  331910 0.2 1659550 4770900 0.2 23854500 
Gstp1 glutathione  S-transferase P  214500 0.2 1072500    
Hk1 hexokinase-1     3521600 0.2 17608000 
Hmha1 histocompatibility (minor) HA-1     1.23E+08 0.2 6.16E+08 
Hspa1l heat shock  70 kDa protein 1L     5278700 0.2 26393500 
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Gene Protein Abbr. 
Experiment 1 Experiment 2 
LFQ 
intensity 
ABE 
LFQ 
intensity 
Control 
Ratio LFQ 
ABE: 
Control 
LFQ 
intensity 
ABE 
LFQ 
intensity 
Control 
Ratio 
LFQ ABE: 
Control 
Ildr2 
immunoglobulin-like 
domain containing 
receptor 2  
159030 0.2 795150    
Ilkap 
integrin-linked  
kinase-associated 
serine/threonine 
phosphatase 
 109980 0.2 549900    
Isg20 interferon-stimulated protein  23658 0.2 118290    
Itpr1 
inositol 1,4,5-
trisphosphate receptor 
type 1 isoform 1  
5541900 0.2 27709500    
Kcnma1 
calcium-activated 
potassium channel 
subunit α1 isoform 3  
5.77E+08 0.2 2.89E+09    
Kcnq5l 
PREDICTED: potassium 
voltage-gated channel 
subfamily KQT  
member 5 isoform 1 
 70216000 0.2 3.51E+08 2.85E+09 0.2 1.42E+10 
Lamtor1 ragulator complex protein LAMTOR1  658130 0.2 3290650    
Ldhb L-lactate dehydrogenase B chain  181770 0.2 908850    
Lepr leptin receptor  isoform B     497060 0.2 2485300 
LOC 
100361349 
hypothetical protein 
LOC100361349  557390 0.2 2786950    
LOC 
494539 spectrin β-like  200880 0.2 1004400    
LOC 
498122 
uncharacterized 
protein LOC498122  138750 0.2 693750    
LOC 
500183 
similar to NGF-binding 
Ig light chain  231800 0.2 1159000    
LOC 
680396 
hypothetical protein 
LOC680396  22957 0.2 114785    
LOC 
682206 
PREDICTED: LOW 
QUALITY PROTEIN:  
zinc finger protein 91  
1.51E+08 0.2 7.57E+08    
LOC 
682914 
similar to zinc finger 
protein 326  18151 0.2 90755    
LOC 
686961 
similar to discs large 
homolog 5     1.33E+08 0.2 6.67E+08 
LOC 
687873 
similar to kallikrein 5 
preproprotein     3.08E+08 0.2 1.54E+09 
LOC 
688272 
PREDICTED: RING 
finger protein 157-like  2087400 0.2 10437000    
Lrrc4b leucine-rich repeat-containing protein  1.2E+08 0.2 6.02E+08    
Lrsam1 
leucine-rich repeat  
and sterile α motif 
containing 1  
380630 0.2 1903150    
Ltbp1 
latent-transforming 
growth factor β-
binding protein 1 
precursor 
 149870 0.2 749350    
Map1a microtubule-associated protein 1  65730 0.2 328650    
Mdh2 malate dehydrogenase, mitochondrial  431680 0.2 2158400 2728000 0.2 13640000 
Med24 mediator complex subunit 24  514170 0.2 2570850    
Mt3 metallothionein 3  369010 0.2 1845050    
Ncdn neurochondrin     3363200 0.2 16816000 
Ndrg2 
N-Myc downstream 
regulated gene 2 
isoform 1     
18938000 0.2 94690000 
Ndufv2 
NADH dehydrogenase 
flavoprotein 2, 
mitochondrial  
206430 0.2 1032150    
Neu4 sialidase 4  301330 0.2 1506650    
Nfxl1 
nuclear transcription 
factor, X-box binding-
like 1  
272930 0.2 1364650    
Nlk similar to  nemo-like kinase     13692000 0.2 68460000 
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Gene Protein Abbr. 
Experiment 1 Experiment 2 
LFQ 
intensity 
ABE 
LFQ 
intensity 
Control 
Ratio LFQ 
ABE: 
Control 
LFQ 
intensity 
ABE 
LFQ 
intensity 
Control 
Ratio 
LFQ ABE: 
Control 
Nsd1 
nuclear receptor 
binding SET domain 
protein 1  
442990 0.2 2214950    
P2rx7 P2X purinoceptor 7     1189200 0.2 5946000 
Pacsin1 
protein kinase C and 
casein kinase substrate 
in neurons protein 1     
17918000 0.2 89590000 
Pafah1b2 
platelet-activating 
factor acetylhydrolase 
IB subunit β2     
4591100 0.2 22955500 
Palm paralemmin     12971000 0.2 64855000 
Pebp1 
phosphatidyl-
ethanolamine-binding 
protein 1     
7370500 0.2 36852500 
Pgam1 phosphoglycerate mutase 1     7212000 0.2 36060000 
Plscr4 phospholipid scramblase 4  17587 0.2 87935    
Prdx1 peroxiredoxin-1  142310 0.2 711550    
Prss7 protease, serine, 7  46090 0.2 230450    
Ptgs1 putative cyclooxygenase 3  29083 0.2 145415    
Rap1gds1 
RAP1,  
GTP-GDP dissociation 
stimulator 1     
4499200 0.2 22496000 
Rap2b Ras-related protein Rap-2B  193690 0.2 968450    
RGD 
1559921 
PREDICTED: 
macrophage migration 
inhibitory factor-like  
2479000 0.2 12395000    
RGD 
1560880 
similar to RIKEN cDNA 
2310002J15     96002 0.2 480010 
RGD 
1561197 
PREDICTED: 
uncharacterized 
protein LOC290392  
3387800 0.2 16939000    
Rplp1 60S acidic ribosomal protein P1  284330 0.2 1421650    
Sdhb 
succinate 
dehydrogenase  
iron-sulphur subunit, 
mitochondrial 
 89003 0.2 445015    
Slc13a1 solute carrier family 13 member 1     336970 0.2 1684850 
Slc25a3 
solute carrier family 25 
(mitochondrial carrier, 
phosphate carrier), 
member 3 
    6428500 0.2 32142500 
Slc38a8 
putative sodium-
coupled neutral amino 
acid transporter 8  
30935000 0.2 1.55E+08    
Spire1 spiro homolog 1  125580 0.2 627900    
Sptbn1 non-erythroid  
spectrin β     877530 0.2 4387650 
Stx19 syntaxin 19  585400 0.2 2927000    
Tgm1 
protein-glutamine  
γ-glutamyltransferase 
K     
649390 0.2 3246950 
Tmeff2 
transmembrane 
protein with EGF-like 
and two follistatin-like 
domains 2 
    1083900 0.2 5419500 
Tmem55b transmembrane protein 55B  20441 0.2 102205    
Tomm70a 
mitochondrial import 
receptor subunit 
TOM70     
4972700 0.2 24863500 
Trappc3 
trafficking protein 
particle complex 
subunit 3 
Bet3 1821400 0.2 9107000    
Ttc39b tetratricopeptide repeat domain 39B  389120 0.2 1945600    
Tuba1a tubulin α1A chain     34861000 0.2 1.74E+08 
Tubb2c tubulin β2C chain     1.5E+09 0.2 7.52E+09 
Tubb3 tubulin β3 chain     59551000 0.2 2.98E+08 
Tubb4 tubulin β4     13823000 0.2 69115000 
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Gene Protein Abbr. 
Experiment 1 Experiment 2 
LFQ 
intensity 
ABE 
LFQ 
intensity 
Control 
Ratio LFQ 
ABE: 
Control 
LFQ 
intensity 
ABE 
LFQ 
intensity 
Control 
Ratio 
LFQ ABE: 
Control 
Tubb5 tubulin β5 chain isoform 1  261100 0.2 1305500    
Ube2l3 ubiquitin-conjugating enzyme E2L 3  693320 0.2 3466600    
Uchl1 ubiquitin carboxyl-terminal hydrolase L1  438910 0.2 2194550    
Usp3 ubiquitin-specific protease 3  53450 0.2 267250    
Vcp 
transitional 
endoplasmic reticulum 
ATPase     
1549100 0.2 7745500 
Vom2r53 vomeronasal 2 receptor, 53     149530 0.2 747650 
Wisp1 
WNT1-inducible-
signaling pathway 
protein 1  
4.18E+08 0.2 2.09E+09 5.14E+08 0.2 2.57E+09 
Ywhag 14-3-3 protein γ     7400200 0.2 37001000 
Ywhaq 14-3-3 protein θ     30465000 0.2 1.52E+08 
Zfp438 zinc finger protein 438  1658700 0.2 8293500    
Znf574 zinc finger protein 574     1091700 0.2 5458500 
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APPENDIX 5: WILD-TYPE C. ELEGANS ACYL-BIOTIN EXCHANGE (ABE) HITS 
APPENDIX 5.1 HITS WITH MULTIPLE UNIQUE PEPTIDES IN THE EXPERIMENTAL SAMPLE 
Hits are coloured according to their mammalian orthologue: those identified in the 
proteomic analysis of rat brain homogenate in this study but not in previous studies are 
highlighted in blue.  Proteins which were not present in the control sample were given an 
arbitrary value of 0.2 to avoid dividing by zero, similar to previous proteomic studies (Dowal 
et al., 2011; Roth et al., 2006; Yang et al., 2010).  Proteins with a ratio of less than 5 were 
discarded (Martin and Cravatt, 2009).  LFQ, label-free quantification. 
Gene Protein description LFQ intensity ABE 
LFQ intensity 
Control 
Ratio LFQ 
ABE:Control 
Mammalian orthologue 
Gene Name 
tbb-2 tubulin β 10213000 0.2 51065000 Tubb4b tubulin β-4B chain 
vit-4 vitellogenin 1.7E+08 0.2 8.52E+08 Apob apolipoprotein B-100 
vit-5 vitellogenin 21978000 0.2 1.1E+08 Cenpe centromere-associated protein E 
vit-6 vitellogenin 93227000 0.2 4.66E+08 Bmper BMP-binding endothelial regulator protein precursor 
 
APPENDIX 5.2 HITS WITH A SINGLE UNIQUE PEPTIDE IN THE EXPERIMENTAL SAMPLE 
Hits are coloured according to their mammalian orthologue: those also identified in 
previous proteomic studies are highlighted in green; those identified in the proteomic 
analysis of rat brain homogenate in this study but not in previous studies are highlighted in 
blue; those identified both in this and previous studies are highlighted in orange.  Proteins 
which were not present in the control sample were given an arbitrary value of 0.2 to avoid 
dividing by zero, similar to previous proteomic studies (Dowal et al., 2011; Roth et al., 2006; 
Yang et al., 2010).  Proteins with a ratio of less than 5 were discarded (Martin and Cravatt, 
2009).  LFQ, label-free quantification. 
Gene Protein description 
LFQ 
intensity 
ABE 
LFQ intensity 
Control 
Ratio LFQ 
ABE:Control 
Mammalian orthologue 
Gene Name 
alh-8 aldehyde dehydrogenase 1320300 0.2 6601500 Aldh6a1 
methylmalonate-
semialdehyde dehydrogenase 
[acylating], mitochondrial 
precursor 
arrd-6 arrestin domain protein 2302700 0.2 11513500 Arrdc3 
arrestin domain-containing 
protein 3 
C06C3.4  2046600 0.2 10233000   
C50F7.3  59495000 0.2 2.97E+08   
cdr-2 cadmium responsive 3.19E+09 0.2 1.59E+10 Faxc 
failed axon connections 
homologue 
ckr-2 cholecystokinin receptor homolog 377720 0.2 1888600 Cckbr 
gastrin/cholecystokinin type 
B receptor 
eef-1A.1 
eukaryotic 
translation 
elongation factor 
7778300 0.2 38891500 Eef1a2 elongation factor 1α 2 
F07G11.3  164880 0.2 824400   
F14F9.3  22427000 0.2 1.12E+08   
F29D10.1  2059000 0.2 10295000   
F43G6.8  724560 0.2 3622800 Trim23 
E3 ubiquitin-protein ligase 
TRIM23 
F46H5.3a.1  32744000 0.2 1.64E+08 Ckm creatine kinase M-type 
fbxc-55 F-box C protein 2504600 0.2 12523000   
grl-6 
ground-like; 
hedgehog-like 
protein 
118690 0.2 593450   
lin-54 abnormal cell lineage 124470 0.2 622350 Lin54 protein lin-54 homologue 
nhr-254 nuclear hormone receptor family 502320 0.2 2511600 Nr1hr bile acid receptor isoform 3 
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Gene Protein description 
LFQ 
intensity 
ABE 
LFQ intensity 
Control 
Ratio LFQ 
ABE:Control 
Mammalian orthologue 
Gene Name 
nhr-98 nuclear hormone receptor family 11677000 0.2 58385000 Nr2e3 
photoreceptor-specific 
nuclear receptor 
npr-33 neuropeptide receptor family 23477000 0.2 1.17E+08 Galr2 galanin receptor type 2 
rap-3 RAP homolog 285890 0.2 1429450 Rap1a Ras-related protein Rap1A 
sun-1 
SUN (S. pombe 
sad1/Ce-UNC-84) 
domain protein 
2.14E+08 0.2 1.07E+09   
T05C3.2 may be involved in apoptosis 2370700 0.2 11853500 Kiaa1239 
leucine-rich repeat and WD 
repeat-containing 
protein KIAA1239 
T06E6.10  3178700 0.2 15893500 Krtap9-1 
keratin-associated protein  
9-1 
T22F7.3  62633000 0.2 3.13E+08 Tfpi 
tissue factor pathway 
inhibitor 
tba-1 tubulin α 4430100 0.2 22150500 Tuba1a tubulin α-1A chain 
tbc-3 
TBC  
(Tre-2/Bub2/Cdc16) 
domain family 
16198000 0.2 80990000 Tbc1d22b TBC1 domain family  member 22B 
tsp-9 tetraspanin family 788320 0.2 3941600 Cd9 CD9 antigen 
vit-2 vitellogenin 5840800 0.2 29204000 Wdr87 WD repeat-containing protein 87 
W02F12.8  175290 0.2 876450   
W09D6.1c  69287000 0.2 3.46E+08 Aasdh 
Acyl-CoA synthetase family 
member 4 
Y45G12B.2a  1.06E+08 0.2 5.32E+08 Zfpl1 zinc finger-like protein 1 
Y49G5A.1  6239400 0.2 31197000 Eppin eppin 
Y71F9AL.6  2582600 0.2 12913000 
HIT 
000048221 
conserved hypothetical 
protein 
ZC13.2  395600 0.2 1978000   
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APPENDIX 6: WILD-TYPE C. ELEGANS ACYL-RESIN-ASSISTED CAPTURE 
(ACYL-RAC) HITS 
APPENDIX 6.1 HITS WITH MULTIPLE UNIQUE PEPTIDES IN THE EXPERIMENTAL SAMPLE 
Hits are coloured according to their mammalian orthologue: those also identified in 
previous proteomic studies are highlighted in green; those identified in the proteomic 
analysis of rat brain homogenate in this study but not in previous studies are highlighted in 
blue; those identified both in this and previous studies are highlighted in orange.  Proteins 
which were not present in the control sample were given an arbitrary value of 0.2 to avoid 
dividing by zero, similar to previous proteomic studies (Dowal et al., 2011; Roth et al., 2006; 
Yang et al., 2010).  Proteins with a ratio of less than 5 were discarded (Martin and Cravatt, 
2009).  LFQ, label-free quantification. 
Gene Protein description 
LFQ 
intensity 
ABE 
LFQ 
intensity 
Control 
Ratio LFQ 
ABE:Control 
Mammalian orthologue 
Gene Name 
aco-2 aconitase 29247000 0.2 1.46E+08 Aco2 aconitate hydratase, mitochondrial 
ahcy-1 
S-adenosyl-
homocysteine 
hydrolase 
55061000 0.2 2.75E+08 Ahcy adenosylhomocysteinase 
aldo-2 fructose-biphosphate aldolase 22058000 0.2 1.1E+08 Aldoa fructose-bisphosphate aldolase A 
alh-8 
methylmalonate-
semialdehyde 
dehydrogenase 
53161000 0.2 2.66E+08 Aldh6a1 
methylmalonate-semialdehyde 
dehydrogenase [acylating], 
mitochondrial precursor 
anc-1 abnormal nuclear anchorage 2.74E+08 0.2 1.37E+09 Syne1 nesprin-1 
atp-2 ATP synthase β chain 3878800 0.2 19394000 Atp5b ATP synthase β subunit, mitochondrial 
C39D10.7  6699300 0.2 33496500 Muc2 mucin-2 
cdc-48.2 P97 protein 8357600 0.2 41788000 Vcp transitional endoplasmic reticulum ATPase 
cpg-2 chondroitin proteoglycan 8083300 0.2 40416500 
HIT 
000056302 conserved hypothetical protein 
daf-21 heat shock protein HSP90 2.75E+08 0.2 1.37E+09 Hsp90ab1 heat shock protein 90β 
eef-1A.1 elongation factor 1α 2.99E+08 0.2 1.5E+09 Eef1a2 elongation factor 1α 2 
eft-2 elongation factor Tu family 32941000 0.2 1.65E+08 Eef2 elongation factor 2 
enol-1 enolase 33173000 0.2 1.66E+08 Eno1 α-enolase 
F09B12.3  61215000 0.2 3.06E+08 Plbd2 putative phospholipase B-like 2 
F46H5.3a  6.05E+08 61143000 9.891239 Ckm creatine kinase M-type 
gdh-1 glutamate dehydrogenase 22755000 0.2 1.14E+08 Glud1 
glutamate dehydrogenase, 
mitochondrial 
gpd-3 
glyceraldehyde-3-
phosphate 
dehydrogenase 
12634000 0.2 63170000 Gapdh glyceraldehyde-3-phosphate dehydrogenase 
hsp-1 heat shock 70 kDa protein A 26086000 0.2 1.3E+08 Hspa8 
heat shock cognate 71 kDa 
protein 
hsp-60 heat shock protein 22092000 0.2 1.1E+08 Hspd1 60 kDa heat shock protein, mitochondrial 
imb-3 importin β nuclear transport factor 9716400 0.2 48582000 Ipo5 importin 5 
inf-1 initiation factor 5995500 0.2 29977500 Eif4a2 eukaryotic initiation factor 4A-II 
paa-1 protein phosphatase 2A 29583000 0.2 1.48E+08 Ppp2r1a 
serine/threonine-protein 
phosphatase 2A 65 kDa 
regulatory subunit A α isoform 
pck-1 phosphoenoylpyruvate kinase 26218000 0.2 1.31E+08 Pck2 
phosphoenolpyruvate 
carboxykinase [GTP], 
mitochondrial 
pck-2 phosphoenoylpyruvate kinase 64737000 0.2 3.24E+08 Pck2 
phosphoenolpyruvate 
carboxykinase [GTP], 
mitochondrial 
pdi-1 protein disulphide isomerase 5402000 0.2 27010000 P4hb protein disulphide-isomerase 
pdi-2 protein disulphide isomerase 33680000 0.2 1.68E+08 P4hb protein disulphide-isomerase 
rla-0 deoxyribonuclease 34886000 0.2 1.74E+08 Rplp0 60S acidic ribosomal protein P0 
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Gene Protein description 
LFQ 
intensity 
ABE 
LFQ 
intensity 
Control 
Ratio LFQ 
ABE:Control 
Mammalian orthologue 
Gene Name 
rps-0 40S ribosomal protein 20489000 0.2 1.02E+08 Rpsa 40S ribosomal protein SA 
spc-1 spectrin 51761000 0.2 2.59E+08 Sptan1 spectrin alpha chain,  non-erythrocytic 1 isoform 3 
tba-2 tubulin α 43641000 0.2 2.18E+08 Tuba1a tubulin α-1A chain 
tbb-2 tubulin β 68335000 0.2 3.42E+08 Tubb4b tubulin β-4B chain 
uba-1 ubiquitin-activating enzyme 54829000 0.2 2.74E+08 Uba1 
ubiquitin-like modifier-activating 
enzyme 1 
unc-54 myosin heavy chain 19660000 0.2 98300000 Myh3 myosin 3 
vha-13 ATP synthase α and β subunits 6488300 0.2 32441500 Atp6v1a 
V-type proton ATPase catalytic 
subunit A 
vit-2 vitellogenin 1.84E+08 0.2 9.22E+08 Wdr87 WD repeat-containing protein 87 
vit-4 vitellogenin 2.51E+08 0.2 1.26E+09 Apob apolipoprotein B-100 
vit-5 vitellogenin 28088000 0.2 1.4E+08 Cenpe centromere-associated protein E 
vit-6 vitellogenin 5.79E+08 0.2 2.9E+09 Bmper BMP-binding endothelial regulator protein precursor 
 
APPENDIX 6.2 HITS WITH A SINGLE UNIQUE PEPTIDE IN THE EXPERIMENTAL SAMPLE 
Hits are coloured according to their mammalian orthologue: those also identified in 
previous proteomic studies are highlighted in green; those identified in the proteomic 
analysis of rat brain homogenate in this study but not in previous studies are highlighted in 
blue; those identified both in this and previous studies are highlighted in orange.  Proteins 
which were not present in the control sample were given an arbitrary value of 0.2 to avoid 
dividing by zero, similar to previous proteomic studies (Dowal et al., 2011; Roth et al., 2006; 
Yang et al., 2010).  Proteins with a ratio of less than 5 were discarded (Martin and Cravatt, 
2009).  LFQ, label-free quantification. 
Gene Protein description 
LFQ 
intensity 
ABE 
LFQ 
intensity 
Control 
Ratio LFQ 
ABE:Control 
Mammalian orthologue 
Gene Name 
aco-1 iron-responsive element-binding like protein; aconitase 1555600 0.2 7778000 Aco1 
cytoplasmic aconitate 
hydratase 
ant-1.3 adenine nucleotide 1250800 0.2 6254000 Slc25a4 ADP/ATP translocase 1 
cct-2 t-complex protein 1 1884500 0.2 9422500 Cct2 T-complex protein 1 subunit β 
cct-5 TCP-1 like chaperonin 1879400 0.2 9397000 Cct5 T-complex protein 1 subunit ε 
clec-122 C-type lectin 5164100 0.2 25820500 Muc21 mucin-21 
csk-1 C-terminal Src kinase 584400 0.2 2922000 Csk tyrosine-protein kinase CSK 
cts-1 citrate synthase 4919500 0.2 24597500 Cs citrate synthase, mitochondrial 
cyc-2.1 cytochrome c 2229900 0.2 11149500 Cycs cytochrome c 
eef-1B.2 eukaryotic translation elongation factor 946520 0.2 4732600 Fdxacb1 
ferredoxin-fold anticodon-
binding domain-containing 
protein 1 
har-2 hemiasterlin resistent 2.3E+08 0.2 1.15E+09 Dspp dentin sialophosphoprotein 
hrp-2 hetergeneous nuclear ribonucleoprotein homologue 2233700 0.2 11168500 Hnrnpr 
heterogeneous nuclear 
ribonucleoprotein R 
hsp-6 heat shock protein 70 kDa family protein 3898300 0.2 19491500 Hspa9 
stress-70 protein, 
mitochondrial 
kars-1 lysyl(K) amino-acyl tRNA synthetase 547560 0.2 2737800 Kars lysine--tRNA ligase 1 
mdh-1 malate dehydrogenase 8413900 0.2 42069500 Mdh1 malate dehydrogenase, cytoplasmic 
mig-6 protease inhibitor 3777700 0.2 18888500 Papln papilin 
mtr-4 RNA helicase 32798000 0.2 1.64E+08 Skiv2l2 superkiller viralicidic activity 2-like 2 
nuc-1 DNase II homolog 2.32E+09 0.2 1.16E+10 Dnase2b deoxyribonuclease-2β 
prdx-2 peroxiredoxin 3443100 0.2 17215500 Prdx2 peroxiredoxin-2 
prmt-1 protein arginine methyltransferase 3743400 0.2 18717000 Hrmt1l2 
protein arginine N-
methyltransferase 1 
R08D7.2  7007400 0.2 35037000 Rpap2 
putative RNA polymerase II 
subunit B1 CTD phosphatase 
RPAP2 
rme-4 receptor mediated endocytosis 81060000 0.2 4.05E+08 Dennd1a 
DENN domain-containing 
protein 1A 
wars-1 tryptophanyl-tRNA synthetase 2506800 0.2 12534000 Wars tryptophanyl-tRNA synthetase 
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Gene Protein description 
LFQ 
intensity 
ABE 
LFQ 
intensity 
Control 
Ratio LFQ 
ABE:Control 
Mammalian orthologue 
Gene Name 
Y22D7AL.9  7E+08 0.2 3.5E+09 Ttc28 
tetratricopeptide repeat 
protein 28 
Y64G10A.7 fibrillin-1 homolog 17415 0.2 87075 Megf6 multiple epidermal growth factor-like domains protein 6 
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APPENDIX 7: ath-1 MUTANT C. ELEGANS ACYL-BIOTIN EXCHANGE (ABE) HITS 
APPENDIX 7.1 HITS WITH MULTIPLE UNIQUE PEPTIDES IN THE EXPERIMENTAL SAMPLE 
Hits are coloured according to their mammalian orthologue: those also identified in 
previous proteomic studies are highlighted in green; those identified in the proteomic 
analysis of rat brain homogenate in this study but not in previous studies are highlighted in 
blue; those identified both in this and previous studies are highlighted in orange.  Proteins 
which were not present in the control sample were given an arbitrary value of 0.2 to avoid 
dividing by zero, similar to previous proteomic studies (Dowal et al., 2011; Roth et al., 2006; 
Yang et al., 2010).  Proteins with a ratio of less than 5 were discarded (Martin and Cravatt, 
2009).  LFQ, label-free quantification. 
Gene Protein description 
LFQ 
intensity 
ABE 
LFQ 
intensity 
Control 
Ratio LFQ 
ABE:Control 
Mammalian orthologue 
Gene Name 
aco-1 aconitase 2444500 0.2 12222500 Aco1 cytoplasmic aconitate hydratase 
alh-8 aldehyde dehydrogenase 8700500 0.2 43502500 Aldh6a1 
methylmalonate-semialdehyde 
dehydrogenase [acylating],  
mitochondrial precursor 
ant-1.1 adenine nucleotide translocator 11436000 0.2 57180000 Slc25a6 ADP/ATP translocase 3 
cts-1 citrate synthase 1519500 0.2 7597500 Cs citrate synthase, mitochondrial 
daf-21 heat shock protein HSP90 1024500 0.2 5122500 Hsp90ab1 heat shock protein 90β 
eef-1A.1 eukaryotic translation elongation factor 98082000 0.2 4.9E+08 Eef1a2 elongation factor 1α 2 
eef-2 eukaryotic translation elongation factor 15635000 0.2 78175000 Eef2 elongation factor 2 
F09B12.3  5765800 0.2 28829000 Plbd2 putative phospholipase B-like 2 
F46H5.3  32668000 0.2 1.63E+08 Ckm creatine kinase M-type 
gpd-3 
glyceraldehyde-3-
phosphate 
dehydrogenase 
40323000 0.2 2.02E+08 Gapdh glyceraldehyde-3-phosphate dehydrogenase 
pck-2 phosphoenoylpyruvate kinase 1344200 0.2 6721000 Pck2 
phosphoenolpyruvate carboxykinase 
[GTP], mitochondrial 
tba-1 tubulin α 7149900 0.2 35749500 Tuba1a tubulin α-1A chain 
tbb-2 tubulin β 10503000 0.2 52515000 Tubb4b tubulin β-4B chain 
uba-1 ubiquitin activating enzyme 1617400 0.2 8087000 Uba1 
ubiquitin-like modifier-activating  
enzyme 1 
vit-2 vitellogenin 2173100 0.2 10865500 Wdr87 WD repeat-containing protein 87 
vit-5 vitellogenin 16044000 0.2 80220000 Cenpe centromere-associated protein E 
vit-6 vitellogenin 2603900 0.2 13019500 Bmper BMP-binding endothelial regulator protein precursor 
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APPENDIX 7.2 HITS WITH A SINGLE UNIQUE PEPTIDE IN THE EXPERIMENTAL SAMPLE 
Hits are coloured according to their mammalian orthologue: those also identified in 
previous proteomic studies are highlighted in green; those identified in the proteomic 
analysis of rat brain homogenate in this study but not in previous studies are highlighted in 
blue; those identified both in this and previous studies are highlighted in orange.  Proteins 
which were not present in the control sample were given an arbitrary value of 0.2 to avoid 
dividing by zero, similar to previous proteomic studies (Dowal et al., 2011; Roth et al., 2006; 
Yang et al., 2010).  Proteins with a ratio of less than 5 were discarded (Martin and Cravatt, 
2009).  LFQ, label-free quantification. 
Gene Protein description 
LFQ 
intensity 
ABE 
LFQ 
intensity 
Control 
Ratio LFQ 
ABE:Control 
Mammalian orthologue 
Gene Name 
abl-1 oncogene Abl-related 72603 0.2 363015 Abl1 c-Abl oncogene 1 
abtm-1 ABC transporter, mitochondrial 43351000 0.2 2.17E+08 Abcb7 
ATP-binding cassette sub-family B 
member 7, mitochondrial 
aco-2 aconitase 120460 0.2 602300 Aco2 aconitate hydratase, mitochondrial 
ahcy-1 S-adenosylhomocysteine hydrolase homolog 2846200 0.2 14231000 Ahcy adenosylhomocysteinase 
alh-9 aldehyde dehydrogenase 932600 0.2 4663000 Aldh7a1 α-aminoadipic semialdehyde dehydrogenase 
asp-1 aspartyl protease 1161300 0.2 5806500 Pgc gastricsin 
bed-1 BED-type zinc finger putative transcription factor 3.66E+08 0.2 1.83E+09   
C08H9.2a.1  686890 0.2 3434450 Hdlbp vigilin 
C09B9.1  8454000 0.2 42270000   
C33H5.8  862690 0.2 4313450 Rpap3 
RNA polymerase II-associated 
protein 3 
C35E7.7  717150 0.2 3585750   
F01G4.6b.1  1459800 0.2 7299000 Slc25a3 
phosphate carrier protein, 
mitochondrial 
F02H6.7  1174800 0.2 5874000 Bai1 
brain-specific angiogenesis  
inhibitor 1 
F09G2.2  173810 0.2 869050 Cnppd1 
cyclin Pas1/PHO80 domain-
containing protein 1 
F46B3.15  100820 0.2 504100   
F46F11.11  1349900 0.2 6749500   
faah-5 fatty acid amide hydrolase homolog 29982000 0.2 1.5E+08 Faah1 fatty-acid amide hydrolase 1 
fbxa-16 F box A protein 238240 0.2 1191200   
gdh-1 glutamate dehydrogenase 1021200 0.2 5106000 Glud1 glutamate dehydrogenase, mitochondrial 
har-2 hemiasterlin resistant 15270000 0.2 76350000 Dspp dentin sialophosphoprotein 
hel-1 helicase 2872900 0.2 14364500 Ddx39a ATP-dependent RNA helicase DDX39 
imb-3 importin β family 422820 0.2 2114100 Ipo5 importin 5 
lim-7 LIM homeodomain protein 3838400 0.2 19192000 Isl2 insulin gene enhancer protein ISL-2 
nhr-134 nuclear hormone receptor 2289900 0.2 11449500 Ppara peroxisome proliferator-activated 
receptor α 
nhr-268 nuclear hormone receptor 667360 0.2 3336800 Rarg retinoic acid receptor γ2 
nsf-1 N-ethylmaleimide sensitive factor homolog 906140 0.2 4530700 Nsf vesicle fusing ATPase 
pck-1 phosphoenoylpyruvate carboxykinase 655470 0.2 3277350 Pck2 
phosphoenolpyruvate 
carboxykinase [GTP], mitochondrial 
pdi-2 protein disulphide isomerase 1720400 0.2 8602000 P4hb protein disulphide-isomerase 
ptr-3 patched-related family 3513600 0.2 17568000 Npc1 Niemann-Pick C1 protein 
R12E2.8  1497700 0.2 7488500 Ush2a usherin 
rps-26 small ribosomal protein subunit S26 893520 0.2 4467600 Rps26 40S ribosomal protein S26 
rps-4 small ribosomal protein subunit S4 892020 0.2 4460100 Rps4x 40S ribosomal protein S4, X isoform 
rps-5 small ribosomal protein subunit S5 1517700 0.2 7588500 Rps5 40S ribosomal protein S5 
sdha-1 succinate dehydrogenase complex subunit A 220670 0.2 1103350 Shda1 
succinate dehydrogenase 
(ubiquinone) flavoprotein subunit, 
mitochondrial 
sphk-1 sphingosine kinase 259010 0.2 1295050 Sphk1 sphingosine kinase 1 
sun-1 SUN (S. pombe sad1/Ce-UNC-84) domain protein 18057000 0.2 90285000   
T04B2.7  314640 0.2 1573200   
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Gene Protein description 
LFQ 
intensity 
ABE 
LFQ 
intensity 
Control 
Ratio LFQ 
ABE:Control 
Mammalian orthologue 
Gene Name 
unc-15 paramyosin homolog 916140 0.2 4580700 Myh7 myosin-7 
W02F12.8  538170 0.2 2690850   
W09D6.1c  55055000 0.2 2.75E+08 Aasdh 
Acyl-CoA synthetase family 
member 4 
Y47D3A.28  19882 0.2 99410 Mcm10 
minichromosome maintenance 
deficient 10 (S. cerevisiae) 
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